WO2001053274A1 - Amide compounds for inhibiting protein kinases - Google Patents

Amide compounds for inhibiting protein kinases Download PDF

Info

Publication number
WO2001053274A1
WO2001053274A1 PCT/US2001/001723 US0101723W WO0153274A1 WO 2001053274 A1 WO2001053274 A1 WO 2001053274A1 US 0101723 W US0101723 W US 0101723W WO 0153274 A1 WO0153274 A1 WO 0153274A1
Authority
WO
WIPO (PCT)
Prior art keywords
benzamide
methyl
phenyl
group
pharmaceutically acceptable
Prior art date
Application number
PCT/US2001/001723
Other languages
French (fr)
Inventor
Steven Lee Bender
Dilip Bhumralkar
Michael Raymond Collins
Stephan James Cripps
Judith Gail Deal
Mitchell David Nambu
Cynthia Louise Palmer
Zhengwei Peng
Michael David Varney
Lei Jia
Original Assignee
Agouron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals, Inc. filed Critical Agouron Pharmaceuticals, Inc.
Priority to BR0108025-3A priority Critical patent/BR0108025A/en
Priority to MXPA02007102A priority patent/MXPA02007102A/en
Priority to EP01906592A priority patent/EP1252146A1/en
Priority to JP2001553276A priority patent/JP2003529558A/en
Priority to CA002394703A priority patent/CA2394703A1/en
Priority to AU2001234484A priority patent/AU2001234484A1/en
Publication of WO2001053274A1 publication Critical patent/WO2001053274A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • This invention is directed to amide compounds that mediate and/or inhibit the activity of certain protein kinases, and to pharmaceutical compositions containing such compounds.
  • the invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amounts of such compounds.
  • Protein kinases are a family of enzymes that catalyze phosphorylation of the hydroxyl group of specific tyrosine, serine, or threonine residues in proteins. Typically, such phosphorylation dramatically perturbs the function of the protein, and thus protein kinases are pivotal in the regulation of a wide variety of cellular processes, including metabolisim, cell proliferation, cell differentiation, and cell survival. Of the many different cellular functions in which the activity of protein kinases is known to be required, some processes represent attractive targets for therapeutic intervention for certain disease states. Two examples are angiogenesis and cell-cycle control, in which protein kinases play a pivotal role; these processes are essential for the growth of solid tumors as well as for other diseases.
  • Angiogenesis is the mechanism by which new capillaries are formed from existing vessels. When required, the vascular system has the potential to generate new capillary networks in order to maintain the proper functioning of tissues and organs. In the adult, however, angiogenesis is fairly limited, occurring only in the process of wound healing and neovascularization of the endometrium during menstruation. See Merenmies, J., Parada, L. F., Henkemeyer, M., Cell Growth & Differentiation, 8, 3-10 (1997). On the other hand, unwanted angiogenesis is a hallmark of several diseases, such as retinopathies, psoriasis, rheumatoid arthritis, age-related macular degeneneration, and cancer (sohd tumors).
  • Protein kinases which have been shown to be involved in the angiogenic process include three members of the growth factor receptor tyrosine kinase family: VEGF-R2 (vascular endothelial growth factor receptor 2, also known as KDR (kinase insert domain receptor) and as FLK-1); FGF-R (fibroblast growth factor receptor); and TEK (also known as Tie-2).
  • VEGF-R2 vascular endothelial growth factor receptor 2, also known as KDR (kinase insert domain receptor) and as FLK-1
  • FGF-R fibroblast growth factor receptor
  • TEK also known as Tie-2
  • VEGF-R2 which is selectively expressed on endothelial cells, binds the potent angiogenic growth factor VEGF and mediates the subsequent signal transduction through activation of its intracellular kinase activity.
  • VEGF-R2 direct inhibition of the kinase activity of VEGF-R2 will result in the reduction of angiogenesis even in the presence of exogenous VEGF (see Strawn et al., Cancer Research, 56, 3540-3545 (1996)), as has been shown with mutants of VEGF-R2 which fail to mediate signal transduction. Millauer et al., Cancer Research, 56, 1615-1620 (1996).
  • VEGF-R2 appears to have no function in the adult beyond that of mediating the angiogenic activity of VEGF. Therefore, a selective inhibitor of the kinase activity of VEGF-R2 would be expected to exhibit little toxicity.
  • FGF-R binds the angiogenic growth factors aFGF and bFGF and mediates subsequent intracellular signal transduction.
  • growth factors such as bFGF may play a critical role in inducing angiogenesis in solid tumors that have reached a certain size.
  • bFGF growth factors
  • FGF-R is expressed in a number of different cell types throughout the body and may or may not play important roles in other normal physiological processes in the adult. Nonetheless, systemic administration of a small molecule inhibitor of the kinase activity of FGF-R has been reported to block bFGF-induced angiogenesis in mice without apparent toxicity. Mohammad et al., EMBO Journal, 17, 5996-5904 (1998).
  • TEK also known as Tie-2
  • Tie-2 is another receptor tyrosine kinase selectively expressed on endothelial cells which has been shown to play a role in angiogenesis.
  • the binding of the factor angiopoietin-1 results in autophosphorylation of the kinase domain of TEK and results in a signal transduction process which appears to mediate the interaction of endothelial cells with peri-endothelial support cells, thereby facilitating the maturation of newly formed blood vessels.
  • the factor angiopoietin-2 appears to antagonize the action of angiopoietin-1 on TEK and disrupts angiogenesis.
  • WO 97/34876 discloses certain cinnoline derivatives that are inhibitors of VEGF-R2, which may be used for the treatment of disease states associated with abnormal angiogenesis and/or increased vascular permeability such as cancer, diabetes, psoriosis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restinosis, autoimmune diseases, acute inflammation and ocular diseases with retinal vessel proliferation.
  • Two documents described hereinafter disclose certain amide derivatives but do not disclose or teach that any of the compounds may be used for modulating or inhibiting the activity of protein kinases: WIPO international Publication No. WO 97/03967; and WIPO International Publication No. WO 96/23783.
  • protein kinases In addition to its role in angiogenesis, protein kinases also play a crucial role in cell-cycle control. Uncontrolled cell proliferation is the insignia of cancer. Cell proliferation in response to various stimuli is manifested by a de-regulation of the cell division cycle, the process by which cells multiply and divide. Tumor cells typically have damage to the genes that directly or indirectly regulate progression through the cell division cycle.
  • Cyclin-dependent kinases are serine-threonine protein kinases that play critical roles in regulating the transitions between different phases of the cell-cycle, such as the progression from a quiescent stage in G j (the gap between mitosis and the onset of DNA replication for a new round of cell division) to S (the period of active DNA synthesis), or the progression from G 2 to M phase, in which active mitosis and cell-division occurs. See, e.g., the articles compiled in Science, 274, 1643-1677 (1996).
  • CDK complexes are formed through association of a regulatory cyclin subunit (e.g., cyclin A, Bl, B2, DI, D2, D3, and E) and a catalytic kinase subunit (e.g., cdc2 (CDK1), CDK2, CDK4, CDK5, and CDK6).
  • a regulatory cyclin subunit e.g., cyclin A, Bl, B2, DI, D2, D3, and E
  • a catalytic kinase subunit e.g., cdc2 (CDK1), CDK2, CDK4, CDK5, and CDK6.
  • CDK4 complexed to the D cyclins that plays a critical part in initiating the cell-division cycle from a resting or quiescent stage to one in which cells become committed to cell division. This progression is subject to a variety of growth regulatory mechanisms, both negative and positive. Aberrations in this control system, particularly those that affect the function of CDK4, have been implicated in the advancement of cells to the highly proliferative state characteristic of malignancies, particularly familial melanomas, esophageal carcinomas, and pancreatic cancers. See, e.g., Hall et al., Adv. Cancer Res., 68, 67-108 (1996); Kamb, Trends in Genetics, 11, 136-140 (1995); Kamb et al., Science, 264, 436-440 (1994).
  • CDK inhibitors A large number of small molecule ATP-site antagonists have been identified as CDK inhibitors.
  • CDK inhibitors See, Webster, Exp. Opin. Invest. Drugs, 7, 865-887 (1998), Stover, Et al., Curr. Opin. Drug Disc. Dev., 2, 274-285(1999), Gray et al., Curr. Med. Chem., 6, 859-875 (1999), Sielecki, et al., J. Med. Chem., 43, 1-18 (2000), Crews, et al., Curr. Opin. Chem. Biol, 4, 47-53 (2000), Buolamwini, Curr.Pharm.
  • WO 97/16447 discloses certain analogs of chromones that are inhibitors of cyclin-dependent kinases, in particular of CDK/cyclin complexes such as CDK4/cyclin DI, which may be used for inhibiting excessive or abnormal cell proliferation, and therefore for treating cancer.
  • WIPO International Publication No. WO 99/21845 describes 4- aminothiazole derivatives that are useful as CDK inhibitors. There is still a need, however, for small-molecule compounds that may be readily synthesized and are effective in inhibiting one or more CDKs or CDK/cyclin complexes.
  • CDK4 may serve as a general activator of cell division in most cells, and complexes of CDK4 and D-type cyclins govern the early G ⁇ phase of the cell-cycle, there is a need for effective inhibitors of CDK4, and D-type cyclin complexes thereof, for treating one or more types of tumors.
  • the pivotal roles of cyclin E/CDK2 and cyclin B/CDK1 kinases in the Gl/S phase and G2/M transitions respectively offer additional targets for therapeutic intervention in suppressing deregulated cell-cycle progression in cancer.
  • Another protein kinase, CHK-1 plays an important role as a checkpoint in cell- cycle progression.
  • Checkpoints are control systems that coordinate cell-cycle progression by influencing the formation, activation and subsequent inactivation of the cyclin-dependent kinases. Checkpoints prevent cell-cycle progression at inappropriate times, maintain the metabolic balance of cells while the cell is arrested, and in some instances can induce apoptosis (programmed cell death) when the requirements of the checkpoint have not been met. See, e.g., O'Connor, Cancer Surveys, 29, 151-182 (1997); Nurse, Cell, 91, 865-867 (1997); Hartwell et al., Science, 266, 1821-1828 (1994); Hartwell et al., Science, 246, 629-634 (1989).
  • G 2 checkpoint is particularly vulnerable to abrogation of the last remaining barrier protecting them from the cancer killing effects of DNA-damaging agents.
  • the G 2 checkpoint is regulated by a control system that has been conserved from yeast to humans. Important in this conserved system is a kinase, CHK-1, which transduces signals from the DNA-damage sensory complex to inhibit activation of the cyclin B/Cdc2 kinase, which promotes mitotic entry.
  • Tyrosine kinases can be of the receptor type (having extracellular, transmembrane and intracellular domains) or the non-receptor type (being wholly intracellular). At least one of the non-receptor protein tyrosine kinases, namely, LCK, is believed to mediate the transduction in T-cells of a signal from the interaction of a cell-surface protein (Cd4) with a cross-linked anti-Cd4 antibody.
  • Cd4 cell-surface protein
  • kinase inhibitors it is desirable for kinase inhibitors to possess both high affinity for the target kinase as well as high selectivity versus other protein kinases.
  • an objective of the invention is to provide potent inhibitors of protein kinases.
  • Another objective of the invention is to provide effective kinase inhibitors having a strong and selective affinity for a particular kinase.
  • compositions containing such agents are useful in treating various diseases and disorders associated with uncontrolled or unwanted angiogenesis and/or cellular proliferation, such as cancer, autoimmune diseases, viral diseases, fungal diseases, neurodegenerative disorders and cardiovascular diseases.
  • pharmaceutical compositions containing such agents are useful in the treatment of diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis.
  • the agents have advantageous properties relating to modulation and/or inhibition of the kinase activity associated with VEGF-R, FGF-R, CDK complexes(e.g., CDKl, CDK2, CDK4 and CDK6), CHK-1, TEK, and LCK.
  • CDK complexes e.g., CDKl, CDK2, CDK4 and CDK6
  • the invention relates to compounds represented by the Formula I:
  • R 1 is a moiety of the formula
  • Z is CH or NH, and Q is a moiety such that R 1 is a substituted or unsubstituted monocyclic or bicyclic heteroaryl which has at least two carbon atoms in the heteroaryl ring system;
  • X is selected from CH 2 , O, S, and NH;
  • Y is selected from CH 2 , O, and S, provided that at least one of X and Y is CH 2 , or X and Y together with the bond there-between form a cyclopropyl;
  • R 2 and R 3 are independently selected from hydrogen, methyl, halogen, trifluoromethyl, and cyano;
  • R 4 is where R 5 is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O-R 7 , NR 8 R 9 , C r C 8 alkyl, or monocyclic heterocycloalkyl group, R 6 is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkenyl, O-R 7 , C(O)R 7 , NR 8 R 9 , C 2 -C 8 alkyl, or monocyclic heterocycloalkyl group, where R 7 is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, R 8 is hydrogen or a substituted or unsubstituted alkyl, and R 9 is a substituted or unsubstituted alkyl, aryl, heteroaryl, cycloalkyl,
  • the invention is also directed to pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts of the compounds of Formula I.
  • Pharmaceutically acceptable salts of such active metabolites are also provided.
  • Advantageous methods of making the compounds of the Formula I are also described.
  • the invention relates to compounds of the Formula I wherein R 1 is a substituted or unsubstituted heteroaryl group selected from:
  • X is selected from CH 2 , O, and S;
  • Y is selected from CH 2 and S, provided that at least one of X and Y is CH 2 ;
  • R 2 and R 3 are independently selected from hydrogen, methyl, fluorine, and chlorine;
  • R 5 is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O-R 7 , NR 8 R 9 , C C 8 alkyl, or monocyclic heterocycloalkyl group
  • R 6 is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkenyl, O-R 7 , C(O)R 7 , NR 8 R 9 , C 2 -C 8 alkyl, or monocyclic heterocycloalkyl group
  • R 7 is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl
  • R 8 is hydrogen or a substituted or unsubstituted alkyl
  • R 9 is a substituted or unsubstituted alkyl, aryl, heteroaryl, cycloalkyl, or heterocyclo
  • X is selected from CH 2 , O, and S;
  • Y is selected from CH, and S, provided that at least one of X and Y is CH 2 ;
  • R 2 and R 3 are independently selected from hydrogen, methyl, fluorine, and chlorine;
  • R 5 and R 6 are each independently a substituted or unsubstituted aryl or heteroaryl; and R 10 is a substituted or unsubstituted alkenyl, aryl, heteroaryl, or NHR 9 , where R 9 is a substituted or unsubstituted alkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl.
  • the present invention is directed to compounds represented by the Formula JJJ:
  • X is selected from CH 2 , O, S, and NH;
  • Y is selected from CH 2 , O, and S, provided that at least one of X and Y is CH 2 , or X and Y together with the bond there-between form a cyclopropyl;
  • R 2 and R 3 are independently selected from hydrogen, methyl, halogen, trifluoromethyl, and cyano; and
  • R 4 is
  • R 5 is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O-R 7 , NR 8 R 9 , -C 8 alkyl, or monocyclic heterocycloalkyl group
  • R 6 is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkenyl, O-R 7 , C(O)R 7 , NR S R 9 , C 2 -C 8 alkyl, or monocyclic heterocycloalkyl group, where R 7 is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, R 8 is hydrogen or a substituted or unsubstituted alkyl, and R 9 is a substituted or unsubstituted alkyl, aryl, heteroaryl, cycloalkyl, or heterocyclo
  • X is selected from CH 2 , O, and S;
  • Y is selected from CH, and S, provided that at least one of X and Y is CH 2 ; R 2 and R 3 are independently selected from hydrogen, methyl, fluorine, and chlorine; and
  • R 5 and R 6 are each independently a substituted or unsubstituted aryl or heteroaryl.
  • R and R 6 are each independently a substituted or unsubstituted aryl or heteroaryl.
  • the invention also relates to a method of modulating and/or inhibiting the kinase activity of VEGF-R, FGF-R, a CDK complex, CHK-1, TEK, and/or LCK by administering a compound of the Formula I, II, or III, or a pharmaceutically acceptable prodrug, pharmaceutically active metabolites, or pharmaceutically acceptable salt thereof.
  • compounds of the present invention have selective kinase activity — i.e., they possess significant activity against one specific kinase while possessing less or minimal activity against a different kinase.
  • compounds of the present invention are those of Formula I, IT, or IJJ, possessing substantially higher potency against VEGF receptor tyrosine kinase than against LCK receptor tyrosine kinase.
  • the invention is also directed to methods of modulating VEGF receptor tyrosine kinase activity without significantly modulating LCK receptor tyrosine kinase activity.
  • the invention also relates to pharmaceutical compositions each comprising: an effective amount of an agent selected from compounds of the Formula I, U, and III, and pharmaceutically acceptable salts, pharmaceutically active metabolites, and pharmaceutically acceptable prodrugs thereof; and a pharmaceutically acceptable carrier or vehicle for such agent.
  • the invention further provides methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, comprising administering effective amounts of such agents to a patient in need of such treatment.
  • inventive compounds of the Formula I, IT, and in are useful for mediating the activity of protein kinases. More particularly, the compounds are useful as anti- angiogenesis agents and as agents for modulating and/or inhibiting the activity of protein kinases, thus providing treatments for cancer or other diseases associated with cellular proliferation mediated by protein kinases.
  • alkyl refers to straight- and branched-chain alkyl groups having one to twelve carbon atoms.
  • exemplary alkyl groups include methyl (Me), ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and the like.
  • alkenyl refers to straight- and branched-chain alkenyl groups having from two to twelve carbon atoms.
  • Illustrative alkenyl groups include prop-2-enyl, but-2-enyl, but-3-enyl, 2-methylprop- 2-enyl, hex-2-enyl, and the like.
  • cycloalkyl refers to saturated or unsaturated carbocycles having from three to twelve carbon atoms, including bicyclic and tricyclic cycloalkyl structures. Suitable cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.
  • heterocycloalkyl is intended to mean a saturated or unsaturated monocyclic radical containing carbon atoms, preferably 4 or 5 ring carbon atoms, and at least one heteroatom selected from nitrogen, oxygen and sulfur.
  • aryl (Ar) and “heteroaryl” refer to monocyclic and polycyclic unsaturated or aromatic ring structures, with “aryl” referring to those that are carbocycles and “heteroaryl” referring to those that are heterocycles.
  • aromatic ring structures include phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, furyl, thienyl, pyrrolyl, pyridyl, pyridinyl, pyrazolyl, imidazolyl, pyrazinyl, pyridazinyl, 1,2,3-triazinyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, l-H-tetrazol-5-yl, indolyl, quinolinyl, benzofuranyl, benzothiophenyl (thianaphthenyl), and the like.
  • Such moieties may be optionally substituted by one or more suitable substituents, for example, a substituent selected from a halogen (F, CI, Br or I); lower alkyl; OH; NO 2 ; CN; CO 2 H; O-lower alkyl; aryl; aryl-lower alkyl; CO 2 CH 3 ; CONH 2 ; OCH 2 CONH 2 ; NH 2 ; SO 2 NH 2 ; OCHF 2 ; CF 3 ; OCF 3 ; and the like.
  • Such moieties may also be optionally substituted by a fused-ring structure or bridge, for example OCH 2 -O.
  • alkoxy is intended to mean the radical -O-alkyl. Illustrative examples include methoxy, ethoxy, propoxy, and the like.
  • halogen represents chlorine, fluorine, bromine or iodine.
  • halo represents chloro, fluoro, bromo or iodo.
  • the various moieties or functional groups for variables in the formulae may be optionally substituted by one or more suitable substituents.
  • substituents include a halogen (F, CI, Br, or I), lower alkyl, -OH, -NO 2 , - CN, -CO 2 H, -O-lower alkyl, -aryl, -aryl-lower alkyl, -CO 2 CH 3 , -CONH 2 , -
  • haloalkyl e.g., -CF 3 , -CH 2 CF 3
  • -O-haloalkyl e.g., - OCF 3 , -OCHF 2
  • inventive compounds may exist as single stereoisomers (i.e., essentially free of other stereoisomers), racemates, and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates and mixtures thereof are intended to be within the scope of the present invention.
  • inventive compounds that are optically active are used in optically pure form.
  • an optically pure compound having one chiral center is one that consists essentially of one of the two possible enantiomers (i.e., is enantiomerically pure), and an optically pure compound having more than one chiral center is one that is both diastereomerically pure and enantiomerically pure.
  • the compounds of the present invention are used in a form that is at least 90% optically pure, that is, a form that contains at least 90% of a single isomer (80% enantiomeric excess ("e.e.") or diastereomeric excess (“d.e.”)), more preferably at least 95% (90% e.e. or d.e.), even more preferably at least 97.5% (95% e.e. or d.e.), and most preferably at least 99%
  • Formulas are intended to cover solvated as well as unsolvated forms of the identified structures.
  • Formula I includes compounds of the indicated structure in both hydrated and non-hydrated forms.
  • Other examples of solvates include the structures in combination with isopropanol, ethanol, methanol,
  • the invention includes pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts of such compounds. Pharmaceutically active salts of such active metabolites are also included.
  • pharmaceutically acceptable means pharmacologically acceptable and substantially non-toxic to the subject being administered the cell-cycle control agent.
  • a pharmaceutically acceptable prodrug is a compound that may be converted under physiological conditions or by solvolysis to the specified compound or to a pharmaceutically acceptable salt of such compound.
  • a pharmaceutically active metabolite is intended to mean a pharmacologically active product produced through metabolism in the body of a specified compound or salt thereof. Metabolites of a compound may be identified using routine techniques known in the art and their activities determined using tests such as those described herein.
  • Prodrugs and active metabolites of a compound may be identified using routine techniques known in the art. See, e.g., Bertolini et al., J. Med. Chem., 40, 2011-2016 (1997); Shan, et al., J. Pharm. Sci., 86 (7), 765-767; Bagshawe, Drug Dev. Res., 34,
  • a pharmaceutically acceptable salt is intended to mean a salt that retains the biological effectiveness of the free acids and bases of the specified compound and that is not biologically or otherwise undesirable.
  • a compound of the invention may possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
  • Exemplary pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with a mineral or organic acid or an inorganic base, such as salts including sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4- dioates, hexyne-l,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates
  • the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyrovic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydrozy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid, or the like.
  • an inorganic acid such as hydrochloric
  • the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like.
  • suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
  • agents that are solids it is understood by those skilled in the art that the inventive compounds and salts may exist in different crystal or polymorphic forms, all of which are intended to be within the scope of the present invention and specified formulas.
  • Therapeutically effective amounts of the agents of the invention may be used to treat diseases mediated by modulation or regulation of protein kinases.
  • An "effective amount" is intended to mean that amount of an agent that, when administered to a mammal in need of such treatment, is sufficient to effect treatment for a disease mediated by the activity of one or more protein kinases, such as tyrosine kinases.
  • a therapeutically effective amount of a compound of the Formula I, salt, active metabolite or prodrug thereof is a quantity sufficient to modulate, regulate, or inhibit the activity of one or more protein kinases such that a disease condition which is mediated by that activity is reduced or alleviated.
  • the amount of a given agent that will correspond to such an amount will vary depending upon factors such as the particular compound, disease condition and its severity, the identity (e.g., weight) of the mammal in need of treatment, but can nevertheless be routinely determined by one skilled in the art.
  • Treating is intended to mean at least the mitigation of a disease condition in a mammal, such as a human, that is affected, at least in part, by the activity of one or more protein kinases, such as tyrosine kinases, and includes: preventing the disease condition from occurring in a mammal, particularly when the mammal is found to be predisposed to having the disease condition but has not yet been diagnosed as having it; modulating and/or inhibiting the disease condition; and/or alleviating the disease condition.
  • inventive agents may be prepared using the reaction routes and synthesis schemes as described below, employing the techniques available in the art using starting materials that are readily available.
  • Compounds of formula I where R 4 is CONHR 5 may be prepared as shown in Scheme 1.
  • the coupling may be carried out employing various peptide coupling reagents, for example l-ethyl-3-(3'- dimethylaminopropyl)carbodiimide ' HCl (EDC), O-(7-azabenzotriazol-l-yl)- NNN',N'-tetramethyluronium hexafluorophosphate (HATU), or benzotriazole-1-yl- oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (pyBop), in polar aprotic solvents, such as ⁇ , ⁇ -dimethylforamide (DMF) or dichloromethane.
  • polar aprotic solvents such as ⁇ , ⁇ -dimethylforamide (DMF) or dichloromethane.
  • the coupling may be carried out employing with various peptide coupling reagents, for example EDC, HATU, or pyBOP, in polar aprotic solvents, such as DMF or dichloromethane.
  • Compounds of formula I-a may be prepared by the reaction shown in Scheme 3.
  • R 11 is hydrogen or a suitable carboxylic acid protecting group, such as methyl, ethyl, or benzyl
  • R 11 is hydrogen or a suitable carboxylic acid protecting group, such as methyl, ethyl, or benzyl
  • Compounds of formula I-c may be prepared by the reaction shown in Scheme
  • W is a suitable group that can participate in a palladium-catalyzed coupling reaction such as bromide, iodide, or triflate
  • acetylenes of formula XIII in the presence of a suitable palladium catalyst, such as dichloiObis(triphenylphosphine)palladium, and a copper catalyst, such as cuprous iodide, in the presence of a suitable base, such as piperidine, triethylamine or diisopropylethylamine, in an aprotic solvent, such as THF or DMF, at a temperature between 25 °C and 125 °C, for 1 to 24 hours.
  • a suitable palladium catalyst such as dichloiObis(triphenylphosphine)palladium
  • a copper catalyst such as cuprous iodide
  • a suitable base such as piperidine, triethylamine or diisopropy
  • silyl protecting group is effected with, for example, either tetrabutylammonium fluoride in THF or sodium hydroxide in methanol, to provide compounds of formula XIV.
  • Thioamides of formula XVII are treated with two molar equivalents of a suitable strong base, such as n-butyllithium or Hthium diisopropylamide, in a suitable solvent, such as THF, at -78 °C to 0 °C, to give a solution of thioamide dianion, which is further treated with less than or equal to 0.5 molar equivalents of compounds of formula XVm.
  • aqueous work-up and purification then provides compounds of formula XIX, which upon treatment with hydrazine, preferably in the presence of acetic acid, in ethanol at 0 °C to 50 °C, preferably at room temperature, provides compounds of formula Il-a.
  • Ketones of formula XX where R 12 is substituted or unsubstituted alkenyl, aryl, or heteroaryl, are converted to hydrazones of formula XXI by treatment with t-butyl carbazate and acetic acid in ethanol.
  • Conventional aqueous work-up and purification then provides compounds of formula XXII, which upon further treatment with a suitable acid, such as trifluoroacetic acid, provides compounds of formula fl-b.
  • compounds of formula XVffl-a and XVITI-b are prepared by alkylation of compounds of formula LX with N-methoxy-N-methyl chloroacetamide in a like manner to that shown in Scheme 3 above.
  • Compounds of formula XVlTf-c may be prepared by (1) reaction of aldehydes of formula XXEI with the anion derived from N- methoxy-N-methyl triethylphosphonoacetamide to give unsaturated amides of formula XXrV, and (2) reduction of compounds of formula XXIV with, for example, hydrogen in the presence of palladium on carbon to provide compounds of formula XVHI-C.
  • the affinity of the compounds of the invention for a receptor may be enhanced by providing multiple copies of the ligand in close proximity, preferably using a scaffolding provided by a carrier moiety. It has been shown that provision of such multiple valence compounds with optimal spacing between the moieties dramatically improves binding to a receptor. See e.g., Lee et al., Biochem, 23, 4255 (1984).
  • the multivalency and spacing can be controlled by selection of a suitable carrier moiety or linker units.
  • Such moieties include molecular supports which contain a multiplicity of functional groups that can be reacted with functional groups associated with the compounds of the invention.
  • a variety of carriers can be used, including proteins such as BSA or HAS, a multiplicity of peptides including, for example, pentapeptides, decapeptides, pentadecapeptides, and the like.
  • the peptides or proteins can contain the desired number of amino acid residues having free amino groups in their side chains; however, other functional groups, such as mercapto (-SH) groups or hydroxyl (-OH) groups, can also be used to obtain stable linkages.
  • the present invention is further directed to methods of modulating or inhibiting protein kinase activity, for example in mammalian tissue, by administering an inventive agent.
  • the activity of the inventive compounds as modulators of protein kinase activity, such as the activity of kinases may be measured by any of the methods available to those skilled in the art, including in vivo and/or in vitro assays.
  • Suitable assays for activity measurements include those described in Parast C. et al, BioChemistry, 37, 16788-16801 (1998); Jeffrey et al., Nature, 376, 313-320 (1995); WIPO International Publication No. WO 97/34876; and WJPO International Publication No. WO 96/14843. These properties may be assessed, for example, by using one or more of the biological testing procedures set out in the examples below.
  • compositions of this invention comprise an effective modulating, regulating, or inhibiting amount of a compound of Formula I, U, or m and an inert, pharmaceutically acceptable carrier or diluent.
  • efficacious levels of the inventive agents are provided so as to provide therapeutic benefits involving modulation of protein kinases.
  • efficacious levels is meant levels in which the effects of protein kinases are, at a minimum, regulated.
  • An inventive agent is administered in conventional dosage form prepared by combining a therapeutically effective amount of an agent (e.g., a compound of Formula I) as an active ingredient with appropriate pharmaceutical carriers or diluents according to conventional procedures. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
  • the pharmaceutical carrier employed may be either a solid or liquid. Exemplary of solid carriers are lactose, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like.
  • the carrier or diluent may include time-delay or time-release material known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate and the like.
  • a variety of pharmaceutical forms can be employed.
  • a solid carrier used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge.
  • the amount of solid carrier may vary, but generally will be from about 25 mg to about 1 g.
  • a liquid carrier is used, the preparation will be in the form of syrup, emulsion, soft gelatin capsule, sterile injectable solution or suspension in an ampule or vial or non-aqueous liquid suspension.
  • a pharmaceutically acceptable salt of an inventive agent is dissolved in an aqueous solution of an organic or inorganic acid, such as 0.3M solution of succinic acid or citric acid.
  • the agent may be dissolved in a suitable cosolvent or combinations of cosolvents.
  • suitable cosolvents include, but are not limited to, alcohol, propylene glycol, polyethylene glycol 300, polysorbate 80, gylcerin and the like in concentrations ranging from 0-60% of the total volume.
  • a compound of Formula I is dissolved in DMSO and diluted with water.
  • the composition may also be in the form of a solution of a salt form of the active ingredient in an appropriate aqueous vehicle such as water or isotonic saline or dextrose solution.
  • an exemplary daily dose generally employed is from about 0.001 to about 1000 mg/kg of body weight, more preferably from about 0.001 to about 50 mg/kg body weight, with courses of treatment repeated at appropriate intervals.
  • Administration of prodrugs are typically dosed at weight levels which are chemically equivalent to the weight levels of the fully active form.
  • compositions of the invention may be manufactured in manners generally known for preparing pharmaceutical compositions, e.g., using conventional techniques such as mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing.
  • Pharmaceutical compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers, which may be selected from excipients and auxiliaries that facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • the agents of the invention may be formulated into aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer.
  • physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer.
  • penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers known in the art.
  • Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
  • Pharmaceutical preparations for oral use can be obtained using a solid excipient in admixture with the active ingredient (agent), optionally grinding the resulting mixture, and processing the mixture of granules after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • Suitable excipients include: fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; and cellulose preparations, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or polyvinylpyrrolidone (PVP).
  • PVP polyvinylpyrrolidone
  • disintegrating agents may be added, such as crosslinked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, polyvinyl pyrrolidone, Carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active agents.
  • compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules can contain the active ingredients in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate, and, optionally, stabilizers.
  • the active agents may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. hi addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
  • the compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of gelatin for use in an inhaler or insufflator and the like may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit-dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • compositions for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active agents may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • a compound of the formula I, ⁇ , or HI is delivered in a pharmaceutically acceptable ophthalmic vehicle such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye, including, for example, the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/cilary, lens, choroid/retina and selera.
  • the pharmaceutically acceptable ophthalmic vehicle may be an ointment, vegetable oil, or an encapsulating material.
  • a compound of the invention may also be injected directly into the vitreous and aqueous humor.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • a suitable vehicle e.g., sterile pyrogen-free water
  • the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g, containing conventional suppository bases such as cocoa butter or other glycerides.
  • the compounds may also be formulated as a depot preparation.
  • Such long-acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion-exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • a pharmaceutical carrier for hydrophobic compounds is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase.
  • the cosolvent system may be a VPD co-solvent system.
  • VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol.
  • the VPD co-solvent system (VPD:5W) contains VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics.
  • co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may be substituted for dextrose.
  • hydrophobic pharmaceutical compounds may be employed.
  • Liposomes and emulsions are known examples of delivery vehicles or carriers for hydrophobic drugs.
  • Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity.
  • the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent.
  • sustained-release materials have been established and are known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.
  • compositions also may comprise suitable solid- or gel- phase carriers or excipients.
  • suitable solid- or gel- phase carriers or excipients include calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
  • Some of the compounds of the invention may be provided as salts with pharmaceutically compatible counter ions.
  • Pharmaceutically compatible salts may be formed with many acids, including hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free-base forms.
  • the reactions set forth below were done generally under a positive pressure of argon or nitrogen or with a drying tube, at ambient temperature (unless otherwise stated), in anhydrous solvents, and the reaction flasks were fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven dried and/or heat dried. Analytical thin layer chromatography (TLC) was performed on glass-backed silica gel 60 F 254 plates and eluted with the appropriate solvent ratios (v/v), and are denoted where appropriate. The reactions were assayed by TLC and terminated as judged by the consumption of starting material.
  • TLC thin layer chromatography
  • TLC plates were generally done by ultraviolet visualization. Work-ups were typically done by doubling the reaction volume with the reaction solvent or extraction solvent and then washing with the indicated aqueous solutions using 25% by volume of the extraction volume unless otherwise indicated. Product solutions were dried over anhydrous Na SO prior to filtration and evaporation of the solvents under reduced pressure on a rotary evaporator and noted as solvents removed in vacuo. Products were purified by employing radial chromatography or flash column chromatography (Still et al., J. Org.
  • NMR spectra were recorded operating at 75 MHz. NMR spectra were obtained as CDC1 3 solutions (reported in ppm), using chloroform as the reference standard (7.25 ppm and 77.00 ppm) or CD 3 OD (3.4 and 4.8 ppm and 49.3 ppm), or internally tetramethylsilane (0.00 ppm) when appropriate. Other NMR solvents were used as needed. When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), q (quartet), br (broadened), dd (doublet of doublets), dt (doublet of triplets). Coupling constants, when given, are reported in Hertz (Hz).
  • IR Infrared
  • HPLC conditions are the following: Hewlett Packard ODS Hypersil (5 ⁇ m, 125 x 4 mm), 10% acetonitrile/0.1 M ammonium acetate from 0-2 minutes to 90% acetonitrile/0.1 M ammonium acetate at 22 minutes, 1.0 mL/minute, detection at 254 nm.
  • Abbreviations for reagents, equipment, and techniques are defined as follows:
  • MTBE methyl t-butyl ether
  • DMSO dimethylsulfoxide
  • DIEA diisopropylethylamine
  • TEA triethylamine
  • AcOH acetic acid
  • DMAP dimethylamino
  • EDC l-ethyl-3-(3'- dimethylaminopropyl)carbodiimide ' HCl
  • HATU O-(7-azabenzotriazol- 1 -yl)- NNN',N'-tetramethyluiOnium hexafluorophosphate
  • HOBt ⁇ - hydroxybenzotriazole
  • PyB op benzotriazole- 1 -yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate
  • MS (ESI) Electrononization mass spectrometry
  • MS (FAB) fast atom bombardment mass spectrometry
  • Example A-l ⁇ -(3,4,5-Trimethoxyphenyl)-3-[(pyrazin-2-yl)suIfanylmethyI]- benzamide
  • Example A-3 N-(4-Isopropyl-3-methylphenyl)-3-[(pyrazin-2-yl)sulfanylmethyl]- benzamide
  • Example A-4 N-(4-Isopropyl-3-methylphenyl)-3-[(5-amino-2H-[l,2,4]triazol-3- yl)sulfanylmethyl]benzamide
  • Example A-4 was prepared in a similar manner to that described for A-1, except that 3- methyl-4-isopropylaniline was used in place of 3, 4,5-trimethoxy aniline in step (a), and 3-amino-5-mercapto-l,2,4-triazole was used in place of 2-pyrazinethiol in step (b):
  • Example A-6 was prepared in a similar manner to that described for A-1, except that 6- amino-2-methylquinoline (Lancaster) was used in place of 3,4,5-trimethoxyaniline in step (a): mp 133-135 °C; 1H NMR (DMSO-d 6 ) ⁇ 10.51 (s, IH), 8.63 (s, IH), 8.53 (t,
  • Example A-8 N-(3,5-Dibromo-4-methylphenyl)-3-[(pyrazm-2-yl)sulfanyl- methyljbenzamide
  • Example B-3 N-(Quinolin-6-yl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4-yl)sulfanyl- methyl]benzamide
  • Example B-5 N-(Pyridin-4-yl)methyl-3-[(lH-pyrazolo[3,4-d]pyrimidin-4-yl)- sulfanylmethyl]benzamide
  • Example B-6 N-(l,3-Benzodioxyl-5-yImethyI)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4- yl)sulfanylmethyl]benzamide
  • Example B-7 N-(2-Methoxybenzyl)-3-
  • Example B-7 was prepared in a similar manner to that described for B-l, except that 2- methoxybenzylamine was used in place of 3,4,5-trimethoxyaniline:
  • Example B-8 N-(2-Phenylethyl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4-yl)sulfanyl- methyljbenzamide
  • Example B-9 N-(2-Methoxyphenyl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4-yl)- sul anylmethyl]benzamide
  • Example B-10 N-[3-(N-Meth
  • Example B-12 N-[4-cyano-3-(trifluoromethyl)
  • Example B-13 N-(3,3-Diphenylpropyl)-3- ⁇ [(5-methyl-lH-l,2.4-triazol-3-yl)- sulfanyl]methyl ⁇ benzamide
  • Example B-13 was prepared in a similar manner to that described for B-l, except that 3,3-diphenyl-l-propylamine was used in place of 3,4,5-trimethoxyaniline, and 3- mercapto-5-methyl-lH-l,2,4-triazole was used in place of 4-mercapto-lH- pyrazolo[3,4-d]pyrimidine: ⁇ NMR (300 MHz, CD 3 OD) ⁇ 7.74 (s, IH), 7.62 (d, IH, J
  • Example B-14 3- ⁇ [(5-Methyl-lH-l,2,4-triazol-3-yl)-sulfonyl]methyl ⁇ -N-phen- ethylbenzamide
  • Example B-15 3-[(lH-Pyrazolo[3,4-
  • Example B-16 3-[(lH-P
  • Example B-17 3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3,5-bis- trifluoromethylphenyl)-benzamide
  • Example B-18 3-[(lH-PyrazoIo[3,4-d]pyrimidin-4-yl)suIfanyImethyl]-N(3-t- butylphenyl)-benzamide
  • Example B-20 was prepared in a similar manner to that described for B-l, except that
  • Example B-22 3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyI]-N(3
  • Example B-24 3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-
  • Example B-26 Example B-26:
  • Example B-26 Using the general procedure described above in Example B-26, the following compounds were made (wherein for convenience, and as understood in the art, not all hydrogen atoms have been expressly indicated as bonding to each carbon and/or nitrogen atom).
  • Example C-1 3-[(5-Cyanoamino-2H-[l,2,4]triazoI-3-yI)suIfanyImethyI]-N-(3,4,5- trimethoxyphenyl)benzamide
  • the aqueous layer was extracted twice with ethyl acetate (30 mL) and the combined organics were washed twice with water (20 mL), once with brine(25 mL), dried over sodium sulfate, and concentrated to dryness.
  • Example D-3 N-(2-Methyl-quinolin-6-yl)-3-(pyridin-3-ylmethylsulfanyl)- benzamide dihydrochloride
  • Example E-2 was prepared in a similar manner to that described for E-l, except that 3,4,5-trimethoxyaniline was used in place of 6-amino-2-methylquinoline in step (b): mp 67-69 °C.
  • HRMS (FAB): Calculated for C 26 H 26 N 4 O 4 S (M+H + ): 491.1753 Found: 491.1737.
  • Example F-2 was prepared in a similar manner to that described for F-1, except that acetophenone was used in place of 4-(4-hydroxy-3-methoxy-phenyl)-but-3-en-2-one in step (a), and the protection/deprotection steps (b) and (e) were not needed: mp 99-101
  • Example F-4 4-Fluoro-3-[ ⁇ 5-((E)-l-propenyI)-2H-pyrazol-3-yl ⁇ methoxy]-N-[4- (pyrrolidin-l-yl)-3-trifluoromethylphenyl]benzamide
  • Example F-4 was prepared in a similar manner to that described for F-1, except that (E)-3-penten-2-one was used in place of (E)-4-(4-hydroxy-3-methoxyphenyl)-but-3- en-2-one in step (a), 4-fluoro-N-[4-(pyrrolidin-l-yl)-3-trifluoromethylphenyl]-3-[2-(N- methoxy-N-methylcarbamoyl)methoxy]benzamide, (prepared in a similar manner as described for 4-fluoro-N-[4-(imidazol-l-yl)-3-trifluoromethyl-phenyl]-3-[(N-methoxy- N-methylcarbamoyl)methoxy]benzamide, J-ld, in Example J-1) was used in place of 3-[(N-methoxy-N-methylcarbamoyl)methylsulfanyl]-N-(2-methylquinolin-6- yl)benz
  • Example F-5 was prepared in a similar manner to that described for F-3, except that (E)-4-(pyridin-3-yl)-3-buten-2-one was used in place of (E)-4-(3,4-dimethoxyphenyl)- but-3-en-2-one in step (a), and 4-[4-(t-butoxycarbonyl)piperazin-l-yl]-3- trifluoromethylaniline, prepared according to the procedure described in WO 99/21845 (p.
  • Example G-2 N-(2-Methylquinolin-6-yl)-3-[2-(5-phenylamino-2H-pyrazol-3- yl)ethyl]benzamide.
  • G-2 Example G-2 was made in a similar manner to that described for G-1, except that 6- amino-2-methylquinoline was used in place of 4-isopropyl-3-methylaniline in step (d), and thioacetanilide was used instead of 4-[N-(diphenylmethyl)-N- methylsulfamoyl]thioacetanilide, G-lc, in step (g), and the final deprotection step (i) was not needed: mp 98-102 °C. !
  • Example G-4 was made in a similar manner to that described for G-1, except that N-(6- methoxy-pyridin-3-yl)acetamide was used instead of N-(diphenylmethyl)-N-methyl-4- (acetylamino)-benzenesulfonamide, G-lb, in step (c).
  • Example G-6 N-(6-Dimethylamino-5-trifluoromethylpyridin-3-yl)-3- ⁇ 2-[5-(6 methoxypyridin-3-yl)amino-2H-pyrazol-3-yl]ethyl ⁇ -benzamide
  • Example G-9 3- ⁇ 2-[5-(6-Methoxypyridin-3-yl)amino-2H-pyrazol-3-yl]-ethyl ⁇ -N- [4-(4- ⁇ -butoxycarbonylpiperazin-l-yl)-3-trifluoromethyIphenyl]benzamide
  • Example G-9 was made in a similar manner to that described for G-1, except that 4- [4- (t-butoxycarbonyl)piperazin-l-yl]-3-trifluoromethylaniline, prepared according to the procedure described in WO 99/21845 (p.
  • N-(4-Isopropyl-3-methyl-phenyl)-3-[2-(N-methoxy-N-methyl-carbamoyl)- cyclopropyl] -benzamide was prepared as follows: To a solution of trimethylsulfoxonium iodide (0.46 g, 2.01 mmol) in 10 mL of DMSO was added sodium hydride (0.08 g, 2.01 mmol, 60% oil dispersion) at -10 °C.
  • Example 1-1 3-[( ⁇ 3-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl] -lH-pyrazoI-5- yl ⁇ methyl)amino]-N-(3-methyl-4-isopropylphenyl)benzamide
  • Vanillin (9.12 g, 0.06 mole) was dissolved in 36 mL of acetone and 12.5 mL of 50% aq. NaOH solution was added dropwise with vigorous stirring. To the resulting solid was added 25 mL of water and the dark red solution was refluxed for 5 min. This reaction mixture was kept at room temperature for 24 h and acidified with acetic acid.
  • Example 1-2 3-[( ⁇ 5-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-LBT-pyrazol-3- yl ⁇ methyl)amino]-N-phenylbenzamide
  • Example J-1 4-Fluoro-N-[4-(imidazol-l-yl)-3-trifluoromethylphenyl]-3-[5-(6- methoxypyridin-3-yl)amino-2H-pyrazol-3-ylmethoxy]-benzamide
  • Example J-2 4-Fluoro-3-[5-(6-methoxy-pyridin-3-yl)amino-2H-pyrazol-3- yl]methoxy-N-(4-pyrrolidin-l-yl-3-trifluoromethyl-phenyl)-benzamide
  • Example K-2 3-(Isoquinolin-4-yl)methoxy-N-(3,4,5-trimethoxyphenyl)benzamide hydrochloride
  • Example K-2 was prepared in a similar manner to that described for K-l, except that 3,4,5-trimethoxyaniline (Aldrich) was used in place of 3-methyl-4-isopropylaniline in step (d).
  • the product was isolated as the hydrochloride salt as follows. A solution of 3-(isoquinolin-4-yl)methoxy-N-(3,4,5-trimethoxyphenyl)benzamide (116 mg, 0.26 25 mmol) in ethanol was treated with concentrated hydrochloric acid (0.1 mL, 1.2 mmol).
  • Example K-4 3-(Isoquinolin-4-yl)methoxy-N-(2-methyl-4-methylsulfanyl- quinolin-6-yl)-benzamide hydrochloride
  • Example K-5 which was obtained as a white solid in a 62% yield, was prepared in a similar manner to that described for K-l, except that 3,4,5-trimethoxyaniline was used in place of 3-methyl-4-isopropylaniline in step (d), and 3-picolyl chloride hydrochloride was used in place of 4-(chloromethyl)isoquinoline hydrochloride, K-lc, in step (e):
  • Example K-12 N-(4-Isopropyl-3-methyI-phenyl)-4-chloro-3-(Isoquinolin-4- yl)methoxy-benzamide
  • reaction mixture was poured into water (500 mL) and extracted with ethyl acetate (3 x 500 mL). The combined organic extracts were washed with brine (200 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a yellow solid (2.3 g).
  • Example N-2 3-(6-Acetylaminopyridin-3-yl)methoxy-N-(4-Isopropyl-3-methyl- phenyl)-benzamide
  • Example O-3 4-Fluoro-N-(2-methyl-l,2,3,4-tetrahydroquinolin-6-yl)-3-(iso- quinolin-4-yI-methoxy)-benzamide bistrifluoroacetic acid salt
  • Example O-3 was prepared in a similar manner to that described for O-l, except that
  • Example R-2 was prepared in a similar manner to that described for R-l, except that 3,5-dibromo-4-methylaniline was used in place of 3,5-diallyl-4-bromoaniline in step (c):
  • 1H NMR 300 MHz, DMSO- ) ⁇ 10.36 (s, IH), 9.36 (s, IH), 8.69 (s, IH), 8.20 (m, IH), 8.14 (s, 2H), 7.89 (m, IH), 7.76 (m, IH), 7.68 (m, IH), 7.58 (m, IH), 7.51 (m, IH), 7.38 (m, IH), 5.65 (s, 2H), 2.48 (s, 3H).
  • Example R-3 was prepared in a similar manner to that described for R-l, except that 2- amino-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene was used in place of 3,5- diallyl-4-bromoaniline in step (c):
  • the intermediate 2-amino-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene was prepared by reduction of 2-nitro-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene (Kagechika, H. et al., J. Med. Chem., 31, 2182-2192 (1998)) in a similar manner to that described in step (b) of Example J-1.
  • Example R-4 was prepared in a similar manner to that described for R-l, except that 3- (trifluoromethoxy)aniline was used in place of 3,5-diallyl-4-bromoaniline in step (c):
  • 1H NMR 300 MHz, CDC1 3 ) ⁇ 9.22 (s, IH), 8.55 (s, IH), ) 7.99 (m, 2H), 7.73 ( m, 2H), 7.65 (m, IH), 7.60 (m, IH), 7.54 (m, IH), 7.47 (m, IH), 7.27-7.40 (m, 2H), 7.18 (m, IH), 6.99 (m, IH), 5.41 (s, 2H).
  • MS (ESI) m/z 439 [M + H] + .
  • Example R-2 was prepared in a similar manner to that described for R-l, except that phenylhydrazine was used in place of 3,5-diallyl-4-bromoaniline in step (c): ! H NMR (300 MHz, CDC1 3 ) ⁇ 9.28 (s, IH), 8.62 (s, IH), ), 8.06 (s, IH), 8.04 (s, IH), 7.94 (m, IH), 7.78 (m, IH), 7.67 (m, IH), 7.59 (m, IH), 7.44 (m, 2H), 7.25 (m, 3H), 6.93 (m, 3H), 6.38 (m, IH), 5.50 (s, 2H).
  • Example R-9 was prepared in a similar manner to that described for R-l, except that 2- amino-5,7-dimethyl[l,8]naphthydrine was used in place of 3,5-diallyl-4-bromoaniline in step (c):
  • Example R-10 3-(Isoquinolin-4-yImethoxy)-N-(l,l,3,3-tetramethyI-l,3- dihydroisoben ⁇ ofuran-5-yl)-ben ⁇ amide
  • Example R-15 4-Fluoro-N-(4-pipera ⁇ in-l-yl-3-trifluoromethyl-phenyl)-3- (isoquinolin-4-ylmethoxy)-benzamide
  • Example R-20 4-Fluoro-N-[4-(piperazm-l-yl)-3-trifluoromethylphenyI]-3- (pyridm-3-yl)methoxybenzamide
  • Example R-22 4-Fluoro-N-(4-pyrazol-l-yl-3-trifluoromethyl-phenyl)-3-(pyridin- 3-ylmethoxy)-benzamide
  • Example R-23 was prepared in a similar manner to that described for R-l, except that
  • Example S-7 was prepared in a similar manner to that described for S-l, except that ethyl 2-chloro-4-fluoro-5-bromobenzoate was used in place of ethyl 3-iodobenzoate in step (c), and 4-isopropyl-3-methylaniline was used in place of aniline in step (f):
  • Example S-8 was prepared in a similar manner to that described for S-l, except that methyl 2,4-difluoro-5-bromobenzoate was used in place of ethyl 3-iodobenzoate in step (c), and 4-isopropyl-3-methylaniline was used in place of aniline in step (f):
  • Example V-2 ⁇ - ⁇ 3-[(lH-pyrazolo[3,4-d]-pyrimidin-4-ylsulfanylmethyl]phenyl ⁇ - 3,5-bis(trifluoromethyl)benzamide
  • Example V-2 was prepared in a similar manner to that described for V-l, except that
  • step (a) 3,5-bis(trifluoromethyl)benzoic acid was used in place of 3-bromo-4-methylbenzoic acid in step (a): ⁇ NMR (300 MHz, DMSO-d 6 ) ⁇ 14.05 (s, IH), 10.60 (s, IH), 8.73
  • Example V-3 was prepared in a similar manner to that described for V-l, except that 4- hydroxy-3-methoxybenzoic acid was used in place of 3-bromo-4-methylbenzoic acid in step (a): 1H NMR (300 MHz, DMSO-_i 6 ) ⁇ 14.05 (s, IH), 9.93 (s, IH), 9.63 (s, IH),
  • Example V-4 was prepared in a similar manner to that described for V-l, except that 3- t-butyl-4-hydroxybenzoic acid was used in place of 3-bromo-4-methylbenzoic acid in step (a):
  • Example V-6 N- ⁇ 3-[(lH-pyrazolo[3,4-rf]-pyrimidin-4
  • 0.1 M solutions of different acids, an amine template, HATU, and triethylamine were prepared in anhydrous DMF.
  • 105 ⁇ L (0.0105) of a different acid was added 100 ⁇ L (0.01 mmol) of the amine solution, 105 ⁇ L (0.0105 mmol) of the triethylamine solution followed by 105 ⁇ L (0.0105 mmol) of the ⁇ -(7-azabenzotriazol-l-yl)-
  • Example V-6d Using the general procedure described in Example V-6c above, the following compounds were made:
  • Example V-7 N- ⁇ 3 (lH yrazoIo[3,4- ⁇ pyrimidin-4-ylsuIfanyl)methy ⁇ ]phenyl ⁇ - N 3,5 >is-(trifluoromethyl)phenyl]urea
  • Example V-8 N- ⁇ 3-[(lH-pyrazolo[3,4-d]pyrimidin-4-ylsulfanyl)methyl]phenyl ⁇ - N'-(pyridin-3-yl)urea
  • Example V-10 was prepared in a manner similar to that described in Example V-6, except that 3-bromo-4-hydroxybenzoic acid was used in place of 4-phenoxybenzoic acid in step (b): 1H ⁇ MR (300 MHz, DMSO- ) ⁇ 10.07 (s, IH), 8.79 (s, IH), 8.30 (s,
  • Example V-12 5-Fluoro-N- ⁇ 3-[(lH-pyrazolo[3,4-df]-pyrimidin-4-yl)suIfanyl- methyl]phenyl ⁇ -indole-2-carboxamide
  • Example V-14 The following compounds were made using the general procedure described above in Example V-6c, except for the use of different acids and amines, which yielded the products indicated below (wherein for convenience, and as understood in the art, not all hydrogen atoms have been expressly indicated for each carbon and/or nitrogen atom).
  • Example W-l 3- -Butyl-4-hydroxy-N- ⁇ 3-[5-(6-methoxy-pyridin-3-yIamino)-2 H- pyrazol-3-ylmethylsulfanyl]-phenyl ⁇ -benzamide.
  • reaction mixture was treated with 5% sodium bicarbonate (100 mL) and extracted with 10% isopropanol/chloroform (3 x 50 mL). The combined organic extracts were washed with brine (50 mL), dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give an off- white solid (569 mg).
  • Example X-2 4-Acetoxy-3- ⁇ -butyl-N-[3-(pyridin-3-yImethoxy)phenyl]-ben ⁇ amide
  • Example X-3 4-Acetoxy-3-t-butyl-N-[3-(isoquinolin-4-ylmethoxy)phenyl]-benz- amide
  • step (a) To a solution of 0.30 g (1.33 mmol) of 3-(chloromethyl)- ⁇ -phenylbenzamide, Z- la, which prepared in a manner similar to that described in Example A-1, step (a), in 6 mL of ethanol was added 0.20 g (2.65 mmol) of thiourea, and the mixture was heated to 80 °C. After 3 h, 1.0 mL (3 mmol) of 2N aq. sodium hydroxide was added, and heating at 80 °C was continued. After an additional 2.5 h, the reaction was cooled to room temperature and 10 mL of water was added. The mixture was extracted with ethyl acetate, and the aqueous layer was neutralized with IN aq.

Abstract

Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Description

AMIDE COMPOUNDS
FOR INHIBITING PROTEIN KINASES
This applications claims the benefit of U.S. Provisional Application Serial No.
60/177,059, filed January 21, 2000, the contents of which are hereby incorporated by reference herein.
FIELD OF THE INVENTION This invention is directed to amide compounds that mediate and/or inhibit the activity of certain protein kinases, and to pharmaceutical compositions containing such compounds. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amounts of such compounds. BACKGROUND OF THE INVENTION
Protein kinases are a family of enzymes that catalyze phosphorylation of the hydroxyl group of specific tyrosine, serine, or threonine residues in proteins. Typically, such phosphorylation dramatically perturbs the function of the protein, and thus protein kinases are pivotal in the regulation of a wide variety of cellular processes, including metabolisim, cell proliferation, cell differentiation, and cell survival. Of the many different cellular functions in which the activity of protein kinases is known to be required, some processes represent attractive targets for therapeutic intervention for certain disease states. Two examples are angiogenesis and cell-cycle control, in which protein kinases play a pivotal role; these processes are essential for the growth of solid tumors as well as for other diseases.
Angiogenesis is the mechanism by which new capillaries are formed from existing vessels. When required, the vascular system has the potential to generate new capillary networks in order to maintain the proper functioning of tissues and organs. In the adult, however, angiogenesis is fairly limited, occurring only in the process of wound healing and neovascularization of the endometrium during menstruation. See Merenmies, J., Parada, L. F., Henkemeyer, M., Cell Growth & Differentiation, 8, 3-10 (1997). On the other hand, unwanted angiogenesis is a hallmark of several diseases, such as retinopathies, psoriasis, rheumatoid arthritis, age-related macular degeneneration, and cancer (sohd tumors). Folkman, Nature Med., 1, 27-31 (1995). Protein kinases which have been shown to be involved in the angiogenic process include three members of the growth factor receptor tyrosine kinase family: VEGF-R2 (vascular endothelial growth factor receptor 2, also known as KDR (kinase insert domain receptor) and as FLK-1); FGF-R (fibroblast growth factor receptor); and TEK (also known as Tie-2).
VEGF-R2, which is selectively expressed on endothelial cells, binds the potent angiogenic growth factor VEGF and mediates the subsequent signal transduction through activation of its intracellular kinase activity. Thus, it is expected that direct inhibition of the kinase activity of VEGF-R2 will result in the reduction of angiogenesis even in the presence of exogenous VEGF (see Strawn et al., Cancer Research, 56, 3540-3545 (1996)), as has been shown with mutants of VEGF-R2 which fail to mediate signal transduction. Millauer et al., Cancer Research, 56, 1615-1620 (1996). Furthermore, VEGF-R2 appears to have no function in the adult beyond that of mediating the angiogenic activity of VEGF. Therefore, a selective inhibitor of the kinase activity of VEGF-R2 would be expected to exhibit little toxicity.
Similarly, FGF-R binds the angiogenic growth factors aFGF and bFGF and mediates subsequent intracellular signal transduction. Recently, it has been suggested that growth factors such as bFGF may play a critical role in inducing angiogenesis in solid tumors that have reached a certain size. Yoshiji et al., Cancer Research, 57, 3924-3928 (1997). Unlike VEGF-R2, however, FGF-R is expressed in a number of different cell types throughout the body and may or may not play important roles in other normal physiological processes in the adult. Nonetheless, systemic administration of a small molecule inhibitor of the kinase activity of FGF-R has been reported to block bFGF-induced angiogenesis in mice without apparent toxicity. Mohammad et al., EMBO Journal, 17, 5996-5904 (1998).
TEK (also known as Tie-2) is another receptor tyrosine kinase selectively expressed on endothelial cells which has been shown to play a role in angiogenesis. The binding of the factor angiopoietin-1 results in autophosphorylation of the kinase domain of TEK and results in a signal transduction process which appears to mediate the interaction of endothelial cells with peri-endothelial support cells, thereby facilitating the maturation of newly formed blood vessels. The factor angiopoietin-2, on the other hand, appears to antagonize the action of angiopoietin-1 on TEK and disrupts angiogenesis. Maisonpierre et al., Science, 211, 55-60 (1997). As a result of the above-described developments, it has been proposed to treat angiogenesis by the use of compounds inhibiting the kinase activity of VEGF-R2, FGF-R, and/or TEK. For example, WIPO International Publication No. WO 97/34876 discloses certain cinnoline derivatives that are inhibitors of VEGF-R2, which may be used for the treatment of disease states associated with abnormal angiogenesis and/or increased vascular permeability such as cancer, diabetes, psoriosis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restinosis, autoimmune diseases, acute inflammation and ocular diseases with retinal vessel proliferation. Two documents described hereinafter disclose certain amide derivatives but do not disclose or teach that any of the compounds may be used for modulating or inhibiting the activity of protein kinases: WIPO international Publication No. WO 97/03967; and WIPO International Publication No. WO 96/23783.
In addition to its role in angiogenesis, protein kinases also play a crucial role in cell-cycle control. Uncontrolled cell proliferation is the insignia of cancer. Cell proliferation in response to various stimuli is manifested by a de-regulation of the cell division cycle, the process by which cells multiply and divide. Tumor cells typically have damage to the genes that directly or indirectly regulate progression through the cell division cycle.
Cyclin-dependent kinases (CDKs) are serine-threonine protein kinases that play critical roles in regulating the transitions between different phases of the cell-cycle, such as the progression from a quiescent stage in Gj (the gap between mitosis and the onset of DNA replication for a new round of cell division) to S (the period of active DNA synthesis), or the progression from G2 to M phase, in which active mitosis and cell-division occurs. See, e.g., the articles compiled in Science, 274, 1643-1677 (1996). CDK complexes are formed through association of a regulatory cyclin subunit (e.g., cyclin A, Bl, B2, DI, D2, D3, and E) and a catalytic kinase subunit (e.g., cdc2 (CDK1), CDK2, CDK4, CDK5, and CDK6). As the name implies, the CDKs display an absolute dependence on the cyclin subunit in order to phosphorylate their target substrates, and different kinase/cyclin pairs function to regulate progression through specific phases of the cell-cycle. It is CDK4 complexed to the D cyclins that plays a critical part in initiating the cell-division cycle from a resting or quiescent stage to one in which cells become committed to cell division. This progression is subject to a variety of growth regulatory mechanisms, both negative and positive. Aberrations in this control system, particularly those that affect the function of CDK4, have been implicated in the advancement of cells to the highly proliferative state characteristic of malignancies, particularly familial melanomas, esophageal carcinomas, and pancreatic cancers. See, e.g., Hall et al., Adv. Cancer Res., 68, 67-108 (1996); Kamb, Trends in Genetics, 11, 136-140 (1995); Kamb et al., Science, 264, 436-440 (1994).
A large number of small molecule ATP-site antagonists have been identified as CDK inhibitors. (See, Webster, Exp. Opin. Invest. Drugs, 7, 865-887 (1998), Stover, Et al., Curr. Opin. Drug Disc. Dev., 2, 274-285(1999), Gray et al., Curr. Med. Chem., 6, 859-875 (1999), Sielecki, et al., J. Med. Chem., 43, 1-18 (2000), Crews, et al., Curr. Opin. Chem. Biol, 4, 47-53 (2000), Buolamwini, Curr.Pharm. Des., 6, 379-392 (2000), and Rosania, et al., Exp. Opin. Ther. Pat., 10, 215-230 (2000)). Moreover, the use of compounds as anti-proliferative therapeutic agents that inhibit CDKs is the subject of several patents and publications. For example, U.S. Patent No. 5,621,082 to Xiong et al., discloses nucleic acid encoding an inhibitor of CDK6 and European Patent Publication No. 0 666 270 A2 describes peptides and peptide mimetics that act as inhibitors of CDK1 and CDK2. WJPO International Publication No. WO 97/16447 discloses certain analogs of chromones that are inhibitors of cyclin-dependent kinases, in particular of CDK/cyclin complexes such as CDK4/cyclin DI, which may be used for inhibiting excessive or abnormal cell proliferation, and therefore for treating cancer. WIPO International Publication No. WO 99/21845 describes 4- aminothiazole derivatives that are useful as CDK inhibitors. There is still a need, however, for small-molecule compounds that may be readily synthesized and are effective in inhibiting one or more CDKs or CDK/cyclin complexes. Because CDK4 may serve as a general activator of cell division in most cells, and complexes of CDK4 and D-type cyclins govern the early Gι phase of the cell-cycle, there is a need for effective inhibitors of CDK4, and D-type cyclin complexes thereof, for treating one or more types of tumors. Also, the pivotal roles of cyclin E/CDK2 and cyclin B/CDK1 kinases in the Gl/S phase and G2/M transitions, respectively offer additional targets for therapeutic intervention in suppressing deregulated cell-cycle progression in cancer. Another protein kinase, CHK-1, plays an important role as a checkpoint in cell- cycle progression. Checkpoints are control systems that coordinate cell-cycle progression by influencing the formation, activation and subsequent inactivation of the cyclin-dependent kinases. Checkpoints prevent cell-cycle progression at inappropriate times, maintain the metabolic balance of cells while the cell is arrested, and in some instances can induce apoptosis (programmed cell death) when the requirements of the checkpoint have not been met. See, e.g., O'Connor, Cancer Surveys, 29, 151-182 (1997); Nurse, Cell, 91, 865-867 (1997); Hartwell et al., Science, 266, 1821-1828 (1994); Hartwell et al., Science, 246, 629-634 (1989).
One series of checkpoints monitors the integrity of the genome and, upon sensing DNA damage, these "DNA damage checkpoints" block cell-cycle progression in Gt & G2 phases, and slow progression through S phase. O'Connor, Cancer Surveys, 29, 151-182 (1997); Hartwell et al., Science, 266, 1821-1828 (1994). This action enables DNA repair processes to complete their tasks before replication of the genome and subsequent separation of this genetic material into new daughter cells takes place. Importantly, the most commonly mutated gene in human cancer, the p53 tumor suppressor gene, produces a DNA damage checkpoint protein that blocks cell-cycle progression in G1 phase and/or induces apoptosis (programmed cell death) following DNA damage. Hartwell et al., Science, 266, 1821-1828 (1994). The p53 tumor suppressor has also been shown to strengthen the action of a DNA damage checkpoint in G2 phase of the cell-cycle. See, e.g., Bunz et al., Science, 28, 1497-1501 (1998); Winters et al., Oncogene, 17, 673-684 (1998); Thompson, Oncogene, 15, 3025-3035 (1997).
Given the pivotal nature of the p53 tumor suppressor pathway in human cancer, therapeutic interventions that exploit vulnerabilities in p53-defective cancer have been actively sought. One emerging vulnerability lies in the operation of the G2 checkpoint in p53 defective cancer cells. Cancer cells, because they lack G1 checkpoint control, are particularly vulnerable to abrogation of the last remaining barrier protecting them from the cancer killing effects of DNA-damaging agents: the G2 checkpoint. The G2 checkpoint is regulated by a control system that has been conserved from yeast to humans. Important in this conserved system is a kinase, CHK-1, which transduces signals from the DNA-damage sensory complex to inhibit activation of the cyclin B/Cdc2 kinase, which promotes mitotic entry. See, e.g., Peng et al., Science, 277, 1501-1505 (1997); Sanchez et al., Science, 277, 1497-1501 (1997). Inactivation of CHK-1 has been shown to both abrogate G2 arrest induced by DNA damage inflicted by either anticancer agents or endogenous DNA damage, as well as result in preferential killing of the resulting checkpoint defective cells. See, e.g., Nurse, Cell, 91, 865-867 (1997); Weinert, Science, 277, 1450-1451 (1997); Walworth et al., Nature, 363, 368-371 (1993); and Al-Khodairy et al., Molec. Biol. Cell, 5, 147-160 (1994). Selective manipulation of checkpoint control in cancer cells could afford broad utilization in cancer chemotherapeutic and radiotherapy regimens and may, in addition, offer a common hallmark of human cancer "genomic instability" to be exploited as the selective basis for the destruction of cancer cells. A number of factors place CHK-1 as a pivotal target in DNA-damage checkpoint control. The elucidation of inhibitors of this and functionally related kinases such as Cdsl/CHK-2, a kinase recently discovered to cooperate with CHK-1 in regulating S phase progression (see Zeng et al., Nature, 395, 507-510 (1998); Matsuoka, Science, 282, 1893-1897 (1998)), could provide valuable new therapeutic entities for the treatment of cancer.
Tyrosine kinases can be of the receptor type (having extracellular, transmembrane and intracellular domains) or the non-receptor type (being wholly intracellular). At least one of the non-receptor protein tyrosine kinases, namely, LCK, is believed to mediate the transduction in T-cells of a signal from the interaction of a cell-surface protein (Cd4) with a cross-linked anti-Cd4 antibody. A more detailed discussion of non-receptor tyrosine kinases is provided in Bolen, Oncogene, 8, 2025- 2031 (1993), which is incorporated herein by reference. In addition to the protein kinases identified above, many other protein kinases have been considered to be therapeutic targets, and numerous publications disclose inhibitors of kinase activity, as reviewed in the following: McMahon et al., Current Opinion in Drug Discovery & Development, 1, 131-146 (1998); Strawn et al., Exp. Opin. Invest. Drugs, 1, 553-573 (1998); Adams et al., Curr. Opin. Drug Disc. Dev., 2, 96-109 (1999), Stover et al., Curr. Opin. Drug Disc. Dev., 2, 274-285 (1999), Toledo et al., Curr. Med. Chem., 6, 775-805 (1999), and Garcia-Echeverria, et al., Med. Res. Rev., 20, 28-57 (2000).
There is still a need, however, for effective inhibitors of protein kinases. Moreover, as is well understood by those skilled in the art, it is desirable for kinase inhibitors to possess both high affinity for the target kinase as well as high selectivity versus other protein kinases.
SUMMARY OF THE INVENTION Thus, an objective of the invention is to provide potent inhibitors of protein kinases. Another objective of the invention is to provide effective kinase inhibitors having a strong and selective affinity for a particular kinase.
These and other objectives of the invention, which will become apparent from the following description, have been achieved by the discovery of amide compounds, pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts thereof (such compounds, prodrugs, metabolites and salts are collectively referred to as "agents") described below, which modulate and/or inhibit the activity of protein kinases.
Pharmaceutical compositions containing such agents are useful in treating various diseases and disorders associated with uncontrolled or unwanted angiogenesis and/or cellular proliferation, such as cancer, autoimmune diseases, viral diseases, fungal diseases, neurodegenerative disorders and cardiovascular diseases. Thus, pharmaceutical compositions containing such agents are useful in the treatment of diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis.
Further, the agents have advantageous properties relating to modulation and/or inhibition of the kinase activity associated with VEGF-R, FGF-R, CDK complexes(e.g., CDKl, CDK2, CDK4 and CDK6), CHK-1, TEK, and LCK. Thus, pharmaceutical compositions containing such agents are useful in the treatment of diseases and disorders mediated by kinase activity, such as cancer.
In a general aspect, the invention relates to compounds represented by the Formula I:
Figure imgf000009_0001
wherein:
R1 is a moiety of the formula
Figure imgf000009_0002
where
Z is CH or NH, and Q is a moiety such that R1 is a substituted or unsubstituted monocyclic or bicyclic heteroaryl which has at least two carbon atoms in the heteroaryl ring system;
X is selected from CH2, O, S, and NH;
Y is selected from CH2, O, and S, provided that at least one of X and Y is CH2, or X and Y together with the bond there-between form a cyclopropyl;
R2 and R3 are independently selected from hydrogen, methyl, halogen, trifluoromethyl, and cyano; and
R4 is
Figure imgf000010_0001
where R5 is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O-R7, NR8R9, CrC8 alkyl, or monocyclic heterocycloalkyl group, R6 is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkenyl, O-R7, C(O)R7, NR8R9, C2-C8 alkyl, or monocyclic heterocycloalkyl group, where R7 is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, R8 is hydrogen or a substituted or unsubstituted alkyl, and R9 is a substituted or unsubstituted alkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl.
The invention is also directed to pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts of the compounds of Formula I. Pharmaceutically acceptable salts of such active metabolites are also provided. Advantageous methods of making the compounds of the Formula I are also described.
In a preferred general embodiment, the invention relates to compounds of the Formula I wherein R1 is a substituted or unsubstituted heteroaryl group selected from:
Figure imgf000011_0001
Figure imgf000011_0002
Figure imgf000011_0003
Figure imgf000011_0004
where
X is selected from CH2, O, and S;
Y is selected from CH2 and S, provided that at least one of X and Y is CH2;
R2 and R3 are independently selected from hydrogen, methyl, fluorine, and chlorine; and
R4 is
Figure imgf000011_0005
where R5 is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O-R7, NR8R9, C C8 alkyl, or monocyclic heterocycloalkyl group, R6 is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkenyl, O-R7, C(O)R7, NR8R9, C2-C8 alkyl, or monocyclic heterocycloalkyl group, where R7 is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, R8 is hydrogen or a substituted or unsubstituted alkyl, and R9 is a substituted or unsubstituted alkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl. Especially preferred are compounds represented by the Formula II:
Figure imgf000012_0001
wherein:
X is selected from CH2, O, and S;
Y is selected from CH, and S, provided that at least one of X and Y is CH2;
R2 and R3 are independently selected from hydrogen, methyl, fluorine, and chlorine;
R4 is
Figure imgf000012_0002
where R5 and R6 are each independently a substituted or unsubstituted aryl or heteroaryl; and R10 is a substituted or unsubstituted alkenyl, aryl, heteroaryl, or NHR9, where R9 is a substituted or unsubstituted alkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl.
In another embodiment, the present invention is directed to compounds represented by the Formula JJJ:
Figure imgf000012_0003
wherein:
X is selected from CH2, O, S, and NH;
Y is selected from CH2, O, and S, provided that at least one of X and Y is CH2, or X and Y together with the bond there-between form a cyclopropyl; R2 and R3 are independently selected from hydrogen, methyl, halogen, trifluoromethyl, and cyano; and R4 is
Figure imgf000013_0001
where R5 is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O-R7, NR8R9, -C8 alkyl, or monocyclic heterocycloalkyl group, R6 is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkenyl, O-R7, C(O)R7, NRSR9, C2-C8 alkyl, or monocyclic heterocycloalkyl group, where R7 is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, R8 is hydrogen or a substituted or unsubstituted alkyl, and R9 is a substituted or unsubstituted alkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl; and pharmaceutically acceptable salts thereof and pharmaceutically acceptable prodrugs thereof.
In preferred embodiments of compounds of Formula HI: X is selected from CH2, O, and S;
Y is selected from CH, and S, provided that at least one of X and Y is CH2; R2 and R3 are independently selected from hydrogen, methyl, fluorine, and chlorine; and
R4 is
Figure imgf000013_0002
where R5 and R6 are each independently a substituted or unsubstituted aryl or heteroaryl.
Especially preferred are compounds represented by the Formula IJJ, wherein: X is CH2; Y is S; R2 and R3 are independently selected from hydrogen, methyl, fluorine, and chlorine; and
Figure imgf000014_0001
where R and R 6 are each independently a substituted or unsubstituted aryl or heteroaryl.
The invention also relates to a method of modulating and/or inhibiting the kinase activity of VEGF-R, FGF-R, a CDK complex, CHK-1, TEK, and/or LCK by administering a compound of the Formula I, II, or III, or a pharmaceutically acceptable prodrug, pharmaceutically active metabolites, or pharmaceutically acceptable salt thereof. Preferably, compounds of the present invention have selective kinase activity — i.e., they possess significant activity against one specific kinase while possessing less or minimal activity against a different kinase. In one preferred embodiment of the invention, compounds of the present invention are those of Formula I, IT, or IJJ, possessing substantially higher potency against VEGF receptor tyrosine kinase than against LCK receptor tyrosine kinase. The invention is also directed to methods of modulating VEGF receptor tyrosine kinase activity without significantly modulating LCK receptor tyrosine kinase activity.
The invention also relates to pharmaceutical compositions each comprising: an effective amount of an agent selected from compounds of the Formula I, U, and III, and pharmaceutically acceptable salts, pharmaceutically active metabolites, and pharmaceutically acceptable prodrugs thereof; and a pharmaceutically acceptable carrier or vehicle for such agent.
The invention further provides methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, comprising administering effective amounts of such agents to a patient in need of such treatment. DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED
EMBODIMENTS The inventive compounds of the Formula I, IT, and in are useful for mediating the activity of protein kinases. More particularly, the compounds are useful as anti- angiogenesis agents and as agents for modulating and/or inhibiting the activity of protein kinases, thus providing treatments for cancer or other diseases associated with cellular proliferation mediated by protein kinases.
The term "alkyl" as used herein refers to straight- and branched-chain alkyl groups having one to twelve carbon atoms. Exemplary alkyl groups include methyl (Me), ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and the like. The term "alkenyl" refers to straight- and branched-chain alkenyl groups having from two to twelve carbon atoms. Illustrative alkenyl groups include prop-2-enyl, but-2-enyl, but-3-enyl, 2-methylprop- 2-enyl, hex-2-enyl, and the like. The term "cycloalkyl" refers to saturated or unsaturated carbocycles having from three to twelve carbon atoms, including bicyclic and tricyclic cycloalkyl structures. Suitable cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.
A "heterocycloalkyl" group is intended to mean a saturated or unsaturated monocyclic radical containing carbon atoms, preferably 4 or 5 ring carbon atoms, and at least one heteroatom selected from nitrogen, oxygen and sulfur.
The terms "aryl" (Ar) and "heteroaryl" refer to monocyclic and polycyclic unsaturated or aromatic ring structures, with "aryl" referring to those that are carbocycles and "heteroaryl" referring to those that are heterocycles. Examples of aromatic ring structures include phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, furyl, thienyl, pyrrolyl, pyridyl, pyridinyl, pyrazolyl, imidazolyl, pyrazinyl, pyridazinyl, 1,2,3-triazinyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, l-H-tetrazol-5-yl, indolyl, quinolinyl, benzofuranyl, benzothiophenyl (thianaphthenyl), and the like. Such moieties may be optionally substituted by one or more suitable substituents, for example, a substituent selected from a halogen (F, CI, Br or I); lower alkyl; OH; NO2; CN; CO2H; O-lower alkyl; aryl; aryl-lower alkyl; CO2CH3; CONH2; OCH2CONH2; NH2; SO2NH2; OCHF2; CF3; OCF3; and the like. Such moieties may also be optionally substituted by a fused-ring structure or bridge, for example OCH2-O.
The term "alkoxy" is intended to mean the radical -O-alkyl. Illustrative examples include methoxy, ethoxy, propoxy, and the like. The term "halogen" represents chlorine, fluorine, bromine or iodine. The term
"halo" represents chloro, fluoro, bromo or iodo.
In general, the various moieties or functional groups for variables in the formulae may be optionally substituted by one or more suitable substituents. Exemplary substituents include a halogen (F, CI, Br, or I), lower alkyl, -OH, -NO2, - CN, -CO2H, -O-lower alkyl, -aryl, -aryl-lower alkyl, -CO2CH3, -CONH2, -
OCH2CONH2, -NH2, -SO2NH2, haloalkyl (e.g., -CF3, -CH2CF3), -O-haloalkyl (e.g., - OCF3, -OCHF2), and the like.
It is understood that compounds of Formula I, II, and HI may exhibit the phenomenon of tautomerism and that the formula drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which modulates and/or inhibits kinase activity and is not to be limited merely to any one tautomeric form utilized within the formula drawings.
Some of the inventive compounds may exist as single stereoisomers (i.e., essentially free of other stereoisomers), racemates, and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates and mixtures thereof are intended to be within the scope of the present invention. Preferably, the inventive compounds that are optically active are used in optically pure form.
As generally understood by those skilled in the art, an optically pure compound having one chiral center (i.e., one asymmetric carbon atom) is one that consists essentially of one of the two possible enantiomers (i.e., is enantiomerically pure), and an optically pure compound having more than one chiral center is one that is both diastereomerically pure and enantiomerically pure. Preferably, the compounds of the present invention are used in a form that is at least 90% optically pure, that is, a form that contains at least 90% of a single isomer (80% enantiomeric excess ("e.e.") or diastereomeric excess ("d.e.")), more preferably at least 95% (90% e.e. or d.e.), even more preferably at least 97.5% (95% e.e. or d.e.), and most preferably at least 99%
(98% e.e. or d.e.).
Additionally, the formulas are intended to cover solvated as well as unsolvated forms of the identified structures. For example, Formula I includes compounds of the indicated structure in both hydrated and non-hydrated forms. Other examples of solvates include the structures in combination with isopropanol, ethanol, methanol,
DMSO, ethyl acetate, acetic acid, or ethanolamine.
In addition to compounds of the Formula I, π, and m, the invention includes pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts of such compounds. Pharmaceutically active salts of such active metabolites are also included.
The term "pharmaceutically acceptable" means pharmacologically acceptable and substantially non-toxic to the subject being administered the cell-cycle control agent. "A pharmaceutically acceptable prodrug" is a compound that may be converted under physiological conditions or by solvolysis to the specified compound or to a pharmaceutically acceptable salt of such compound.
"A pharmaceutically active metabolite" is intended to mean a pharmacologically active product produced through metabolism in the body of a specified compound or salt thereof. Metabolites of a compound may be identified using routine techniques known in the art and their activities determined using tests such as those described herein.
Prodrugs and active metabolites of a compound may be identified using routine techniques known in the art. See, e.g., Bertolini et al., J. Med. Chem., 40, 2011-2016 (1997); Shan, et al., J. Pharm. Sci., 86 (7), 765-767; Bagshawe, Drug Dev. Res., 34,
220-230 (1995); Bodor, Advances in Drug Res., 13, 224-331 (1984); Bundgaard,
Design of Prodrugs (Elsevier Press 1985); and Larsen, Design and Application of
Prodrugs, Drug Design and Development (Krogsgaard-Larsen et al., eds., Harwood
Academic Publishers, 1991). "A pharmaceutically acceptable salt" is intended to mean a salt that retains the biological effectiveness of the free acids and bases of the specified compound and that is not biologically or otherwise undesirable. A compound of the invention may possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. Exemplary pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with a mineral or organic acid or an inorganic base, such as salts including sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4- dioates, hexyne-l,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ-hydroxybuty rates, glycollates, tartrates, methane-sulfonates, propanesulfonates, naphthalene- 1 -sulfonates, naphthalene-2-sulfonates, and mandelates.
If the inventive compound is a base, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyrovic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydrozy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid, or the like.
If the inventive compound is an acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like. Illustrative examples of suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
In the case of agents that are solids, it is understood by those skilled in the art that the inventive compounds and salts may exist in different crystal or polymorphic forms, all of which are intended to be within the scope of the present invention and specified formulas. Therapeutically effective amounts of the agents of the invention may be used to treat diseases mediated by modulation or regulation of protein kinases. An "effective amount" is intended to mean that amount of an agent that, when administered to a mammal in need of such treatment, is sufficient to effect treatment for a disease mediated by the activity of one or more protein kinases, such as tyrosine kinases. Thus, e.g., a therapeutically effective amount of a compound of the Formula I, salt, active metabolite or prodrug thereof is a quantity sufficient to modulate, regulate, or inhibit the activity of one or more protein kinases such that a disease condition which is mediated by that activity is reduced or alleviated.
The amount of a given agent that will correspond to such an amount will vary depending upon factors such as the particular compound, disease condition and its severity, the identity (e.g., weight) of the mammal in need of treatment, but can nevertheless be routinely determined by one skilled in the art. "Treating" is intended to mean at least the mitigation of a disease condition in a mammal, such as a human, that is affected, at least in part, by the activity of one or more protein kinases, such as tyrosine kinases, and includes: preventing the disease condition from occurring in a mammal, particularly when the mammal is found to be predisposed to having the disease condition but has not yet been diagnosed as having it; modulating and/or inhibiting the disease condition; and/or alleviating the disease condition.
The inventive agents may be prepared using the reaction routes and synthesis schemes as described below, employing the techniques available in the art using starting materials that are readily available. Compounds of formula I where R4 is CONHR5 may be prepared as shown in Scheme 1. Scheme 1
Figure imgf000020_0001
IV V I (R = CONHR3)
As shown in Scheme 1, carboxylic acids of formula IV are coupled to amines of formula V to give compounds of formula I (R4 = CONHR5). The coupling may be carried out employing various peptide coupling reagents, for example l-ethyl-3-(3'- dimethylaminopropyl)carbodiimide'HCl (EDC), O-(7-azabenzotriazol-l-yl)- NNN',N'-tetramethyluronium hexafluorophosphate (HATU), or benzotriazole-1-yl- oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (pyBop), in polar aprotic solvents, such as Ν, Ν-dimethylforamide (DMF) or dichloromethane. Alternatively, the acid IN may be first converted to an acid chloride by treatment with, for example, oxalyl chloride or thionyl chloride, and then, without purification, reacted with amines of formula V to give compounds of formula I (R4 = COΝHR5).
Compounds of formula I where R4 is ΝHCOR6 may be prepared as shown in Scheme 2.
Figure imgf000020_0002
Carboxylic acids of formula VII are coupled to amines of formula VI to give compounds of formula I (R4 = NHCOR6). The coupling may be carried out employing with various peptide coupling reagents, for example EDC, HATU, or pyBOP, in polar aprotic solvents, such as DMF or dichloromethane. Alternatively, the acid VIJ may be first converted to an acid chloride by treatment with, for example, oxalyl chloride or thionyl chloride, and then, without purification, reacted with amines of formula VI to give compounds of formula I (R4 = NHCOR6). Compounds of formula I-a may be prepared by the reaction shown in Scheme 3. Scheme 3
Figure imgf000021_0001
Nm IX I-a: R = R4
X = O, S, NH IV-a: R = CO2Rn
Vl-a: R = NH2 Compounds of formula IX (R=R4) are treated with compounds of formula VIII, where Lg is a suitable leaving group such as chloride, bromide, or mesylate, in a dipolar aprotic solvent such as acetone, DMF, or DMSO, in the presence of a suitable base, such as potassium carbonate, cesium carbonate, sodium hydride, and the like, to provide, after extractive workup and conventional purification, compounds of formula I-a. Alternatively, this reaction may be carried out in the same manner with compounds of formula XI (R = CO2Rn, where R11 is hydrogen or a suitable carboxylic acid protecting group, such as methyl, ethyl, or benzyl) to give compounds of formula IV-a. In addition, the reaction carried out with compounds of formula TX (R = NH2) provides compounds of formula Vl-a.
Compounds of formula I-b may be prepared by the reaction shown in Scheme 4. Scheme 4
Figure imgf000022_0001
X XI I-b: R = R4
Y = O, S IV-b: R = CO2R 11 Vl-b: R = NH2 Compounds of formula XI (R=R4), where Lg is a suitable leaving group such as chloride, bromide, or mesylate, are treated with compounds of formula X in a dipolar aprotic solvent such as acetone, DMF, or DMSO, in the presence of a suitable base, such as potassium carbonate, cesium carbonate, sodium hydride, and the like, to provide, after extractive workup and conventional purification, compounds of formula I-b. Alternatively, this reaction may be carried out in the same manner with compounds of formula XI (R = CO2Ru, where R11 is hydrogen or a suitable carboxylic acid protecting group, such as methyl, ethyl, or benzyl) to give compounds of formula IV-b. In addition, the reaction carried out with compounds of formula XI (R = NH2) provides compounds of formula Vl-b. Compounds of formula I-c may be prepared by the reaction shown in Scheme
5. Scheme 5
Figure imgf000022_0002
Vl-d: R = NH2 Compounds of formula XU, where W is a suitable group that can participate in a palladium-catalyzed coupling reaction such as bromide, iodide, or triflate, are allowed to react with acetylenes of formula XIII in the presence of a suitable palladium catalyst, such as dichloiObis(triphenylphosphine)palladium, and a copper catalyst, such as cuprous iodide, in the presence of a suitable base, such as piperidine, triethylamine or diisopropylethylamine, in an aprotic solvent, such as THF or DMF, at a temperature between 25 °C and 125 °C, for 1 to 24 hours. After extractive work-up and conventional purification, removal of the silyl protecting group is effected with, for example, either tetrabutylammonium fluoride in THF or sodium hydroxide in methanol, to provide compounds of formula XIV.
Under similar catalyzed coupling conditions as those described above, compounds of formula XV can be reacted with those of formula XIV to yield compounds of formula XVI. Catalytic hydrogenation of alkynes of formula XVI provides compounds of formula I-c after filtration and convention purification. Typical catalytic conditions include catalysts such as palladium, rhodium, preferably palladium-on-carbon, in a suitable solvent such as Cr C4 alcohols, preferably ethanol.
Compounds of formula Il-a may be prepared as shown in Scheme 6. Scheme 6
RSAcH3 +
Figure imgf000023_0001
XVII xviπ
Figure imgf000023_0002
Il-a
Thioamides of formula XVII are treated with two molar equivalents of a suitable strong base, such as n-butyllithium or Hthium diisopropylamide, in a suitable solvent, such as THF, at -78 °C to 0 °C, to give a solution of thioamide dianion, which is further treated with less than or equal to 0.5 molar equivalents of compounds of formula XVm. Conventional aqueous work-up and purification then provides compounds of formula XIX, which upon treatment with hydrazine, preferably in the presence of acetic acid, in ethanol at 0 °C to 50 °C, preferably at room temperature, provides compounds of formula Il-a.
Compounds of formula JJ-b may be prepared as shown in Scheme 7. Scheme 7
Figure imgf000025_0001
Il-b XXII
Ketones of formula XX, where R12 is substituted or unsubstituted alkenyl, aryl, or heteroaryl, are converted to hydrazones of formula XXI by treatment with t-butyl carbazate and acetic acid in ethanol. Treatment of hydrazones of formula XXI with two molar equivalents of a suitable strong base, such as n-butyllithium or lithium diisopropylamide, in a suitable solvent, such as THF, at -78 °C to 0 °C, generates a solution of hydrazone dianion, which is further treated with less than or equal to 0.5 molar equivalents of compounds of formula XViπ. Conventional aqueous work-up and purification then provides compounds of formula XXII, which upon further treatment with a suitable acid, such as trifluoroacetic acid, provides compounds of formula fl-b.
Compounds of formula XVIII are prepared as shown in Scheme 8. Scheme 8
Figure imgf000026_0001
XViπ-a: X=O XVIII-b: X=S
Figure imgf000026_0002
xviπ-c
Thus, compounds of formula XVffl-a and XVITI-b are prepared by alkylation of compounds of formula LX with N-methoxy-N-methyl chloroacetamide in a like manner to that shown in Scheme 3 above. Compounds of formula XVlTf-c may be prepared by (1) reaction of aldehydes of formula XXEI with the anion derived from N- methoxy-N-methyl triethylphosphonoacetamide to give unsaturated amides of formula XXrV, and (2) reduction of compounds of formula XXIV with, for example, hydrogen in the presence of palladium on carbon to provide compounds of formula XVHI-C.
Other compounds of Formula I, JJ, and JJf may be prepared in manners analogous to the general procedures described above or the detailed procedures described in the examples herein.
The affinity of the compounds of the invention for a receptor may be enhanced by providing multiple copies of the ligand in close proximity, preferably using a scaffolding provided by a carrier moiety. It has been shown that provision of such multiple valence compounds with optimal spacing between the moieties dramatically improves binding to a receptor. See e.g., Lee et al., Biochem, 23, 4255 (1984). The multivalency and spacing can be controlled by selection of a suitable carrier moiety or linker units. Such moieties include molecular supports which contain a multiplicity of functional groups that can be reacted with functional groups associated with the compounds of the invention. Of course, a variety of carriers can be used, including proteins such as BSA or HAS, a multiplicity of peptides including, for example, pentapeptides, decapeptides, pentadecapeptides, and the like. The peptides or proteins can contain the desired number of amino acid residues having free amino groups in their side chains; however, other functional groups, such as mercapto (-SH) groups or hydroxyl (-OH) groups, can also be used to obtain stable linkages.
Compounds that potently regulate, modulate, or inhibit the protein kinase activity associated with receptors VEGF, FGF, CDK complexes, TEK, CHK-1, and LCK, among others, and which inhibit angiogenesis and/or cellular profileration is desirable and is one preferred embodiment of the present invention. The present invention is further directed to methods of modulating or inhibiting protein kinase activity, for example in mammalian tissue, by administering an inventive agent. The activity of the inventive compounds as modulators of protein kinase activity, such as the activity of kinases, may be measured by any of the methods available to those skilled in the art, including in vivo and/or in vitro assays. Examples of suitable assays for activity measurements include those described in Parast C. et al, BioChemistry, 37, 16788-16801 (1998); Jeffrey et al., Nature, 376, 313-320 (1995); WIPO International Publication No. WO 97/34876; and WJPO International Publication No. WO 96/14843. These properties may be assessed, for example, by using one or more of the biological testing procedures set out in the examples below.
The active agents of the invention may be formulated into pharmaceutical compositions as described below. Pharmaceutical compositions of this invention comprise an effective modulating, regulating, or inhibiting amount of a compound of Formula I, U, or m and an inert, pharmaceutically acceptable carrier or diluent. In one embodiment of the pharmaceutical compositions, efficacious levels of the inventive agents are provided so as to provide therapeutic benefits involving modulation of protein kinases. By "efficacious levels" is meant levels in which the effects of protein kinases are, at a minimum, regulated. These compositions are prepared in unit-dosage form appropriate for the mode of administration, e.g., parenteral or oral administration. An inventive agent is administered in conventional dosage form prepared by combining a therapeutically effective amount of an agent (e.g., a compound of Formula I) as an active ingredient with appropriate pharmaceutical carriers or diluents according to conventional procedures. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. The pharmaceutical carrier employed may be either a solid or liquid. Exemplary of solid carriers are lactose, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time-delay or time-release material known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate and the like.
A variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier may vary, but generally will be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation will be in the form of syrup, emulsion, soft gelatin capsule, sterile injectable solution or suspension in an ampule or vial or non-aqueous liquid suspension.
To obtain a stable water-soluble dose form, a pharmaceutically acceptable salt of an inventive agent is dissolved in an aqueous solution of an organic or inorganic acid, such as 0.3M solution of succinic acid or citric acid. If a soluble salt form is not available, the agent may be dissolved in a suitable cosolvent or combinations of cosolvents. Examples of suitable cosolvents include, but are not limited to, alcohol, propylene glycol, polyethylene glycol 300, polysorbate 80, gylcerin and the like in concentrations ranging from 0-60% of the total volume. In an exemplary embodiment, a compound of Formula I is dissolved in DMSO and diluted with water. The composition may also be in the form of a solution of a salt form of the active ingredient in an appropriate aqueous vehicle such as water or isotonic saline or dextrose solution.
It will be appreciated that the actual dosages of the agents used in the compositions of this invention will vary according to the particular complex being used, the particular composition formulated, the mode of administration and the particular site, host and disease being treated. Optimal dosages for a given set of conditions can be ascertained by those skilled in the art using conventional dosage- determination tests in view of the experimental data for an agent. For oral administration, an exemplary daily dose generally employed is from about 0.001 to about 1000 mg/kg of body weight, more preferably from about 0.001 to about 50 mg/kg body weight, with courses of treatment repeated at appropriate intervals. Administration of prodrugs are typically dosed at weight levels which are chemically equivalent to the weight levels of the fully active form.
The compositions of the invention may be manufactured in manners generally known for preparing pharmaceutical compositions, e.g., using conventional techniques such as mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing. Pharmaceutical compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers, which may be selected from excipients and auxiliaries that facilitate processing of the active compounds into preparations which can be used pharmaceutically.
Proper formulation is dependent upon the route of administration chosen. For injection, the agents of the invention may be formulated into aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained using a solid excipient in admixture with the active ingredient (agent), optionally grinding the resulting mixture, and processing the mixture of granules after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include: fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; and cellulose preparations, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as crosslinked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, polyvinyl pyrrolidone, Carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active agents.
Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active agents may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. hi addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration. For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
For administration intranasally or by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of gelatin for use in an inhaler or insufflator and the like may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch. The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit-dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active agents may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. For administration to the eye, a compound of the formula I, π, or HI is delivered in a pharmaceutically acceptable ophthalmic vehicle such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye, including, for example, the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/cilary, lens, choroid/retina and selera. The pharmaceutically acceptable ophthalmic vehicle may be an ointment, vegetable oil, or an encapsulating material. A compound of the invention may also be injected directly into the vitreous and aqueous humor.
Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g, containing conventional suppository bases such as cocoa butter or other glycerides. h addition to the formulations described above, the compounds may also be formulated as a depot preparation. Such long-acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion-exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. A pharmaceutical carrier for hydrophobic compounds is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The cosolvent system may be a VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD:5W) contains VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may be substituted for dextrose.
Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.
The pharmaceutical compositions also may comprise suitable solid- or gel- phase carriers or excipients. Examples of such carriers or excipients include calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
Some of the compounds of the invention may be provided as salts with pharmaceutically compatible counter ions. Pharmaceutically compatible salts may be formed with many acids, including hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free-base forms.
The preparation of preferred compounds of the present invention is described in detail in the following examples, but the artisan will recognize that the chemical reactions described may be readily adapted to prepare a number of other protein kinase inhibitors of the invention. For example, the synthesis of non-exemplified compounds according to the invention may be successfully performed by modifications apparent to those skilled in the art, e.g., by appropriately protecting interfering groups, by changing to other suitable reagents known in the art, or by making routine modifications of reaction conditions. Alternatively, other reactions disclosed herein or known in the art will be recognized as having applicability for preparing other compounds of the invention.
EXAMPLES In the examples described below, unless otherwise indicated all temperatures are set forth in degrees Celsius and all parts and percentages are by weight. Reagents were purchased from commercial suppliers such as Aldrich Chemical Company or Lancaster Synthesis Ltd. and were used without further purification unless otherwise indicated. Tetrahydrofuran (THF) and N, N-dimethylforamide (DMF) were purchased from Aldrich in Sure seal bottles and used as received. All solvents were purified using standard methods readily known to those skilled in the art, unless otherwise indicated. The reactions set forth below were done generally under a positive pressure of argon or nitrogen or with a drying tube, at ambient temperature (unless otherwise stated), in anhydrous solvents, and the reaction flasks were fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven dried and/or heat dried. Analytical thin layer chromatography (TLC) was performed on glass-backed silica gel 60 F 254 plates and eluted with the appropriate solvent ratios (v/v), and are denoted where appropriate. The reactions were assayed by TLC and terminated as judged by the consumption of starting material.
Visualization of the TLC plates was generally done by ultraviolet visualization. Work-ups were typically done by doubling the reaction volume with the reaction solvent or extraction solvent and then washing with the indicated aqueous solutions using 25% by volume of the extraction volume unless otherwise indicated. Product solutions were dried over anhydrous Na SO prior to filtration and evaporation of the solvents under reduced pressure on a rotary evaporator and noted as solvents removed in vacuo. Products were purified by employing radial chromatography or flash column chromatography (Still et al., J. Org. Chem., 43, 2923 (1978)), the latter using Merck grade flash silica gel (47-61 μm) and a silica gel: crude material ratio of about 20:1 to 100:1 unless otherwise stated. Hydrogenolysis was done at the pressure indicated in the examples or at ambient pressure. 1H-NMR spectra were recorded on an instrument operating at 300 or 500 MHz,
1 and C-NMR spectra were recorded operating at 75 MHz. NMR spectra were obtained as CDC13 solutions (reported in ppm), using chloroform as the reference standard (7.25 ppm and 77.00 ppm) or CD3OD (3.4 and 4.8 ppm and 49.3 ppm), or internally tetramethylsilane (0.00 ppm) when appropriate. Other NMR solvents were used as needed. When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), q (quartet), br (broadened), dd (doublet of doublets), dt (doublet of triplets). Coupling constants, when given, are reported in Hertz (Hz).
Infrared (IR) spectra were recorded on a Perkin-Elmer FT-IR Spectrometer as neat oils, as KBr pellets, or as CDC13 solutions, and when given are reported in wave numbers (cm"1). All melting points (mp) are uncorrected. Unless otherwise stated, the HPLC conditions are the following: Hewlett Packard ODS Hypersil (5 μm, 125 x 4 mm), 10% acetonitrile/0.1 M ammonium acetate from 0-2 minutes to 90% acetonitrile/0.1 M ammonium acetate at 22 minutes, 1.0 mL/minute, detection at 254 nm. Abbreviations for reagents, equipment, and techniques are defined as follows:
MTBE (methyl t-butyl ether); DMSO (dimethylsulfoxide); DIEA (diisopropylethylamine); TEA (triethylamine); AcOH (acetic acid); DMAP (4- (dimethylamino)pyridine); EDC (l-ethyl-3-(3'- dimethylaminopropyl)carbodiimide'HCl) ; HATU (O-(7-azabenzotriazol- 1 -yl)- NNN',N'-tetramethyluiOnium hexafluorophosphate); HOBt (Ν- hydroxybenzotriazole) ; PyB op (benzotriazole- 1 -yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate); MS (ESI) (Electrospray ionization mass spectrometry); MS (FAB) (fast atom bombardment mass spectrometry); HRMS (FAB) (high resolution fast atom bombardment mass spectrometry); HRMS (MALDI) (high resolution matrix-assisted laser desorption/ionization mass spectrometry); and APCTMS (atmospheric pressure chemical ionization mass spectrometry).
Example A-l : Ν-(3,4,5-Trimethoxyphenyl)-3-[(pyrazin-2-yl)suIfanylmethyI]- benzamide
Figure imgf000035_0001
CsCOg, DMF,
Figure imgf000035_0002
(a) To a solution of 3,4,5-trimethoxyaniline (3.0 g, 16.4 mmol) and triethylamine (2.5 mL, 18 mmol) in 100 mL dichloromethane at room temperature was added, via pipette,
3-(chloromethyl)benzoyl chloride (2.4 mL, 16.9 mmol). After stirring at room temperature for 4 h, the mixture was partitioned between chloroform (100 mL) and water (200 mL). The aqueous layer was extracted twice with chloroform (100 mL) and the combined organics were washed with brine (100 mL), dried over Na2SO4, and concentrated to dryness. The crude residue was triturated with MTBE to obtain 5.22 g (95%) of N-(3,4,5-trimethoxyphenyl)-3-(chloiOmethyl)benzamide, A-la, as an off- white solid which was collected by filtration: mp 138-145 °C; 1H NMR (DMSO-d6) δ 7.98 (s, IH), 7.89 (d, IH, J = 7.8 Hz), 7.63 (d, IH, J = 7.8 Hz), 7.52 (t, IH, J = 7.7 Hz), 7.20 (s, 2H), 4.83 (s, 2H), 3.75 (s, 6H), 3.62 (s, 3H). Anal, calc'd for C17H18NO4Cl • 0.2 H2O: C, 60.16; H, 5.47; N, 4.13; CI, 10.45. Found: C, 60.18; H, 5.38; N, 4.17; CI, 10.68.
(b) To a solution of 0.112 g (1 mmol) of 2-pyrazinethiol (Specs) and N-(3,4,5- trimethoxyphenyl)-3-(chloromethyl)benzamide, A-la, (0.335 g, 1 mmol) in 5 mL anhydrous DMF under an argon purge was added cesium carbonate (0.814 g, 2.5 mmol). The resulting suspension was stirred at ~65 °C for 17 hr. The mixture was allowed to cool to room temperature and then was partitioned between ethyl acetate (50 mL) and water (75 mL). The aqueous layer was extracted twice with ethyl acetate (50 mL) and the combined organics were washed with brine (25 mL), dried over Na^O^ and concentrated to dryness. The crude residue was purified on silica gel using a gradient of 0% to 6% methanol in 1:1 ethyl acetate:hexane as eluent to obtain N-(3,4,5-trimethoxyphenyl)-3-[(pyrazin-2-yl)sulfanylmethyl]benzamide as a pale yellow oil (0.18 g, 43%) which crystallized upon standing: mp 112-119 °C; 1H NMR (DMSO-d6) δ 10.13 (s, IH), 8.63 (d, IH, J = 1.55 Hz), 8.53 (dd, IH, J = 2.60, 1.58 Hz), 8.36 (d, IH, J = 2.64 Hz), 8.00 (s, IH), 7.83 (d, IH, J = 7.81 Hz), 7.64 (d, IH, J = 7.72 Hz), 7.47 (t, IH, J = 7.7 Hz), 7.21 (s, 2H), 4.56 (s, 2H), 3.77 (s, 6H), 3.65 (s, 3H). Anal, calc'd for C21H21N3O4S • 0.2 MTBE: C, 61.58; H, 5.50; N, 9.79; S, 7.47. Found: C, 61.34; H, 5.43; N, 9.69;S, 7.34. Example A-2: N-(3,4,5-TrimethoxyphenyI)-3-[(5-amino-2H-[l,2>4]triazoI-3-yI) sulfanylmethyl]benzamide
Figure imgf000037_0001
Example A-2 was prepared in a similar manner to that described for A-1, except that 3- amino-5-mercapto-l,2,4-triazole (Aldrich) was used in place of 2-pyrazinethiol in step (b): 1H NMR (DMSO-d6) δ 11.96 (br s, IH), 10.12 (s, IH), 7.95 (s, IH), 7.82 (d, IH, J = 7.8 Hz), 7.59 (d, IH, J = 7.6 Hz), 7.46 (t, IH, J = 7.69 Hz), 7.23 (s, 2H), 6.05 (br s, 2H), 4.32 (s, 2H), 3.78 (s, 6H), 3.65 (s, 3H); HR MS (FAB): Calculated for C19H22N5O4S (M+H+): 416.1393. Found: 416.1408. Anal, calc'd for C19H21N5O4S • 0.3 EtOAc: C, 54.90; H, 5.34; N, 15.85; S, 7.26. Found: C, 54.87; H, 5.50; N, 15.71; S, 7.03.
Example A-3: N-(4-Isopropyl-3-methylphenyl)-3-[(pyrazin-2-yl)sulfanylmethyl]- benzamide
Figure imgf000037_0002
Example A-3 was prepared in a similar manner to that described for A-1, except that 3- methyl-4-isopropylaniline hydrochloride (Maybridge) was used in place of 3,4,5- trimethoxyaniline in step (a): mp 69-73 °C; 1H NMR (DMSO-d6) δ 10.07 (s, IH), 8.62 (d, IH, J = 1.6 Hz), 8.52 (dd, IH, J = 2.6, 1.6 Hz), 8.35 (d, IH, J = 2.6 Hz), 7.99 (s, IH), 7.83 (d, IH, J = 7.8 Hz), 7.62 (d, IH, J = 7.7 Hz), 7.56-7.51 (m, 2H), 7.46 (t, IH, J = 7.7 Hz), 7.20 (d, IH, J = 8.3 Hz), 4.55 (s, 2H), 3.10-3.05 (m, IH), 2.69 (s, 3H),
1.17 (d, 6H, J = 6.9 Hz). Anal, calc'd for C22H23N3OS • 0.2 MTBE: C, 69.91; H, 6.48;
N, 10.64; S, 8.12. Found: C, 70.03; H, 6.40; N, 10.41;S, 7.81.
Example A-4: N-(4-Isopropyl-3-methylphenyl)-3-[(5-amino-2H-[l,2,4]triazol-3- yl)sulfanylmethyl]benzamide
Figure imgf000038_0001
Example A-4 was prepared in a similar manner to that described for A-1, except that 3- methyl-4-isopropylaniline was used in place of 3, 4,5-trimethoxy aniline in step (a), and 3-amino-5-mercapto-l,2,4-triazole was used in place of 2-pyrazinethiol in step (b): H NMR (DMSO-d6) δ 11.93 (br s, IH), 10.05 (s, IH), 7.92 (s, IH), 7.80 (d, IH, J = 7.8 Hz), 7.57-7.51 (m, 3H), 7.43 (t, IH, J = 7.7 Hz), 7.19 (d, IH, J = 8.3 Hz), 6.02 (br s, 2H), 4.30 (s, 2H), 3.09-3.04 (m, IH), 2.29 (s, 3H), 1.17 (d, 6H, J = 6.9 Hz). Anal. calc'd for C20H23N5OS • 0.1 MTBE: C, 63.08; H, 6.25; N, 17.94; S, 8.22. Found: C,
62.78; H, 6.26; N, 17.78;S, 8.00.
Example A-5 : N-(4-Isopropyl-3-methylphenyl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-
4-yl)sulfanylmethyl]benzamide
Figure imgf000038_0002
Example A-5 was prepared in a similar manner to that described for A-1, except that 3- methyl-4-isopropylaniline was used in place of 3,4,5-trimethoxyaniline in step (a), and 4-mercapto-lH-pyrazolo[3,4-d]pyrimidine was used in place of 2-pyrazinethiol in step (b): mp 187-189 °C; 1H NMR (DMSO-d6) δ 10.09 (s, IH), 8.81 (s, IH), 8.31 (s, IH), 8.05 (s, IH), 7.85 (d, IH, J = 7.9 Hz), 7.69 (d, IH, J = 7.7 Hz), 7.55-7.47 (m, 3H), 7.20 (d, IH, J = 8.4 Hz), 4.78 (s, 2H), 3.09-3.06 (m, IH), 2.29 (s, 3H), 1.18 (d, 6H, J = 6.9 Hz). Anal, calc'd for C23H23N5OS: C, 66.16; H, 5.55; N, 16.77; S, 7.68. Found: C, 65.90; H, 5.51; N, 16.98; S, 7.40. Example A-6: N-(2-Methylquinolin-6-yl)-3-[(pyrazin-2-yl)sulfanylmethyl]benz- amide
Figure imgf000039_0001
A-6
Example A-6 was prepared in a similar manner to that described for A-1, except that 6- amino-2-methylquinoline (Lancaster) was used in place of 3,4,5-trimethoxyaniline in step (a): mp 133-135 °C; 1H NMR (DMSO-d6) δ 10.51 (s, IH), 8.63 (s, IH), 8.53 (t,
IH, J = 1.9 Hz), 8.44 (t, IH, J = 3.0 Hz), 8.35 (d, IH, J = 2.6 Hz), 8.20 (d, IH, J = 2.4
Hz), 8.04 (s, IH), 7.96 (d, IH, J = 9.0 Hz), 7.89 (d, 2H, J= 9.1 Hz), 7.66 (d, IH, J =
7.7 Hz), 7.50 (t, IH, J= 7.7 Hz), 7.38 (d, IH, J= 8.4 Hz), 4.57 (s, 2H), 2.63 (s, 3H). Anal, calc'd for C22H18N4OS: C, 68.37; H, 4.69; N, 14.50; S, 8.30. Found: C, 68.41;
H, 4.72; N, 14.52; S, 8.30.
Example A-7: N-(3-Isopropylphenyl)-3-[(pyrazin-2-yl)sulfanylmethyl]benzamide
Figure imgf000039_0002
A-7
Example A-7 was prepared in a similar manner to that described for A-1, except that 3- isopropylaniline (Maybridge) was used in place of 3,4,5-trimethoxyaniline in step (a): 1H NMR (DMSO-d6) δ 10.02 (s, IH), 8.63 (d, IH, J = 1.6 Hz), 8.52 (dd, IH, J = 2.42, 1.5 Hz), 8.34 (d, IH, J = 2.6 Hz), 7.99 (s, IH), 7.83 (d, IH, J = 7.7 Hz), 7.63-7.60 (m, 3H), 7.46 (t, IH, J = 7.7 Hz), 7.25 (t, IH, J = 7.8 Hz), 6.97 (d, IH, J = 7.6 Hz), 4.55 (s, 2H), 2.88-2.85 (m, IH), 1.21 (d, 6H, J = 6.9 Hz). Anal, calc'd for C21H21N3OS • 0.3 MTBE: C, 69.31; H, 6.36; N, 10.78; S, 8.22. Found: C, 69.34; H, 6.15; N, 10.54; S, 7.96.
Example A-8: N-(3,5-Dibromo-4-methylphenyl)-3-[(pyrazm-2-yl)sulfanyl- methyljbenzamide
Figure imgf000040_0001
A-8
Example A-8 was prepared in a similar manner to that described for A-1, except that 3,5-dibomo-4-methylaniline (Lancaster) was used in place of 3,4,5-trimethoxyaniline in step (a): mp 119-127 °C; 1H NMR (DMSO-d6) δ 10.39 (s, IH), 8.61 (d, IH, J = 1.30 Hz), 8.51 (t, IH, J = 2.1 Hz), 8.34 (d, IH, J = 2.61 Hz), 8.12 (s, 2H), 7.99 (s, IH), 7.82 (d, IH, J = 7.96 Hz), 7.65 (d, IH, J = 7.73 Hz), 7.48 (t, IH, J = 7.74 Hz), 4.54 (s, 2H), 2.47 (s, 3H). Anal, calc'd for C19H15N34S • 0.25 EtOAc: C, 46.62; H, 3.33; N, 8.16; S, 6.22. Found: C, 46.33; H, 3.24; N, 7.90; S, 5.83.
Example B-l : N-(3,4,5-Trimethoxyphenyl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4- yl)sulfanylmethyljbenzamide
Figure imgf000040_0002
To a solution of 3,4,5-trimethoxyaniline (400 mg, 2.18 mmol) and triethylamine (0.30 mL, 2.18 mmol) in dichloromethane was added 0.31 mL (2.18 mmol) of 3- chloromethylbenzoyl chloride (Aldiich). After 10 min, the solvent was removed and the residual crude N-(3,4,5-trimethoxyphenyl)-3-(chloromethyl)benzamide, A-la, was dissolved in DMF (10 mL) under argon. To the resulting solution was added 4- mercaρto-lH-pyrazolo[3,4-d]pyrimidine (332 mg, 2.18 mmol) followed by triethylamine (0.30 mL, 2.18 mmol). The resulting solution was heated at 70 °C for 2 h, then cooled and poured into water. The solid was collected by filtration and washed with water. After air-drying, the solid was sequentially triturated with ethyl acetate/hexane and with dichloromethane, and the solid collected by filtration to provide 360 mg (37%) of N-(3,4,5-trimethoxyphenyl)-3-[(lH-pyrazolo[3,4- d]pyrimidin-4-yl)sulfanylmethyl)benzamide, B-l: Η NMR (300MHz, DMSO-d6) δ 14.12 (s, IH), 10.15 (s, IH), 8.79 (s, IH), 8.03 (s, IH), 7.83 (d, IH, J = 7.7 Hz), 7.68 (d, IH, J = 7.7 Hz), 7.48 (t, IH, J = 7.7 Hz), 7.20 (s, 2H), 4.77 (s, 2H), 3.75 (s, 6H), 3.62 (s, 3H). Anal, calc'd for C22H21N5O4S • 0.7 H2O: C, 56.93; H, 4.87; N, 15.09; S, 6.91. Found: C, 56.89; H, 4.76; N, 14.85; S, 6.91. Example B-2: N-(3,4,5-Trimethoxyphenyl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4- yl)sulfanylmethyl]benzamide
Figure imgf000041_0001
B-2
Example B-2 was prepared in a similar manner to that described for B-l, except that 5- amino-2-methoxypyridine was used in place of 3,4,5-trimethoxyaniline: Η NMR (300 MHz, DMSO-d6) δ 14.10 (s, IH), 10.20 (s, IH), 8.75 (s, IH), 8.43 (d, J = 2.5 Hz, IH), 8.25 (s, IH), 7.95-8.00 (m, 2H), 7.81 (d, IH, J = 7.8 Hz), 7.65 (d, IH, J = 7.7 Hz), 7.41- 7.46. (dd, IH), 6.78 (d, IH, J = 8.8 Hz), 4.70 (s, 2H), 3.80 (s, 3H); APCTMS m/z 393 [M + H]+. Example B-3: N-(Quinolin-6-yl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4-yl)sulfanyl- methyl]benzamide
Figure imgf000041_0002
B-3
Example B-3 was prepared in a similar manner to that described for B-l, except that 6- aminoquinoline was used in place of 3,4,5-trimethoxyaniline: mp 236-240 °C (dec); 1H NMR (DMSO-d6) δ 14.15 (s, IH), 10.60 (s, IH), 8.80 (s, 2H), 8.52 (s, IH), 8.34- 8.29 (m, 2H), 8.10 (s, IH), 8.05-7.98 (m, 2H), 7.91 (d, IH, J = 7.7 Hz), 7.72 (d, IH, J = 7.4 Hz), 7.54-7.48 (m, 2H), 4.79 (s, 2H). Anal, calc'd for C22HI6N6OS • 0.7 H2O: C, 62.16; H, 4.13; N, 19.77; S, 7.54. Found: C, 62.34; H, 3.83; N, 19.48; S, 7.61 . Example B-4: N-(5-Methylisoxazol-3-yl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4- yl)sulfanylmethyl]benzamide
Figure imgf000042_0001
B-4
Example B-4 was prepared in a similar manner to that described for B-l, except that 3- amino-5-methylisoxazole was used in place of 3,4,5-trimethoxyaniline: *H NMR (300 MHz, DMSO- 6) δ 13.99 (s, IH), 11.34 (s, IH), 8.79 (s, IH), 8.31 (s, IH), 8.11 (s, IH), 7.90 (d, IH, J = 8.0 Hz), 7.72 (d, IH, J = 8.0 Hz), 7.47 (dd, IH, J = 7.5, 7.6 Hz), 6.74 (s, IH), 4.76 (s, 2H), 2.41 (s, 3H); APCTMS m/z 367 [M + H]+ . Example B-5: N-(Pyridin-4-yl)methyl-3-[(lH-pyrazolo[3,4-d]pyrimidin-4-yl)- sulfanylmethyl]benzamide
Figure imgf000042_0002
B-5
Example B-5 was prepared in a similar manner to that described for B-l, except that 4- picolylamine was used in place of 3,4,5-trimethoxyaniline: Η NMR (300 MHz, DMSO- 6) δ 14.05 (s, IH), 9.08-9.12 (t, IH, J = 5.8 Hz), 8.74 (s, IH), 8.44 (d, IH, J = 5.7 Hz), 8.25 (s, IH), 7.96 (s, IH), 7.76 (d, IH, J = 7.9 Hz), 7.62 (d, IH, J = 7.7 Hz), 7.40 (dd, IH, J = 7.7, 7.9 Hz), 7.24 (d, IH, J = 5.7 Hz), 4.70 (s, 2H), 4.43 (d, 2H, J = 5.9 Hz); APCTMS m/z 377 [M + H]+.
Example B-6: N-(l,3-Benzodioxyl-5-yImethyI)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4- yl)sulfanylmethyl]benzamide
Figure imgf000043_0001
B-6
Example B-6 was prepared in a similar manner to that described for B-l, except that 3,4-(methylenedioxy)benzylamine was used in place of 3,4,5-trimethoxyaniline: TI NMR (300 MHz, DMSO- 6) δ 14.05 (s, IH), 8.98 (t, IH, J = 6.0 Hz), 8.78 (s, IH), 8.30 (s, IH), 7.99 (s, IH), 7.77 (d, IH, J = 7.9 Hz), 7.64 (d, IH, J = 7.5 Hz), 7.42 (dd, IH, J = 7.6, 7.9 Hz), 6.84-6.87 (m, 2H), 6.78 (d, IH, J = 7.9 Hz), 5.97 (s, 2H), 4.74 (s, 2H), 4.36 (d, 2H, J = 6.1 Hz); APCIMS m/z 420 [M + H]+. Example B-7: N-(2-Methoxybenzyl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4-yl)- sulfanylmethyljbenzamide
Figure imgf000043_0002
Example B-7 was prepared in a similar manner to that described for B-l, except that 2- methoxybenzylamine was used in place of 3,4,5-trimethoxyaniline: XH NMR (300 MHz, DMSO- 6) δ 14.12 (s, IH), 8.86 (t, IH, J = 6.0 Hz), 8.79 (s, IH), 8.30 (s, IH), 8.02 (s, IH), 7.81 (d, IH, J = 7.9 Hz), 7.64 (d, IH, J = 7.6 Hz), 7.44 (dd, IH, J = 7.6, 7.9 Hz), 7.23 (m, IH), 7.16 (d, IH, J = 7.2 Hz), 6.98 (d, IH, J = 7.9 Hz), 6.89 (dd, IH, J = 7.5, 6.8 Hz), 4.75 (s, 2H), 4.43 (d, 2H, J = 6.1 Hz), 3.82 (s, 3H); APCIMS m/z 406 [M + H]+.
Example B-8: N-(2-Phenylethyl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4-yl)sulfanyl- methyljbenzamide
Figure imgf000043_0003
B-8
Example B-8 was prepared in a similar manner to that described for B-l, except that phenethylamine was used in place of 3,4,5-trimethoxyaniline: *H NMR (300 MHz, DMSO-d6) δ 14.13 (s, IH), 8.79 (s, IH), 8.61 (t, IH J = 5.7 Hz), 8.30 (s, IH), 7.93 (s,
IH), 7.70 (d, IH, J = 7.9 Hz), 7.62 (d, IH, J = 7.9 Hz), 7.41 (dd, IH, J = 7.6, 7.9 Hz),
7.16-7.31 (m, 5H), 4.73 (s, 2H), 3.43-3.50 (m, 2H), 2.83 (dd, 2H, J = 7.2, 7.9 Hz);
APCIMS m/z 390 [M + H]+.
Example B-9: N-(2-Methoxyphenyl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4-yl)- sul anylmethyl]benzamide
Figure imgf000044_0001
B-9
Example B-9 was prepared in a similar manner to that described for B-l, except that 2- methoxyaniline was used in place of 3,4,5-trimethoxyaniline: TI NMR (300 MHz, DMSO- 6) δ 14.12 (s, IH), 9.43 (s, IH), 8.81 (s, IH), 8.32 (s, IH), 8.08 (s, IH), 7.87 (d, IH, J = 7.9 Hz), 7.77 (d, IH, J = 7.5 Hz), 7.70 (d, IH, J = 7.9 Hz), 7.48 (dd, IH, J = 7.5, 7.6 Hz), 7.19 (m, IH), 7.09 (d, IH, J = 7.2 Hz), 6.97 (dd, IH, J = 7.1, 8.0 Hz), 4.79 (s, 2H), 3.83 (s, 3H); APCIMS m/z 392 [M + H]+. Example B-10: N-[3-(N-Methyl-N-phenylamino)propyl]-3-[(5-methyl-lH-l,2,4- triazol-3-yl)sulfanylmethyl]benzamide
Figure imgf000044_0002
Example B-10 was prepared in a similar manner to that described for B-l, except that N-(3-aminopropyl)-N-methylaniline was used in place of 3,4,5-trimethoxyaniline, and 3-mercapto-5-methyl-lH-l,2,4-triazole was used in place of 4-mercapto-lH- pyrazolo[3,4-d]pyrimidine: Η NMR (300 MHz, CD3OD) δ 7.80 (s, IH), 7.68 (d, IH, J = 7.9 Hz), 7.52 (d, IH, J = 7.5 Hz), 7.38 (dd, IH, J = 7.5, 8.0 Hz), 7.15 (m, 2H), 6.74- 6.77 (m, 2H), 6.64 (dd, IH, J = 7.1, 7.1 Hz), 4.36 (s, 2H), 3.41-3.45 (m, 4H), 2.93 (s, 3H), 2.38 (s, 3H), 1.85-1.96 (m, 2H); APCIMS m/z 396 [M + H]+. Example B-ll: N-(l,3-Benzodioxyl-5-ylmethyl)-3-[(5-methyl-lH-l,2,4-triazoI-3- yl)sulfanylmethyl]benzamide
Figure imgf000045_0001
Example B-l 1 was prepared in a similar manner to that described for B-l, except that (3,4-methylenedioxy)benzylamine was used in place of 3,4,5-trimethoxyaniline, and 3- mercapto-5-methyl-lH-l,2,4-triazole was used in place of 4-mercapto-lH- pyrazolo[3,4-d]pyrimidine: Η NMR (300 MHz, CD3OD) δ 7.83 (s, IH), 7.71 (d, IH, J = 7.5 Hz), 7.52 (d, IH, J = 7.2 Hz), 7.38 (dd, IH, J = 7.50, 7.6 Hz), 6.76-6.86 (m, 3H), 5.93 (s, 2H), 4.47 (s, 2H), 4.35 (s, 2H), 2.38 (s, 3H); APCIMS m/z 383 [M + H]+. Example B-12: N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(lH-pyrazolo[3,4-d]- pyrimidin-4-yl-sulfanyl)methyl]benzamide
Figure imgf000045_0002
Example B-12 was prepared in a similar manner to that described for B-l, except that 4-cyano-3-trifluoromethylaniline was used in place of 3,4,5-trimethoxyaniline: Η NMR (300 MHz, DMSO-d6) δ 14.07 (s, IH), 10.98 (s, IH), 8.80 (s, IH), 8.44 (s, IH), 8.26-8.31 (m, 2H), 8.15 (d, IH, J = 7.9 Hz), 8.08 (s, IH), 7.89 (d, IH, J = 7.5 Hz), 7.76 (d, IH, J = 7.9 Hz), 7.53 (dd, IH J = 7.50, 7.9 Hz), 4.79 (s, 2H); APCIMS m/z 455 [M + H]+.
Example B-13: N-(3,3-Diphenylpropyl)-3-{[(5-methyl-lH-l,2.4-triazol-3-yl)- sulfanyl]methyl}benzamide
Figure imgf000045_0003
Example B-13 was prepared in a similar manner to that described for B-l, except that 3,3-diphenyl-l-propylamine was used in place of 3,4,5-trimethoxyaniline, and 3- mercapto-5-methyl-lH-l,2,4-triazole was used in place of 4-mercapto-lH- pyrazolo[3,4-d]pyrimidine: Η NMR (300 MHz, CD3OD) δ 7.74 (s, IH), 7.62 (d, IH, J
= 7.6 Hz), 7.50 (d, IH, J = 7.6 Hz), 7.25-7.38 (m, 9H), 7.13-7.18 (m, 2H), 4.35 (s, 2H),
4.05 (dd, IH, J = 7.6, 7.9 Hz), 3.34-3.37 (m, 2H), 2.38 (m, 5H); APCIMS m/z 443 [M
+ H]+.
Example B-14: 3-{[(5-Methyl-lH-l,2,4-triazol-3-yl)-sulfonyl]methyl}-N-phen- ethylbenzamide
Figure imgf000046_0001
Example B-14 was prepared in a similar manner to that described for B-l, except that 2-phenylethylamine was used in place of 3,4,5-trimethoxyaniline, and 3-mercapto-5- methyl- lH-l,2,4-triazole was used in place of 4-mercapto-lH-pyrazolo[3,4- d]pyrimidine: Η NMR (300 MHz, CD3OD) δ 7.78 (s, IH), 7.64 (d, IH, J = 7.9 Hz), 7.51 (d, IH, J = 7.5 Hz), 7.38 (dd, IH, J = 7.5, 7.9 Hz), 7.18-7.33 (m, 5H), 4.35 (s, 2H), 3.57-3.62 (m, 2H), 2.90-2.93 (m, 2H), 2.40 (s, 3H); APCIMS m/z 353 [M + H]+. Example B-15: 3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3-iso- propylphenyl)-benzamide o
Figure imgf000046_0002
B-15
Example B-15 was prepared in a similar manner to that described for B-l, except that 3 -isopropylaniline was used in place of 3,4,5-trimethoxyaniline: *H NMR (300 MHz, DMSO- ) δ 14.13 (s, IH), 10.19 (s, IH), 8.80 (s, IH), 8.31 (s, IH), 8.05 (s, IH), 7.85 (d, IH, J = 7.9 Hz), 7.69 (d, IH, J = 7.9 Hz), 7.61 (m, 2H), 7.48 (dd, IH, J = 7.6, 7.6 Hz), 7.25 (dd, IH, J = 7.5, 8.0 Hz), 6.99 (d, IH, J = 7.9 Hz), 4.78 (s, 2H), 2.83-2.91 (m, IH), 1.21 (d, 6H, J = 6.0 Hz); APCIMS m/z 404 [M + H]\ Example B-16: 3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3-tri- fluoromethyl-5-methoxyphenyl)-benzamide
Figure imgf000047_0001
Example B-l 6 was prepared in a similar manner to that described for B-l, except that 3-trifluoromethyl-5-trifluoiOmethoxyaniline was used in place of 3,4,5- trimethoxyaniline: Η NMR (300 MHz, DMSO-d6) δ 14.13 (s, IH), 10.51 (s, IH), 8.80 (s, IH), 8.30 (s, IH), 8.06 (s, IH), 7.86 (d, IH, J = 7.9 Hz), 7.81 (s, IH), 7.73 (m, 2H), 7.50 (dd, IH, J = 7.50, 8.0 Hz), 6.98 (s, 2H), 6.46-6.50 (m, IH), 4.78 (s, 2H), 3.83 (s, 3H); APCIMS m/z 460 [M + H]+.
Example B-17: 3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3,5-bis- trifluoromethylphenyl)-benzamide
Figure imgf000047_0002
Example B-17 was prepared in a similar manner to that described for B-l, except that 3,5-bis(trifluoromethyl)aniline was used in place of 3,4,5-trimethoxyaniline: :H NMR (300 MHz, DMSO-d6) δ 14.20 (s, IH), 10.92 (s, IH), 8.87 (s, IH), 8.57 (s, 2H), 8.37 (s, IH), 8.17 (s, IH), 7.97 (d, IH, J = 7.9 Hz), 7.89 (s, IH), 7.83 (d, IH, J = 7.6 Hz), 7.60 (dd, IH, J = 7.50, 8.0 Hz), 4.86 (s, 2H); APCIMS m z 498 [M + H]+. Example B-18: 3-[(lH-PyrazoIo[3,4-d]pyrimidin-4-yl)suIfanyImethyl]-N(3-t- butylphenyl)-benzamide
Figure imgf000047_0003
B-18
Example B-18 was prepared in a similar manner to that described for B-l, except that 3-(tert-butyl)aniline was used in place of 3,4,5-trimethoxyaniline: Η NMR (300 MHz, DMSO-d6) δ 14.13 (s, IH), 10.19 (s, IH), 8.81 (s, IH), 8.30 (s, 2H), 8.05 (s, IH), 7.85-7.88 (d, IH, J = 7.6 Hz), 7.75 (s, IH), 7.65-7.71 (m, IH), 7.48 (dd, IH, J = 7.6, 7.9 Hz), 7.26 (dd, IH, J = 7.5, 8.0 Hz), 7.13 (d, IH, J = 7.9 Hz), 4.78 (s, 2H), 1.29
(s, 9H); APCIMS m/z 418 [M + H]+.
Example B-19: 3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(4- isopropylphenyl)-benzamide
Figure imgf000048_0001
Example B-19 was prepared in a similar manner to that described for B-l, except that 4-isopropylaniline was used in place of 3,4,5-trimethoxyaniline: *H NMR (300 MHz, DMSO-d6) δ 14.13 (s, IH), 10.19 (s, IH), 8.80 (s, IH), 8.30 (s, IH), 8.04 (s, IH), 7.84 (d, IH, J = 7.6 Hz), 7.64-7.70 (m, 3H), 7.47 (dd, IH, J = 7.5, 8.0 Hz), 7.21 (d, 2H, J = 8.3 Hz), 4.78 (s, 2H), 2.81-2.90 (m, IH), 1.19 (d, 6H, J = 6.0 Hz); APCIMS m/z 404 [M+H]+.
Example B-20: 3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(4- trifluoromethoxyphenyl)-benzamide
Figure imgf000048_0002
B-20
Example B-20 was prepared in a similar manner to that described for B-l, except that
3-trifmoromefhoxy aniline was used in place of 3,4,5-trimethoxyaniline: *H NMR (300
MHz, DMSO-d6) δ 14.13 (s, IH), 10.54 (s, IH), 8.80 (s, IH), 8.30 (s, IH), 8.06 (s,
IH), 7.93 (s, IH), 7.86 (d, IH, J = 7.6 Hz), 7.71-7.78 (m, 2H), 7.46-7.53 (m, 2H), 7.09
(d, IH, J = 8.3 Hz), 4.79 (s, 2H); APCIMS m/z 446 [M + H]+.
Example B-21: 3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3,5- dimethylphenyl)-benzamide
Figure imgf000048_0003
Example B-21 was prepared in a similar manner to that described for B-l, except that 3,5-dimethylaniline was used in place of 3,4,5-trimethoxyaniline: H NMR (300 MHz, DMSO-ώ?6) δ 14.13 (s, IH), 10.10 (s, IH), 8.80 (s, IH), 8.30 (s, IH), 8.04 (s, IH), 7.83- 7.85 (d, IH, J = 7.5 Hz), 7.68-7.71 (d, IH, J = 7.6 Hz), 7.45-7.50 (dd, IH, J = 7.50, 7.6 Hz), 7.39 (s, 2H), 6.74 (s, IH), 4.78 (s, 2H), 2.26 (s, 6H); APCIMS m/z 390 [M + H]+. Example B-22: 3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyI]-N(3-(2- hydroxyethyl)phenyl)-benzarnide
Figure imgf000049_0001
B-22
Example B-22 was prepared in a similar manner to that described for B-l, except that 3-(l-hydroxyethyl)aniline was used in place of 3,4,5-trimethoxyaniline: ]H NMR (300 MHz, DMSO- 6) δ 14.13 (s, IH), 10.23 (s, IH), 8.80 (s, IH), 8.30 (s, IH), 8.06 (m, IH), 7.86 (d, IH, J = 7.9 Hz), 7.73 (s, IH), 7.74-7.84 (m, 2H), 7.48 (dd, IH, J = 7.6, 7.9 Hz), 7.27 (dd, IH, J = 7.9, 8.0 Hz), 7.06 (d, IH, J = 7.9 Hz), 5.18 (d, IH, J = 3.0), 4.78 (s, 2H), 4.68 (q, IH), 1.32 (d, 3H, J = 9.0 Hz); APCIMS m/z 406 [M + H]+. Example B-23: 3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(4- dimethylaminophenyl)-benzamide
Figure imgf000049_0002
Example B-23 was prepared in a similar manner to that described for B-l, except that 4-dimethylaminoaniline was used in place of 3,4,5-trimethoxyaniline: *H NMR (300 MHz, DMSO-d6) 13.76 (s, IH), 9.63 (s, IH), 8.44 (s, IH), 7.94 (s, IH), 7.66 (s, IH), 7.46 (d, IH, J = 7.9 Hz), 7.301 (d, IH, J = 7.5 Hz), 7.18 (d, IH, J = 9.0 Hz), 7.10 (dd, IH, J = 7.5, 7.6 Hz), 6.35 (d, IH, J = 9.0 Hz), 4.56 (s, 2H), 2.13 (s, 6H); APCIMS m/z 405 [M + H]+. Example B-24: 3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3- trifluoromethylsuIfonylphenyI)-benzamide
Figure imgf000050_0001
B-24
Example B-24 was prepared in a similar manner to that described for B-l, except that 3-(trifluoromethylsulfonyl)aniline was used in place of 3,4,5-trimethoxyaniline: Η NMR (300 MHz, DMSO-d6) δ 14.13 (s, IH), 10.83 (s, IH), 8.80 (s, IH), 8.66 (s, IH), 8.35-8.39 (m, IH), 8.30 (s, IH), 8.09 (s, IH), 7.90 (d, IH, J = 7.9 Hz), 7.85 (m, 2H), 7.75 (d, IH, J = 7.60), 7.53 (dd, IH, J = 7.5, 7.6 Hz), 4.79 (s, 2H); APCIMS m/z 494 [M + H]+.
Example B-25: 3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3- dimethylaminophenyl)-benzamide
Figure imgf000050_0002
B-25
Example B-25 was prepared in a similar manner to that described for B-l, except that 3-dimethylaminoaniline was used in place of 3,4,5-trimethoxyaniline: *H NMR (300 MHz, DMSO-d6) 14.14 (s, IH), 10.06 (s, IH), 8.80 (s, IH), 8.30 (s, IH), 8.04 (s, IH), 7.84 (d, IH, J = 8.0 Hz), 7.680 (d, IH, J = 7.5 Hz), 7.46 (dd, IH, J = 7.5, 7.6 Hz), 7.20 (s, IH), 7.13 (m, 2H), 6.46-6.50 (m, IH), 4.78 (s, 2H), 2.89 (s, 6H); APCIMS m/z 405 [M + H]+. Example B-26:
(a) To an array of 40 μL of 0.25 M solution of different amines (0.01 mmol) in acetonitrile distributed in the eleven columns of a 96-well plate was added 40 μL of 0.25 M solution of triethylamine (0.01 mmol) and the array of reactions was agitated briefly. To each of the wells was added 40 μL of a 0.25 M solution of 3- (chloromethyl) benzoylchloride (0.01 mmol) in acetonitrile and the plate was agitated in a shaker at room temperature for 2 h.
(b) An 0.25 M solution of different mercapto compounds was prepared in DMF and 40 μL (0.01 mmol) and was added in eight different rows to the appropriate intermediate from step (a) above. To each reaction mixture was add approximately 8-15 mg of cesium carbonate and the reactions were heated at 60 °C on a Vortex heater for 16 h. The solvents were removed using the SpeedVac™ apparatus and the crude reaction mixtures were redissolved in DMSO and transferred using a liquid handler to a 1 mL 96-well plate to give a final theoretical concentration of 10 mM.
Example B-27:
Using the general procedure described above in Example B-26, the following compounds were made (wherein for convenience, and as understood in the art, not all hydrogen atoms have been expressly indicated as bonding to each carbon and/or nitrogen atom).
Figure imgf000052_0001
Figure imgf000053_0001
52
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Example C-1: 3-[(5-Cyanoamino-2H-[l,2,4]triazoI-3-yI)suIfanyImethyI]-N-(3,4,5- trimethoxyphenyl)benzamide
Figure imgf000060_0001
To a suspension of 0.300 g (0.73 mmol) of N-(3,4,5-trimethoxyphenyl)-3-[(5-amino- 2H-[l,2,4]triazol-3-yl)sulfanylmethyl]benzamide, A-2, in 10 mL THF was added ethanol until the mixture became homogeneous. The mixture was cooled to 0 °C and 4-methylmorpholine (0.095 mL, 0.86 mmol) was added followed by cyanogen bromide (0.115 g, 1.08 mmol) in one portion. After stirring at 0 to 20 °C over 2 h, the mixture was partitioned between ethyl acetate (50 mL) and brine (50 mL). The aqueous layer was extracted twice with ethyl acetate (50 mL) and the combined organics were washed with brine (25 mL), dried over Na^O^ and concentrated to dryness. The crude residue was triturated with a mixture of MTBE, ethyl acetate, and hexanes to yield the desired product as a pale yellow solid (0.27 g, 85%) that was collected by filtration: mp>165 °C (dec); 1H NMR (DMSO-d6) δ 10.14 (s, IH), 8.19 (s, IH), 7.96 (s, IH), 7.84 (d, IH, J = 7.8 Hz), 7.62 (d, IH, J = 7.7 Hz), 7.49 (t, IH, J = 7.7 Hz), 7.18 (s, 2H), 4.39 (s, 2H), 3.77 (s, 6H), 3.69 (s, 3H). Anal, calc'd for C20H20N6O4S • 0.3 EtOAc: C, 54.53; H, 4.84; N, 18.00; S, 6.87. Found: C, 54.86; H, 4.83; N, 17.91;S, 6.64. Example C-2: 3-[(5-(Methoxycarbonylamino)-2H-[l,2,4]triazol-3-yl)sulfaπyl-
Figure imgf000060_0002
methyl]-N-(3,4,5-Trimethoxyphenyl)benzamide To a suspension of 0.154 g (0.37 mmol) of N-(3,4,5-trimethoxyphenyl)-3-[(5-amino- 2H-[l,2,4]triazol-3-yl)sulfanylmethyl]benzamide, A-2, in dichloromethane (5 mL) at room temperature was added DMF until the mixture became homogeneous. To the mixture was added N-methylmorpholine (0.075 mL, 0.7 mmol) followed by methyl chloroformate (0.050 mL, 0.65 mmol). After stirring room temperature for 2 h, the mixture was partitioned between MTBE (50 mL) and brine (50 mL). The aqueous layer was extracted with 1:1 MTBE/ethyl acetate (2 x 50 mL) and the combined organics were washed with brine (25 mL), dried over Naβ0 , and concentrated to dryness. The crude residue was triturated with MTBE and filtered. The solid was triturated a second time with MTBE/ethyl acetate to yield N-(3,4,5-trimethoxyphenyl)- 3-[(5-methylcarbamoyl-2H-[l,2,4]triazol-3-yl) sulfanylmethyl]benzamide, C-2, as a white solid (0.13 g, 74%): mp >150 °C (dec); 1H NMR (DMSO-d6) δ 10.10 (s, IH), 7.97 (s, IH), 7.84 (d, IH, J = 7.7 Hz), 7.61 (d, IH, J = 7.7 Hz), 7.48-7.45 (m, 2H), 7.21 (s, 2H), 4.38 (s, 2H), 3.90 (s, 3H), 3.77 (s, 6H), 3.64 (s, 3H). Anal, calc'd for C21H23N5O6S • 0.75 H2O: C, 51.79; H, 5.07; N, 14.38; S, 6.58. Found: C, 52.13; H, 5.29; N, 14.11;S, 6.17.
Example C-3 : N-(3,4,5-Trimethoxyphenyl)-3-[(5-acetylamino-2H-[l,2,4]triazol-3- yl)sulfanylmethyl]benzamide
Figure imgf000061_0001
To a solution of 0.15 g (0.37 mmol) of N-(3,4,5-trimethoxyphenyl)-3-[(5-amino-2H- [l,2,4]triazol-3-yl)sulfanylmethyl]benzamide, A-2, in acetic acid (5 mL) at room temperature was added acetic anhydride (0.200 mL, 2.1 mmol). After stirring at room temperature for 1.5 hr, the mixture was added dropwise to a cold solution of phosphate buffer (IM, pH 7, 60 mL). The resulting precipitate was collected by filtration, washed with water, and dried under vacuum. The dried solid was triturated with MTBE/ethyl acetate and filtered to yield N-(3,4,5-trimethoxyphenyl)-3-[(5- acetylamino-2H-[l,2,4]triazol-3-yl) sulfanylmethyl]benzamide, C-3, as a white solid (0.12 g, 71%): mp 196-201 °C; 1H NMR (DMSO-d6) δ 10.14 (s, IH), 8.02 (s, IH), 7.85 (d, IH, J = 7.8 Hz), 7.65 (d, IH, J = 7.8 Hz), 7.49 (t, IH, J = 7.7 Hz), 7.22 (s, 2H), 4.40 (s, 2H), 3.78 (s, 6H), 3.65 (s, 3H), 2.50 (s, 3H, obscured by DMSO). Anal. calc'd for C21H23N5O5S«0.9 H2O: C, 53.24; H, 5.28; N, 14.78; S, 6.77. Found: C,
53.28; H, 4.98; N, 14.48; S, 6.68.
Example D-l: N-(4-Isopropyl-3-methylphenyl)-3-[(pyrazin-2-yl)methyl- sulfanyl]benzamide
Figure imgf000062_0001
-1a
Figure imgf000062_0002
(a) A suspension of methyl pyrazine (5 g, 53 mmol) and N-bromosuccinimide (9.45g, 53 mmol) in carbon tetrachloride (200 mL) was heated at reflux while exposed to a 100 watt light source. After 4 hr, the dark mixture was allowed to cool to room temperature and was decanted. The supernatant was filtered and the filtrate reduced to -25 mL volume then passed through silica gel using a gradient of 0% to 5% ethyl acetate in CHC13. Decomposition was evident upon concentration of chromatographed product. The residue was taken up in CH2C12, washed with water, dried over sodium sulfate, and concentrated cold. Unstable oily 2-(bromomethyl)pyrazine, D-la, (2 g, 22%) was used quickly in next reaction: 1H NMR (CDC13) δ 8.72 (s, IH), 8.55 (d, IH, J = 1.8 Hz), 8.51 (d, IH, J = 2.5 Hz), 4.56 (s, 2H). (b) 3-[(Pyrazin-2-yl)methylsulfanyl]benzoic acid, D-lb, was prepared in a manner similar to that described in example A-1, step (b): mp 131-135 °C.
(c) To a solution of 3-[(pyrazin-2-yl)methylsulfanyl]benzoic acid, D-lb, (0.15 g, 0.61 mmol), 4-isopropyl-3-methylaniline hydrochloride (0.113 g, 0.61 mmol), and triethylamine (0.09 mL, 0.65 mmol) in 2 mL DMF at room temperature was added EDC (0.116 g, 0.61 mmol). After stirring at room temperature for 24 hr, the mixture was partitioned between ethyl acetate (30 mL) and brine (30 mL). The aqueous layer was extracted twice with ethyl acetate (30 mL) and the combined organics were washed twice with water (20 mL), once with brine(25 mL), dried over sodium sulfate, and concentrated to dryness. The residue was filtered through silica gel using 10% methanol in chloroform and then purified by radial chromatography with a 2 mm rotor using a gradient of 0% to 50% ethyl acetate in hexanes as eluent to yield N-(4- isopropyl-3-methylphenyl)-3-[(ρyrazin-2-yl)methylsulfanyl]benzamide, D-l, as a pale amber oil (0.09g, 35%): *H NMR (DMSO-d6) δ 10.10 (s, IH), 8.68 (s, IH), 8.57 (d, IH, J = 1.6 Hz), 8.51 (d, IH, J = 2.4 Hz), 7.92 (s, IH), 7.76 (d, IH, J = 7.7 Hz), 7.59 (d, IH, J = 7.9 Hz), 7.55 (d, IH, J = 8.3 Hz), 7.52 (d, IH, J = 1.9 Hz), 7.46 (t, IH, J = 7.8 Hz), 7.21 (d, IH, J = 8.4 Hz), 4.50 (s, 2H), 3.11-3.05 (m, IH), 2.30 (s, 3H), 1.18 (d, 6H, J = 6.8 Hz). Anal, calc'd for C22H23N3OS.0.4 H2O: C, 68.68; H, 6.24; N, 10.92; S, 8.33. Found: C, 68.86; H, 6.11; N, 10.70; S, 8.23 Example D-2: N-(2-Methylquinolin-6-yl)-3-[(pyrazin-2-yl)methylsulfanyl]- benzamide
Figure imgf000063_0001
D-2
Example D-2 was prepared in a similar manner to that described for D-l, except that 6- amino-2-methylquinoline was used in place of 4-isopropyl-3-methylaniline in step (c): mp 102-105 °C; 1H NMR (DMSO-d6) δ 10.53 (s, IH), 8.69 (s, IH), 8.57 (d, IH, J = 1.3 Hz), 8.52 (d, IH, J = 2.4 Hz), 8.46 (s, IH), 8.22 (d, IH, J = 8.4 Hz), 7.80-7.97 (m, 2H), 7.91 (d, IH, J = 9.1 Hz), 7.82 (d, IH, J = 7.8 Hz), 7.63 (d, IH, J = 7.8 Hz), 7.51 (d, IH, J = 7.8 Hz), 7.40 (d, IH, J = 8.5 Hz), 4.52 (s, 2H), 2.65 (s, 3H). Anal, calc'd for C22H18N4OS • 0.3 H2O • 0.2 EtOAc: C, 66.87; H, 4.97; N, 13.68; S, 7.83. Found: C, 66.77; H, 5.18; N, 13.40; S, 7.61.
Example D-3: N-(2-Methyl-quinolin-6-yl)-3-(pyridin-3-ylmethylsulfanyl)- benzamide dihydrochloride
Figure imgf000064_0001
D-3
Example D-3 was prepared in a similar manner to that described for D-l, except that 3- picolyl chloride was used in place of 2-(bromomethyl)pyrazine in step (b), and 6- amino-2-methylquinoline was used in place of 4-isopropyl-3-methylaniline in step (c): HPLC R, = 12.2 min.; TLC R = 0.4 (5% methanol/chloroform); Η ΝMR (500 MHz, DMSO-d6 w/ D2O) δ 8.95 (d, IH, J = 8.6 Hz), 8.77-8.73 (m, 2H), 8.66 (dd, IH, J = 1.1, 5.5 Hz), 8.41-8.33 (m, 2H), 8.20 (d, IH, J = 9.2 Hz), 7.97-7.83 (m, 4H), 7.66-7.53 (m, 2H), 4.51 (s, 2H), 2.94 (s, 3H); 13C ΝMR (75 MHz, DMSO-d6 w/ D2O) δ 167.8, 158.4, 146.8, 146.4, 144.5, 143.8, 140.5, 139.5, 136.7, 136.6, 136.4, 134.9, 131.7, 130.5, 130.4, 129.2, 128.4, 128.2, 126.0, 122.7, 119.0, 35.2, 22.3; MS (ESI) m/z 386 [M + H]\ Anal, calc'd for C23H19Ν3O2S • 2 HCI • 0.3 H2O: C, 59.56; H, 4.69; N, 9.06; S, 6.91. Found: C, 59.56; H, 4.66; N, 9.00; S, 6.82. Example E-l : N-(2-methyl-quinolin-6-yl)-3-[{5-(phenylamino)-2-H-pyrazol-3- yl}methylsulfanyl]benzamide
Figure imgf000065_0001
E-1a
Figure imgf000065_0002
Figure imgf000065_0003
E-1
(a) To a solution of 3-thiobenzoic acid (5.0 g, 32.4 mmol) in 150 mL of acetone was added cesium carbonate (22.2 g, 68.1 mmol) and 2-chloro-N -methoxy-N - methylacetamide (4.9 g, 35.7 mmol). After stirring for lh, the reaction was quenched with dropwise addition of IN HCI. The reaction mixture was partitioned between 100 mL of ethyl acetate and 50 mL of IN HCI, dried over sodium sulfate, and evaporated. The residue was chromatographed on silica gel using 33% hexane/66% ethyl acetate/1% acetic acid to afford 2-[(3-carboxyphenyl)sulfanyl]-Ν-methoxy-Ν-methyl- acetamide, E-la, as a white solid 8.5 g (96%). Η NMR (500 MHz, CDCL) δ 8.15 (t, IH, J = 1.5 Hz), 8.06 (br s, IH), 7.92 (dt, IH, J = 7.8, 1.2 Hz), 7.68 (dq, IH, J = 6.0, 1.2 Hz), 3.88 (s, 2H), 3.74 (s, 3H), 3.22 (s, 3H).
(b) To a solution of 2-[(3-carboxyphenyl)sulfanyl]-N-methoxy-N-methylacetamide, E- la, (0.84 g, 3.1 mmol) and EDC (0.66 g, 3.4 mmol) in 10 mL of THF was added 6- amino-2-methylquinoline (0.54 g, 3.4 mmol). After 3 h, the solution was concentrated and the residue was purified by column chromatography with 1:2 hexane/ethyl acetate to afford 3-[(N-methoxy-N-methylcarbamoyl)methylsulfanyl]-N-(2-methylquinolin-6- yl)benzamide, E-lb, as a white crystalline solid 0.89 g (72 %): Η NMR (500 MHz, CDC13) δ 8.50 (br s, IH), 8.45 (d, IH, J = 1.2 Hz ), 8.05-7.97 (m, 3H), 7.73 (dd, IH, J = 7.8, 1.5 Hz), 7.57 (dt, IH, J = 13.4, 4.8 Hz), 7.56 (d, IH, 4.5 Hz), 7.39 (t, IH, J = 4.5 Hz), 7.27 (d, IH, J = 4.8 Hz), 3.88 (s, 2H), 3.80 (s, 3H), 3.24 (s, 3H), 2.71 (s, 3H); MS (ESI): Calculated for C21H21N3O3S (M+H+): 395. Found: 395. Anal, calc'd for C20H24N2O6S • 0.2 H2O: C, 63.20; H, 5.41; N, 10.53; S, 8.03. Found: C, 63.03; H, 5.32; N, 10.35; S, 7.92. (c) To a solution of thioacetanilide (0.30 g, 1.95 mmol) in 10 mL of anhydrous THF at -78 °C was added n- BuLi (1.56 mL, 3.89 mmol, 2.5 M in hexane) over a 5 min period. The mixture was warmed to 0 °C for lh, then recooled to -78 °C. To this solution was added a solution of 3-[(N-methoxy-N-methylcarbamoyl)methylsulfanyl]- N-(2-methylquinolin-6-yl)benzamide, E-lb, (0.35 g, 0.89 mmol) in 5 mL in THF, and the resulting solution was warmed to 0 °C. After 1 h, a solution of 1:1 methanol: acetic acid (1.0 mL) was added dropwise over 1 min. The reaction solution was partitioned between 30 mL of MTBE and extracted with IN hydrochloric acid (2 x 20 mL) and saturated brine (1 x 30 mL), and the organic layer was dried over sodium sulfate and concentrated to give a yellow oil. Purification using column chromatography with 3:1 hexane/ethyl acetate afforded N-(2-methyl-quinolin-6-yl)-[2-oxo-3- phenylthiocarbamoyl-propylsulfanyl]benzamide, E-lc, as a pale yellow foam 0.25 g (56%): Η NMR (500 MHz, CDC13) δ 8.66 (br s, IH), 8.26 (br s, IH), 7.94-7.85 (3H, m), 7.81 (br s, IH), 7.71-7.66 (m, 2H), 7.51 (br s, IH), 7.45-7.41 (m, IH), 7.26-7.21 (m 4H), 7.13-7.10 (m, IH), 3.50 (br s, 2H), 2.67 (s, 3H), 2.03 (s, 2H); MS (ESI): Calculated for C27H23N3O2S2 (M+H+): 486 Found: 486.
(d) To a solution containing N-(2-methyl-quinolin-6-yl)-[2-oxo-3- phenylthiocarbamoyl-propylsulfanyl]benzamide, E-lc, in 4 mL of ethanol was added acetic acid (0.038 mL, 0.67 mmol) followed by hydrazine monohydrate (0.032 mL, 0.63 mmol). The solution was stirred for 2 h, then concentrated to give the crude product as an amber oil. Purification by radial chromatography (1mm silica plate) with 90% ethyl acetate/10% methanol as eluant afforded a tan solid. Precipitation of product from dichloromethane by dropwise addition of hexane gave 0.12 g (58%) of N-(2-methyl-quinolin-6-yl)-3 - [ { 5-(phenylamino)-2-H-pyrazol-3 -yl } methylsulf anyl] - benzamide, E-l, as a white solid: mp 172-174 °C. HPLC Rt = 13.51 min.; Η NMR (500 MHz, Acetone-d6) δ 8.40-8.38 (m, IH), 8.01 (d, IH, J = 8.5 Hz), 7.91 (s, IH),
7.86 (dd, IH, J = 8.0, 1.2 Hz), 7.76 (t, 2H, J = 9.5 Hz), 7.47 (d, IH, J = 8.0 Hz), 7.35 (t, IH, J = 7.5 Hz), 7.24 (d, IH, J = 8.5 Hz), 7.16 (br s, 2H), 7.02 (t, 2H, J = 7.0 Hz), 6.59
(t, IH, J = 7.0 Hz), 5.73 (s, IH), 4.18 (s, 2H), 2.52 (s, 3H); HRMS (FAB): Calculated for C27H23N5OS (M+H+): 466.1702. Found: 466.1715. Anal, calc'd for C27H23N5OS«0.5
CH2C12: C, 65.05; H, 4.76; N, 13.79; S, 6.31. Found C, 64.94; H, 4.72; N, 13.47; S,
6.51.
Example E-2 N-(3,4,5-trimethoxyphenyl)-3-[2-(5-phenylamino-2H-pyrazol-3- yl)ethyl]benzamide.
Figure imgf000067_0001
E-2
Example E-2 was prepared in a similar manner to that described for E-l, except that 3,4,5-trimethoxyaniline was used in place of 6-amino-2-methylquinoline in step (b): mp 67-69 °C. 1H NMR (500 MHz, CDC13) δ 8.20 (br s, IH), 7.75 (br s, IH), 7.64 (d, IH, J = 7.8 Hz), 7.42 (d, IH, J = 7.2 Hz), 7.29 (t, IH, J = 7.5 Hz), 6.96-6.91 (m, 3H), 6.83 (t, IH, J = 7.2 Hz), 5.89 (s, IH), 4.05 (s, 2H), 3.80 (s, 3H), 3.75 (s, 6H); HRMS (FAB): Calculated for C26H26N4O4S (M+H+): 491.1753 Found: 491.1737. Anal, calc'd for C26H26N4O4S • 0.4 Et2O: C, 63.72; H, 5.81; N, 10.77; S, 6.16. Found: C, 63.47; H, 5.88; N, 10.52; S, 6.34.
Example F-l 3-[{5-((E)-2-(4-Hydroxy-3-methoxyphenyl)ethenyl)-2H-pyrazol-3- yl}methylsulfanyl]-N-(2-methylquinolin-6-yl)benzamide
+ H2NS
Figure imgf000068_0001
Figure imgf000068_0002
Figure imgf000068_0003
(a) To 5 mL of ethanol was added (E)-4-(4-hydroxy-3-methoxy-phenyl)-but-3-en-2- one (0.50 g, 2.60 mmol), 1 g of 4 A molecular sieves, acetic acid (0.16 mL, 2.60 mmol), and hydrazine carboxylic acidt-butyl ester (0.34 g, 2.60 mmol). After stirring for 18 h, the mixture was filtered and the filtrate was concentrated to give a crude product as a tan solid, which was chromatographed on silica with 2: 1 hexane/ethyl acetate to furnish N-[3-(4-hydroxy-3-methoxy-phenyl)-l-methyl-(E)-2- propenylidene]hydrazinecarboxylic acid t-butyl ester, F-la, 0.68 g (86%) as a white solid. TLC Rf = 0.45 (40 % hexane/60 % ethyl acetate). Η NMR (500 MHz, CDC13) δ 7.87 (br s, IH), 7.11-7.08 (m, 2H), 6.98-6.52 (m, 2H), 6.89 (d, IH, J = 8.0 Hz), 5.82 (br s, IH), 3.93 (s, 3H), 2.13 (s, 3H), 1.53 (s, 9H); LRFAB: Calculated for C16H22N2O4 (M+H+): 307. Found: 307.
(b) To a solution of N-[3-(4-hydroxy-3-methoxy-phenyl)-l-methyl-(E)-2- propenylidene]hydrazinecarboxylic acid t - butyl ester, F-la, (0.50 g, 1.63) in 5 mL of dichloromethane was added diisopropylethylamine (64 mL, 3.92 mmol) and chlorotriisopropylsilane (0.77 mL, 3.59 mmol). After 20 h, the mixture was concentrated and the residue was partitioned between 30 mL of MTBE and saturated sodium bicarbonate (2 x 30 mL). The organic layer was filter through 10 g of silica and concentrated to afford a yellow oil. Purification was accomplished using chromatotron with a 2 mm rotor eluting with 80% hexane/20% ethyl acetate to give 0.48 g (65%) of N-{3-[4-methoxy-3-(triisopropyl-silanyloxy)-phenyl]-l-methyl-(E)-2-propenylidene]- hydrazinecarboxylic acid t-butyl ester, F-lb, as a white solid: TLC Rf = 0.82 (60% hexane/40% ethyl acetate); Η NMR (500 MHz, CDC13) δ 7.47 (br s, 1H),7.02 (d, IH, J = 1.5 Hz), 6.94 (d, IH, J = 16.5 Hz), 6.87 (dd, IH, J = 8.3 Hz, 1.5 Hz), 6.82 (d, IH, J = 8.0 Hz), 6.77 (d, IH, J = 16.5 Hz), 3.81 (s, 3H), 2.02 (s, 3H), 1.50 (s, 9H), 1.29-1.23 (m, 3H), 1.09 (d, 18H, J = 7.0 Hz); LRFAB: Calculated for C25H42N2O4Si (M + H+): 463; Found: 463. (c) To a -78 °C solution of N-{3-[4-methoxy-3-(triisopropylsilanyloxy)-phenyl]-l- methyl-(E)-2-propenylidene]hydrazinecarboxylic acid t-butyl ester, F-lb, (0.33 g, 0.72 mmol) in 10 mL of anhydrous THF was added n- BuLi (0.61 mL, 3.89 mmol, 2.5 M in hexane) over 5 minutes. After the addition was complete, the mixture was warmed to 0 °C for 1 h and then recooled to -78 °C. To the resulting mixture was added a solution of 3-[(N-methoxy-N-methylcarbamoyl)methylsulfanyl]-N-(2-methylquinolin-6- yl)benzamide, E-lb, (0.14 g, 0.36 mmol) in 5 mL in THF, and the resulting mixture was warmed to 0 °C. After 1 h, the reaction was cooled to -78 °C and quenched by adding 1:1 acetic acid:methanol (1 mL). The reaction mixture was then partitioned between 30 mL of MTBE and 1 N aq. HCI (2 x 20 mL). The organic layer was dried over sodium sulfate and concentrated to give a yellow oil. Purification by silica gel chromatography, with 2:1 hexane/ethyl acetate as eluant, afforded 0.12 g (43%) of N2- [ 1 - { 4-methoxy-3 -(triisopropylsilanyloxy)-phenyl } -6- { 3-(2-methyl-quinolin-6- ylcarbamoyl)phenylsulfanyl}-5-oxo-(E)-hex-l-en-3-ylidene]-hydrazinecarboxylic acid t-butyl ester, F-lc, as a pale yellow foam: TLC Rf = 0.50 (60% ethyl acetate/hexane); lLrL NMR (500 MHz, CDC13) δ 8.64 (s, IH), 8.12-8.10 (m, 2H), 8.03 (br s, IH), 7.90 (d, IH, J = 8.0 Hz), 7.77 (d, 2H, J = 7.0 Hz), 7.46 (t, IH, J = 8.0 Hz), 7.31 (d, IH, J = 5.0 Hz), 6.91-6.78 (m, 5H), 3.92-3.60 (m, 4H), 2.73 (s, 3H), 1.54-1.43 (m, 3H), 1.20 (s, 9H), 1.07 (d, 18H, J = 9.5 Hz), (d) To a solution of 0.10 g (0.14 mmol) of N2-[l-{4-methoxy-3- (triisopropylsilanyloxy)-phenyl } -6- { 3-(2-methyl-quinolin-6- ylcarbamoyl)phenylsulfanyl}-5-oxo-(E)-hex-l-en-3-ylidene]-hydrazinecarboxy lie acid t-butyl ester, F-lc, in 5 mL of dichloromethane was added 5 mL of trifluoroacetic acid. After 1 h, the reaction mixture was concentrated, 5 mL of toluene added, and the solvent removed again to give an amber oil. The residue was purified by silica gel chromatography with 1:1:1 hexane/dichloromethane/ethyl acetate as eluant to give 0.089 g (92%) of 3-[{5-{(E)-2-(3-methoxy-4-triisopropylsilanyloxyphenyl)ethenyl}- 2H-pyrazol-3-yl}methylsulfanyl]-N-(2-methylquinolin-6-yl)benzamide, F-ld, as tan solid: TLC Rf = 0.18 (50% ethyl acetate/hexane); Η NMR (300 MHz, Acetone-d6) δ 10.21 (br s, IH), 8.95 (d, IH, J = 1.5 Hz), 8.71 (d, IH, J = 8.4 Hz), 8.43-8.31 (m, 3H), 8.10 (d, IH, J = 7.5 Hz), 7.88-7.82 (m, 2H), 7.85 (t, IH, J = 7.8 Hz), 7.41-7.19 (m, 4H), 7.11 (d, IH, J = 8.1 Hz), 6.69 (s, IH), 4.57 (s, 2H), 4.10 (s, 3H), 3.05 (s, 3H), 1.57-1.47 (m, 3H), 1.34 (d, 18H, J = 8.5 Hz); MS (ESI): Calculated for C39H46N3OSi (M + H+): 678; Found: 678.
(e) To a solution of 3-[{5-{(E)-2-(3-methoxy-4-triisopropylsilanyloxyphenyl)ethenyl}- 2H-pyrazol-3-yl }methylsulfanyl]-N-(2-methylquinolin-6-yl)benzamide, F-ld, (0.057 g, 0.084 mmol) in 5 mL THF was added tetrabutylammonium fluoride (IM) in tetrahydrofuran (0.093 mL, 0.092 mmol). After 3 h, the solution was concentrated and the residue was partitioned between 20 mL of ethyl acetate and 20 mL of IM phosphate buffer at 7.0 pH. The organic layer was filtered through 10 g of silica with 50 mL dichloromethane and concentrated to give the crude product as an amber oil. The residue was further purified by radial chromatography on a 1 mm plate with 3:1 hexane/ethyl acetate as eluant. The purified product was dissolved in 1 mL of dichloromethane and hexane was added dropwise to precipitate 0.34 g (77%) of 3-[{5- ((E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl)-2H-pyrazol-3-yl}methylsulfanyl]-N-(2- methylquinolin-6-yl)benzamide, F-l, as a white solid: HPLC Rt = 13.12 min.; TLC Rf = 0.30 (50% ethyl acetate/hexane); Η NMR (500 MHz, CDCL.) δ 9.67 (br s, IH), 8.41 (br s, IH), 8.03 (d, IH, J = 8.5 Hz), 7.89-7.87 (m, 2H), 8.79 (d, IH, J = 9.0 Hz), 7.71 (d, IH, J = 7.5 Hz), 7.33 (t, IH, J = 8.0 Hz), 7.25 (d, IH, J = 8.5 Hz), 7.01 (s, IH), 6.78 (d, IH, J =16.5 Hz), 6.83-6.78 (m, 2H), 6.67 (d, IH, J = 8 Hz), 6.29 (s, IH), 4.19 (s, 2H), 3.74 (s, 3H), 2.53 (s, 3H). HRMS (FAB): Calculated for C30H26N4O3S (M+H+): 655.0780 Found: 655.0804. Anal, calc'd for CJrϊ iΛ03S «0.8 EtOAc: C, 67.23; H, 5.51; N, 9.45; S, 5.41. Found: C, 67.08; H, 5.60; N, 9.73; S, 5.45. Example F-2: 3-[5-(2-(3,4-Dimethoxyphenyl)ethenyl)-2H-pyrazol-3-yl)methyl- sulfanyl]-N-(2-methylquinolin-6-yl)benzamide
Figure imgf000071_0001
Example F-2 was prepared in a similar manner to that described for F-1, except that acetophenone was used in place of 4-(4-hydroxy-3-methoxy-phenyl)-but-3-en-2-one in step (a), and the protection/deprotection steps (b) and (e) were not needed: mp 99-101
°C; TLC Rf = 0.50 (75% dichloromethane/25% ethyl acetate); HPLC Rt = 14.04 min.;
Η NMR (500 MHz, CDCL) δ 8.33 (br s, IH), 8.21 (d, IH, J = 2.0 Hz) 7.95 (br s, IH),
7.80 (d, IH, J = 8.5 Hz), 7.75 (d, IH, J = 9.1 Hz), 7.70 (d, IH, J = 7.5 Hz), 7.61 (d, 2H, J = 7.5 Hz), 7.51 (dd, IH, J = 9.3, 2.5 Hz), 7.43 (d, IH , J = 8.0 Hz), 7.32-7.25 (m,
5H), 7.15 (d, 8.5 Hz), 6.57 (s, IH), 4.26 (s, 2H), 2.61 (s, 3H). HRMS (FAB):
Calculated for C27H22N4OS (M + H+): 451.1593. Found: 451.1580.
Anal, calc'd for C27H22N4OS»0.8 EtOAc: C, 70.42; H, 5.30; N, 11.33; S, 6.48. EtOAc
Found: C, 70.39; H, 5.34; N, 11.29; S, 6.48. Example F-3. 3-(2-{5-[(E)-2-(3,4-Dimethoxyphenyl)ethenyl]-2H-pyrazoI-3-yl}- ethyl)-N-(3-methyl-4-isopropylphenyl)-benzamide
Figure imgf000071_0002
F-3 Example F-3 was prepared in a similar manner to that described for F-1, except that (E)-4-(3,4-dimethoxyphenyl)-but-3-en-2-one was used in place of (E)-4-(4-hydroxy-3- methoxyphenyl)-but-3-en-2-one in step (a), N-(4-isopropyl-3-methyl-phenyl)-3-[2-(N- methoxy-N-methylcarbamoyl)-ethyl]benzamide, G-lf, (from Example G-l, step (f)) was used in place of 3-[(N-methoxy-N-methylcarbamoyl)methylsulfanyl]-N-(2- methylquinolin-6-yl)benzamide, E-lb, in step (c) and the protection/deprotection steps (b) and (e) were not needed: HPLC Rt = 16.37 min.; Η NMR (300 MHz, CDCL δ 7.71 (br s, IH), 7.69-7.66 (m, 2H), 7.44-7.17 (m, 5H), 7.01-6.81 (m, 5H), 6.25 (s, IH), 3.89 (d, 6H, J = 1.5 Hz), 3.12-3.01 (m, 5H), 2.32 (s, 3H), 1.20 (d, 6H, J = 5.1 Hz); HRMS (FAB): Calculated for m/z C32H35N3O3 (M+Cs+): 642.1733, Found: 642.1712. Anal, calc'd for C32H35N3O3: C, 75.42; H, 6.92; N, 8.24. Found C, 75.45; H, 7.08; N, 8.16.
Example F-4: 4-Fluoro-3-[{5-((E)-l-propenyI)-2H-pyrazol-3-yl}methoxy]-N-[4- (pyrrolidin-l-yl)-3-trifluoromethylphenyl]benzamide
Figure imgf000072_0001
F-4 Example F-4 was prepared in a similar manner to that described for F-1, except that (E)-3-penten-2-one was used in place of (E)-4-(4-hydroxy-3-methoxyphenyl)-but-3- en-2-one in step (a), 4-fluoro-N-[4-(pyrrolidin-l-yl)-3-trifluoromethylphenyl]-3-[2-(N- methoxy-N-methylcarbamoyl)methoxy]benzamide, (prepared in a similar manner as described for 4-fluoro-N-[4-(imidazol-l-yl)-3-trifluoromethyl-phenyl]-3-[(N-methoxy- N-methylcarbamoyl)methoxy]benzamide, J-ld, in Example J-1) was used in place of 3-[(N-methoxy-N-methylcarbamoyl)methylsulfanyl]-N-(2-methylquinolin-6- yl)benzamide, E-lb, in step (c) and the protection/deprotection steps (b) and (e) were not needed: HPLC Rt = 16.27 min. Η NMR (300 MHz, CDC13) δ 7.75 (m, 4H), 7.45 (d, IH, J = 8.7 Hz), 7.42-7.37 (m, IH), 7.35-7.28 (m, 2H), 7.15 (t, IH, J = 8.4 Hz), 7.00 (d, IH, J = 8.7 Hz), 6.56 (d, IH, J = 8.9 Hz), 6.37 (s, IH), 6.27-6.15 (m, 2H), 5.60 (s, IH), 5.23 (s, IH), 3.30-3.29 (m, 4H), 1.98-1.95 (m, 4H), 1.92 (d, 3H, J = 6.3 Hz); MS (ESI): m/z Calculated for C25H24F4N4O2 (M+H+): 489, Found:489. Anal, calc'd for C25H24F4N4O2: C, 61.47; H, 4.95; N, 11.47. Found C, 61.32; H, 5.06; N 11.33. Example F-5: 3-(2-{5-[(E)-2-(3,4-Dimethoxyphenyl)ethenyl]-2H-pyrazoI-3-yI}- ethyl)-N-(3-methyl-4-isopropyIphenyl)-benzamide
Figure imgf000073_0001
Example F-5 was prepared in a similar manner to that described for F-3, except that (E)-4-(pyridin-3-yl)-3-buten-2-one was used in place of (E)-4-(3,4-dimethoxyphenyl)- but-3-en-2-one in step (a), and 4-[4-(t-butoxycarbonyl)piperazin-l-yl]-3- trifluoromethylaniline, prepared according to the procedure described in WO 99/21845 (p. 58) for the preparation of l-methyl-4-(4-nitrophenyl)piperazine, was used in place of 4-isopropyl-3-methylaniline in step (d) of Example G-1, and the final deprotection step (e) was carried out in a manner similar to that described in Example G-10: HPLC Rt = 13.53 min.; Η NMR (300 MHz, DSMO-d6) δ 8.69 (s, IH), 8.44 (d, IH, J = 3.3 Hz), 8.14 (s, IH), 8.07-7.82 (m, 2H), 7.86 (s, IH), 7.81-7.79 (m, IH), 7.54-7.43 (m, 3H), 7.39-7.37 (m, IH), 7.25-7.04 (m, 2H), 310-2.98 (m, 4H), 2.83-2.78 (m, 8H); HRMS (FAB): Calculated for C30H29 F3N 6O (M+H+): 547.2433 Found: 547.2445. Anal, calc'd for C28H30N4O«0.5 H2O • 0.2 CH2C12: C, 63.35; H 5.35; N, 14.68. Found C, 63.26; H, 5.38; N 14.25. Example G-1: N-(4-Isopropyl-3-methyl-phenyl)-3-{2-[5-(4-(methylsuIfamoyl)- phenylamino)-2H-pyrazol-3-yI]-ethyl}-benzamide
Figure imgf000074_0001
G-1 a: R =H G-1c G-1b: R = e
Figure imgf000074_0002
G-1d
Figure imgf000074_0003
hydrazine, AcOH
Figure imgf000074_0004
Figure imgf000074_0005
G-1 h G-1
(a) To a solution of 4-acetylamino-benzenesulfonyl chloride (2.00 g, 8.56 mmol) in 25 mL of DMF was added 4-dimethylaminopyridine (0.11 g, 0.86 mmol) and diphenylaminomethane (1.79 mL, 10.27 mmol). After 4 h, the reaction mixture was added to 125 mL of water, and the precipitate was collected by filtration, washed with diethyl ether (2 x 20 mL), then dried under high vacuum for 4 h to afford 1.98 g (61%) of N-(diphenylmethyl)-4-(acetylamino)benzenesulfonamide, G-la: HPLC Rt =12.90 min.; Η NMR (500 MHz, CDCL) δ 10.20 (br s, IH), (8.82 (d, IH, J = 2.0 Hz), 7.57 (s, 4H), 7.24-7.20 (m, 8H), 7.18-7.13 ( , 2H), 5.58-7.52 (m, IH), 3.38 (s, 3H); LRFAB: Calculated for C21H20N2O3S (M+H+): 381 Found:381. (b) To DMF (15 mL) was added N-(diphenylmethyl)-4-
(acetylamino)benzenesulfonamide, G-la, (1.50 g, 3.94 mmol), potassium carbonate (1.37 g, 9.86 mmol), and iodomethane (0.37 mL, 5.93 mmol). The reaction mixture was stirred for 3 h at 60 °C, cooled to 25 °C, and partitioned between 50 mL of MTBE and IN HCI (2 x 50 mL). The organic layer was dried over sodium sulfate and concentrated to give an amber oil, which was purified by chromatography on silica gel (3:1 hexane:ethyl acetate) to give 1.50 g (98%) of N-(diphenylmethyl)-N-methyl-4- (acetylamino)benzenesulfonamide, G-lb: TLC Rf = 0.62 40% hexane/ethyl acetate; Η NMR (300 MHz, CDCL) δ 7.67-7.64 (m, IH), 7.58-7.52 (m, 2H), 7.28-7.23 (m, 8H), 7.21-7.08 (m, 3H), 6.47 (s, IH), 2.68 (s, 3H), 2.20 (s, 3H).
(c) To a solution of 2.00 g, (5.30 mmol) of N-(diphenylmethyl)-N-methyl-4- (acetylamino)benzenesulfonamide, G-lb, in toluene (30 mL) was added 2,4-bis(4- methoxyphenyl)-l,3-dithia-2,4-diphosphetane-2,4-disulfide (1.07 g, 2.64 mmol). The solution was warmed to 100 °C for 2 h then cooled to 25 °C. The reaction mixture was filtered through a silica gel plug using 50 mL of MBTE and concentrated. The residue was purified by chromatography on silica gel (5:1 hexane/ethyl acetate) to afforded 1.62 g (77%) of 4- [N-(diphenylmethyl)-N-methylsulfamoyl] -thioacetanilide, G-lc, as a yellow oil: HPLC Rt =18.67 min.; Η NMR (300 MHz, CDCL) δ 7.84 (d, IH, J = 8.7 Hz), 7.72 (d, IH, J = 8.5 Hz), 7.28-7.25 (m, 8H), 7.09-7.07 (m, 2H), 6.46 (s, IH), 2.77 (s, 3H), 2.56 (s, 3H).
(d) To a solution of 5.00 g (33.26 mmol) 3-formylbenzoic acid in dichloromethane at 0 °C was added oxalyl chloride (3.48 mL, 39.92 mmol) and DMF (0.01 mL). The reaction was stirred for 3 h at 25 °C, and then concentrated to dryness. The residue (2.1 g, 12.45 mmol) was dissolved in dichloromethane (30 mL) and 4-isopropyl-3- mefhylanilinerHCl (2.55 g, 13.70 g) added, followed by diisopropylethylamme (4.48 mL). After stirring for 2 h, the solution was washed with sat. sodium bicarbonate (2 x 20 mL) and IN HCI (2 x 20 mL) and the organic layer dried over sodium sulfate and concentrated to dryness. The residue was purified on silica gel (3:1 hexane:ethyl acetate) to provide 2.99 g (90%) of 3-formyl-N-(4-isopropyl-3- methylphenyl)benzamide, G-ld, as a off-white solid: Η NMR (300 MHz, CDC13) δ 10.12 (s, IH), 8.60-8.58 (m, IH), 8.38-8.36 (m, IH), 8.21-8.15 (m, 2H), 8.07-8.04 (m, IH), 7.93 (br s, IH), 7.71-7.67 (m, IH), 7.44 (br s, IH), 7.27-7.24 (s, IH), 3.15-3.10 (m, IH), 2.35 (s, 3H), ), 1.23 (d, 6H, J = 6.7 Hz).
(e) To a solution of 2-diethyl (N-methoxy-N methyl-carbamoylmethyl)phosphonate (1.70 mL, 7.82 mmol) in 15 ml of THF at -78 °C was added sodium bis(trimethylsilyl)amide (9.24 mL, IM in THF) dropwise over 2 min. After the addition was complete, the reaction was warmed to 0 °C for lh. To this solution was added a solution of 2.00 g (7.11 mmol) of 3-formyl-N-(4-isopropyl-3-methyl-phenyl)- benzamide, G-ld, in 20 mL of THF. The solution was stirred for lh, then quenched with 1:1 MeOH/AcOH (1 mL). The mixture was partitioned between 50 mL of ethyl acetate and IN HCI (2 x 20 mL), and the organic layer was dried over sodium sulfate and concentrated. The residue was purified on silica gel (2: 1 hexane:ethyl acetate) and to afford 1.33 g (51%) of N-(4-isopropyl-3-methylphenyl)-3-[(E)-2-(N-methoxy-N- methylcarbamoyl)ethenyl]-benzamide, G-le, as a white solid foam: *H NMR (300 MHz, CDCL) δ 8.10 (br s, IH), 7.83-7.79 (m, 2H), 7.73-7.68 (m, 2H), 7.52-7.45 (m, 3H), 7.28-7.24 (m, IH), 7.12 (d, IH, J = 15.9 Hz), 3.78 (s, 3H), 3.31 (s, 3H), 3.15-3.10 (m, IH), 2.36 (s, 3H), 1.23 (d, 6H, J = 6.0 Hz).
(f) A mixture of 0.90 g (2.46 mmol) N-(4-isopropyl-3-methylphenyl)-3-[(E)-2-(N- methoxy-N-methylcarbamoyl)ethenyl]-benzamide, G-le, and 0.1 g of 10% palladium on carbon in 20 ml of 1:1 MeOH:EtOAc was stirred under 1 atm H2 for 18 h. The reaction was filtered though a 0.5 uM teflon filter and concentrated to give 0.90 g (100%) of N-(4-isoproρyl-3-methylphenyl)-3-[2-(N-methoxy-N- methylcarbamoyl)ethyl]-benzamide, G-lf: Η NMR (300 MHz, CDCL) δ 7.74 (s, 2H), 7.68 (d, IH, J = 4.2 Hz), 7.44-7.40 (m, 4H), 7.25-7.23 (m, IH ), 3.63 (s, 3H), 3.18 (s, 3H), 3.14-3.11 (m, IH), 3.06-3.03 (m, 2H), 2.79 (t, 2H, J = 4.5 Hz), 2.36 (s, 3H), 1.22 (d, 6H, J = 4.2 Hz).
(g) To a solution of 0.45 g (1.34 mmol) of 4-[N-(diphenylmethyl)-N- methylsulfamoyl]thioacetanilide, G-lc, and 0.16 mL (1.34 mmol) of N,N'- dimethylpropyleneurea (DMPU) in 15 mL of THF at -78 °C was added 1.07 mL (2.68 mmol) of 2.5 M n-BuLi in hexane. After 0.25 h, the reaction was warmed to 0 °C for 0.5 h, then recooled to -78 °C. To the reaction mixture was added a solution of 0.23 g (0.62 mmol) of N-(4-isopropyl-3-methylphenyl)-3-[2-(N-methoxy-N- methylcarbamoyl)ethyl]-benzamide, G-lf, in 5 mL of THF. The reaction was warmed to 0 °C for 1 hour and then quenched by dropwise addition of 0.5 mL of 1:1 MeOH/AcOH. The mixture was partitioned between 30 mL of ethyl acetate and sat. sodium bicarbonate (2 X 10 mL). The organic layer was dried over sodium sulfate and concentrated. The residue was purified by chromatography on silica gel (1:2 ethyl acetate.-hexane) to afford 0.24 g (54%) of 3-[4-{4-(N-(diphenylmethyl)-N- methylsulfamoyl)phenylthiocarbamoyl}-3-oxo-butyl]-N-(4-isopropyl-3-methyl- phenyl)benzamide, G-lg, as an amber oil: Η NMR (500 MHz, CDC13) δ 7.91-7.83 (m, 2H), 7.74-7.64 (m, 3H), 7.59-7.47 (m, 3H), 7.41-7.23 (m, 8H) 7.12-7.04 m, 6H), 6.43 (s, IH), 7.25-7.23 (m, IH ), 3.63 (s, 3H), 3.18 (s, 3H), 3.18-3.13 (m, IH), 3.11- 3.01 (m, 2H), 2.83 (s, 2H), 2.78 (s, 3H), 2.37-2.32(m, 2H), 1.21 (d, 6H, 1.5 Hz). (h) To a solution of 0.36 g (0.51 mmol) of 3-[4-{4-(N-(diphenylmethyl)-N-methyl- sulfamoyl)phenylthiocarbamoyl}-3-oxo-butyl]-N-(4-isopropyl-3-methyl- phenyl)benzamide, G-lg, in 5 ml of ethanol were added acetic acid (0.20 mL, 0.34 mmol) and hydrazine monohydrate (0.016 mL, 0.34 mmol). After 1 h, the solution was partitioned between ethyl acetate (30 mL) and IN HCL (2 x 20 mL). The organic layer was washed with sat. sodium bicarbonate (2 X 20 mL), dried over sodium sulfate, and concentrated to give a yellow oil. Purification by chromatography on silica gel (25% ethyl acteate:hexane) afforded 0.28 g (79%) of 3-{2-[5-{4-(N- (diphenylmethyl)-N-methylsulf amoyl)phenylamino } -2H-pyrazol-3-yl]ethyl } -N-(4- isopropyl-3-methyl-phenyl)-benzamide, G-lh, as yellow solid: 1H NMR (300 MHz, CDCL) δ 8.09 (s, IH), 7.67 (br s, IH), 7.63 (d, IH, J = 7.5 Hz), 7.48-7.42 (m, 3H), 7.60-7.22 (m, 10H), 7.01-7.04 (m, 3H), 7.01 (d, 2H, J = 8.4 Hz), 6.43 (s, IH), 5.78 (s, lh), 3.13-3.04 (m, IH), 2.93-2.84 (m, 4H), 2.61 (s, 3H), 2.28 (s, 3H),1.19 (d, 6H, J = 6.6 Hz); MS (ESI): m/z Calculated for C42H43N5O3S (M-H ): 696 Found 696. (i) To a solution of 3-{2-[5-{4-(N-(diphenylmethyl)-N-methyl- sulf amoyl)phenylamino } -2H-pyrazol-3 -yl] ethyl } -N-(4-isopropyl-3 -methyl-phenyl)- benzamide, G-lh, in 0.025 mL of formic acid and 1.2 mL of acetic acid was added 0.08 g of 10% palladium on carbon. The mixture was stirred at 80 °C for 96 h, then cooled to room temperature and filtered though a 0.5 μM Teflon filter. The filtrate was concentrated and the residue was purified by chromatography on silica gel (2: 1 ethyl acetate:hexane) to afford N-(4-isopropyl-3-methyl-phenyl)-3-{2-[5-(4-(N-methyl- sulfamoyl)phenylamino)-2H-pyrazol-3-yl]ethyl}benzamide, G-1, (0.053 g, 87 %): HPLC Rt =14.65 min; !H NMR (Acetone-d6) δ 7 91 (br s, 1H),.7.59 (br s, IH),. 7.69 (d, IH, J = 6.0 Hz), 7.52-7.25 (m, 7H), 7.08 (d, IH, J = 8.1 Hz), 3.51-2.89 (m, 5H), 2.40 (s, 3H), 2.19 (s, 3H), 1.08 (d, 6H, J = 6.9 Hz); HRMS (FAB): Calculated for C29H33N5O3S (M+H+): 532.2382, Found: 532.2891
Example G-2: N-(2-Methylquinolin-6-yl)-3-[2-(5-phenylamino-2H-pyrazol-3- yl)ethyl]benzamide.
Figure imgf000078_0001
G-2 Example G-2 was made in a similar manner to that described for G-1, except that 6- amino-2-methylquinoline was used in place of 4-isopropyl-3-methylaniline in step (d), and thioacetanilide was used instead of 4-[N-(diphenylmethyl)-N- methylsulfamoyl]thioacetanilide, G-lc, in step (g), and the final deprotection step (i) was not needed: mp 98-102 °C. !H NMR (500 MHz, CDCL) δ 8.79 (d, IH, J = 2 Hz), 8.32 (br s, IH), 7.95 (d, IH, J = 8.5 Hz), 7.92 (d, IH, J = 9.0 Hz), 7.22 (d, IH, J = 7.5 Hz), 6.74 (dd, IH, J = 9.0, 2.0 Hz), 7.37 (t, IH, J = 7.5 Hz), 7.31-7.20 (m, 6H), 7.06 (d, 2H, J = 8.0 Hz), 6.85 (t. IH, J = 7.5 Hz), 5.81 (s, IH), 2.96 (t, 2H, J = 6.0 Hz), 2.91 (t, 2H, J = 6.0 Hz) 2.65 (s, 3H); HRMS (FAB): Calculated for C28H25N5O (M+H+): 448.2137 Found:448.2129. Anal, calc'd for C28H25N5O»0.3 EtOAc: C, 73.99; H, 5.83; N, 14.78. Found C, 73.72; H, 5.88; N, 14.78.
Example G-3: N-(4-isopropyI-3-methylphenyI)-3-[2-(5-phenylamino-2H-pyrazol- 3-yl)ethyI]benzamide
Figure imgf000079_0001
G-3
Example G-3 was made in a similar manner to that described for G-1, except thioacetanilide was used instead of 4-[N-(diphenylmethyl)-N- methylsulfamoyl]thioacetanilide, G-lc, in step (g), and the final deprotection step (i) was not needed: mp 150-151 °C; Η NMR (500 MHz, CDCL) δ 7.84 (s, IH), 7.65 (d, IH, J = 7.5 Hz), 7.62 (s, IH), 7.42-7.35 (m, 3H), 7.36 (t, IH, J = 7.5 Hz), 7.28-7.17 (m, 4H), 7.05 (d, 2H, J = 8.5 Hz), 5.80 (s, IH), 3.12-3.07 (m, IH), 2.97 (t, 2H, J = 7.5 Hz), 2.90 (t, 2H, J = 7.0 Hz), 2.30 (s, 3H); HRMS (FAB): Calculated for C28H30N4O (M+H+): 439.2498 Found: 439.2488. Anal, calc'd for C28H30N4O»0.1CH2C12 Found: C, 75.49; H 6.81; N, 12.53. Found C, 75.44; H, 6.81; N 12.53. Example G-4 : N-(4-Isopropyl-3-methyl-phenyl)-3-{2-[5-(6-methoxypyridin-3- yl)amino-2H-pyrazol-3-yI]-ethyl}-benzamide.
Figure imgf000079_0002
G-4
Example G-4 was made in a similar manner to that described for G-1, except that N-(6- methoxy-pyridin-3-yl)acetamide was used instead of N-(diphenylmethyl)-N-methyl-4- (acetylamino)-benzenesulfonamide, G-lb, in step (c). Η NMR (300 MHz, CDC13) δ 7.97 (d, IH, J = 2.7 Hz), 7.84 (br s, IH), 7.67-7.62 (m, 2H), 7.49 (dd, IH, J = 8.9, 3.0 Hz), 7.42-7.40 (m, 3H), 7.30-7.61 (m, 2H), 7.19 (d, IH, J = 9.0 Hz), 5.66 (s, IH), 3.88 (s, 3H), 3.10 (q, IH, J = 6.6 Hz), 2.97-2.90 (m, 4H), 2.17 (s, 3H), 1.23 (d, 6H, J =4.2 Hz); HRMS (FAB): Calculated for C28H31N5O2 (M+H+): 470.2556, Found: 470.2563. Anal, calc'd for C28H33N5O2Cl2: C, 61.99; H, 6.13; N, 12.91. Found C, 61.83; H, 6.39; N 12.83. Example G-5: N-(4-Dimethylamino-3-trifluoromethylphenyl)-3-{2-[5-(6- methoxypyridin-3-yl)amino-2H-pyrazol-3-yI]ethyl}-benzamide
Figure imgf000080_0001
G-5 Example G-5 was made in a similar manner to that described for G-1, except that 4- (dimethylamino)-3-trifluoromethylaniline, prepared according to the procedure described in WO 99/21845 (p. 58) for the preparation of l-methyl-4-(4- nitrophenyl)piperazine, was used in place of 4-isopropyl-3-methylaniline in step (d), and N-(6-methoxy-pyridin-3-yl)acetamide was used instead of N-(diphenylmethyl)-N- methyl-4-(acetylamino)-benzenesulfonamide, G-lb, in step (c): 1H NMR (300 MHz, CDCL) δ 8.27 (br s, IH), 7.93 (d, IH, J = 1.5 Hz), 7.84 (dd, IH, J = 4.5, 1.5 Hz), 7.88 (d, IH, J = 2.7 Hz), 7.64 (d, IH, J = 5.7 Hz), 7.60 (s, IH), 7.37 (dd, IH, J = 8.7, 3.0 Hz), 7.66 (d, IH, 4.5 Hz), 7.58 (s, IH), 7.43 (dd, IH, J = 5.40, 1.5 Hz), 7.33 (t, IH, J = 4.8 Hz), 7.29-7.26 (m, 2H), 6.63 (d, IH, J = 5.4 Hz), 5.62 (s, IH) 3.86 (s, 3H), 2.94- 2.86 (m, 4H), 2.69 (s, 6H); HRMS (FAB): Calculated for C27H27F3N6O2 (M+H+):
525.2226, Found: 525.2208. Anal, calc'd for C27H27F3N6O2»0.5H2O: C, 60.78; H, 5.29;
N, 15.75. Found C, 61.15; H, 5.25; N 15.7
Example G-6: N-(6-Dimethylamino-5-trifluoromethylpyridin-3-yl)-3-{2-[5-(6 methoxypyridin-3-yl)amino-2H-pyrazol-3-yl]ethyl}-benzamide
Figure imgf000080_0002
G-6
Example G-6 was made in a similar manner to that described for G-1, except that 5- amino-2-(dimethylamino)-3-trifluoromethylpyridine, prepared according to the procedure described in WO 99/21845 (p. 58) for the preparation of l-methyl-4-(4- nitrophenyl)piperazine, was used in place of 4-isopropyl-3-methylaniline in step (d), and N-(6-methoxy-pyridin-3-yl)acetamide was used instead of N-(diphenylmethyl)-N- methyl-4-(acetylamino)-benzenesulfonamide, G-lb, in step (c): HPLC Rt = 14.04 min; Η NMR (300 MHz, CDCL) δ 8.73 (br s, IH), 8.47 (d, IH, J = 2.4 Hz), 8.18 (d, IH, J = 2.0 Hz), 7.88 (d, IH, J = 2.7 Hz), 7.64 (d, IH, J = 5.7 Hz), 7.60 (s, IH), 7.37 (dd, IH, J = 8.7, 3.0Hz), 7.29-7.21 (m, 2H), 6.58 (d, IH, J = 8.7 Hz), 5.78 (s, IH), 3.83 (s, 3H), 2.94 (s, 6H), 2.86-2.76 (m, 4H); HRMS (FAB): Calculated for C26H26F3N7O3 (M+H+): 526.2178, Found: 526.2194. Anal, calc'd for C26H26F3N7O3»0.4 Et2O: C, 59.71; H, 5.45; N, 17.66. Found C, 59.58; H, 5.44; N 17.53. Example G-7: N-(3,5-Dichloro-4-dimethylaminophenyl)-3-{2-[5-(6-methoxy- pyridin-3-yl)amino-2H-pyrazol-3-yl]ethyI}benzamide
Figure imgf000081_0001
G-7
Example G-7 was made in a similar manner to that described for G-1, except that 3,5- dichloro-4-(pyrrolidino)aniline, prepared according to the procedure described in WO 99/21845 (p. 58) for the preparation of l-methyl-4-(4-nitrophenyl)piperazine, was used in place of 4-isopropyl-3-methylaniline in step (d), and N-(6-methoxy-pyridin-3- yl)acetamide was used instead of N-(diphenylmethyl)-N-methyl-4-(acetylamino)- benzenesulfonamide, G-lb, in step (c): HPLC Rt = 16.07 min; Η NMR (300 MHz, Acetone-d6) δ 8.25 (d, IH, J = 2.7 Hz), 7.91 (br s, 2H), 7.87 (s, IH), 7.82-7.78 (m, 2H), 7.45-7.38 (m, 3H), 6.61 (d, IH, J = 9.3 H), 5.62 9s, IH), 3.78 (s, 3H), 3.31-2.97 (m, 4H), 2.84 (m, 6H); HRMS (FAB): Calculated for C26H26N6O2 (M+H+): 525.1573, Found: 525.1559. Anal, calc'd for C^N ^O.3 Et2O: C, 59.65; H, 5.34; N, 15.35. Found C, 59.35; H, 5.25; N 17.35. Example G-8: 3-{2-[5-(6-Methoxypyridin-3-yl)amino-2H-pyrazol-3-yl]-ethyl}-N- (4-pyrrolidin-l-yl-3-trifluoromethylphenyl)benzamide
Figure imgf000082_0001
G-8
Example G-8 was made in a similar manner to that described for G-1, except that 4- (pyrrolidin-l-yl)-3-trifluoromethylaniline, prepared according to the procedure described in WO 99/21845 (p. 58) for the preparation of l-methyl-4-(4- nitrophenyl)piperazine, was used in place of 4-isopropyl-3-methylaniline in step (d), and N-(6-methoxy-pyridin-3-yl)acetamide was used instead of N-(diphenylmethyl)-N- methyl-4-(acetylamino)-benzenesulfonamide, G-lb, in step (c): HPLC Rt = 15.66 min; Η NMR (300 MHz, CDCL) δ 8.35 (br s, IH), 7.91 (d, IH, J = 1.5 Hz), 7.70 (d, IH, J = 1.2 Hz), 7.64 (dd, 2H, J = 12.5, 4.5 Hz), 7.57 (s, IH), 7.38 (dd, IH, J = 5.3, 1.5 Hz), 7.27-7.20 (m, IH), 6.90 (d. IH, J = 5.4 Hz), 6.59 (d, IH, J = 5.1 Hz), 5.60 (s, IH), 3.84 (s, 3H), 3.25 (t, 4H, 3.6 Hz), 2.88-2.76 (m, 4H), 1.94-1.90 (m, 4H); HRMS (FAB): Calculated for C29H29F3N6O2 (M+H+): 551.2382, Found: 551.2389. Anal, calc'd for C29H29F3N6O2 «0.2CH2C12: C, 61.09; H, 5.18; N, 14.59. Found C, 61.36; H, 5.18; N 14.59.
Example G-9: 3-{2-[5-(6-Methoxypyridin-3-yl)amino-2H-pyrazol-3-yl]-ethyl}-N- [4-(4-^-butoxycarbonylpiperazin-l-yl)-3-trifluoromethyIphenyl]benzamide
Figure imgf000082_0002
G-9
Example G-9 was made in a similar manner to that described for G-1, except that 4- [4- (t-butoxycarbonyl)piperazin-l-yl]-3-trifluoromethylaniline, prepared according to the procedure described in WO 99/21845 (p. 58) for the preparation of l-methyl-4-(4- nitrophenyl)piperazine, was used in place of 4-isopropyl-3-methylaniline in step (d), and N-(6-methoxy-pyridin-3-yl)acetamide was used instead of N-(diphenylmefhyl)-N- methyl-4-(acetylamino)-benzenesulfonamide, G-lb, in step (c): *H NMR (300 MHz, CDC13) δ 8.27 (br s, IH), 7.95-7.87 (m, 3H), 7.70 (d, IH, J = 7.5 Hz), 7.59 (br s, IH), 7.57 (s, IH), 7.47 (dd, IH, J = 8.7, 3.0 Hz), 7.43-7.32 (m, 2H), 7.29-7.21 (m, 2H), 7.28-7.26 (m, 2H), 6.66 (d, IH, J = 8.7 Hz), 5.60 (s, IH), 3.88 (s, 3H), 3.56-3.51 (m, 4H), 3.26-3.24 (m, 4H), 3.00-2.93 (m, 4H), 2.83-2.82 (m, 4H), 1.49 (s, 9H); HRMS (FAB): Calculated for C34H38F3N7O4 (M+Na+): 688.2835, Found: 688.2856. Anal, calc'd for C34H38F3N7O4-0.4H2O: C, 60.68; H, 5.81; N, 14.57. Found C, 60.90; H, 5.88; N 14.57. Example G-10: 3-{2-[5-(6-Methoxypyridin-3-yl)amino)-2H-pyrazol-3-yI]ethyl}-N- (4-piperazin-l-yl-3-trifluoromethylphenyl)benzamide
Figure imgf000083_0001
G-10
To a solution of 0.075 g (0.113 mmol) of 3-{2-[5-(6-Methoxypyridin-3-yl)amino-2H- pyrazol-3 -yl] -ethyl } -N- [4-(4-t-butoxycarbonyl)piperazin- 1 -yl-3 - trifluoromethylphenyl]benzamide, G-9, in 5 mL of dichloromethane was added 5 mL of trifluoroacetic acid. After 2 h, the reaction mixture was concentrated. The residue was dissolved in 20 mL chloroform/isopropanol (10:1) and washed with sat. aq. sodium bicarbonate (2 x 10 mL). The organic layer was filtered though a silica plug using ethanol to elute product and concentrated to afford 3-{2-[5-(6-methoxypyridin-3- yl)amino)-2H-pyrazol-3-yl]ethyl } -N-(4-piperazin- 1 -yl-3- trifluoromethylρhenyl)benzamide, G-10, as off-white solid (0.056 g, 88%): HPLC Rt = 12.95 min.; Η NMR (300 MHz, CDCL) δ 11.38 (br s, IH), 8.51 (br s, IH), 7.95 (d, IH, J = 2.1 Hz), 8.20-8.10 (m, IH), 8.01 (d, IH, J = 8.7), 7.87 (s, IH), 7.75 (d, IH, J = 6.6 Hz), 7.64 (dd, IH, J = 6.5, 2.7 Hz), 7.45 (d, IH, J = 8.7 Hz), 7.35-7.28 (m, 2H),
6.56 (d, IH, J = 8.9 Hz), 5.60 (s, IH), 3.85 (s, 3H), 2.99-2.80 (m, 12H); HRMS (FAB): Calculated for C29H30F3N7O2 (M+H+): :566.2491, Found: 566.2511. Example G-ll: 4-Fluoro-3-[{5-(pyridin-3-yl)amino-2H-pyrazol-3-yl}methoxy]-N- [((4-pyrrolidin-l-yl)-3-trifluoromethylphenyl)benzamide
Figure imgf000084_0001
G-11
Example G-l l was made in a similar manner to that described for G-1, except that 4- (pyrrolidin-l-yl)-3-trifluoromethylaniline, prepared according to the procedure described in WO 99/21845 (p. 58) for the preparation of l-methyl-4-(4- nitrophenyl)piperazine, was used in place of 4-isopropyl-3-methylaniline in step (d), and N-(pyridin-3-yl)acetamide was used instead of N-(diphenylmethyl)-N-methyl-4- (acetylamino)-benzenesulfonamide, G-lb, in step (c): HPLC Rt = 14.78 min; *H NMR (300 MHz, Acetone-d6) δ 9.53 (br s, IH), 8.55 (d, IH, J = 2.1 H), 8.10 (d, IH, J = 2.7 Hz), 7.93-7.76 (m, 6H), 7.45-7.37 (m, 2H), 7.20 (d, IH, J = 9.0 Hz), 7.14-7.10 (m, IH), 3.28-3.21 (m, 4H), 3.09-2.96 (m, 4H, 1.96-1.92 (m, 4H); HRMS (FAB): Calculated for C28H27F3N6O (M+H+): 521.2277, Found: 521.266. Anal, calc'd for C28H27F3N6O»0.9H2O: C, 62.65; H, 5.41; N, 15.66. Found C, 62.84; H, 5.33; N 15.66. Example H-l: N-(4-Isopropyl-3-methyl-phenyl)-3-[2-(5-phenylamino-2-H- pyrazol-3-yl)-cyclopropyl]-benzamide
Figure imgf000084_0002
H-l
Example H-l was made in a similar manner to that described for E-l, except that N-(4- isopropyl-3-methylphenyl)-3-[2-(Ν-methoxy-Ν- methylcarbamoyl)cyclopropyl]benzamide, prepared as described below, was used instead of in step (c): HPLC Rt = 16.47 min.;Η NMR (300 MHz, CDCL) δ 8.13 (br s, IH), 7.59-7.50 (m, IH), 7.44-7.40 (m, 2H), 7.31-7.25 (m, 3H), 7.22-7.17 (m, 3H), 7.02 (d, 2H, J = 7.8 Hz), 6.83 (t, IH, J = 7.5Hz), 5.71 (s, IH), 3.14-3.53 (m, IH), 2.18-2.16 (m, IH), 2.08-2.04 (m, IH), 1.38-1.35 (m, 2H), 1.23 (d, 6H, J = 6.9 Hz); HRMS (FAB): Calculated for C29H30N4O (M+H*): 451.2498, Found: 451.2510. Calculated for C29H30N4O«0.5H20: C, 75.79; H, 6.80; N, 12.19. Found C, 75.83; H, 6.81; N 12.19. N-(4-Isopropyl-3-methyl-phenyl)-3-[2-(N-methoxy-N-methyl-carbamoyl)- cyclopropyl] -benzamide was prepared as follows: To a solution of trimethylsulfoxonium iodide (0.46 g, 2.01 mmol) in 10 mL of DMSO was added sodium hydride (0.08 g, 2.01 mmol, 60% oil dispersion) at -10 °C. After 30 min, to the reaction solution was added dropwise a solution of 0.35 g (0.96 mmol) of N-(4- isopropyl-3 -methylphenyl)-3 - [2-(Ν-methoxy-Ν-methylcarbamoyl)ethenyl] -benzamide, G-le, in 5 ml of DMSO. The reaction was allowed to warm to 25 °C. After 2 h, the reaction was quenched with dropwise addition of IN HCI. The reaction mixture was partitioned between 30 mL dichloromethane and 30 mL of saturated NaHCO3 and the organic layer was dried over sodium sulfate and evaporated to a give a crude yellow oil. The oil was purified by silica gel chromatography using 75% hexane/25% ethyl acetate to afford 0.1 lg (29%) of N-(4-isopropyl-3-methylphenyl)-3-[2-(N-methoxy-N- methylcarbamoyl)cyclopropyl]benzamide as a clear oil: H NMR (300 MHz, CDC13) δ 8.18 (br s, IH), 7.67-7.62 (m, 2H), 7.46-7.44 (m, 2h), 7.36-7.26 (m, 3H), 7.20 (d, IH, J = 9.0 Hz), 3.67 (s, 3H), 3.21 (S, 3H), 2.55-2.45 (m, 2H), 2.31 (s, 3H), 1.65-1.59 (m, IH), 1.37-1.31 (m, IH), 1.21 (d, 6H, J = 6.9 Hz); MS (ESI): Calculated for C23H28N2O3 (M-H): 379, Found: 379.
Example 1-1 : 3-[({3-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl] -lH-pyrazoI-5- yl}methyl)amino]-N-(3-methyl-4-isopropylphenyl)benzamide
Figure imgf000086_0001
NH2NH DIBAL, THF
Figure imgf000086_0002
Figure imgf000086_0003
Figure imgf000086_0004
Figure imgf000086_0005
HATU, DIPEA, DMF
Figure imgf000086_0006
(a) Vanillin (9.12 g, 0.06 mole) was dissolved in 36 mL of acetone and 12.5 mL of 50% aq. NaOH solution was added dropwise with vigorous stirring. To the resulting solid was added 25 mL of water and the dark red solution was refluxed for 5 min. This reaction mixture was kept at room temperature for 24 h and acidified with acetic acid. The reaction mixture was concentrated to provide a yellow solid, which was filtered, washed with water and dried to yield 10.2 g (88%) of (E)-l-(3-methoxy-4- hydiOxyphenyl)-l-butene-3-one, I-la: Η NMR (300 MHz, CDC13) δ 7.43 (d, IH, J = 16.3 Hz), 7.04-7.09 (m, 2H), 6.91 (d, IH, J = 7.9 Hz), 6.57 (d, IH, J = 16.3 Hz), 6.02 (s, IH), 3.92 (s, 3H), 2.35 (s, 3H).
(b) Sodium metal (3.7 g, 0.16 mole) was dissolved in 100 mL of absolute ethanol under an inert atmosphere. An solution of 16.2g (953 mmol) of E-l-(3-methoxy-4- hydroxyρhenyl)-l-butene-3-one, I-la, of ethanol was then added slowly over 30 min to the sodium ethoxide solution. After the addition the reaction mixture was stirred at for 15 min followed by the addition of diethyl oxalate (7.7 g, 0.53 mole) and the dark red solution was stirred at room temperature for 5 h. Concentrated HCI was added to the reaction mixture until acidic. A dark yellow solid separated out which was stirred in an ice bath for 1 h. The solid was filtered, washed and dried to afford 8.4 g (55%) of the desired ethyl (E)-6-(4-hydroxy-3-methoxyphenyl)-2,4-dioxo-5-hexenoate, I- lb: Η NMR (300 MHz, CDC13) δ 14.86 (br s, IH), 7.54 (d, IH, J = 15.9 Hz), 7.00 (d, IH, J = 8.3 Hz), 6.93 (s, IH), 6.81 (d, IH, J = 8.3 Hz), 6.36-6.41 (m, 2H), 5.84 (s, IH), 4.23 (q, 2H, J = 7.2 Hz), 3.81 (s, 3H), 1.25 (t, 3H, J = 7.2 Hz).
(c) To a solution of 8.1 g (27.7 mmol) of ethyl 6-(3'-methoxy-4'-hydroxyphenyl)-2,4- dioxo-5-hexenoate, I-lb, in 125 mL of acetic acid was added 1 mL of hydrazine (30.5 mmol) and the reaction was stirred at 65 °C or 90 min. The reaction was cooled to room temperature and added slowly to 500 mL of ice cold water upon which a white solid separated out. The solid was filtered, washed and dried to afford 7.25 g (91%) of ethyl (Ε)-3-[( )-(4-hydroxy-3-methoxyphenyl)ethenyl]-lH-pyrazole-5-carboxylate, I- lc: Η NMR (300 MHz, DMSO- β) δ 13.61 (s, IH), 9.34 (s, IH), 7.23 (d, IH, J = 16.6 Hz), 7.19 (s, 1 H), 6.92-7.01 (m, 2H), 6.84 (d, IH, J = 7.9 Hz), 4.32 (q, 2H, J = 7.2 Hz) (s, IH), 3.88 (s, 3H), 1.36 (t, 3H, J = 7.2 Hz); APCIMS m/z 289 [M + H]+.
(d) To 40 ml of 1 M diisobutylauminum hydride in THF was added dropwise 2.5 g (9.8 mmol) of ethyl (E)-3-[2-(3-methoxy-4-hydroxyphenyl)ethenyl]-lH-pyrazole-5- carboxylate, I-lc, in 25 mL of THF and the reaction was stirred at room temperature. The reaction was monitored by TLC and quenched after 6 h with water and extracted with 3x150 mL of ethyl actate. The combined organic layers were concentrated and the residue was purified using silica gel column chromatography to afford 1.2 g (53%) of 4-{ (E)-2-[5-(hydroxymethyl)-lH-pyrazol-3-yl]ethenyl}-2-methoxyphenol, I-ld: Η NMR (300 MHz, DMSO- 6) δ 12.58 (br s, IH), 9.13 (s, IH), 7.12 (s, 1 H), 6.98 (d, IH, J = 16.6 Hz), 6.88-6.92 (m, 2H), 6.74 (d, IH, J = 8.4 Hz), 6.34 (s, IH), 5.10 (bis, IH), 4.42 (d, 2H, J = 5.6 Hz), 3.81 (s, 3H); APCIMS m/z 247 [M + H]+.
(e) To 72 mg (0.3 mmol) of 4-{(E)-2-[5-(hydroxymethyl)-lH-pyrazol-3-yl]ethenyl}-2- methoxyphenol, I-ld, was added 1 mL of thionyl chloride. After 10 min, the reaction was quenched by adding 10 mL of ice cold water slowly and the mixture was extracted with 2x10 mL of ethyl acetate. The extracts were combined, concentrated, and filtered through a silica gel plug. All the washings were collected, the solvent removed under vacuo to obtain 32 mg (76%) of 4-{(E)-2-[5-(chloromethyl)-lH-pyrazol-3-yl]ethenyl}- 2-methoxyphenol, I-le: Η NMR (300 MHz, DMSO-d6) δ 12.89 (brs, IH), 9.20 (s, IH), 7.11 (s, 1 H), 7.04 (d, IH, J = 16.7 Hz), 6.74-6.90 (m, 2H), 6.75 (d, IH, J = 8.0 Hz), 6.45 (s, IH), 4.69 (s, 2H), 3.81 (s, 3H); APCIMS m/z 265 [M + H]+.
(f) To 132 mg (0.5 mmol) of 4-{(E)-2-[5-(chloromethyl)-lH-pyrazol-3-yl]ethenyl}-2- methoxyphenol, I-le, in 2 mL of DMF was added 3-aminobenzoic acid (75 mg, 0.55 mmol) and an excess of NaΗCO3 and the reaction mixture stirred at room temperature for 16 h. The crude reaction mixture was filtered through a plug of silica gel to remove NaHCO3 and washed with ethyl acetate. The filtrates were collected and the solvents removed in vacuo to yield 60 mg of crude 3-[({3-[(Ε)-2-(4-hydroxy-3- methoxyphenyl)ethenyl]-lH-pyrazol-5-yl}methyl)amino]benzoic acid, I-lf, which was redissolved in 2 mL of DMF. To the resulting solution were added HATU (95 mg, 0.25 mmol) and diisopropylethylamine (0.04 mL, 0.23 mmol) followed by 3-methyl-4- isopropylaniline (90 mg, 0.6 mmol) and the reaction mixture stirred at room temperature for 16 h. After conventional aqueous work-up, 16 mg of 3-[({3-[(E)-2-(4- hydroxy-3-methoxyphenyl)ethenyl]-lH-pyrazol-5-yl}methyl)amino]-N-(3-methyl-4- isopropylphenyl)benzamide, 1-1, was isolated using HPLC; Η NMR (300 MHz, DMSO-d6) δ 9.91 (s, IH), 7.51-7.54 (m, 2H), 7.03-7.20 (m, 7H), 6.98 (d, IH, J = 15.5 Hz), 6.82-6.90 (m, 4H), 6.74 (d, IH, J = 9.0 Hz), 6.35 (s, IH), 4.28 (s, 2H), 3.80 (s, 3H), 3.01-3.08 (m, IH), 2.27 (s, 3H), 1.16 (d, 6H, J = 6.0 Hz); APCIMS m/z 497 [M + H]+.
Example 1-2: 3-[({5-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-LBT-pyrazol-3- yl}methyl)amino]-N-phenylbenzamide
Figure imgf000088_0001
1-2
Example 1-2 was prepared in a similar manner to that described for 1-1, except that aniline was used in place of 3-methyl-4-isopropylaniline in step (f): HPLC R( = 6.38 min.; Η ΝMR (300 MHz, CD3OD) δ 7.55 (d, 2H, J = 9.0 Hz), 7.21-7.26 (m, 2H), 7.11-7.16 (m, 2H), 7.02-7.08 (m, 2H), 6.97-6.98 (m, IH), 6.90 (d, IH, J = 15.0 Hz),
6.78-6.86 (m, 2H), 6.74 (d, IH, J = 15.0 Hz), 6.65-6.67 (m, IH), 6.33 (s, IH), 4.27 (s,
2H), 3.77 (s, 3H); APCIMS m/z 441 [M + H]+.
Example J-1: 4-Fluoro-N-[4-(imidazol-l-yl)-3-trifluoromethylphenyl]-3-[5-(6- methoxypyridin-3-yl)amino-2H-pyrazol-3-ylmethoxy]-benzamide
Figure imgf000089_0001
J-1c J-1d
Figure imgf000089_0002
(a) To a solution of 2-bromo-5-nitrobenzotrifluoride (1.50 g, 5.54 mmol) in toluene (11 mL) under argon purge was added imidazole (0.57 g, 8.31 mmol), trans,trans- dibenzylidene acetone (0.13g, 0.56 mmol), 1,10-phenanthroline (1.00 g, 5.54 mmol), cesium carbonate (1.99 g, 6.10 mmol) and copper^triflate'benzene (0.015 g, 0.028 mmol). The slurry was heated at 90 °C for 18 h, and then cooled to 25 °C. The mixture was filtered through a silica gel plug with 30 mL of ethyl acetate and the filtrate was concentrated. The residue was purified by chromatography on silica gel (hexane/ethyl acetate) to afford 0.83 g (58.2%) of l-(4-Nitro-2-triiluoromethylphenyl)- lH-imidazole, J-la, as an amber solid: HPLC Rt = 10.45 min.; Η NMR (300 MHz, CDCL) δ 8.72 (d, IH, J = 2.1 Hz), 8.58 (dd, IH, J = 8.7, 2.7Hz), 7.70-7.67 (m, 2H), 7.26 (s, IH), 7.21 (s, IH); MS (ESI): Calculated for C10H6F3N3O2 (M+H+): 257, Found: 257.
(b) To a solution of 0.60 g (2.33 mmol) of l-(4-nitro-2-trifluoromethylphenyl)-lH- imidazole, J-la, in 10 mL of methanol was added 0.10 g of 10% Pd/C. The mixture was stirred under a hydrogen atmosphere (1 atm) for 18h, and then filtered through a 0.22 μM teflon filter membrane. The filtrate was concentrated to afford 0.51 g (100%) of l-(4-amino-2-trifluomethylphenyl)imidazole, J-lb, as a yellow solid: HPLC Rt = 8.89 min.; Η NMR (300 MHz, CDCL) δ 7.62 (s, IH), 7.13-7.02 (m, 4H), 6.86 (d, IH, J = 8.4, 2.4 Hz). MS (ESI): Calculated for C10H8F3N3 (M+H+): 228, Found: 228. (c) To a solution of 3-acetoxy-4-fluorobenzoic acid (0.49 g, 2.48 mmol) in dichloromethane (5 mL) was added oxayl chloride (0.26 ml, 2.97 mmol) and DMF (0.1 mL). After 1 h, the mixture was concentrated and then re-dissolved in 5 mL of dichloromethane. To this solution was added 0.56 g (2.47 mmol) of l-(4-amino-2- trifluomethylphenyl)imidazole, J-lb, and diisopropylethylamme (0.39 mL, 2.48 mmol). After 1 h the solution was partitioned between 30 mL of ethyl acetate and sat. aq. sodium bicarbonate (2 x 20 mL). The organic layer was dried over sodium sulfate and concentrated. The residue was purified by chromatography on silica gel (1:1 hexane:ethyl acetate) to provide 0.49 g (57%) of 3-acetoxy-4-fluoro-N-[4-(imidazol-l- yl)-3-trifluoromethylphenyl]-benzamide, J-lc, as clear oil: Η NMR (300 MHz, CDC13) δ 8.12-8.02 (m, 3H), 7.92-7.89 (m, IH), 7.63 (s, IH), 7.37-7.12 (m, 5H), 2.36 (s, IH); MS (ESI): Calculated for C19H13F4N3O3 (M+H+): 408, Found: 408. (d) To a solution of 0.33 g (0.83 mmol) 3-acetoxy-4-fluoro-N-[4-(imidazol-l-yl)-3- trifluoromethylphenyl]-benzamide, J-lc, in 5 mL acetone and 0.5 mL of methanol was added cesium carbonate (0.54 g, 1.65 mmol) and 2-chloro-N-methoxy-N-methyl- acetamide (0.15 g, 1.07 mmol) and the resulting mixture was stirred for 6 h at 45 °C. After cooling to room temperature, the mixture was partitioned between ethyl acetate and sat. brine (2 x 20 mL). The organic layer was filtered though a silica gel plug and concentrated. The residue was purified by titurated with diethyl ether (2 x 20 mL) to give 0.35 g (92%) of 4-fluoro-N-[4-(imidazol-l-yl)-3-trifluoromethylphenyl]-3-[(N- methoxy-N-methylcarbamoyl)methoxy]benzamide, J-ld, as a white solid: Rt = 11.95 min.; Η NMR (300 MHz, CDCL) δ 8.34 (d, IH, J = 2.4 Hz), 8.11 (dd, lh, J = 8.7 Hz), 7.64-7.54 (m, 3H), 7.42 (d, IH, J = 8.7 Hz), 7.22-7.15 (m, 2H), 6.97 (s, IH), 502 (s, 2H), 3.72 (s, 3H), 3.06 (s, 3H); MS (ESI): Calculated for C21H18F4N4O4 (M+H+): 467, Found: 467. (e) To a -78 °C solution of 0.13 g (0.71 mmol) N-(6-methoxy-pyridin-3-yl)- thioacetamide in 5 mL of dry THF was added dropwise 0.71 mL (1.42 mmol) of LDA (2.0 M in THF). The solution was stirred for 15 min at -78 °C, warmed to 0 °C for lh, and then cooled to -78 °C. To the resulting solution was added, over a 5 min period, a solution of 0.15 g (0.32 mmol) 4-fluoro-N-[4-(imidazol-l-yl)-3-trifluoromethyl- phenyl]-3-[(N-methoxy-N-methylcarbamoyl)methoxy]benzamide, J-ld, in 5 mL of THF. After stirring for 1 h at 0 °C, the reaction was quenched with 1 mL of 1:1 methanol: acetic acid. The mixture was partitioned between ethyl acetate and sat. sodium carbonate (2 x 20 mL) and the organic layer was dried over sodium sulfate and concentrated. The residual yellow oil was purified by radial chromatography (2 mm plate eluting with 1:2:1 hexane:ethyl acetate: dichloromethane) to give 0.091 g (49%) of 4-fluoro-N-[4-(imidazol-l-yl)-3-trifluoromethylphenyl]-3-[3-(6-methoxypyridin-3- yl)thiocarbamoyl-2-oxo-propoxy]-benzamide, J-le, as a yellow solid: !H NMR (300 MHz, CDC13) δ 8.74 (br s, IH), 8.19 (d, 2H, J = 2.7 Hz), 8.05 (d, IH, J = 2.7 Hz), 7.96 (dd, 2H, J = 10.2, 3.0 Hz), 7.41 (dd, IH, J = 8.4, 2.7 Hz), 7.28 (s, IH), 6.82-6.77 (m, 4H), 2.74 (s, 2H); MS (ESI): Calculated for C27H21F4N5O4S (M+H+): 588, Found: 588. (e) To a solution of 0.061g (0.10 mmol) of 4-fluoro-N-[4-(imidazol-l-yl)-3- trifluoromethylphenyl] -3 - [3 -(6-methoxypyridin-3-yl)thiocarbamoyl-2-oxo-propoxy] - benzamide, J-le, in ethanol (2 mL) was added hydrazine monohydrate (0.080 mL, 0.16 mmol) and acetic acid (0.09 mL, 0.16 mmol). After 2 h the solution was concentrated and the residue was purified by chromatography on silica gel (1:2 hexane:ethyl acetate) to afford 0.031 g (54%) of 4-fluoro-N-(4-(imidazol- l-yl)-3- trifluoromethyl-phenyl)-3-[5-(6-methoxy-pyridin-3-yl)amino-2H-pyrazol-3- ylmethoxy]benzamide, J-1, as a off white solid: *H NMR (300 MHz, CDCL) δ 8.34 (s, IH), 8.12-8.10 (m, 2H), 7.85 (t, IH, 3.0 Hz), 7.69-7.57 (m, 2H), 7.41 (d, IH, J = 8.7 Hz), 7.22-7.13 (m, 2H), 6.97 (d, IH, J = 6.0 Hz), 6.52 (d, IH, J = 9.0 Hz), 5.88 (s, IH), 5.19 (s, 2H), 3.68 (s, 3H); LCESI: Calculated for C27H21F4N7O3 (M+H+): 568, Found: 568. Anal, calc'd for C27H21F4N7O3 •1.2CH2C12 Found: C, 50.59; H 3.52; N, 14.65. Found C, 50.69; H, 3.78; N 14.79.
Example J-2: 4-Fluoro-3-[5-(6-methoxy-pyridin-3-yl)amino-2H-pyrazol-3- yl]methoxy-N-(4-pyrrolidin-l-yl-3-trifluoromethyl-phenyl)-benzamide
Figure imgf000092_0001
J-2
Example J-2, was prepared in a similar manner to that described for J-1, except that 4- (pyrrolidino)-3-trifluoromefhylaniline (see example G-8) was used in place of l-(4- amino-2-trifluomethylphenyl)imidazole, J-lb, in step (c): HPLC Rt = 15.55 min.; Η NMR (300 MHz, CDCL) δ 7.98 (d, IH, J = 2.7 Hz), 7.85 (br s, IH), 7.68-7.63 (m, 3H), 7.49 (dd, IH, J = 8.7, 3.0 Hz), 7.18-7.11 (m, IH), 6.95 (d, IH, J = 8.7 Hz), 6.67 (d, IH, J = 8.7 Hz), 5.93 (s, IH), 5.87 (s, IH), 5.17 (s, 2H), 3.88 (s, 3H), 3.31-3.27 (m, 4H), 2.05-1.96 (m, 4H); HRMS (MALDI):: Anal. Calculated for C28H26F4N6O3 (M+Na+): 593.1900, Found: 593.1873. Anal, calc'd for C28H26F4N6O3: C, 58.95; H, 4.95; N, 14.73. Found C, 58.87; H, 4.91; N 14.87. Example J-3: 4-FIuoro-3-[5-(6-methoxypyridm-3-yI)amino-2H-pyrazoI-3- yl]methoxy-N-(3-methoxy-5-trifluoromethyl-phenyl)-benzamide
Figure imgf000092_0002
J-3 Example J-3, was prepared in a similar manner to that described for J-1, except that 5- methoxy-3-trif uoromethylaniline (Aldrich) was used in place of l-(4-amino-2- trifluomethylphenyl)imidazole, J-lb, in step (c): Rt = 14.50 min.; Η NMR (300 MHz, CDCL) δ 8.05 (d, IH, J = 3.0 Hz), 7.88 (s, IH), 7.68 (dd, IH, J = 9.5, 2.1 Hz), 7.56- 7.53 (m , 2H), 7.42-7.39 (m, IH), 7.34 (s, IH), 7.26-7.17 (m, IH), 6.94 (s, IH), 7.70 (d, IH, J = 9.0 Hz), 5.95 (s, IH), 5.76 (br s, IH), 5.21 (s, 2H), 3.90 (s, 3H), 3.87 (s, 3H); HRMS (FAB): Calculated for Cy JF4N5O4 (M+Na÷): 554.1427, Found: 554.1423. Anal, calc'd for C25H21F4N5O4* 0.2hexane: C, 57.35; H, 4.37; N, 12.76. Found C, 57.00; H, 4.60; N 13.00.
Example K-l: N-(4-Isopropyl-3-methyl-phenyI)-3-(IsoquinoIin-4-yl)methoxy- benzamide
Figure imgf000093_0001
(a) A 2.6 M solution of n-BuLi in hexanes (7.4 mL, 19.2 mmol, 2.0 eq) was added to a solution of THF (40 mL) and ether (40 mL) and cooled to -78 °C. 4- Bromoisoquinoline (Aldrich, 2.0 g, 9.6 mmol, 1.0 eq) was added to the anion in one portion and the dark orange solution was aged at -78 °C for 30 minutes to give a brown slurry. The mixture was treated with DMF (1.7 mL, 24.0 mmol, 2.5 eq) to give a brown solution. After 15 min, the reaction was quenched with ethanol (40 mL). The resultant pale yellow solution was treated with a saturated solution of ammonium chloride (200 mL) and extracted with MTBE (3 x 200 mL). The combined organic extracts were washed with brine (200 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give an orange solid (1.8 g). The crade product was purified by flash chromatography over silica gel using 50% ethyl acetate/cyclohexane (R^O.5) to give isoquinoline-4-carbaldehyde, K-la, as a yellow solid (1.3 g, 84%): HPLC R, = 8.8 min.; TLC R/ = 0.2 (5% ethyl acetate/35% cyclohexane/dichloromethane); Η NMR (300 MHz, CDCL) δ 10.41 (s, IH), 9.46 (s, IH), 9.23 (d, IH, J = 8.5 Hz), 8.95 (s, IH), 8.12 (d, IH, J = 8.1 Hz), 7.97 (t, IH, J = 7.6 Hz), 7.78 (t, IH, J = 7.3 Hz); MS (ESI) m/z 158 [M + H]+.
(b) To a solution of 1.4 g (8.9 mmol) of isoquinoline-4-carbaldehyde, K-la, in ethanol (50 mL) at 0 °C was added with sodium borohydride (372 mg, 9.8 mmol, 1.1 eq). The mixture was stirred at 0 °C for 1.5 hours and at room temperature for 1.0 h. The reaction was quenched with 25% ammonium acetate (500 mL). The ethanol was removed under reduced pressure and the resultant mixture was extracted with ethyl acetate (3 x 500 mL). The combined organic extracts were washed with brine (200 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a yellow oil (1.5 g). The crude product was purified by radial chromatography over silica gel using 5-10% methanol/dichloromethane to give, after concentration from 50% ethyl acetate/cyclohexane, 4-(hydroxymethyl)isoquinoline, K-lb, as a tan solid (0.95 g, 68%): HPLC R, = 6.7 min.; TLC Rf = 0.2 (50% ethyl acetate/cyclohexane); Η NMR (300 MHz, DMSO-d6) δ 9.24 (s, IH), 8.49 (s, IH), 8.14 (d, IH, J = 8.4 Hz), 7.82 (t, IH, J = 7.6 Hz), 7.70 (t, IH, J = 7.6 Hz), 5.36 (t, IH, J = 5.4 Hz), 4.95 (d, 2H, J = 5.2 Hz); MS (FAB) m/z 160 [M + H]+.
(c) A solution of 4-(hydroxymethyl)isoquinoline, K-lb, (900 mg, 5.7 mmol, 1.0 eq) in ethanol (10 mL) was treated with concentrated hydrochloric acid (1.0 mL, 12.6 mmol, 2.1 eq). The mixture was stirred for 30 min and then the solvent was removed under reduced pressure. The tan residue was repeatedly evaporated from toluene (3 x 10 mL) to give a tan solid (1.1 g, 100%). The resulting unpurified 4-
(hydroxymethyl)isoquinoline hydrochloride was then treated with thionyl chloride (10 mL) and the resultant mixture was heated to 70 °C. After 1.5 hours, the solvent was removed under reduced pressure to give 4-(chloromethyl)isoquinoline hydrochloride, K-lc, as a tan solid (1.1 g, 95%): HPLC R, = 11.2 min.; Η NMR (300 MHz, DMSO- d6) δ 9.81 (s, IH), 8.83 (s, IH), 8.52 (d, IH, J = 8.1 Hz), 8.42 (d, IH, J = 8.6 Hz), 8.23 (t, IH, J = 7.8 Hz), 8.01 (t, IH, J = 7.8 Hz), 5.41 (s, 2H); 13C NMR (75 MHz, DMSO- d6) δ 149.6, 136.2, 135.9, 134.1, 131.9, 131.4, 130.6, 127.8, 124.2; MS (FAB) m/z 177/179 PVTJ. Anal, calc'd for C10H8C1N • HCI: C, 56.10; H, 4.24; CI, 33.12; N, 6.54. Found: C, 56.15; H, 4.32; CI, 33.23; N, 6.37.
(d) A suspension of 3-methyl-4-isopropyl aniline hydrochloride (6.7 g, 36.2 mmol, 1.0 eq) in THF (240 mL) was treated with triethylamine (5.0 mL, 36.2 mmol, 1.0 eq). The gray mixture was then treated with 3-hydroxybenzoic acid (Aldrich, 5.0 g, 36.2 mmol, 1.0 eq), followed by l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (7.6 g, 39.8 mmol, 1.1 eq). The resultant slurry was stirred at room temperature for 18 h. The solvent was removed under reduced pressure and the residue was extracted with water (200 mL) and ethyl acetate (3 x 200 mL). The combined organic extracts were washed with 5% KHSO4 (2 x 200 mL), water, (200 mL), brine (200 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a brown solid (8.0 g). The crude product was purified by flash chromatography on silica gel using 3-5% methanol/dichloromethane to give 3-hydroxy-N-(4-isopropyl-3- methyl-phenyl)-benzamide, K-ld, as an off-white solid (1.1 g, 11%): HPLC R, = 13.9 min.; TLC R/ = 0.4 (3% methanol/dichloromethane); Η ΝMR (500 MHz, DMSO- ) δ 9.99 (s, IH), 9.71 (s, IH), 7.55-7.29 (m, 5H), 7.19 (d, IH, J = 8.1 Hz), 7.97-7.95 (m, IH), 3.09-3.06 (m, IH), 2.29 (s, 3H), 1.18 (d, 6H, J = 6.9 Hz); 13C ΝMR (75 MHz, DMSO-d6) δ 165.6, 157.7, 142.0, 136.9, 134.9, 129.7, 125.0, 122.4, 118.8, 118.7, 118.4, 114.8, 28.7, 23.5, 19.5; MS (ESI) m/z 268 [M - H]\ Anal, calc'd for C17H19ΝO2: C, 75.81; H, 7.11; N, 5.20. Found: C, 75.35; H, 7.23; N, 5.12.
(e) To a clear solution of 3-hydroxy-N-(4-isopropyl-3-methyl-phenyl)-benzamide, K- ld, (0.538 g, 2.0 mmol, 1.0 eq) in acetone (40 mL) was added cesium carbonate (5.2 g, 16.0 mmol, 8.0 eq). The resultant mixture was stirred at room temperature for 30 minutes, treated with 4-chloromethyl-isoquinoline hydrochloride, K-lc, (0.469 g, 2.2 mmol, 1.1 eq) and warmed to 50 °C. After 18 hours, the reaction was diluted with water (200 mL) and extracted with ethyl acetate (3 x 200 mL). The combined organic extracts were washed with brine (300 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a yellow oil (1.7 g). The oil was purified by radial chromatography over silica gel eluting with 50% ethyl acetate/cyclohexane
' 5 (Rf 0.3) to give, after concentration from MTBE, N-(4-isopropyl-3-methyl-phenyl)-3- (Isoquinolin~4-yl)methoxy-benzamide, K-l, (0.69 g, 83%) as a light yellow foam: HPLC R, = 16.9 min.; TLC R/ = 0.6 (3% methanol/chloroform); Η ΝMR (500 MHz, DMSO- ) δ 10.06 (s, IH), 9.37 (s, IH), 8.69 (s, IH), 8.22 (d, IH, J = 8.1 Hz), 8.17 (d, IH, J = 8.5 Hz), 7.90 (t, IH J = 7.7 Hz), 7.77 (t, IH, J = 7.5 Hz), 7.69 (s, IH), 7.60-
10 7.34 (m, 5H), 7.21 (d, IH, J = 8.4 Hz), 5.66 (s, 2H), 3.09-3.07 (m, IH), 2.30 (s, 3H), ' 1.18 (d, 6H, J = 6.8 Hz); 13C ΝMR (75 MHz, DMSO- 6) δ 165.1, 158.6, 153.9, 143.5, 142.2, 136.8, 136.7, 135.0, 134.1, 131.5, 130.0, 128.6, 128.3, 128.0, 126.0, 125.0, 123.6, 122.5, 120.7, 118.8, 118.3, 114.3, 66.2, 28.7, 23.5, 19.4; MS (ESI) m/z 411 [M + H]\ Anal, calc'd for C27H26Ν2O2 • 0.3 H2O: C, 77.97; H, 6.45; N, 6.74. Found: C,
15 77.76; H, 6.64; N, 6.48.
Example K-2: 3-(Isoquinolin-4-yl)methoxy-N-(3,4,5-trimethoxyphenyl)benzamide hydrochloride
Figure imgf000096_0001
20 K-2
Example K-2 was prepared in a similar manner to that described for K-l, except that 3,4,5-trimethoxyaniline (Aldrich) was used in place of 3-methyl-4-isopropylaniline in step (d). The product was isolated as the hydrochloride salt as follows. A solution of 3-(isoquinolin-4-yl)methoxy-N-(3,4,5-trimethoxyphenyl)benzamide (116 mg, 0.26 25 mmol) in ethanol was treated with concentrated hydrochloric acid (0.1 mL, 1.2 mmol). After several minutes, the solvent was removed under reduced pressure to give 3- (isoquinolin-4-yl)methoxy-N-(3,4,5-trimethoxyphenyl)benzamide hydrochloride as a white solid (126 mg, 100%): HPLC R, = 13.4 min.; TLC R = 0.5 (5% methanol/chloroform); Η NMR (300 MHz, DMSO- 6) δ 10.10 (s, IH), 9.70 (s, IH), 8.72 (s, IH), 8.41 (d, IH, J = 8.1 Hz), 8.30 (d, IH, J = 8.5 Hz), 8.10 (t, IH, J = 7.8 Hz), 7.90 (t, IH, J = 7.6 Hz), 7.67 (s, IH), 7.53 (d, IH, J = 7.7 Hz), 7.41 (t, IH, J = 7.9 Hz), 7.29 (dd, IH, J = 8.2, 1.6 Hz), 7.16 (s, 2H), 5.70 (s, 2H), 3.66 (s, 6H), 3.53 (s, 3H); 13C NMR (75 MHz, DMSO- 6) δ 165.1, 158.2, 152.9, 149.5, 136.7, 136.1, 135.8, 135.6, 134.2, 133.5, 131.0, 130.9, 130.3, 130.0, 127.6, 124.4, 121.0, 118.6, 114.5, 98.6, 65.4, 60.5, 56.1; MS (ESI) m/z 445 [M + H]+. Anal, calc'd for C25H22N4O3 • HCI • 0.5 H2O: C, 63.73; H, 5.35; N, 5.72. Found: C, 63.52; H, 5.51; N, 5.50. Example K-3: 3-(Isoquinolin-4-yl)methoxy-N-(2-methyl-quinolin-6-yl)- benzamide hydrochloride
Figure imgf000097_0001
K-3 Example K-3, which was isolated as a dihydrochloride salt as described in Example K- 2, was prepared in a similar manner to that described for K-l, except that 6-amino-2- methylquinoline (Maybridge) was used in place of 3-methyl-4-isopropylaniline in step (d): HPLC R, = 13.2 min.; TLC R/ = 0.5 (5% methanol/chloroform); Η ΝMR (300 MHz, DMSO- 6 w/ D2O) δ 9.78 (s, IH), 9.0 (d, IH, J = 8.7 Hz), 8.84 (d, 2H, J = 1.9 Hz), 8.55 (d, IH, J = 8.2 Hz), 8.45-8.40 (m, 2H) 8.27-8.22 (m, 2H), 8.05 (t, IH, J = 7.5 Hz), 7.92 (d, IH, J = 8.7 Hz), 7.83 (t, IH, J = 1.8 Hz), 7.72 (d, IH, J = 7.7 Hz), 7.60 (t, IH, J = 8.0 Hz), 7.48 (dd, IH, J = 8.2, 1.8 Hz), 5.84 (s, 2H), 2.95 (s, 3H); 13C ΝMR (75 MHz, DMSO- 6 w/ D2O) δ 167.9, 159.8, 158.2, 151.2, 146.7, 140.7, 137.6, 137.4, 136.3, 135.4, 132.6, 132.2, 132.1, 132.0, 130.3, 129.2, 129.1, 125.9, 125.7, 122.9, 122.7, 120.8, 118.7, 116.1, 66.9, 22.0; MS (FAB) m/z 420 [M + H]+. Anal, calc'd for C27H21Ν3O2 • 2HC1 • 0.3 H2O: C, 65.14; H, 4.78; N, 8.44. Found: C, 65.18; H, 4.84; N, 8.38.
Example K-4: 3-(Isoquinolin-4-yl)methoxy-N-(2-methyl-4-methylsulfanyl- quinolin-6-yl)-benzamide hydrochloride
Figure imgf000098_0001
K-4
Example K-4, which was isolated as a dihydrochloride salt as described in Example K- 2, was prepared in a similar manner to that described for K-l, except that 2-methyl-4- methylsulfanyl-quinolin-6-ylamine, K-4d (vide infra), was used in place of 3-methyl- 4-isopropylaniline in step (d): HPLC R, = 14.4 min.; TLC R = 0.5 (5% methanol/chloroform); Η NMR (500 MHz, DMSO-d6) δ 11.10 (s, IH), 9.80 (s, IH), 9.07 (s, IH), 8.89 (s, IH), 8.54 (t, 2H, J = 7.6 Hz), 8.46 (d, IH, J = 8.5 Hz), 8.33 (d, IH, J = 9.2 Hz), 8.22 (t, IH, J = 7.5 Hz), 8.04 (t, 2H, J = 7.6 Hz), 7.95 (s, IH), 7.79- 7.78 (m, 2H), 7.63 (t, IH, J = 7.9 Hz), 7.52 (d, IH, J = 6.6 Hz), 5.88 (s, 2H), 2.94 (s, 3H), 2.92 (s, 3H); HRMS (FAB) calcd for C28H23N3O2S [M + H]+ 466.1589, found 466.1577.
The intermediate 2-methyl-4-methylsulfanyl-quinolin-6-ylamine, K-4d, was prepared as follows:
Figure imgf000099_0001
K-4d K-4c
(a) A solution of 2-methyl-quinolin-4-ol (Aldrich, 9.2 g, 57.9 mmol. 1.0 eq) in concentrated sulfuric acid (60 mL) was cooled to 0 °C and treated with fuming nitric acid (3.9 mL, 57.9 mmol, 1.0 eq). The dark orange solution was stirred at 0 °C for 15 minutes and then poured into ice water (1000 mL) to give a yellow precipitate. After standing for 18 hours, the mixture was filtered and the yellow precipitate was washed with ice water to give 2-methyl-6-nitro-quinolin-4-ol, K-4a, as a yellow solid (6.9 g, 58%): HPLC R, = 6.8 min.; Η NMR (500 MHz, DMSO-i6) δ 8.10 (s, IH), 8.42 (dd, IH, J = 9.2, 2.6 Hz), 7.70 (d, IH, J = 9.1 Hz), 6.15 (s, IH), 2.42 (s, 3H); MS (ESI) m/z 203 [M - H]\
(b) A solution of 2-methyl-6-nitro-quinolin-4-ol, K-4a, (6.9 g, 33.8 mmol) in phosphorus oxychloride (70 mL) was heated to 95 °C. After 1 hour, the reaction mixture gives no starting material by HPLC analysis. The black solution was cooled to room temperature and poured into ice water (500 mL). The aqueous layer was made basic by the addition of concentrated ammonium hydroxide, and extracted with chloroform (3 x 500 mL). The combined organic extracts were washed with 5.0 N ammonium hydroxide (500 mL), water (500 mL), brine (500 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was passed through a silica gel plug, eluting with 20% ethyl acetate/chloroform, to give a brown solid (6.4 g). The product was crystallized from hot ethanol to give 4-chloro-2-methyl-6-nitro-quinoline, K-4b, as tan needles (3.6 g, 48%): mp 142-144 °C; HPLC R( = 13.5 min.; TLC R = 0.3 (20% ethyl acetate/cyclohexane); Η NMR (500 MHz, DMSO-d6) δ 8.92, (d, IH, J = 2.5 Hz), 8.52 (dd, IH, J = 9.2, 2.6 Hz), 8.20 (d, IH, J = 9.2 Hz), 7.94 (s, IH), 2.73 (s, 3H); MS (ESI) m/z 223 [M + H]+. (c) A solution of 4-chloro-2-methyl-6-nitro-quinoline, K-4b, (372 mg, 1.7 mmol, 1.0 eq) in anhydrous ethanol (70 mL) was treated with sodium thiomethoxide (619 mg, 8.8 mmol, 5.2 eq), and the resultant green slurry was heated at 50 °C. After 2.5 hours, the solvent was removed under reduced pressure and the residue was partitioned between water (100 mL) and chloroform (3 x 100 mL). The combined organic extracts were washed with brine (100 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a yellow solid (430 mg). The crude product was purified by radial chromatography over silica gel using 5% ethyl acetate/chloroform, followed by crystallization from hot ethanol, to give 2-methyl-4-methylsulfanyl-6- nitro-quinoline, K-4c, as yellow needles (250 mg, 46%): HPLC R, = 13.1 min.; TLC Rf = 0.5 (10% ethyl acetate/chloroform); Η NMR (500 MHz, DMSO-cy δ 8.70 (d, IH, J = 2.4 Hz), 8.32 (dd, IH, J = 9.2, 2.5 Hz), 7.97 (d, IH, J = 9.2 Hz), 7.35 (s, IH), 2.61 (s, 3H), 2.58 (s, 3H); MS (ESI) m/z 235 [M + H]+.
(d) A mixture of 2-methyl-4-methylsulfanyl-6-nitro-quinoline, K-4c, (200 mg, 0.85 mmol, 1.0 eq), and tin(II) chloride dihydrate (965 mg, 4.27 mmol, 5.0 eq) in anhydrous ethanol (50 mL) was heated to 75 °C to give an orange solution. After 30 minutes, the reaction mixture was concentrated under reduced pressure to about 10 mL. The resultant mixture was poured into ice water (100 mL), and the aqueous layer was adjusted to pH 10 using concentrated ammonium hydroxide. The aqueous layer was extracted with ethyl acetate (3 x 100 mL), the combined organic layers were washed with brine (100 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a yellow solid (250 mg). The crude product was purified by radial chromatography over silica gel using 30% ethyl acetate/dichloromethane w/ 0.5% methanol to give 2-methyl-4-methylsulfanyl-quinolin-6-ylamine, K-4d, as a yellow solid (70 mg, 40%): HPLC R, = 9.0 min.; TLC 1^= 0.6 (5% methanol/chloroform); Η NMR (500 MHz, DMSO- ) δ 7.58 (d, IH, J = 8.9 Hz), 7.08 (dd, IH, J = 8.9, 2.4 Hz), 7.02 (s, IH), 6.90 (d, IH, J = 2.4 Hz), 5.58 (s, 2H), 2.58 (s, 3H), 2.51 (s, 3H); MS (ESI) m/z 205 [M + H]+. Example K-5: 3-(Pyridin-3-yI)methoxy-N-(3,4,5-trimethoxyphenyI)benzamide
Figure imgf000101_0001
K-5 Example K-5, which was obtained as a white solid in a 62% yield, was prepared in a similar manner to that described for K-l, except that 3,4,5-trimethoxyaniline was used in place of 3-methyl-4-isopropylaniline in step (d), and 3-picolyl chloride hydrochloride was used in place of 4-(chloromethyl)isoquinoline hydrochloride, K-lc, in step (e): HPLC R, = 18.1 min.; TLC R = 0.5 (5% methanol/chloroform); Η ΝMR (500 MHz, CDC13) δ 8.73 (s, IH), 8.60 (d, IH, J = 2.9 Hz), 8.22 (s, IH), 7.91 (d, IH, J = 7.4 Hz), 7.61 (s, IH), 7.52-7.41 (m, 3H), 7.16 (d, IH, J = 7.6 Hz), 7.04 (s, 2H), 5.19 (s, 2H), 3.87 (s, 6H), 3.85 (s, 3H); 13C ΝMR (125 MHz, CDCL) δ 165.2, 158.5, 153.3, 147.9, 147.4, 136.6, 136.4, 134.9, 134.0, 133.0, 130.0, 124.0, 119.7, 118.8, 113.3, 98.0, 67.4, 61.0, 56.1; MS (FAB) m/z 395 [M + H]+. Anal, calc'd for C22H22Ν2O5: C, 66.99; H, 5.62; N, 7.10. Found: C, 67.00; H, 5.65; N, 7.09.
Example K-6: N-(Naphthalen-2-yl)-3-(pyridin-3-yl)methoxybenzamide
Figure imgf000101_0002
K-6 Example K-6, which was obtained as a white solid in a 19% yield, was prepared in a similar manner to that described for K-l, except 2-aminonaphthalene (Aldrich) was used in place of 3-methyl-4-isopropylaniline in step (d), and 3-picolyl chloride hydrochloride was used in place of 4-(chloromethyl)isoquinoline hydrochloride, K-lc, in step (e): HPLC Rt = 22.5 min.; TLC Rf = 0.4 (5% methanol/chloroform); Η NMR (300 MHz, CDCL) δ 10.41 (s, IH), 8.72 (d, IH, I = 1.8 Hz), 8.58 (dd, IH, I = 4.8, 1.6 Hz), 8.44 (d, IH, J = 1.5 Hz), 7.94-7.81 (m, 5H), 7.68-7.62 (m, 2H), 7.53-5.28 (m,
5H), 5.27 (s, 2H); 13C NMR (125 MHz, DMSO- 6) δ 165.6, 158.5, 149.6, 149.5, 137.0, 136.7, 136.1, 133.7, 132.8, 130.4, 130.0, 128.5, 127.8, 127.7, 126.7, 125.2, 124.0, 121.3, 120.7, 118.4, 117.0, 114.4, 67.6; MS (FAB) m/z 355 [M + H]+. Anal, calcd for C23H18N2O2: C, 77.95; H, 5.12; N, 7.70. Found: C, 77.41; H, 5.22; N, 7.79. Example K-7: N-(l-Allyl-liϊ-indol-5-yl)-3-(pyridin-3-yl)methoxy-benzamide
Figure imgf000102_0001
K-7
Example K-7, which was obtained as a light yellow solid in a 25% yield, was prepared in a similar manner to that described for K-l, except l-allyl-lH-indol-5-ylamine, K-7b (vide infra), was used in place of 3-methyl-4-isopropylaniline in step (d), and 3-picolyl chloride hydrochloride was used in place of 4-(chloromethyl)isoquinoline hydrochloride, K-lc, in step (e): ΗPLC R, = 21.6 min.; TLC Rf = 0.7 (5% methanol/chloroform); Η ΝMR (300 MHz, DMSO- 6) δ 10.14 (s, IH), 8.77 (d, IH, J = 1.5 Hz), 8.62 (d, IH, J = 5.1 Hz), 8.05 (s, IH), 7.98 (d, IH, J = 8.1 Hz), 7.68-7.66 (m, 2H), 7.53-7.28 (m, 7H), 6.49 (d, IH, J = 2.9 Hz), 6.10-6.01 (m, IH), 5.30 (s, 2H), 5.20 (d, IH, J = 10.3 Hz), 5.05 (d, IH, J = 17.3 Hz), 4.86 (d, 2H, J = 5.2 Hz); HRMS (FAB) calcd for C24H21Ν3O2 [M + H]+ 384.1712, found 384.1708. The intermediate l-allyl-lH-indol-5-ylamine, K-7b, was prepared as follows:
Figure imgf000102_0002
(a) A solution of 5-nitro-lH-indole (Acros, 2.0 g, 13.5 mmol, 1.0 eq) in DMF (125 mL) was cooled to 0 °C, treated with sodium hydride (60% in mineral oil, 600 mg, 14.9 mmol, 1.1 eq) and stirred for 2.0 hours. The resulting red solution was treated with allyl bromide (1.3 mL, 14.9 mmol, 1.1 eq) and stirred for 1.0 hour at room temperature. The reaction was diluted with water (1.0 L) and extracted with MTBE (3 x 500 mL). The combined organic extracts were washed with water (500 mL), brine (200 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a brown oil (2.7 g). The crude product was purified by radial chromatography over silica gel using 5-30% ethyl acetate/cyclohexane to give 1-allyl- 5-nitro-lH-indole, K-7a, as a light yellow oil (2.5 g, 90%): TLC Rf = 0.3 (5% ethyl acetate/cyclohexane); Η NMR (300 MHz, CDCL) δ 6.60 (d, J = 2.2 Hz, IH), 8.11 (dd, IH, J = 9.2, 2.2 Hz), 7.34 (d, IH, J = 9.2 Hz), 7.26-7.24 (m, IH), 6.70 (d, IH, J = 3.3 Hz), 6.06-5.94 (m, IH), 5.26 (dd, 2H, J = 10.3, 0.7 Hz), 5.08 (dd, IH, J = 17.3, 0.7 Hz), 4.79 (d, 2H, J = 5.5 Hz); MS (FAB) m/z 203 [M + H]+. (b) A mixture of water (20 mL), methanol (20 mL), zinc (4.2 g, 64.2 mmol, 5.6 eq) and l-allyl-5-nitro-lH-indole, K-7a, (2.3 g, 11.4 mmol, 1.0 eq) was treated with concentrated sulfuric acid (6 mL, 333 mmol, 29 eq) at 0 °C. The mixture was gradually warmed to room temperature. After 18 hours, the mixture was filtered, and the pΗ of the resulting brown solution was adjusted to 9 with a saturated sodium bicarbonate solution. The resulting slurry was filtered and extracted with chloroform (3 x 500 mL). The combined organic extracts were washed with brine (200 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a black oil (0.94 g). The crude product was purified by radial chromatography over silica gel using 40% ethyl acetate/cyclohexane with 0.5% methanol to give 1-allyl-lH- indol-5-ylamine, K-7b, as a dark brown oil (233 mg, 5%): TLC Rf = 0.3 (30% ethyl acetate/cyclohexane); Η NMR (300 MHz, CDCL) δ 7.16 (d, IH, J = 8.4 Hz), 7.07- 7.03 (m, 2H), 6.77 (dd, IH, J = 8.6, 2.0 Hz), 6.36 (d, IH, I = 2.9 Hz), 6.04-5.91 (m, IH), 5.18 (dd, IH, J = 10.3, 1.1 Hz), 5.05 (dd, IH, J = 16.9, 1.1 Hz), 4.67 (d, 2H, J = 5.5 Hz), 3.8 (br s, 2H); MS (FAB) m/z 171 [M - H]\ Example K-8: 3-(Pyridin-3-yl)methoxy-N-quinolin-6-yl-benζamide
Figure imgf000104_0001
K-8 Example K-8, which was obtained as a white solid in a 20% yield, was prepared in a similar manner to that described for K-l, except 6-aminoquinoline (Fluka) was used in place of 3-methyl-4-isopropylaniline in step (d), and 3-picolyl chloride hydrochloride was used in place of 4-(chloromethyl)isoquinoline hydrochloride, K-lc, in step (e): HPLC R, = 17.0 min.; TLC R = 0.6 (5% methanol/chloroform); Η NMR (300 MHz, DMSO- ) δ 10.60 (s, IH), 8.86 (d, IH, J = 3.3 Hz), 8.78 (s, IH), 8.63-8.60 (m, 2H), 8.39 (d, IH, J = 8.5 Hz), 8.12-8.04 (m, 2H), 7.98 (d, IH, J = 8.1 Hz), 7.74-7.70 (m, 2H), 7.67-7.49 (m, 3H), 7.37-7.34 (m, IH), 5.32 (s, 2H); HRMS (FAB) calcd for C22H17N3O2 [M + H]+ 356.1399, found 384.1406. Example K-9: N-(2-Methyl-quinolin-6-yl)-3-(pyridin-3-yl)methoxy-benzamide
Figure imgf000104_0002
K-9 Example K-9, which was obtained as a white solid in a 16% yield, was prepared in a similar manner to that described for K-l, except 6-amino-2-methylquinoline (Maybridge) was used in place of 3-methyl-4-isopropylaniline in step (d), and 3- picolyl chloride hydrochloride was used in place of 4-(chloromethyl)isoquinoline hydi-ochloride, K-lc, in step (e): HPLC R, = 19.9 min.; TLC R = 0.2 (3% methanol/chloroform); Η ΝMR (300 MHz, DMSO-d6) δ 10.54 (s, IH), 8.77 (d, IH, J = 0.7 Hz), 8.62 (dd, IH, J = 4.8, 1.4 Hz), 8.52 (d, IH, J = 1.9 Hz), 8.26 (d, IH, J = 8.8 Hz), 8.05-7.93 (m, 3H), 7.71-7.69 (m, 2H), 7.66-7.43 (m, 3H), 7.36-7.33 (m, IH), 5.32 (s, 2H), 2.69 (s, 3H); 13C ΝMR (125 MHz, DMSO- 6) δ 165.4, 158.1, 157.4, 149.3, 149.2, 144.5, 136.3, 135.8, 132.4, 129.7, 128.5, 126.3, 124.1, 123.6, 122.4, 120.4, 118.1, 116.4, 114.1, 67.3, 24.7; HRMS (FAB) calcd for C23H19Ν3O2 [M+H]+ 370.1556, found 370.1549. Example K-10: N-(4-Isopropyl-3-methyl-phenyl)-4-fluoro-3-(Isoquinolin-4- yl)methoxy-benzamide
Figure imgf000105_0001
Example K-10 was prepared in a similar manner to that described for K-l, except 4- fluoro-3-hydroxybenzoic acid was used in place of 3-hydroxybenzoic acid in step (d): Η NMR (300 MHz, CDCL) δ 9.28 (s, IH), 8.63 (s, IH), ), 8.11(d, IH, J = 8.23 Hz) 8.05 (d, IH, J = 8.11 Hz), 7.79 (m, 2H), 7.68 (m, 2H), 7.40 (m, 3H), 7.22 (m, 2H), 5.60 (s, 2H), 3.12 (br, IH), 2.35 (s, 3H), 1.22 (d, 6H, J = 6.9 Hz). MS (FAB) m/z 429 [M + H]+. Anal, calcd for C27H25 FN2O2 « 0.8H2O: C, 73.22; H, 6.05; N, 6.33. Found: C, 73.21; H, 5.73; N, 6.19. Example K-ll: N-(4-Isopropyl-3-methyI-phenyl)-4-methyl-3-(IsoquinoIin-4- yl)methoxy-benzamide
Figure imgf000105_0002
Example K-ll was prepared in a similar manner to that described for K-l, except 4- methyl-3-hydroxybenzoic acid was used in place of 3-hydroxybenzoic acid in step (d): Η ΝMR (300 MHz, CDCL) δ 9.29 (s, IH), 8.67 (s, IH), ), 8.07 (s, IH,) 8.04 (s, IH), 7.80-7.64 (m, 4H), 7.46-7.30 (m, 4H), 7.23 (m, IH), 5.54 (s, 2H), 3.19-3.06 (m, IH), 2.36 (s, 3H), 2.25 (s, 3H), 1.23 (d, 6H, J = 6.84 Hz). MS (ESI) m/z 425 [M + H]+. Anal, calc'd for C28H28 Ν2O2: C, 79.22; H, 6.65; N, 6.60. Found: C, 79.27; H, 6.74; N, 6.60.
Example K-12: N-(4-Isopropyl-3-methyI-phenyl)-4-chloro-3-(Isoquinolin-4- yl)methoxy-benzamide
Figure imgf000106_0001
Example K-12 was prepared in a similar manner to that described for K-l, except 4- chloro-3-hydroxybenzoic acid was used in place of 3-hydroxybenzoic acid in step (d): Η NMR (300 MHz, CDCL) δ 9.30 (br, s,lH), 8.70 (br, s, IH), ), 8.14-8.04 (m, 2H), 7.82-7.65 (m, 4H), 7.50-7.32 (m, 4H), 7.23 (m, IH), 5.61 (s, 2H), 3.13 (m, IH), 2.36 (s, 3H), 1.23(d, 6H, J = 6.89 Hz). EEVIS m/z 444 [M+]. Anal, calc'd for C27H25 ClN2O2: C, 72.88; H, 5.66; N, 6.30. Found: C, 72.86; H, 5.71; N, 6.24. Example L-1 : 3-(6- Aminopyridin-3-yl)methoxy-N-(4-Isopropyl-3-methyl-phenyl)- benzamide
Figure imgf000106_0002
NaO-tBu Dioxane, 80°C
Figure imgf000106_0003
TFA
L-1; R = H
(a) A solution of 6-chloronicotinic acid (Aldrich, 10.0 g, 63.7 mmol, 1.0 eq) in dioxane (300 mL) was treated with a 1.0 M solution of borane in THF (320 mL, 329 mmol, 5.0 eq) at room temperature. The resultant orange solution was stirred for one hour and then heated to 75 °C. After 2.5 h, the reaction was quenched with ethanol (100 mL), and the solvent was removed under reduced pressure. The crude product was stirred in 1.2 M HCI (350 mL) and the pH was subsequently adjusted to 9 with solid NaOH. The aqueous layer was extracted with ethyl acetate (3 x 200 mL) and the combined organic extracts were washed with water (200 mL), brine (200 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a yellow oil (23.4 g). The crude product was purified by flash chromatography over silica gel using 30-60% ethyl acetate/cyclohexane to give (6-chloropyridin-3- yl)methanol, L-la, as a white crystalline solid (5.0 g, 54%): HPLC R( = 2.9 min.; TLC R/ = 0.5 (5% methanol/dichloromethane); Η NMR (300 MHz, DMSO-d6) δ 8.35 (d, IH, J = 1.9 Hz), 7.79 (dd, IH, J = 8.2, 2.4 Hz), 7.48 (d, IH, J = 8.2 Hz), 5.42 (t, IH, J = 5.6 Hz), 4.53 (d, 2H, J = 5.7 Hz); 13C NMR (75 MHz, DMSO- 6) δ 148.9, 148.4, 138.5,
137.6, 124.2, 60.2; MS (ESI) /z 144 [M + H]+. (b) A solution of the (6-chloropyridin-3-yl)-methanol, L-la, (186 mg, 1.3 mmol, 1.0 eq), 3-hydroxy-N-(4-isopropyl-3-methyl-phenyl)-benzamide, K-ld, (350 mg, 1.3 mmol, 1.0 eq) and triphenylphosphine (1.0 g, 3.9 mmol, 3.0 eq) in THF (15 mL) was protected from light and treated with diethyl azodicarboxylate (0.62 mL, 3.9 mmol, 3.0 eq). After 18 h, the resultant light yellow solution was poured into 50% brine (200 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic extracts were washed with brine (200 mL), dried over magnesium sulfate, filtered through a silica gel plug, and concentrated under reduced pressure to give a yellow oil (2.6 g). The crude product was purified by radial chromatography over silica gel using 5-10% ethyl acetate/45% cyclohexane/dichloromethane to give 3-(6-chloropyridin-3- yl)methoxy-N-(4-isopropyl-3-methyl-phenyl)-benzamide, L-lb, as a white solid (380 mg, 74%): HPLC R, = 16.2 min.; TLC R = 0.4 (30% ethyl acetate/cyclohexane); Η ΝMR (300 MHz, DMSO-d6) δ 10.07 (s, IH), 8.56 (d, IH, J = 2.3 Hz), 7.99 (dd, IH, J = 8.2, 2.4 Hz), 7.60-7.44 (m, 6H), 7.27-7.19 (m, 2H), 5.25 (s, 2H), 3.31-3.03 (m, IH), 2.29 (s, 3H), 1.18 (d, 6H, J = 6.9 Hz); 13C ΝMR (75 MHz, DMSO-d6) δ 165.1, 158.2, 150.2, 149.6, 142.2, 139.8, 136.8, 136.7, 135.0, 132.4, 130.0, 125.0, 124.6, 122.5,
120.7, 118.8, 118.2, 114.2, 66.6, 28.7, 23.5, 19.5; MS (ESI) m/z 393 [M - HT. (c) A solution of 3-(6-chloropyridin-3-yl)methoxy-N-(4-isopropyl-3-methyl-phenyl)- benzamide, L-lb, (300 mg, 0.76 mmol, 1.0 eq), 4-methoxybenzylamine (Aldrich, 0.12 mL, 0.91 mmol, 1.2 eq), palladium acetate (Strem, 6.8 mg, 0.03 mmol, 4 mol%), and CyMAPl (I. Am. Chem. Soc. 1998, 120, 9722-23, 11.8 mg, 0.03 mmol, 4 mol%) in dioxane (10 mL) was treated with sodium-tert-butoxide (169 mg, 1.82 mmol, 1.4 eq). The resultant orange solution was warmed to 80 °C for 18 hours. The reaction mixture was poured into 50% brine (100 mL) and extracted with ethyl acetate (3 x 75 mL). The combined organic extracts were washed with brine (200 mL), dried over magnesium sulfate, filtered through a silica gel plug, and concentrated under reduced pressure to give a yellow oil (330 mg). The crude product was purified by radial chromatography over silica gel using 45% ethyl acetate/cyclohexane to give, from MTBE, N-(4-isopropyl-3-methyl-phenyl)-3-[6- { (4-methoxybenzyl)amino }pyridin-3- ylmethoxyj-benzamide, L-lc, as a white solid (189 mg, 50%): HPLC Rt = 14.7 min.; TLC R/ = 0.4 (4% methanol/dichloromethane); Η ΝMR (300 MHz, DMSO- 6) δ 9.43 (s, IH), 7.74 (s, IH), 7.27-7.18 (m, 3H), 7.02-6.82 (m, 6H), 6.70-6.62 (m, 4H), 6.41 (d, IH, J = 8.5 Hz), 4.79 (s, 2H), 4.32 (d, 2H, J = 5.5 Hz), 3.69 (s, 3H), 2.97-2.90 (m, IH), 2.13 (s, 3H), 1.05 (d, 6H, J = 6.7 Hz); 13C ΝMR (75 MHz, DMSO- 6) δ 169.9, 158.4, 158.3, 157.0, 147.4, 144.8, 140.4, 138.0, 137.2, 135.7, 132.7, 129.0, 128.8, 125.8, 125.3, 120.8, 119.2, 116.7, 115.5, 113.9, 108.2, 55.4, 50.7, 44.0, 28.7, 23.3, 19.2; MS
Figure imgf000108_0001
(d) A solution of N-(4-isopropyl-3-methyl-phenyl)-3-[6-{(4- methoxybenzyl)amino}pyridin-3-ylmethoxy]-benzamide, L-lc, (120 mg, 0.24 mmol) in trifluoroacetic acid (6 mL) was stirred at room temperature. After 18 hours, the resultant cherry red solution was concentrated under reduced pressure and extracted with 50% sodium bicarbonate (25 mL) and ethyl acetate (3 x 25 mL). The combined organic extracts were washed with 5% sodium bicarbonate (50 mL), brine (50 mL), dried over magnesium sulfate, and concentrated under reduced pressure to give a clear oil (132 mg). The crude product was purified by radial chromatography over silica gel using 5% methanol/chloroform with 0.1% ammonium hydroxide to give, 3-(6-amino- pyridin-3-yl)methoxy-N-(4-isopropyl-3-methyl-phenyl)-benzamide, L-1, as a white solid (75 mg, 82%): mp 78-81 °C; HPLC R, = 12.1 min.; TLC R = 0.4 (8% methanol/chloroform); *H NMR (300 MHz, DMSO- 6) δ 9.32 (s, IH), 7.54 (d, IH, J = 2.0 Hz), 7.13 (dd, IH, J = 8.4, 2.4 Hz), 6.90-6.71 (m, 2H), 6.58 (d, IH, J = 1.5 Hz), 6.54-6.47 (m, 4H), 6.23 (d, IH, J = 8.5 Hz), 5.70 (s, 2H), 4.66 (s, 2H), 2.94-2.78 (m, IH), 2.02 (s, 3H), 0.94 (d, 6H, J = 6.8 Hz); MS (ESI) m/z 494 [M - HT. Anal, calcd for C23H25N3O2 • 0.4 hexane: C, 74.42; H, 7.52; N, 10.25. Found: C, 74.09; H, 7.49; N, 10.00.
Example M-l: 3-(6-Aminopyridin-3-yl)methoxy-N-(2-methyl-quinolin-6-yl)-benz- amide
Figure imgf000109_0001
(a) A mixture of 6-chloronicotinic acid (Aldrich, 5.0 g, 31.6 mmol, 1.0 eq), water (10 mL) and ethanol (35 mL) was treated with sodium azide (2.15 g, 33.8 mmol, 1.1 eq). The resulting orange solution was heated to 75 °C. After 18 h, the solvent was removed under reduced pressure and the resultant white slurry was repeatedly evaporated with toluene to give the crude 6-azido-nicotinic acid/NaCl mixture, M-la, as a white solid (6.9 g, 98%): TLC Rf 0.2 (6% methanol/dichloromethane w/ 0.1 % Acetic acid); Η NMR (500 MHz, DMSO- 6) δ 9.41 (s, IH), 7.98 (s, IH), 7.97 (s, IH). (b) A mixture of 6-azidonicotinic acid/NaCl, M-la, (6.9 g, 31.1 mmol), and thionyl chloride (100 mL) was heated to 75 °C. After 2 hours, the crude acid chloride hydrochloride salt was obtained by removing the thionyl chloride under pressure. The resultant slurry was evaporated from toluene and then added to a slurry of isopropanol (100 mL) and sodium borohydride at -10 °C. The resultant yellow slurry was warmed to room temperature over several hours and stirred at room temperature for 12 h. The reaction mixture was poured into water (500 mL) and extracted with ethyl acetate (3 x 500 mL). The combined organic extracts were washed with brine (200 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a yellow solid (2.3 g). The crude product was purified by radial chromatography over silica gel using 1-3% methanol/dichloromethane to give (6-azidopyridin-3-yl)-methanol, M-lb, as a white solid (850 mg, 18%): TLC R/ = 0.4 (5% methanol/chloroform); Η NMR (500 MHz, DMSO- ) δ 9.14 (s, IH), 8.19 (d, IH, J = 9.0 Hz), 7.84 (dd, IH, J = 9.4, 1.0 Hz), 5.67 (t, IH, J = 5.6 Hz), 4.66 (d, 2H, J = 5.6 Hz). (c) A solution of (6-azidopyridin-3-yl)-methanol, M-lb, (350 mg, 2.3 mmol, 1.0 eq) in THF (25 mL) was cooled to -78 °C and treated with mesyl chloride (265 μL, 3.4 mmol, 1.5 eq). After 60 minutes at -78 °C, the clear solution was treated with triethylamine (0.70 mL, 5.1 mmol, 2.2 eq), and the reaction mixture was warmed to -20 °C over 2.5 hours. The resultant cloudy reaction mixture was monitored by TLC (3% methanol/dichloromethane), which gave only product (Rf 0.4) and no starting material (Rf O.2). To obtain an analytical sample, an aliquot of the reaction mixture was diluted in 25% ammonium acetate and extracted with ethyl acetate. The organic extract was washed with water, brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure to give (6-azidopyridin-3-yl)methyl methanesulfonate, M-lc, as a tan solid: TLC Rf = 0.6 (5% methanol/chloroform); Η NMR (500 MHz, DMSO- d6) δ 9.5 (s, IH), 8.30 (d, IH, J = 9.4 Hz), 7.94 (d, IH, J = 9.6 Hz), 5.46 (s, 2H), 3.35 (s, 3H).
(d) A solution of 3-acetoxybenzoic acid (Aldrich, 1.8 g, 9.9 mmol, 1.0 eq) and 6- amino-2-methylquinoline (Avocado, 1.6 g, 9.9 mmol, 1.0 eq) in ethyl acetate (50 mL) was treated with a solution of l-(3-dimethylaminoproρyl)-3-ethylcarbodiimide hydrochloride (2.3 g, 11.8 mmol, 1.2 eq) in dichloromethane (50 mL). After 18 h, the resultant tan slurry was poured into 5% sodium bicarbonate (200 mL) and extracted with 10% isopropyl alcohol/chloroform (3 x 150 mL). The combined organic extracts were washed with brine (200 mL), dried over magnesium sulfate, filtered through a silica gel plug and concentrated under reduced pressure to give a yellow solid (2.8 g). The crude product was purified by radial chromatography over silica gel using 1-2% methanol/dichloromethane to give an unpure product as a yellow solid (2.6 g). The unpure product was washed with MTBE and the solids were collected to give 3- acetoxy-N-(2-methyl-quinolin-6-yl)benzamide, M-ld, as a light yellow solid (2.3 g, 84%): HPLC R( = 11.2 min.; TLC Ry= 0.3 (3% methanol/dichloromethane); Η NMR (300 MHz, DMSO- ) δ 10.40 (s, IH), 8.29 (d, IH, J = 2.2 Hz), 8.04 (d, IH, J = 8.5 Hz), 7.83-7.72 (m, 3H), 7.59 (t, IH, J = 1.8 Hz), 7.45 (t, IH, J = 7.9 Hz), 7.24 (d, IH, J = 8.4 Hz), 2.48 (s, 3H), 2.16 (s, 3H); MS (ESI) m/z 321 [M + H]+.
(e) A solution of 3-acetoxy-N-(2-methyl-quinolin-6-yl)benzamide, M-ld, (2.2 g, 6.9 mmol, 1.0 eq) in methanol (65 mL) and THF (60 mL) was treated with a solution of potassium carbonate (4.8 g, 34.5 mmol, 5.0 eq) in water (45 mL). After 3.0 h, the cloudy reaction mixture was concentrated under reduced pressure and extracted with water (100 mL) and ethyl acetate (3 x 100 mL). The combined organic extracts were washed with brine (200 mL), dried over magnesium sulfate and concentrated under reduced pressure to give a light yellow solid (2.0 g). The crude product was washed with dichloromethane and the solids were collected to give 3-hydroxy-N-(2-methyl- quinolin-6-yl)-benzamide, M-le, as a light yellow solid (1.6 g, 83%): HPLC Rt = 9.5 min.; TLC R/ = 0.3 (5% methanol/dichloromethane); 1H NMR (300 MHz, DMSO- 6) δ 10.43 (s, IH), 9.78 (s, IH), 8.47 (d, IH, J = 2.2 Hz), 8.20 (d, IH, J = 8.4 Hz), 8.00-7.87 (m, 2H), 7.44-7.32 (m, 4H), 7.01-6.98 (m, IH), 2.64 (s, 3H); 13C NMR (75 MHz, DMSO- ) δ 166.2, 157.7, 157.6, 144.8, 136.8, 136.6, 136.1, 129.8, 128.8, 126.7, 124.4, 122.8, 119.0, 118.6, 116.6, 114.9, 25.0; MS (ESI) m/z 279 [M + H]+.
(f) A mixture of 3-hydroxy-N-(2-methyl-quinolin-6-yl)-benzamide, M-le, (0.64 g, 2.3 mmol, 1.0 eq) and cesium carbonate (3.0 g, 9.2 mmol, 4.0 eq) in acetone (45 mL) was treated with unpurified (6-azidopyridin-3-yl)methyl methanesulfonate, M-lc, (524 mg, 2.3 mmol, 1.0 eq). After 18 h at 50 °C, the resultant pink slurry was poured into 5% sodium bicarbonate (400 mL) and extracted with 5% isopropyl alcohol/chloroform (3 x 300 mL). The combined organic extracts were washed with brine (300 mL), dried over magnesium sulfate and concentrated under reduced pressure to give a light yellow solid (0.99 g). The crude product was washed with diethyl ether and the solids were collected to give 3-(6-azidopyridin-3-yl)methoxy-N-(2-methyl-quinolin-6-yl)- benzamide, M-lf, as a light yellow solid (0.87 g, 92%): HPLC R( = 11.7 min. ; TLC Rf = 0.5 (5% methanol/dichloromethane); Η ΝMR (500 MHz, DMSO- 6) δ 10.51 (s, IH), 9.53 (s, IH), 8.46 (d, IH, J = 2.0 Hz), 8.30 (d, IH, J = 9.2 Hz), 8.21 (d, IH, J = 9.0 Hz), 8.02-7.98 (m, 2H), 7.91 (d, IH, J = 9.1 Hz), 7.72 (s, IH), 7.66 (d, IH, J = 7.8 Hz), 7.54 (t,.lH, J = 8.0 Hz), 7.40 (d, IH, J = 8.4 Hz), 7.36 (dd, IH, J = 8.2, 2.0 Hz), 5.40 (s, 2H), 2.51 (s, 3H); MS (ESI) m/z 411 [M + H]+.
(g) A solution of 3-(6-azidopyridin-3-yl)methoxy-N-(2-methyl-quinolin-6-yl)- benzamide, M-lf, (58 mg, 0.14 mmol, 1.0 eq) in anhydrous ethanol (20 mL) was treated with tin(II) chloride dihydrate (158 mg, 0.70 mmol, 5.0 eq) and warmed to 70 °C. After 18 h, the light yellow solution was concentrated under reduced pressure and treated with a saturated sodium bicarbonate solution (100 mL). The aqueous layer was extracted with ethyl acetate (3 x 100 mL) and the combined organic extracts were washed with brine (200 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a white foam (60 mg). The crude product was purified by radial chromatography over silica gel using 5% methanol/chloroform to give 3-(6- arninopyridin-3-yl)methoxy-N-(2-methyl-quinolin-6-yl)-benzamide, M-1, as a white solid (23 mg, 42%): mp 189-192 °C; HPLC R, = 11.4 min.; TLC R/ = 0.3 (5% methanol/chloroform); Η ΝMR (500 MHz, DMSO-d6) δ 10.48 (s, IH), 8.49 (d, IH, J = 2.0 Hz), 8.22 (d, IH, I = 8.5 Hz), 8.05 (d, IH, J = 1.8 Hz), 8.00 (dd, IH, J = 9.1, 2.2 Hz), 7.92 (d, IH, J = 9.1 Hz), 7.64-7.41 (m, 4H), 7.41 (d, IH, J = 8.4 Hz), 7.26 (dd, IH, J = 8.2, 1.9 Hz), 6.49 (d, IH, J = 8.4 Hz), 6.05 (s, 2H), 5.01 (s, 2H), 2.66 (s, 3H); MS (ESI) m/z 385 [M + H]+.
Anal, calcd for C23H20Ν4O2 • 0.5 fLO: C, 70.21; H, 5.38; N, 14.24. Found: C, 70.42; H, 5.34; N, 13.85. Example N-l : 3-(6- Acetylaminopyridin-3-yl)methoxy-N-(2-methyl-quinolin-6-yl)- benzamide
Figure imgf000113_0001
M-1 ; R = H
Ac2O N-1; R = Ac ■*■
A cloudy suspension of 3-(6-amino-pyridin-3-yl)methoxy-N-(2-methyl-quinolin-6-yl)- benzamide, M-1, (40 mg, 0.10 mmol) in acetic anhydride (5 mL), THF (5 mL) and dichloromethane (3 mL) was stirred at room temperature. After 18 h, the resultant yellow solution was concentrated under reduced pressure and chased with toluene to give a yellow solid (56 mg). The crude product was purified by radial chromatography over silica gel using 3-10% methanol/dichloromethane to give 3-[6- (acetylaminopyridin-3-yl)methoxy-N-(2-methyl-quinolin-6-yl)-benzamide, Ν-l, as a white solid (40 mg, 91 %): HPLC R, = 11.5 min.; TLC R = 0.5 (8% methanol/chloroform); Η NMR (300 MHz, OMSO-d6) δ 10.63 (s, IH), 10.56 (s, IH), 8.54 (s, IH), 8.50 (s, IH), 8.29 (d, IH, J = 8.4 Hz), 8.18 (d, IH, J = 8.6 Hz), 8.07-7.95 (m, 3H), 7.71-7.67 (m, 2H), 7.56 (t, IH, J = 8.0 Hz), 7.47 (d, IH, J = 8.1 Hz), 7.35 (d, IH, J = 7.2 Hz), 5.25 (s, 2H), 2.71 (s, 3H), 2.71 (s, 3H); MS (ESI) m/z 427 [M + H]+. Anal, calc'd for C25H22N4O3 • 0.1 H2O: C, 70.11; H, 5.23; N, 13.08. Found: C, 69.71; H, 5.33; N, 12.82.
Example N-2: 3-(6-Acetylaminopyridin-3-yl)methoxy-N-(4-Isopropyl-3-methyl- phenyl)-benzamide
Figure imgf000113_0002
N-2 A clear solution of 3-(6-amino-pyridin-3-yl)methoxy-N-(4-isopropyl-3-methyl- phenyl)-benzamide, L-1, (30 mg, 0.08 mmol) in acetic anhydride (1.0 mL) was stirred at room temperature for 18 h. The resultant clear solution was concentrated under reduced pressure and chased with toluene to give a clear oil. The crude product was extracted with 5% sodium bicarbonate (25 mL) and ethyl acetate (3 x 25 mL). The combined ethyl acetate extracts were dried using brine (25 mL) and magnesium sulfate to give a clear oil (30 mg), which was identified as 3-(6-diacetylamino-pyridin-3- yl)methoxy-N-(4-isopropyl-3-methyl-phenyl)-benzamide by MS (ESI) (m/z 460). After purification by radial chromatography over silica gel, the diacetylated compound (24 mg, 0.05 mmol, 1.0 eq) was dissolved in methanol (0.5mL) and treated with calcium carbonate (10 mg, 0.1 mmol, 2.1 eq) and water (0.5 mL). The resultant white slurry was heated at 60 °C for 18 hours. The reaction mixture was poured into water (25 mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic extracts were washed with brine (50 mL), dried over magnesium sulfate, and concentrated under reduced pressure to give a clear oil (40 mg). The crude product was purified by radial chromatography over silica gel using 2-5% methanol/dichloromethane to give 3- (6-acetylaminopyridin-3-yl)methoxy-N-(4-isopropyl-3-methyl-phenyl)-benzamide, Ν- 2, as a white solid (20 mg, 61%): mp 98-101 °C; HPLC R, = 12.4 min.; Η ΝMR (300 MHz, DMSO-d6) δ 10.51 (s, IH), 9.54 (s, IH), 8.19 (s, IH), 8.06 (d, IH, J = 8.2 Hz), 7.72 (d, IH, J = 8.3 Hz), 7.11-6.97 (m, 3H), 6.82-6.71 (m, 4H), 5.04 (s, 2H), 3.08-3.01 (m, IH), 2.22 (s, 3H), 2.13 (s, 3H), 1.13 (d, 6H, J = 6.7 Hz); MS (ESI) m/z 418 [M + H]+. Anal, calc'd for C25H27Ν3O3 • 0.4 hexane • 0.5 H2O: C, 71.39; H, 7.35; N, 9.12. Found: C, 71.11; H, 7.48; N, 8.70. Example O-l: 4-Fluoro-N-(l,2,3,4-tetrahydroquinolin-6-yl)-3-(isoquinolin-4-yl- methoxy)-benzamide bistrifluoroacetic acid salt
Figure imgf000115_0001
B BOOCC2200
Figure imgf000115_0003
Figure imgf000115_0002
Figure imgf000115_0004
(a) To a stirred mixture of 4-fluoro-3-hydroxy-benzoic acid (0.73 g, 4.7 mmol) and Cs2CO3(4.58 g, 14.1 mmol) in dioxane/H2O (1:1, 20 ml) was added 1.0 g (4.7 mmol) of 4-chloromethyl-isoquinoline«HCl, K-lc. After heating at 65 °C for 24 hrs, the solvent was removed, water was added, the pH was adjusted to 6, and the solution was extracted with ethyl acetate (30 ml x 3). The combined extracts were washed with IN HCI. A precipitate formed and was filtered and dried to provide 0.41 g (29%) of 4- fluoro-3-(isoquinolin-4-yl)methoxy-benzoic acid hydrochloride, O-la, as a solid. *H NMR (300 MHz, DMSO-d6) δ 9.84 (s, IH), 8.79 (s, IH), 8.54 (d, J = 8.1 Hz, IH), 8.44 (d, J- 8.36 Hz, IH), 8.21 (m, IH), 8.02 (m, 2H), 7.65 (m, IH), 7.40 (dd, J = 11.00, 8.46 Hz, IH), 5.865 (s, 2H).
(b) To an ice cooled solution of 0.45 g (1.85 mmol) of 6-(2,2,2-trifluoroacetylamino)- 1,2,3,4-tetrahydroquinoline (Forbes, et al., /. Med. Chem., 38, 2524 (1995)) in THF (20 ml) was added di-t-butyl-dicarbonate (0.89 g, 4.08 mmol). After refluxing for 24 h, the solvent was removed and the residue was purified on silica gel using a gradient of 0% to 2% ethyl acetate in dichloromethane as eluant to obtain 0.42 g (66%) of 1- (tert-butoxycarbonyl)-6-(2,2,2-trifluoroacetylamino)- 1 ,2,3 ,4-tetrahydroquinoline, O- lb, as a solid: Η NMR (300 MHz, CDCL) δ 7.78 (br s, IH), 7.71 (d, J = 8.9 Hz, IH), 7.43 (d, I = 2.6 Hz, IH), 7.19 (dd, I = 8.9, 2.6 Hz, IH), 3.70 (m, 2H), 2.77 (t, J = 6.5 Hz, 2H), 1.90 (t, J = 6.4 Hz, 2H), 1.52 (s, 9H). (c) To stirred solution of 0.41 g (1.19 mmol) of l-(tert-butoxycarbonyl)-6-(2,2,2- trifluoroacetylamino)-l,2,3,4-tetrahydroquinoline, O-lb, in methanol (20 ml) was added KjCO;, (0.25 g, 1.79 mmol). After refluxing for 24 h, the methanol was removed, followed by addition of water and ethyl acetate. The layers were separated, and the aqueous layer was extracted with ethyl acetate. The combined extracts were washed with brine, dried over MgSO4, and concentrated to leave 0.228 g (77%) of 6- amino-l-(tert-butoxycarbonyl)-l,2,3,4-tetrahydroquinoline, O-lc, as an oil: lH NMR (300 MHz, CDCL) δ 7.38 (d, J = 8.5 Hz, IH), 6.47 (dd, J = 8.7, 2.7 Hz, IH), 6.39 (m, IH), 3.64 (m, 2H), 3.40 (bis, IH), 2.65 (t, J = 6.6 Hz, 2H), 1.86 (t, J = 6.2 Hz, 2H), 1.50, (s, 9H).
(d) A solution of 0.35 g (1.17 mmol) of 4-fluoro-3-(isoquinolin-4-yl)methoxy-benzoic acid hydrochloride, O-la, in SOCl2 (5 ml) was stirred and heated at 60 °C for 3 h. The thionyl chloride was removed under reduced pressure to provide crude acid chloride O-ld, which was dissolved in dichloromethane (15 ml) under argon. The solution was cooled to 0 °C followed by addition of 0.260 g (1.07 mmol) of 6-amino-l-(tert- butoxycarbonyl)-l,2,3,4-tetrahydroquinoline, O-lc, and diisopropylethylamine (0.3 g, 2.34 mmol). After stirring for 24 hrs, dichloromethane (15 ml) was added, and the solution was washed with sat. NaHCO3, and dried over sodium sulfate and concentrated. The residue was purified on silica gel using a gradient of 0% to 5% ethyl acetate in dichloromethane as eluant to obtain 0.190 g (30%) of 4-fluoro-N-{ 1- (tert-butoxycarbonyl)-l,2,3,4-tetrahydroquinolin-6-yl}-3-(isoquinolin-4-yl-methoxy)- benzamide, O-le.
(e) A solution of O-le (0.185 g, 0.35 mmol) in 4N HCI in dioxane (5 ml) was stirred for 6 hrs at 0 °C. The solvent was removed under reduced pressure to give 0.123 g (82%) of4-Fluoro-N-(l,2,3,4-tetrahydroquinolin-6-yl)-3-(isoquinolin-4-yl-methoxy)- benzamide hydrochloride as a solid. This product was further purified on semi- preparative C18-reverse phase HPLC eluting with 5 to 95% acetonitrile/water containing 0.1% trifluoroacetic acid to provide 4-fluoro-N-(l,2,3,4-tetrahydroquinolin- 6-yl)-3-(isoquinolin-4-yl-methoxy)-benzamide bistrifluoroacetic acid salt, O-l: !H NMR (300 MHz, DMSO- 6 ) δ 10.59 (s, IH), 9.81 (s, IH), 8.83 (s, IH), 8.52 (d, IH, J = 8.37 Hz) 8.45 (d, IH, J = 8.59 Hz), 8.24-8.17 (m, 2H), 8.01 (dd, IH, J = 7.35 Hz, J = 7.6 Hz), 7.79-7.70 (m, 3H), 7.43 (dd, IH, J = 10.87 Hz, J = 10.7 Hz), 7.25 (d, IH, J = 8.46 Hz), 5.93 (s, 2H), 3.73-3.64 (m, IH), 3.52-3.45 (m, IH), 3.37-3.35 (m, IH), 2.87 2.83 (m, 2H), 2.02 - 1.94 (m, 2H). MS (ESI) m/z 428 [M]+. Anal, calc'd for C26H22 FN3O2 » 2 CF3CO2H • 0.8 H2O: C, 53.78; H, 3.85; N, 6.27. Found: C, 53.58; H, 4.00; N, 6.20. Example O-2: N-(2,2-Difluoro-benzo[l,3]dioxol-4-yl)-3-(2-isoquinolin-4-yl-ethyl)- benzamide trifluoro-acetic acid salt
Figure imgf000117_0001
Example O-2 was prepared in a similar manner to that described for O-l, except that 4-amino-(2,2-difluoro-benzo[l,3]dioxole was used in place of 6-amino-l-(tert- butoxycarbonyl)-l,2,3,4-tetrahydroquinoline, O-lc, and 3-{2-(isoquinolin-4- yl)ethyl}benzoic acid, S-le (from example S-l below), was used in place of 4-fluoro- 3-(isoquinolin-4-yl)methoxy-benzoic acid, O-la, in step (d), and the final deprotection step was not needed: Η NMR (300 MHz, DMSO-d6) δ 10.70 (s, IH), 9.88 (s, IH), 8.63-8.51 (m, 3H), 8.26 (dd, IH, J = 8.3 Hz, J = 8.5 Hz), 8.05 (m, 2H), 7.87 (m, IH), 7.62-7.43 (m, 2H), 7.31-7.25 (m, 3H), 3.62-3.51 (m, 2H), 3.17-3.09 (m, 2H). MS (ESI) m/z 433 [M]+. Anal, calc'd for C25H18F2N2O3 • C2F3OOH: C, 59.35; H, 3.50; N, 5.31. Found: C, 59.35; H, 3.60; N, 5.12.
Example O-3: 4-Fluoro-N-(2-methyl-l,2,3,4-tetrahydroquinolin-6-yl)-3-(iso- quinolin-4-yI-methoxy)-benzamide bistrifluoroacetic acid salt
Figure imgf000117_0002
Example O-3 was prepared in a similar manner to that described for O-l, except that
6-amino-l-(tert-butoxycarbonyl)-2-methyl-l,2,3,4-tetrahydroquinoline was used in place of 6-amino- 1 -(tert-butoxycarbonyl)- 1 ,2,3 ,4-tetrahydroquinoline in step (d) : H NMR (300 MHz, DMSO-d6) δ 10.15 (s, IH), 9.54 (s, IH), 8.73 (s, IH), ), 8.35-8.26 (m, 2H), 8.04-7.98 (m, 2H), 7.86 (dd, IH, J = 7.12 Hz, J = 7.08 Hz), 7.67-7.62 (m, IH), 7.52-7.49 (m, 2H), 7.41 (dd, IH, J = 10.96 Hz, J = 10.99 Hz), 6.90 (d, IH, J = 8.37 Hz), 5.78 (s, 2H), 3.46 (m, IH), 2.87 - 2.68 (m, 2H), 2.01 - 1.97 (m, IH), 1.69- 1.63 (m, IH), 1.27 (d, 3H, J = 6.41 Hz). MS (ESI) m/z 442 [M]+. Anal, calc'd for C27H24 FN3O2« 2 CF3CO2H: C, 55.61; H, 3.91; N, 6.28. Found: C, 55.51; H, 3.88; N, 6.22. Example P-l : N'-{4-[3-(4-IsopropyI-3-methyl-phenylcarbamoyl)-phenoxy
Figure imgf000118_0001
NaBHt EtOH
Figure imgf000118_0002
(a) A solution of 4-bromoisoquinoline (Aldrich, 7.7 g, 37.0 mmol, 1.0 eq) and perrhenic acid (70% in H2O, 33 μL, 0.2 mmol, 0.5 mol%) in dichloromethane (20 mL) was treated with bis(trimethylsilyl)peroxide (Gelest, 9.9 g, 55.5 mmol, 1.5 eq). After 18 hours, the resultant yellow suspension was cooled to 0 °C and diluted with cyclohexane (30 mL). The solids were collected and washed with cold cyclohexane to give 4-bromoisoquinoline N-oxide, P-la, as a yellow solid (7.1 g, 86%): HPLC R, = 7.7 min.; TLC Rf = 0.5 (5% methanol/dichloromethane); Η ΝMR (300 MHz, DMSO- d6) δ 8.97 (s, IH), 8.58 (d, IH, J = 1.7 Hz), 7.97-7.87 (m, 2H), 7.74-7.67 (m, 2H); 13C ΝMR (75 MHz, DMSO-d6) δ 138.6, 135.5, 130.6, 130.2, 129.6, 127.4, 126.0, 125.7, 120.1 ; MS (ESI) m/z 224/226 [M + H]+.
(b) A yellow suspension of 4-bromoisoquinoline N-oxide, P-la, (6.9 g, 30.8 mmol. 1.0 eq) in 1,2-dichloroethane (60 mL) was treated with phosphorus oxychloride (Aldrich, 9.0 mL, 96.4 mmol, 1.8 eq) and warmed to 80 °C. After 1.5 hours, the resultant green suspension was carefully poured into a cold solution of 50% saturated sodium bicarbonate (500 mL) and the aqueous layer was extracted with diethyl ether (3 x 300 mL). The combined organic extracts were washed with water (200 mL), brine (200 mL), dried over magnesium sulfate, and concentrated under reduced pressure to give a tan solid (6.8 g). The crude product was dissolved in a minimal amount of dichloromethane and purified by flash chromatography over silica gel using 5% ether/cyclohexane to give 4-bromo-l-chloro-isoquinoline, P-lb, as a white solid (5.7 g, 77%): HPLC R, = 15.4 min.; TLC R = 0.4 (5% ether/cyclohexane); Η ΝMR (300 MHz, DMSO- ) δ 8.68 (s, IH), 8.42 (d, IH, J = 8.4 Hz), 8.26 (d, IH, J = 8.3 Hz), 8.15 (t, IH, J = 7.6 Hz), 8.02 (t, IH, J = 7.6 Hz); 13C ΝMR (75 MHz, DMSO- 6) δ 150.4, 143.0, 135.8, 133.8, 130.8, 127.3, 126.8, 126.5, 119.0; MS (ESI) m/z 242/244 [M + H]+.
(c) l-Chloro-isoquinoline-4-carbaldehyde, P-lc, which was obtained as a white solid in a 95% yield, was prepared in a similar manner to that described for isoquinoline-4- carbaldehyde, K-la, in example K-l, except that 4-bromo-l-chloro-isoquinoline, P-lb, was used in place of 4-bromoisoquinoline: HPLC R, = 11.9 min.; TLC Rf = 0.6 (20% ethyl acetate/cyclohexane); Η ΝMR (300 MHz, DMSO-d6) δ 10.40 (s, IH), 9.15 (d, IH, J = 8.5 Hz), 8.93 (s, IH), 8.46 (d, IH, J = 8.5 Hz), 8.12 (t, IH, I = 7.1 Hz), 8.00 (t, IH, J = 7.8 Hz); 13C ΝMR (75 MHz, DMSO-d6) δ 193.6, 156.5, 151.4, 134.8, 133.9, 130.4, 126.9, 126.0, 124.9, 124.6; MS (ESI) m/z 192 [M + H]+.
(d) (l-Chloro-isoquinolin-4-yl)-methanol, P-ld, which was obtained as a white solid in a 96% yield, was prepared in a similar manner to that described for isoquinolin-4-yl- methanol, K-lb, except that l-chloro-isoquinoline-4-carbaldehyde, P-lc, was used in place isoquinoline-4-carbaldehyde, K-la: HPLC R, = 9.0 min.; TLC R = 0.2 (2% methanol/dichloromethane); Η NMR (300 MHz, DMSO- 6) δ 8.52 (d, IH, I = 8.5 Hz), 8.50 (s, IH), 8.42 (d, IH, J = 8.3 Hz), 8.15 (t, IH, J = 7.6 Hz), 8.05 (t, IH, I = 7.6 Hz), 5.71 (br s, IH), 5.15 (s, 2H); 13C NMR (75 MHz, DMSO-d6) δ 150.1, 140.0,
136.0, 131.9, 131.8, 129.3, 126.3, 125.8, 124.6, 59.0; MS (ESI) m/z 194 [M + H]+. (e) 3-(l-Chloro-isoquinolin-4-ylmethoxy)-N-(4-isopropyl-3-methyl-phenyl)- benzamide, P-le, which was obtained as a white solid in a 64% yield, was prepared in a similar manner to that described for 3-(6-chloropyridin-3-yl)methoxy-N-(4- isopropyl-3 -methyl-phenyl)-benzamide, L- lb , except that ( 1 -chloro-isoquinolin-4-yl)- methanol, P-ld, was used in place of (6-chloropyridin-3-yl)-mefhanol, L-la: HPLC R, = 18.0 min.; TLC Rf = 0.5 (5% ethyl acetate/45% dichloromethane/cyclohexane); Η ΝMR (300 MHz, DMSO-d6) δ 10.06 (s, IH), 8.52 (s, IH), 8.38 (d, IH, J = 8.5 Hz), 8.25 (d, IH, J = 8.3 Hz), 8.01 (t, IH, J = 7.6 Hz), 7.90 (t, IH, J = 8.2 Hz), 7.68 (s, IH), 7.61-7.46 (m, 4H), 7.35 (d, IH, J = 7.9 Hz), 7.20 (d, IH, J = 8.4 Hz), 5.65 (s, 2H),
3.12-3.05 (m, IH), 2.29 (s, 3H), 1.17 (d, 6H, J = 6.9 Hz); 13C ΝMR (75 MHz, DMSO- d6) δ 165.1, 158.4, 151.5, 142.2, 141.9, 136.8, 136.7, 136.3, 135.0, 132.6, 130.0, 129.8,
127.1, 126.6, 126.1, 125.0, 124.7, 122.5, 120.8, 118.9, 118.3, 114.3, 65.6, 28.7, 27.2, 23.5, 19.4; MS (ESI) m/z 443 [M - H]". (f) A mixture of 3-(l-chloro-isoquinolin-4-ylmethoxy)-N-(4-isopropyl-3-methyl- phenyl)-benzamide, P-le, (50 mg, 0.11 mmol, 1.0 eq), tert-butyl carbazate (75 mg, 0.56 mmol, 5.0 eq) andpαrα-toluenesulfonic acid monohydrate, (31 mg, 0.16 mmol, 1.5 eq) in isopropyl alcohol (1.5 mL) was warmed to 60 °C. After 4.5 h the resultant white suspension was poured into 5% sodium bicarbonate (25 mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic extracts were washed sequentially with water (25 mL), sodium citrate (0.5 M, pH 4.5, 25 mL), water (25 mL) and brine (25 mL). The organic extracts were dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give a clear oil (90 mg). The crude product was purified by radial chromatography over silica gel using 2-3% methanol/dichloromethane to give, from methyl tert-butyl ether, N'-{4-[3-(4-isopropyl- 3-methyl-phenylcarbamoyl)-phenoxymethyl]-isoquinolin-l-yl}-hydrazinecarboxylic acid tert-butyl ester, P-l, as a white solid (55 mg, 93%): mp 125-129 °C; HPLC R( = 16.5 min.; TLC R/ = 0.5 (4% methanol/dichloromethane); Η NMR (300 MHz, DMSO- ) δ 10.04 (s, IH), 9.35 (s, IH), 8.78 (s, IH), 8.33 (d, IH, J = 8.3 Hz), 8.10 (s, IH), 7.96 (d, IH, J = 8.3 Hz), 7.76 (t, IH, J = 7.6 Hz), 7.64-7.27 (m, 7H), 7.20 (d, IH, J = 8.4 Hz), 5.41 (s, 2H), 3.09-3.05 (m, IH), 2.29 (s, 3H), 1.40 (s, 9H), 1.17 (d, 6H, J = 6.8 Hz); 13C NMR (75 MHz, DMSO-d6) δ 165.8, 159.4, 157.2, 155.6, 143.8, 141.5, 137.1, 136.3, 136.1, 135.6, 131.2, 130.2, 127.1, 125.7, 124.2, 122.4, 122.3, 119.7, 119.0, 118.6, 118.5, 117.8, 113.9, 81.9, 67.3, 29.3, 28.6, 27.3, 23.6, 19.8; MS (ESI) m/z 541 [M + H]\ Anal, calc'd for C32H36N4O4 • 0.25 hexane: C, 71.57; H, 7.08; N, 9.97. Found: C, 71.38; H, 7.18; N, 9.66.
Example Q-l: N-(4-Isopropyl-3-methyl-phenyl)-3-{l-[N'-(3-methoxy-benzyl- idene)-hydrazino]-isoquinolin-4-ylmethoxy}-benzamide
Figure imgf000121_0001
A solution of N-{4-[3-(4-isopropyl-3-methyl-phenylcarbamoyl)-phenoxymethyl]- isoquinolin-l-yl}-hydrazinecarboxylic acid tert-butyl ester, P-l, (94 mg, 0.21 mmol, 1.0 eq) in dichloromethane (2.0 mL) was treated with trifluoroacetic acid (0.5 mL). After 1.5 hours, the resultant yellow solution was carefully poured into 5% sodium bicarbonate (50 mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic extracts were washed with brine (25 mL), dried over magnesium sulfate, and concentrated under reduced pressure to give a yellow solid (97 mg). The crude product was dissolved in ethyl alcohol (4 mL) and treated with acetic acid (3 drops), and 3-methoxybenzaldehyde (Aldrich, 40 μL, 0.32 mmol, 1.5 eq). After 18 hours, the resultant yellow suspension was poured into 5% sodium bicarbonate (25 mL). The aqueous layer was diluted with brine (15 mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic extracts were washed with brine (50 mL), dried over magnesium sulfate, and concentrated under reduced pressure to give a yellow residue (128 mg). The crude product was purified by radial chromatography over silica gel using 1-2% methanol/dichloromethane to give N-(4-isopropyl-3-methylphenyl)-3-{ l- [N-(3-methoxybenzylidene)hydrazino]isoquinolin-4-yl}methoxy-benzamide, Q-1, as a yellow solid (25 mg, 21%): mp 125-129 °C; HPLC R, = 18.3 min.; TLC R/ = 0.5 (4% methanol/dichloromethane); Η ΝMR (300 MHz, DMSO- 6) δ 10.94 (s, IH), 8.43 (br s, 2H), 7.65-7.22 (m, 13H), 7.20 (d, IH, J = 8.4 Hz), 6.99 (d, IH, J = 8.2 Hz), 5.24 (s, 2H), 3.84 (s, 3H), 3.10-3.05 (m, IH), 2.29 (s, 3H), 1.17 (d, 6H, J = 6.8 Hz); MS (ESI) m/z 559 [M + H]+. Anal, calc'd for C35H34Ν4O3 • 0.5 hexane: C, 75.84; H, 6.87; N, 9.31. Found: C, 75.81; H, 6.89; N, 9.09.
Example R-l: N-(3,5-Diallyl-4-methyl-phenyl)-3-(isoquinolin-4-ylmethoxy)- benzamide
Figure imgf000122_0001
(a) To a solution of 1.0 g (4.7 mmol) of 4-(chloromethyl)isoquinoline hydrochloride, K-lc, in DMF (10 mL) and acetone (25 mL) was added methyl 3-hydroxybenzoate (800 mg, 5.3 mmol) and cesium carbonate (3.8 g, 11.7 mmol). After refluxing for 20 h the solution was cooled, concentrated and diluted with dichloromethane. The solution was washed with sodium bicarbonate and brine. After drying over the sodium sulfate the product was precipitated from diethyl ether/hexanes yielding 1.15 grams (84% yield) of methyl 3-(isoquinolin-4-yl)methoxy-benzoate, R-la, as a white solid: 1H NMR (300 MHz, DMSO- ) δ 9.35 (s, IH), 8.67 (s, IH), 8.20 (d, J = 8.0 Hz, IH), 8.15 (d, J = 8.6 Hz, IH), 7.88 (ddd, J = 7.0, 7.0, 1.3 Hz, IH), 7.75 (ddd, J = 7.5, 7.5, 1.0 Hz, IH), 7.65 (m, IH), 7.60 (m, IH), 7.49 (dd, J = 8.1 Hz, IH), 7.41 (m, IH), 5.64 (s, 2H), 3.86 (s, 3H).
(b) To methyl 3-(isoquinolin-4-yl)methoxy-benzoate, R-la, (2.24 g, 7.64 mmol) in 95% EtOH (50 mL) was added 1 N NaOH (8 ml). After stirring for two hours at 70 °C the solution was cooled and concentrated to about 10 mL. With ice cooling the solution was acidified with IN HCI. The resulting white precipitate was filtered yielding 1.3 g of 3-(isoquinolin-4-yl)methoxy-benzoic acid hydrochloride, R-lb, as a white solid. Extraction of the mother liquors with dichloromethane three times resulted in 480 mg more product. (74% overall yield). 1H NMR (300 MHz, DMSO- ) δ 9.77 (s, IH), 8.81 (s, IH), 8.50 (d, J = 8.2 Hz, IH), 8.39 (d, I = 8.5 Hz, IH), 8.18 (dd, J = 8.4, 8.4 Hz, IH), 7.99 (dd, J = 7.5, 7.5 Hz, IH), 7.69 (m, IH), 7.61 (m, IH), 7.48 (dd, J = 8.1, 8.1 Hz, IH), 7.41 (m, IH), 5.76 (s, 2H).
(c) To a solution of 72 mg (0.38 mmol) 3,5-diallyl-4-methylaniline, prepared as described in steps (d) through (f) below, in DMF (6 mL) was added 120 mg (0.380 mmol) of 3-(isoquinolin-4-ylmethoxy)-benzoic acid hydrochloride, R-lb, 160 μL (0.92 mmol) of diisopropylethylamme and PyBop (240 mg, 0.46 mmol). After stirring for 2.5 h, DMAP (3 mg) was added. At five hours all but 3 mL of solvent was removed, and the remaining solution was diluted with dichloromethane (40 ml) and washed with water, and brine. After drying over sodium sulfate, the solution was concentrated and chromatographed with silica gel eluting with 20 to 40% ethyl acetate/dichloromethane yielding 130 mg (75% yield) of N-(3,5-diallyl-4-methyl-phenyl)-3-(isoquinolin-4- yl)methoxy-benzamide, R-l, as a white foam. 1H NMR (300 MHz, CDC13) δ 9.29 (s, IH), 8.63 (s, IH), ), 8.06 (m, 2H), 7.79 (m, IH), 7.62-7.82 (m, 3H), 7.44 (m, 2H), 7.35 (s, 2H), 7.23 (m, IH), 5.97 (m, 2H), 5.53 (s, 2H), .5.03 (m, 4H), 3.41 (d, 4H, J = 6.2 Hz), 2.18 (s, 3H). MS (FAB) m/z 449 [M + H]+. Anal, calcd for C30H28 N2O2 .0.35 H2O: C, 79.22; H, 6.36; N, 6.16. Found: C, 79.14; H, 6.24; N, 6.43. (d) To 3,5-dibromoaniline (2.0 g, 6.5 mmol) in CH2C12 (40 mL) was added diisopropylethylamine (2.27 mL, 13 mmol). The solution was cooled to 0 °C followed by addition of trifluoroacetic anhydride (1.37 mL, 9.8 mmol) in CH C1 (5 mL) over three minutes. After addition the cooling bath was removed, and DMAP (approximately 3 mgs) was added. At one hour the solution was diluted with CH2C1 (40 mL) and washed with water and brine and dried over sodium sulfate. The solution was concentrated and chromatographed though a short plug of silica gel eluting with 30% ethyl acetate/hexanes which resulted in 2.68 g, (quantitative yield), of N-(3,5- dibromo-4-methyl-phenyl)-2,2,2-trifluoro-acetamide an off-white solid. 1H NMR (300 MHz, CDC13) δ 7.80 (s, 3 H, including NH), 2.56 (s, 3H).
(e) To dry, degassed toluene (25 mL) was added N-(3,5-dibromo-4-methyl-phenyl)- 2,2,2-trifluoroacetamide (1.0 g, 2.78 mmol) , allyltributyltin (2.6 mL, 8.4 mmol) and Pd(PPh3)4 (200 mgs, 0.160 mmol). After refluxing for 14 hours, most of the solvent was removed and the solution was diluted with diethyl ether. Approximately 100 mL of water was added followed by DBU (1.4 mL, 0.92 mmol) which resulted in a gummy precipitate. This heterogeneous solution was filtered through a short plug of silica gel eluting with diethyl ether. After concentration the residue was chromotographed twice with 10 to 20% ethyl acetate/hexanes resulting in 315 mg (40% yield) of N-(3,5- diallyl-4-methyl-phenyl)-2,2,2-trifluoroacetamide as a white solid. 1H NMR (300 MHz, CDC13) δ 7.72 (br s, IH), 7.25 (s, 2H), 5.94 (m, 2H), 5.09 (dd, J = 10.2, 1.5 Hz, 2H), 4.98 (dd, J = 15.4, 1.8 Hz), 3.40 (d, J = 6.2 Hz), 2.18 (s, 3H).
(f) To N-(3,5-diallyl-4-methyl-phenyl)-2,2,2-trifluoroacetamide (255 mg, 0.90 mmol) in 95% ethanol (lOmL) was added IN NaOH(aq) (2mL). After heating to 80 °C for 16 h, the solution was cooled to room temperature. After concentration the residue was diluted with ethyl acetate (30 mL) and washed with water and brine and dried over sodium sulfate. Removal of the solvent led to 160 mg (95% yield) of 3,5-diallyl-4- methylaniline as an orange oil. 1H NMR (300 MHz, CDC13) δ 6.42 (s, 2H), 5.91 (m, 2H), 5.04 (dd, J = 10.6, 1.7 Hz, 2H), 4.98 (dd, J = 17.2. 1.8 Hz), 3.31 (d, J = 6.3 Hz), 2.08 (s, 3H). Example R-2: N-(3,5-Dibromo-4-methyl-phenyl)-3-(isoquinolin-4-ylmethoxy)- benzamide
Figure imgf000125_0001
R-2
Example R-2 was prepared in a similar manner to that described for R-l, except that 3,5-dibromo-4-methylaniline was used in place of 3,5-diallyl-4-bromoaniline in step (c): 1H NMR (300 MHz, DMSO- ) δ 10.36 (s, IH), 9.36 (s, IH), 8.69 (s, IH), 8.20 (m, IH), 8.14 (s, 2H), 7.89 (m, IH), 7.76 (m, IH), 7.68 (m, IH), 7.58 (m, IH), 7.51 (m, IH), 7.38 (m, IH), 5.65 (s, 2H), 2.48 (s, 3H). Anal, calc'd for C24H18N2O2Br2 • 0.4 H2O: C, 54.04; H, 3.55; N, 5.25. Found: C, 53.96; H, 3.50; N, 5.08. Example R-3 : 3-(Isoqumolm-4-yImethoxy)-N-(5,5,8,8-tetramethyl-5,6,7,8- tetrahydro-naphthaIen-2-yl)-benzamide
Figure imgf000125_0002
R-3
Example R-3 was prepared in a similar manner to that described for R-l, except that 2- amino-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene was used in place of 3,5- diallyl-4-bromoaniline in step (c): 1H NMR (300 MHz, DMSO-d6 ) δ 10.12 (s, IH), 9.77 (s, IH), 8.23 (s, IH), 8.49 (d, IH, J = 8.2 Hz), 8.39 (d, IH, I = 8.4 Hz), 8.18 (dd, IH, J = 7.8 Hz, J = 7.7 Hz ), 7.99 (dd, IH, I = 7.4 Hz, J = 7.4 Hz), 7.76 (s, IH), 7.70 (d, IH, J = 2.2 Hz), 7.63 (d, IH, J = 7.7 Hz), 7.58 (dd, IH, J = 8.6 Hz, J = 2.2 Hz), 7.51 (dd, IH, I = 7.7 Hz, J = 7.7 Hz), 7.38 (dd, IH, I = 8.2 Hz, J = 1.9 Hz), 7.28, (d, IH, 8.6 Hz), 5.79 (s, 2H), 1.64 (s, 4H), 1.25 (s, 6H), 1.24 (s, 6H). MS (ESI) m/z 465 [M + H]+. Anal, calc'd for C31H32N2O2 • 1.0 HCI • 0.8 H2O: C, 72.23; H, 6.77; N, 5.43. Found: C, 72.07; H, 6.63; N, 5.43.
The intermediate 2-amino-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene was prepared by reduction of 2-nitro-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene (Kagechika, H. et al., J. Med. Chem., 31, 2182-2192 (1998)) in a similar manner to that described in step (b) of Example J-1.
Example R-4: 3-(Isoquinolin-4-ylmethoxy)-N-(3-trifluoromethoxy-phenyl)- benzamide
Figure imgf000126_0001
R-4
Example R-4 was prepared in a similar manner to that described for R-l, except that 3- (trifluoromethoxy)aniline was used in place of 3,5-diallyl-4-bromoaniline in step (c): 1H NMR (300 MHz, CDC13) δ 9.22 (s, IH), 8.55 (s, IH), ) 7.99 (m, 2H), 7.73 ( m, 2H), 7.65 (m, IH), 7.60 (m, IH), 7.54 (m, IH), 7.47 (m, IH), 7.27-7.40 (m, 2H), 7.18 (m, IH), 6.99 (m, IH), 5.41 (s, 2H). MS (ESI) m/z 439 [M + H]+. Anal, calc'd for C2 H17F3 N2O3: C, 65.75; H, 3.91; N, 6.39. Found: C, 65.58; H, 4.02; N, 6.37. Example R-5: N-(2,4-Dimethylquinolin-6-yl)-3-(isoquinolin-4-ylmethoxy)- benzamide
Figure imgf000126_0002
R-5
Example R-5 was prepared in a similar manner to that described for R-l, except that 6- amino-2,4-dimethylquinoline was used in place of 3,5-diallyl-4-bromoaniline in step (c): 1H NMR (300 MHz, CDC13) δ 10.50 (s, IH), 9.36 (s, IH), 8.70 (s, IH), 8.56 (d, IH, J = 2.2 Hz), 8.20 (m, 2H), 8.06 ( m, IH), 7.9 (m, 2H), 7.76 (m, 2H), 7.66 (m, IH), 7.53 (dd, IH, J = 7.8, 7.8 Hz), 7.39 (m, IH), 7.27 (s, IH), 5.67 (s, 2H), 2.61 (s, 3H), 2.58 (s, 3H). MS (FAB) m/z 435 [M + H]+. Anal, calcd for C27H22 N4O2 • 0.1 H2O: C, 74.33; H, 5.13; N, 12.84. Found: C, 79.13; H, 4.97; N, 12.74. The intermediate 6-amino-2,4-dimethylquinoline was prepared by reduction of 6-nitro- 2,4-dimethylquinoline (Price, C. et al., /. Org. Chem., 12, 203 (1947)) in a similar manner to that described in step (b) of Example J-1. Example R-6: 3-(Isoquinolin-4-ylmethoxy)-benzoic acid N'-(4-trifluoromethyl- phenyl)-hydrazide
Figure imgf000127_0001
R-6
Example R-6 was prepared in a similar manner to that described for R-l, except that 4- trifluoromethylphenylhydrazine was used in place of 3,5-diallyl-4-bromoaniline in step (c): 1H NMR (300 MHz, CDC13) δ 9.28 (s, IH), 8.62 (s, IH), ), 8.05 (m, 3H), 7.79(dd, IH, J = 8.36 Hz, J = 8.27 Hz), 7.67 (dd, IH, J = 7.98 Hz, J = 8.14 Hz), 7.59 (m, IH), 7.51-7.42 (m, 4H), 7.27 (m, IH), 6.98 (s, IH), 6.95 (s, IH), 6.47 (br, IH), 5.51 (s, 2H). MS (ESI) m/z 438 [M + H]+. Anal, calc'd for C24H18 F3N3O2: C, 65.90; H, 4.15; N, 9.61. Found: C, 65.75; H, 4.20; N, 9.51. Example R-7: N-Benzyloxy-3-(isoquinolin-4-ylmethoxy)-benzamide
Figure imgf000127_0002
R-7
Example R-2 was prepared in a similar manner to that described for R-l, except that O-benzylhydroxylamine was used in place of 3,5-diallyl-4-bromoaniline in step (c): 1H NMR (300 MHz, CDC13) δ 9.26 (s, IH), 8.59 (s, IH), ), 8.57 (s, IH), 8.05 (m, 2H), 7.78 (dd, IH, J = 8.23 Hz, J = 8.44 Hz), 7.67 (dd, IH, J = 7.89 Hz, J = 8.16 Hz), 7.47- 7.43 (m, 3H), 7.42-7.32 (m, 3H), 7.24-7.16 (m, 3H), 5.47 (s, 2H), 5.05 (s, 2H). MS (ESI) m/z 385 [M + H]+. Anal, calc'd for C24H20N2O3: C, 74.98; H, 5.24; N, 7.29. Found: C, 74.85; H, 5.31; N, 7.18. Example R-8: 3-(IsoquinoIin-4-ylmethoxy)-benzoic acid N'-phenyl-hydrazide
Figure imgf000127_0003
R-8 Example R-2 was prepared in a similar manner to that described for R-l, except that phenylhydrazine was used in place of 3,5-diallyl-4-bromoaniline in step (c): !H NMR (300 MHz, CDC13) δ 9.28 (s, IH), 8.62 (s, IH), ), 8.06 (s, IH), 8.04 (s, IH), 7.94 (m, IH), 7.78 (m, IH), 7.67 (m, IH), 7.59 (m, IH), 7.44 (m, 2H), 7.25 (m, 3H), 6.93 (m, 3H), 6.38 (m, IH), 5.50 (s, 2H). MS (ESI) m/z 370 [M + H]+. Anal, calcd for C23H19 N3O2 .0.35 H2O: C, 73.52; H; 5.29; N, 11.18. Found: C, 73.72; H, 5.36; N, 10.90. Example R-9: N-(5,7-dimethyI[l,8]naphthydrin-2-yI)-3-(isoquinoIin-4- ylmethoxy)-benζamide
Figure imgf000128_0001
Example R-9 was prepared in a similar manner to that described for R-l, except that 2- amino-5,7-dimethyl[l,8]naphthydrine was used in place of 3,5-diallyl-4-bromoaniline in step (c): 1H NMR (300 MHz, CDC13) δ 9.30 (s, IH), 8.96 (s, IH), 8.64 (s, 2H), 8.40 (d, IH, J = 9.0 Hz), 8.08 (m, 2H), 7.81 (m, IH), 7.73 (m, IH), 7.69 (m, IH), 7.62 (m, IH), 7.48 (dd, IH, J = 7.8, 7.8 Hz), 7.29 (m, IH), 7.15 (d, J = 0.7 Hz), 5.55 (s, 2H), 2.72 (s, 3H), 2.69 (d, 3H, J = 0.7 Hz). MS (FAB) m/z 435 [M + H]+. Anal, calc'd for C27H22 N4O2 • 0.1 H2O: C, 74.33; H, 5.13; N, 12.84. Found: C, 79.13; H, 4.97; N, 12.74
Example R-10: 3-(Isoquinolin-4-yImethoxy)-N-(l,l,3,3-tetramethyI-l,3- dihydroisobenζofuran-5-yl)-benζamide
Figure imgf000128_0002
Example R-10 was prepared in a similar manner to that described for R-l, except that 5-amino-l,l,3,3-tetramethyl-l,3-dihydiOisobenzofuran was used in place of 3,5- diallyl-4-bromoaniline in step (c): δ 1H NMR (300 MHz, CDC13 9.29 (s, IH), 8.63 (s, IH), 8.06 (m, 2H), 7.90 (m, IH), 7.79 (dd, IH, J = 8.38 Hz, J = 7.72 Hz ), 7.68 (dd, IH, J = 8.05 Hz, J = 8.08 Hz), 7.62 (m, IH), 7.55 (d, IH, J = 1.8 Hz), 7.45 (m, 2H), 7.40 (m, IH), 7.22 (m, IH), 7.08 (d, IH, J = 8.12 Hz), 5.52 (s, 2H), 1.54 (s, 6H), 1.51
(s, 6H). MS (ESI) m/z 453 [M + H]+. Anal, calcd for C29H28N2O3x 0.4 H2O: C,
75.76; H, 6.31; N, 6.09. Found: C, 75.72; H, 6.31; N, 5.94.
Example R-ll: N-(3,5-Dichloro-4-pyrrolidin-l-yl-phenyl)-4-fluoro-3-(pyridin-3- ylmethoxy)-benzamide
Figure imgf000129_0001
R-ll Example R-ll was prepared in a similar manner to that described for R-l, except that ethyl 4-fluoro-3-hydroxybenzoate, prepared by conventional Fischer esterification of 4- fluoro-3-hydroxybenzoic acid, was used in place of methyl 3-hydroxybenzoate and 3- picolyl chloride hydrochloride was used in place of 4-(chloromethyl)isoquinoline hydrochloride, K-lc,in step (a), and l-(4-amino-2,6-dichlorophenyl)pyrrolidine was used in place of 3,5-diallyl-4-bromoaniline in step (c): mp 163-167 °C; HPLC Rt = 17.7 min.; TLC R = 0.3 (40% ethyl acetate/cyclohexane); 1H NMR (300 MHz, DMSO- ) δ 10.40 (s, IH), 8.72 (s, IH), 8.60 (d, IH, J = 3.9 Hz), 7.94-7.84 (m, 4H), 7.66-7.62 (m, IH), 7.49-7.42 (m, 2H), 5.33 (s, 2H), 3.24-3.20 (m, 4H), 1.98-1.96 (m, 4H); MS (ESI) m/z 460 [M + H]+. Anal, calc'd for C23H2oCl2FN3O2: C, 60.01; H, 4.38; N, 9.13. Found: C, 60.08; H, 4.49; N, 9.02. Example R-12: 4-Fluoro-N-(4-morpholin-4-yl-3-trifluoromethyl-phenyl)-3- (pyridin-3-ylmethoxy)-benzamide
Figure imgf000129_0002
R-12 Example R-12 was prepared in a similar manner to that described for R-l, except that ethyl 4-fluoro-3-hydroxybenzoate, prepared by conventional Fischer esterification of 4- fluoro-3-hydroxybenzoic acid, was used in place of methyl 3-hydroxybenzoate and 3- picolyl chloride hydrochloride was used in place of 4-(chloromethyl)isoquinoline hydrochloride, K-lc,in step (a), and l-(4-amino-2-trifluoromethylphenyl)morpholine was used in place of 3,5-diallyl-4-bromoaniline in step (c): mp 160-161 °C; HPLC Rt = 14.4 min.; TLC R = 0.2 (50% ethyl acetate/cyclohexane); 1H NMR (300 MHz, DMSO- ) δ 10.46 (s, IH), 8.72 (s, IH), 8.60 (d, IH, J = 4.1 Hz), 8.14 (d, IH, J = 2.4 Hz), 8.06 (dd, IH, J = 8.8, 2.4 Hz), 7.94-7.86 (m, 2H), 7.69-7.61 (m, 2H), 7.50-7.41 (m, 2H), 5.34 (s, 2H), 3.71 (t, 4H, J = 4.4 Hz), 2.85 (t, 4H, J = 4.4 Hz); MS (ESI) m/z 476 [M + H]+. Anal, calc'd far C24H21F4N3O3: C, 60.63; H, 4.45; N, 8.84. Found: C, 60.84; H, 4.57; N, 8.81. Example R-13: 4-Fluoro-N-[4-(piperaζin-l-yl)-3-trifluoromethylphenyl]-3- (pyridin-3-yl)methoxybenzamide
Figure imgf000130_0001
(a) 4-Fluoro-N- [4- { 4-(t-butoxycarbonyl)piperazin- 1 -yl } -3-trifluoromethylphenyl] -3 - (pyridin-3-yl)methoxybenzamide, R-13a, was prepared in a similar manner to that described for Example R-l, except that ethyl 4-fluoro-3-hydroxybenzoate, prepared by conventional Fischer esterification of 4-fluoro-3-hydroxybenzoic acid, was used in place of methyl 3-hydroxybenzoate and 3-picolyl chloride hydrochloride was used in place of 4-(chloromethyl)isoquinoline hydrochloride, K-lc,in step (a), and l-(4-amino- 2-trifluoromethylphenyl)-4-(t-butoxycarbonyl)piperazine was used in place of 3,5- diallyl-4-bromoaniline in step (c).
(b) A solution of 4-fluoro-N-[4-{4-(t-butoxycarbonyl)piperazin-l-yl}-3- trifluoromethylphenyl]-3-(pyridin-3-yl)methoxybenzamide, R-13a, (65 mg, 0.11 mmol) in methyiene chloride (4 mL) was treated with trifluoroacetic acid (1 mL). After 18 hours, the solution was concentrated under reduced pressure. The resultant residue was treated with 5% sodium bicarbonate (25 mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic extracts were washed with water (50 mL), brine (50 mL), dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give a tan solid (48 mg). The crude product was purified by radial chromatography over silica gel using 5-15% methanol/chloroform with 0.1% ammonium hydroxide to give 4-fluoro-N-[4-(piperazin-l-yl)-3-trifluoromethylphenyl]- 3-(pyridin-3-yl)methoxybenzamide, R-13, as a white solid (34 mg, 63%): mp 123-131 °C; HPLC Rf = 13.2 min.; TLC R = 0.3 (6% methanol/chloroform w/ 0.1% NH4OH); 1H NMR (300 MHz, DMSO- ) δ 10.43 (s, IH), 8.72 (d, IH, J = 1.6 Hz), 8.60 (dd, IH, J = 4.8, 1.5 Hz), 8.12 (d, IH, J = 2.3 Hz), 8.05-8,02 (m, IH), 7.94-7.86 (m, 2H), 7.69-7.64 (m, IH), 7.54 (d, IH, J = 8.8 Hz), 7.49-7.41 (m, 2H), 5.33 (s, 2H), 2.82-2.79 (m, 4H), 2.78-2.75 (m, 4H); MS (ESI) m/z 475 [M + H]+. Anal, calc'd for C2 H22F4N4O2: C, 60.76; H, 4.67; N, 11.81. Found: C, 60.66; H, 4.98; N, 11.38. Example R-14: 4-Fluoro-N-(4-morpholin-4-yI-3-trifluoromethyl-phenyl)-3- (isoquinolin-4-ylmethoxy)-benzamide
Figure imgf000131_0001
R-14 Example R-14 was prepared in a similar manner to that described for R-l, except that ethyl 4-fluoro-3-hydroxybenzoate, prepared by conventional Fischer esterification of 4- fluoro-3-hydroxybenzoic acid, was used in place of methyl 3-hydroxybenzoate in step (a), and l-(4-amino-2-trifluoromethylphenyl)morpholine was used in place of 3,5- diallyl-4-bromoaniline in step (c): mp 175-180 °C; HPLC R, = 15.3 min.; TLC R = 0.3 (1% methanol/methylene chloride); 1H NMR (300 MHz, DMSO-d6) δ 10.67 (s, IH), 9.80 (s, IH), 8.83 (s, IH), 8.52 (d, IH, J = 8.2 Hz), 8.44 (d, IH, / = 8.5 Hz), 8.23- 8.17 (m, 3H), 8.12 (dd, IH, /= 8.8, 2.3 Hz), 8.00 (t, IH, / = 7.4 Hz), 7.74-7.70 (m, IH), 7.62 (d, IH, J= 8.7 Hz), 7.46 (dd, IH, /= 11.0, 8.4 Hz), 5.91 (s, 2H), 3.71 (t, 4H, J = 4.2 Hz), 2.84 (t, 4H, J = 4.2 Hz); MS (ESI) m/z 526 [M + H]+. Anal, calcd for C28H23F4N3O3 • 1.3 HCI: C, 58.70; H, 4.28; N, 7.33; CI, 8.05. Found: C, 59.05; H, 4.59; N, 7.28; CI, 8.01.
Example R-15: 4-Fluoro-N-(4-piperaζin-l-yl-3-trifluoromethyl-phenyl)-3- (isoquinolin-4-ylmethoxy)-benzamide
Figure imgf000132_0001
R-15 Example R-15 was prepared in a similar manner to that described for R-l 3, except that 4-(chloromethyl)isoquinoline hydrochloride, K-lc,was used in place of 3-picolyl chloride hydrochloride in step (a): mp 103-107 °C; HPLC Rt = 14.7 min.; TLC Rf = 0.3 (5% methanol/chloroform with 0.1% NH4OH); 1H NMR (300 MHz, DMSO- ) δ 10.45 (s, IH), 9.37 (s, IH), 8.68 (s, IH), 8.23-8.17 (m, 2H), 8.14-8.13 (m, IH), 8.06- 8.02 (m, 2H), 7.92-7.87 (m, IH), 7.79-7.74 (M, IH), 7.69-7.65 (m, IH), 7.55 (d, IH, / = 8.5 Hz), 7.42 (dd, IH, 7= 11.0, 8.6 Hz), 5.72 (s, 2H), 2.80 (br. s, 4H), 2.77 (br. s, 4H); MS (ESI) m/z 525 [M + H]+. Anal, calcd for C28H24F4N4O2 • 0.1 hexanes (MW 533.1 g/mol): C, 64.43; H, 4.80; N, 10.51. Found: C, 64.68; H, 5.07; N, 10.16. Example R-16: 4-Fluoro-N-(4-morpholin-4-yl-3-trifluoromethyl-phenyl)-3- (quinolin-3-ylmethoxy)-benzamide
Figure imgf000132_0002
R-16
Example R-16 was prepared in a similar manner to that described for R-l, except that ethyl 4-fluoro-3-hydroxybenzoate, prepared by conventional Fischer esterification of 4- fluoro-3-hydroxybenzoic acid, was used in place of methyl 3-hydroxybenzoate and 3- chloromethylquinoline hydrochloride was used in place of 4- (chloromethyl)isoquinoline hydrochloride, K-lc,in step (a), and l-(4-amino-2- trifluoromethylphenyl)morpholine was used in place of 3,5-dialιyl-4-bromoaniline in step (c): mp 81-84 °C; HPLC Rf = 15.4 min.; TLC Rf= 0.5 (1% methanol/methylene chloride); 1H ΝMR (300 MHz, DMSO- 6) δ 10.46 (s, IH), 9.04 (d, IH, /= 2.2 Hz), 8.49 (s, IH), 8.14 (d, IH, J= 2.4 Hz), 8.08-8.04 (m, 3H), 7.93 (dd, IH, J= 8.2, 1.8 Hz), 7.83-7.78 (m, IH), 7.70-7.60 (m, 3H), 7.46 (dd, IH, /= 11.0, 8.5 Hz), 5.52 (s, 2H), 3.70 (t, 4H, J = 4.3 Hz), 2.84 (t, 4H, J = 4.3 Hz); MS (ESI) m/z 526 [M + H]+. Anal, calc'd for C28H23F4N3O3: C, 64.00; H, 4.41; N, 8.00. Found: C, 64.15; H, 4.53; N, 7.97. Example R-17: 4-Fluoro-N-(4-piperazin-l-yl-3-trifluoromethyl-phenyl)-3- (quinolin-3-yImethoxy)-benzamide
Figure imgf000133_0001
Example R-17 was prepared in a similar manner to that described for R-13, except that 3-(chloromethyl)quinoline hydrochloride was used in place of 3-picolyl chloride hydrochloride in step (a): mp 76-78 °C; HPLC R, = 14.7 min.; TLC Rf = 0.3 (3% methanol/chloroform w/ 0.1% ΝH4OH); 1H NMR (300 MHz, DMSO- 6) δ 10.44 (s, IH), 9.04 (d, IH, J= 2.0 Hz), 8.48 (s, IH), 8.12 (d, IH, J= 2.1 Hz), 8.08-8.02 (m, 3H), 7.93-7.91 (m, IH), 7.83-7.78 (m, IH), 7.68-7.63 (m, 2H), 7.54 (d, IH, J= 8.9 Hz), 7.46 (dd, IH, J= 11.0, 8.5 Hz), 5.52 (s, 2H), 2.81 (br. s, 4H), 2.78 (br. s, 4H); MS (ESI) m/z 525 [M + H]+. Anal, calc'd for C28H24F4N4O2: C, 64.12; H, 4.61; N, 10.68. Found: C, 64.53; H, 4.99; N, 10.25.
Example R-18: N-(3,5-Dichloro-4-morpholin-4-yI-phenyI)-4-fluoro-3-(pyridin-3- ylmethoxy)-benzamide
Figure imgf000133_0002
Example R-18 was prepared in a similar manner to that described for R-l, except that ethyl 4-fluoro-3-hydroxybenzoate, prepared by conventional Fischer esterification of 4- fluoro-3-hydroxybenzoic acid, was used in place of methyl 3-hydroxybenzoate and 3- picolyl chloride hydrochloride was used in place of 4-(chloromethyl)isoquinoline hydrochloride, K-lc,in step (a), and l-(4-amino-2,6-dichlorophenyl)morpholine was used in place of 3,5-diallyl-4-bromoaniline in step (c): mp 209-211 °C; HPLC Rt = 15.0 min.; TLC R/= 0.3 (40% ethyl acetate/cyclohexane); 1H NMR (300 MHz, DMSO- ) δ 10.41 (s, IH), 8.71 (s, IH), 8.58 (d, IH, J = 4.7 Hz), 7.93-7.82 (m, 4H), 7.63-7.60 (m, IH), 7.49-7.41 (m, 2H), 5.32 (s, 2H), 3.70 (br. s, 4H), 3.12 (br. s, 4H); 13C NMR (75 MHz, DMSO-d6) δ 164.4, 154.0 (d, JCF = 250 Hz), 149.4, 149.2, 146.0 (d, JCF = 11 Hz), 139.5, 137.4, 136.0, 134.2, 131.8, 130.9 (d, JCF = 3 Hz), 123.8, 121.6 (d, JcF = 8 Hz), 120.4, 116.1 (d, JCF = 19 Hz), 115.0 (d, JCF = 2 Hz), 68.3, 67.0, 49.4; MS (ESI) m/z 476 [M + H]+. Anal, calc'd for C23H2oCl2FN3O3: C, 58.00; H, 4.23; CI, 8.82; N, 14.89. Found: C, 57.89; H, 4.24; CI, 14.88; N, 8.69. Example R-19: N-(3,5-Dichloro-4-piperazin-l-yl-phenyl)-4-fluoro-3-(pyridin-3- ylmethoxy)-benzamide
Figure imgf000134_0001
Example R-19 was prepared in a similar manner to that described for R-l 3, except that l-(4-amino-2,6-dichlorophenyl)-4-(t-butoxycarbonyl)piperazine was used in place of l-(4-amino-2-trifluoromethylphenyl)-4-(t-butoxycarbonyl)piperazine in step (a) mp 81- 85 °C; HPLC Rt = 11.7 min.; TLC R/= 0.4 (5% methanol/chloroform w/ 0.1% ΝH4OH); 1H NMR (300 MHz, DMSO- ) δ 10.38 (s, IH), 8.71 (d, IH, J = 1.8 Hz), 8.58 (dd, IH, J = 4.7, 1.3 Hz), 7.93-7.82 (m, 4H), 7.65-7.60 (m, IH), 7.49-7.41 (m, 2H), 5.32 (s, 2H), 3.05-3.02 (m, 4H), 2.88-2.79 (m, 4H); 13C NMR (75 MHz, DMSO- d6) δ 164.7, 152.2 (d, JCF = 250 Hz), 149.8, 149.5, 146.2 (d, JCF = 11 Hz), 140.7, 137.3, 136.2, 134.4, 132.1, 131.2 (d, JCF = 3 Hz), 124.0, 121.8 (d, JCF = 8 Hz), 120.7, 116.4 (d, JcF = 19 Hz), 115.3, 68.6, 50.8, 46.6; MS (ESI) m/z 475 [M + H]+. Anal, calc'd for C23H2ιCl2FN4O2: C, 58.12; H, 4.45; CI, 14.92; N, 11.79. Found: C, 57.99; H, 4.60; CI, 14.59; N, 11.38. Example R-20: 4-Fluoro-N-[4-(piperazm-l-yl)-3-trifluoromethylphenyI]-3- (pyridm-3-yl)methoxybenzamide
Figure imgf000135_0001
R-20 Example R-20 was prepared in a similar manner to that described for R-l, except that ethyl 4-fluoro-3-hydroxybenzoate, prepared by conventional Fischer esterification of 4- fluoro-3-hydroxybenzoic acid, was used in place of methyl 3-hydroxybenzoate and 3- picolyl chloride hydrochloride was used in place of 4-(chloromethyl)isoquinoline hydrochloride, K-lc,in step (a), and l-(4-amino-2-trifluoromethylphenyl)-4- methylpiperazine was used in place of 3,5-diallyI-4-bromoaniline in step (c): mp 61- 66 °C; HPLC Rt = 13.0 min.; TLC R = 0.5 (5% methanol/chloroform w/ 0.1% NH4OH); 1H NMR (300 MHz, DMSO-d6) δ 10.46 (s, IH), 8.72 (s, IH), 8.59 (d, IH, J = 4.4 Hz), 8.14 (d, IH, J= 2.0 Hz), 8.05 (dd, IH, J = 8.6, 1.6 Hz), 7.94-7.86 (m, 2H), 7.69-7.65 (m, IH), 7.60 (d, IH, J= 8.8 Hz), 7.49-7.41 (m, 2H), 5.33 (s, 2H), 2.92 (s, 4H), 2.88 (br. s, 4H), 2.42 (s, 3H); MS (ESI) m/z 489 [M + H]+. Anal, calc'd for C25H24F4N4θ2 x 1.3 H2O: C, 58.66; H, 5.24; N, 10.95. Found: C, 58.17; H, 4.80; N, 10.52.
Example R-21 : 4-Fluoro-N-(4-imidazol-l-yl-3-trifluoromethyl-phenyl)-3-(pyridin- 3-ylmethoxy)-benzamide
Figure imgf000135_0002
Example R-21 was prepared in a similar manner to that described for R-l, except that imidazol-1-yl-trifluoromethyl-phenylamine, j-lb, was used in place of 3,5-diallyl-4- bromoaniline and 4-fluoro-3-(pyridin-3-ylmethoxy)-benzoic acid, which was prepared as described in R-ll, was used in place of 3-(isoquinolin-4-ylmethoxy)-benzoic acid, R-lb: HPLC Rt 12.8 min.; TLC Rf 0.3 (5% methanol-chloroform w/ 0.1% ammonium hydroxide); Η NMR (DMSO-^, 300 MHz) δ 10.73 (s, IH), 8.73 (s, IH), 8.59 (s, IH), 8.39 (d, IH, J = 2.2 Hz), 8.21 (dd, IH, J = 8.6, 2.1 Hz), 7.94-7.83 (m, 3H), 7.73-7.68 (m, IH), 7.60 (d, IH, J = 8.7 Hz), 7.51-7.40 (m, 3H), 7.10 (s, IH), 5.35 (s, 2H); MS (ESI) m/z 457 (M + H)+. Anal, calcd for C23H16F4N4O2: C, 60.53; H, 3.53; N, 12.28. Found: C, 60.37; H, 3.62; N, 12.21.
Example R-22: 4-Fluoro-N-(4-pyrazol-l-yl-3-trifluoromethyl-phenyl)-3-(pyridin- 3-ylmethoxy)-benzamide
Figure imgf000136_0001
Example R-22 was prepared in a similar manner to that described for R-l, except that pyrazol-1-yl-trifluoromethyl-phenylamine was used in place of 3,5-diallyl-4- bromoaniline and 4-fluoro-3-(pyridin-3-ylmethoxy)-benzoic acid, which was prepared as described in R-ll, was used in place of 3-(isoquinolin-4-ylmethoxy)-benzoic acid, R-lb: HPLC Rt 13.9 min.; TLC Rf 0.2 (2% methanol-chloroform w/ 0.1% ammonium hydroxide); Η NMR (DMSO- 6, 300 MHz) δ 10.72 (s, IH), 8.72 (d, IH, J = 1.8 Hz), 8.60 (dd, IH, J = 4.6, 1.2 Hz), 8.38 (d, IH, J = 2;3 Hz), 8.21 (dd, IH, J = 8.7, 2.3 Hz), 8.02 (d, IH, J = 2.2 Hz), 7.95-7.89 (m, 2H), 7.74-7.69 (m, 2H), 7.68 (d, IH, J = 8.7 Hz), 7.51-7.44 (m, 2H), 6.52-6.51 (m, IH), 5.35 (s, 2H); MS (ESI) m/z 457 (M + H)+. Anal, calcd for C23H16F4N4O2: C, 60.53; H, 3.53; N, 12.28. Found: C, 60.39; H, 3.64; N, 12.19.
Example R-23: 4-Fϊuoro-3-(pyridin-3-ylmethoxy)-N-(4-[l,2,4]triazol-l-yl-3- trifluoromethyI-phenyI)-benzamide
Figure imgf000136_0002
Example R-23 was prepared in a similar manner to that described for R-l, except that
[l,2,4]triazol-l-yl-trifluoromethyl-phenylamine was used in place of 3,5-diallyl-4- bromoaniline and 4-fluoro-3-(pyridin-3-ylmethoxy)-benzoic acid, which was prepared as described in R-ll, was used in place of 3-(isoquinolin-4-ylmethoxy)-benzoic acid, R-lb: HPLC Rt 12.4 min.; TLC Rf 0.3 (5% methanol-chloroform w/ 0.1% ammonium hydroxide); Η NMR (DMSO-d6, 300 MHz) δ 10.79 (s, IH), 8.89 (s, IH), 8/73 (d, IH,
J = 1.7 Hz), 8.60 (dd, IH, J = 4.8, 1.8 Hz), 8.44 (d, IH, J = 2.3 Hz), 8.28-8.24 (m, 2H),
7.96-7.90 (m, 2H), 7.74-7.69 (m, 2H), 7.52-7.45 (m, 2H), 5.35 (s, 2H); MS (ESI) m/z
458 (M + H)+. Anal, calcd for C22H15F4N5O2: C, 56.65; H, 3.46; N, 15.02. Found: C,
56.53; H, 3.44; N, 14.96.
Example R-24: N-(3,5-Dichloro-4-imidazol-l-yl-phenyl)-4-fluoro-3-(pyridin-3- ylmethoxy)-benzamide
Figure imgf000137_0001
Example R-24 was prepared in a similar manner to that described for R-l, except that 3,5-dichloro-4-imidazol-l-yl-phenylamine was used in place of 3,5-diallyl-4- bromoaniline and 4-fluoro-3-(pyridin-3-ylmethoxy)-benzoic acid, which was prepared as described in R-ll, was used in place of 3-(isoquinolin-4-ylmethoxy)-benzoic acid, R-lb: HPLC Rt 13.0 min.; TLC Rf 0.7 (5% methanol-dichloromethane); Η NMR (DMSO-d6, 300 MHz) δ 10.65 (s, IH), 8.89 (s, IH), 8.72 (d, IH, J = 1.9 Hz), 8.60 (dd, IH, J = 4.8, 1.6 Hz), 8.11 (s, 2H), 7.95-7.91 (m, IH), 7.88 (dd, IH, J = 8.2, 2.0 Hz), 7.81 (s, IH), 7.71-7.66 (m, IH), 7.51-7.44 (m, 2H), 7.33 (s, IH), 7.13 (s, IH), 5.34 (s, 2H); 13C NMR (DMSO-d6, 75 MHz) δ 165.2, 154.6 (d, JCF = 251.1 Hz), 149.9, 149.6, 146.4 (d, JCF = 11.1 Hz), 141.2, 138.4, 136.3, 133.1, 132.2, 130.9 (d, JCF = 3.5 Hz), 129.2, 128.3, 124.1, 122.0 (d, JCF = 7.6 Hz), 121.3, 119.9, 116.6 (d, JCF = 18.7 Hz), 115.6 (d, JCF = 1.7 Hz), 68.8; MS (ESI) m/z 457 (M + H)+. Anal, calcd for
C22H15CLFN4O2: C, 57.78; H, 3.31; N, 12.25; CI, 15.51. Found: C, 57.38; H, 3.52; N,
11.90; CI, 16.40.
Example R-25: 3-(5-Bromo-pyridin-3-ylmethoxy)-4-fluoro-N-(4-piperazin-l-yl-3- trifluoromethyl-phenyl)-benzamide R-25b,
Figure imgf000138_0001
(a) (5-Bromo-pyridin-3-yl)-methanol hydrochloride, R-25a, was prepared according to the procedure described in J. Med. Chem., 1997, 40, 2866-2875: HPLC Rt 3.9 min.; TLC Rf 0.2 (free base; 40% ethyl acetate-cyclohexane); Η NMR (DMSO-d6, 300 MHz) δ 8.70 (d, IH, J = 2.2 Hz), 8.58-8.57 (m, IH), 8.11 (t, IH, J = 2.0 Hz), 4.57 (s, 2H); 13C NMR (DMSO- 6, 75 MHz) δ 144.1, 141.9, 140.2, 120.8, 59.9; MS (ESI) m/z 188/190 (M + H)+.
(b) To a solution of (5-bromo-pyridin-3-yl)-methanol hydrochloride, R-25a, (1.9 g, 8.5 mmol, 1.0 eq) was added thionyl chloride (6 mL, 85 mmol, 10 eq). The amber solution was warmed to 70 °C for 2 h. The crude product was cooled to room temperature, diluted with toluene (50 mL) and concentrated under reduced pressure to give 3-bromo-5-chloromethyl-pyridine hydrochloride, R-25b, as a tan solid: HPLC Rt 10.1 min.; Η NMR (DMSO-d6, 300 MHz) δ 8.72 (d, IH, J = 2.2 Hz), 8.68 (d, IH, J = 1.7 Hz), 8.21 (t, IH, J = 2.0 Hz), 4.43 (s, 2H); 13C NMR (DMSO-d6, 75 MHz) δ 149.8, 148.0, 140.2, 136.4, 120.5, 42.3; MS (ESI) m/z 206/208 (M + H)+.
(c) 4- [( { 1 -[3 -(5-Bromo-pyridin-3-ylmethoxy)-4-fluoro-phenyl]-methanoyl } -amino)- trifluoromethyl-phenyl]-piperazine-l -carboxylic acid tert-butyl ester, R-25c, was prepared in a similar manner to that described for R-la, except that 3-bromo-5- chloromethyl-pyridine hydrochloride, R-25b, was used in place of 4- (chloromethyl)isoquinoline hydrochloride, K-lc, and 4-({ [l-(4-fluoro-3-hydroxy- phenyl)-methanoy 1] -amino } -trifluoromethyl-phenyl)-piperazine- 1 -carboxylic acid tert- butyl ester, DD-la, was used in place of 3-hydroxybenzoate: HPLC Rt 19.2 min.; TLC Rf 0.3 (2% methanol-dichloromethane); Η NMR (DMSO-d6, 300 MHz) δ 10.44 (s, IH), 8.74 (d, IH, j = 2.2 Hz), 8.72 (d, IH, J = 1.7 Hz), 8.21 (t, IH, J = 2.0 Hz), 8.14 (d, IH, J = 2.4 Hz), 8.04 (dd, IH, J = 8.6, 2.4 Hz), 7.86 (dd, IH, J = 8.2, 2.0 Hz), 7.71- 7.66 (m, IH), 7.60 (d, IH, J = 8.8 Hz), 7.46 (dd, IH, J = 11.0, 8.5 Hz), 5.34 (s, 2H), 3.44 (br. s, 4H), 2.80 (t, 4H, J = 4.7 Hz), 1.44 (s, 9H); MS (ESI) m/z 653/655 (M + H)+. (d) 3-(5-Bromo-pyridin-3-ylmethoxy)-4-fluoro-N-(4-piperaζin- 1 -yl-3-trifluoromeιhyl- phenyl)-benzamide dihydrochloride, R-25, was prepared in the manner similar to that described in example AA-1, step (i), except 4-[({ l-[3-(5-bromo-pyridin-3-ylmethoxy)- 4-fluoro-phenyl] -methanoyl } -amino)-trifluoromethyl-phenyl]-piperazine- 1 -carboxylic acid tert-butyl ester, R-25c, was used in place of 4-{[(l-{3-[2-(6-acetylamino-pyridin- 3-yl)-ethyl] -phenyl } -methanoyl)-amino] -trifluoromethyl-phenyl } -piperazine- 1 - carboxylic acid tert-butyl ester, AA-lh: HPLC Rt 13.1 min.; Η NMR (DMSO-d6, 300 MHz) δ 10.59 (s, IH), 9.05 (br. s, 2H), 8.74-8.72 (m, 2H), 8.20 (d, 2H, J = 1.9 Hz), 8.12 (d, IH, J = 8.7 Hz), 7.92 (d, IH, J = 7.9 Hz), 7.71-7.68 (m, IH), 7.56 (d, IH, J = 8.7 Hz), 7.44 (dd, IH, J = 11.0, 8.6 Hz), 5.36 (s, 2H), 3.17 (br. s, 4H), 3.07 (br. s, 4H); MS (ESI) m/z 553/555 (M + H)+. Anal, calcd for C24H21BrF4N4O2 x 2.0 HCI x 0.6 H2O: C, 45.24; H, 3.83; N, 8.79; Br, 12.54; CI, 11.13. Found: C, 45.20; H, 3.94; N, 8.50; Br, 12.18; CI, 10.81.
Example S-l: 3-(2-Isoquinolin-4-yl-ethyl)-N-phenyl-benzamide
Figure imgf000139_0001
S-1a: R=TMS S-1c S-1b:R=H
Figure imgf000139_0002
S-1d:R1=Et S-1
S-1e: R1 =H
(a) 4-Bromoisoquinoline (1.0 g, 4.8 mmol), dichlorobis(triphenylphosphine)palladium
(20.4 mg, 0.029 mmol), copper iodide (1.5 mg, 0.008 mmol), trimethylsilylacetylene
(707 mg, 7.2 mmol) and triethylamine (20 ml) were heated in a sealed tube at 65 °C for 16 h. After concentration the residue was diluted with ethyl acetate, washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The crude residue was purified on silica gel using a gradient of 10% to 20% ethyl acetate in hexanes as eluant to obtain 1.01 g (93%) of 4-(trimethyl-silanylethynyl)-isoquinoline, S-la, as a yellow liquid: 1H NMR (300 MHz, CDC13) δ 9.18 (s, IH), 8.70 (s, IH), 8.34 (m, IH), 8.14 (m, IH), 7.78 (m, IH), 7.65 (m, IH), 0.35 (s, 9H).
(b) To a solution of NaOH (0.23 g, 5.78 mmol) in methanol was added 1.0 g (4.44 mmol) 4-(trimethyl-silanylethynyl)-isoquinoline, S-la. After stirring for 2 h at room temperature the methanol was removed followed by addition of ethyl acetate. The organic solution was washed with water, brine and dried over sodium sulfate.
Removal of solvent led to 0.65 g (96%) of 4-ethynyl-isoquinoline, S-lb: 1H NMR (300 MHz, CDC13) δ 9.22 (s, IH), 8.74 (s, IH), 8.27 (m, IH), 7.99 (m, IH), 7.80 (m, IH), 7.67 (m, IH), 3.55 (s, IH).
(c) 4-Ethynyl-isoquinoline, S-lb, (0.64 g, 4.18 mmol), ethyl 3-iodobenzoate (1.15 g, 4.18 mmol), dichlorobis(triphenylphosphine)palladium (7.02 mg, 0.010 mmol) and copper iodide (0.4 mg, 0.002 mmol) in triethylamine (20 ml) were stirred at room temperature for 14 h. The mixture was filtered through celite, and the filtrate was concentrated to remove triethylamine. To this residue was added ethyl acetate, and this solution was washed with brine, dried over sodium sulfate, and concentrated to dryness. The crude residue was purified on silica gel using a gradient 0% to 5% ethyl acetate in dichloromethane as eluant to obtain 1.1 g (87%) of ethyl 3-(isoquinolin-4- ylethynyl)benzoate, S-lc, as a semisolid: 1H NMR (300 MHz, CDC13) δ 9.23 (brs, IH), 8.80 (br s, IH), 8.32 (m, 2H), 8.07 (m, IH), 8.03 (m, IH), 7.84 (m, 2H), 7.69 (m, 2H), 7.50 (dd, IH, J = 7.4 Hz), 4.43 (q, 2H, J = 7.1 Hz), 1.44 (t, 3H, J = 7.1 Hz). (d) Ethyl 3-(isoquinolin-4-ylethynyl)benzoate, S-lc, (1.1 g, 3.64 mmol) and 10% Pd/C (0.5 g ) in ethanol (20 ml) were stirred under one atm of hydrogen at room temperature for 16 h. The solution was filtered through celite, and the filtrate was concentrated leaving 1.02 g (91.6%) of ethyl 3-(isoquinolin-4-ylethyl)benzoate, S-ld, as a liquid: 1H NMR (300 MHz, CDC13) δ 9.14 (s, IH), 8.32 (s, IH), 8.01 (m, 2H), 7.91 (m, 2H), 7.75 (m, IH), 7.62 (m, IH), 7.34 (m, 2H), 4.39 (q„ 2H J = 7.1 Hz), 3.35 (m, 2H), 3.10 (m, 2H), 1.40 (t, 3H, J = 7.1 Hz). (e) To a stirred solution of ethyl 3-(isoquinolin-4-ylethyl)benzoate, S-ld, (1.02 g, 3.3 mmol) in methanol (20 ml) was added IN NaOH (3.63 ml, 3.63 mmol). After refluxing for 4 h, the methanol was removed. The solution was diluted with water and upon acidification to pH 3 a white precipitate formed which was subsequently filtered and dried under high vacuum to obtain 0.92 g (100%) of 3-(2-isoquinolin-4-yl-ethyl)- benzoic acid, S-le: 1H NMR (300 MHz, CDC13) δ 9.75 (s, IH), 8.54 (m, 3H), 8.21 (m, IH), 8.02 (m, IH), 7.89 (br s, IH), 7.80 (m, IH), 7.57 (m, IH), 7.43 (dd, IH, J = 7.7 Hz), 3.52 (m, 2H), 3.11 (m, 2H).
(f) To a stirred solution of 3-(2-isoquinolin-4-yl-ethyl)-benzoic acid, S-le, (0.2 g, 0.64 mmol), N-hydroxybenzotriazole (0.11 g, 0.70 mmol), and aniline (0.06 g, 0.65 mmol) in DMF (10 ml) was added l-ethyl-3-(3'-dimethylaminopropyl)carbodiimide'HCl (0.148 g, 0.77 mmol) at 0 °C. After stirring for 16 hrs. the DMF was removed, and ethyl acetate was added. This solution was washed with sat. NaHCO3, brine and dried over sodium sulfate. The crude residue was purified on silica gel using a gradient of 0% to 30% ethyl acetate in dichloromethane as eluant to obtain 0.18 g (80%) of 3-(2- isoquinolin-4-yl-ethyl)-N-phenyl-benzamide, S-l, as a solid: 1H NMR (300 MHz, CDC13) δ 9.16 (s, IH), 8.30 (s, IH), 8.04 - 7.99 (m, 2H), 7.76 (dd, IH, J = 8.34 Hz, J = 8.37 Hz), 7.71-7.69 (m, IH), 7.67-7.60 (m, 5H), 7.44-7.35 (m, 4H), 7.19-7.12 (m, IH), 3.39-3.34 (m, 2H), 3.16-3.11 (m, 2H). MS (ESI) m/z 353 [M + H]+. Anal, calc'd for C24H20N2O • 0.2 H2O: C, 80.96; H, 5.78; N, 7.87. Found: C, 80.88; H, 5.85; N, 8.03. Example S-2: 3-(2-Isoquinolin-4-yl-ethyl)-N-(3,3,5-trimethyl-cyclohexyl)- benzamide
Figure imgf000141_0001
S-2
Example S-2 was prepared in a similar manner to that described for S-l, except that (±)-cis/trans-3,3,5-trimethylcyclohexylamine was used in place of aniline in step (f): 1H NMR (300 MHz, CDC13) δ 9.14 (s, IH), 8.31 (s, IH), 8.01 (m, 2H), 7.75 (dd, IH, J = 8.4 Hz, J = 8.4 Hz ), 7.63 (dd, IH, J = 8.0 Hz, J = 8.0 Hz), 7.56 (m, IH), 7.52 (m, IH), 7.36-7.28 (m, 2H), 5.72 (d, IH, J = 7.9 Hz), 4.16 (m, IH), 3.37 (m, 2H), 3.10 (m, 2H), 2.90 (m, IH), 1.78 (m, 2H), 1.38 (m, IH), 1.03 (s, 3H), 0.97(s, 3H), 0.92 (d, 3H, J = 6.5 Hz), 0.84-0.64 (m, 3H). MS (ESI) m/z 401 [M + H]+. Anal, calc'd for C27H32N2O • 0.1 H2O: C, 80.60; H, 8.07; N, 6.96. Found: C, 80.40; H, 8.20; N.6.85. Example S-3: N-(4-Isopropyl-3-methyl-phenyl)-3-(2-isoquinolin-4-yl-ethyl)- benzamide
Figure imgf000142_0001
S-3
Example S-3 was prepared in a similar manner to that described for S-l, except that 4- isopropyl-3-methylaniline was used in place of aniline in step (f): 1H NMR (300 MHz, CDC13) δ 9.16 (s, IH), 8.31 (s, IH), 8.04 - 7.99 (m, 2H), 7.76 (dd, IH, J = 8.3 Hz, J = 8.4 Hz ), 7.68-7.61 (m, 4H), 7.45-7.34 (m, 4H), 7.23 (m, IH ), 3.39-3.34 (m, 2H), 3.15-3.10 (m, 3H), 2.36 (s, 3H), 1.23 (d, 6H, J = 6.9 Hz). MS (ESI) m/z 409 [M + H]+. Anal, calc'd for C28H28N2O ' 0.2 ^0: C, 81.60; H, 6.95; N, 6.80. Found: C, 81.51; H, 6.99; N, 6.85. Example S-4: 3-(2-Isoquinolin-4-yl-ethyl)-N-(2-methyl-quinolin-6-yl)-benzamide
Figure imgf000142_0002
S-4
Example S-4 was prepared in a similar manner to that described for S-l, except that 6- amino-2-methylquinoline was used in place of aniline in step (f): 1H NMR (300 MHz, CDC13) δ 9.16 (s, IH), 8.44 (d, IH, J = 2.4 Hz), 8.29 (s, IH), 8.07-7.97 (m, 5H), 7.79- 7.71 (m, 2H), 7.68-7.61 (m, 3H), 7.46-7.38 (m, 2H), 7.29 (d, IH, J = 8.4 Hz), 3.40- 3.35 (m, 2H), 3.17-3.10 (m, 2H), 2.74 (s, 3H). MS (ESI) m/z 418 [M + H]+. Anal, calc'd for C28H23N3O • 0.4 H2O: C, 79.18; H, 5.65; N, 9.89. Found: C, 79.01; H, 5.86; N, 9.67. Example S-5 : N-(3,5-Dibromo-4-methyl-phenyl)-3-(2-isoquinolin-4-yl-ethyl)- benzamide
Figure imgf000143_0001
Example S-5 was prepared in a similar manner to that described for S-l, except that 3,5-dibromo-4-methylaniline was used in place of aniline in step (f): 1H NMR (300 MHz, CDC13) δ 9.16 (s, IH), 8.25 (s, IH), 8.01 (m, 2H), 7.88 (s, 2H), 7.76 (dd, IH, J = 8.16 Hz, J = 8.51 Hz), 7.68 -7.61 (m, 3H), 7.52 (m, IH), 7.43-7.35 (m, 2H), 3.41- 3.32 (m, 2H), 3.15-3.09 (m, 2H), 2.54 (s, 3H). MS (ESI) m/z 525 [M + H]+. Anal, calcd for C25H2oN2OBr2 • C2F3 OOH: C, 50.80; H, 3.32; N, 4.39. Found: C, 50.84; H, 3.40; N, 4.51.
Example S-6: N-(4,6-Dimethyl-pyridm-2-yl)-3-(2-isoquinoIin-4-yI-ethyl)- benzamide
Figure imgf000143_0002
Example S-6 was prepared in a similar manner to that described for S-l, except that 2- amino-4,6-dimethylpyridine was used in place of aniline in step (f): 1H NMR (300 MHz, CDC13) δ 9.16 (s, IH), 8.40 (m,lH), 8.35 (s, IH), 8.03 (m, 3H), 7.80-7.73 (m, 3H), 7.63 (dd, IH, J = 8.04 Hz, J = 7.9 Hz ), 7.44-7.36 (m, 2H), 6.79 (s, IH), 3.39-3.34 (m, 2H), 3.16-3.10 (m, 2H), 2.45 (s, 3H), 2.37 (s, 3H). MS (ESI) m/z 382 [M + H]+. Anal, calcd for C25H23N3O • 2C2F3 OOH • 0.5 H2O: C, 56.31; H, 4.24; N, 6.79. Found: C, 56.16; H, 4.17; N, 6.75.
Example S-7: 2-Chloro-4-fluoro-N-(4-isopropyl-3-methyl-phenyl)-5-(2- isoquinolin-4-yl-ethyl)-benzamide
Figure imgf000144_0001
S-7
Example S-7 was prepared in a similar manner to that described for S-l, except that ethyl 2-chloro-4-fluoro-5-bromobenzoate was used in place of ethyl 3-iodobenzoate in step (c), and 4-isopropyl-3-methylaniline was used in place of aniline in step (f): H NMR (300 MHz, CDC13) δ 9.15 (s, IH), 8.27 (s, IH), ), 8.03(m, 2H), 7.81 - 7.76 (m, 2H), 7.64 (dd, IH, J 7.17 Hz, J = 7.11Hz), 7.33 (d, IH, J = 7.91 Hz), 7.44-7.41 (m, 2H), 7.21-7.16 (m, 2H), 3.34-3.32 (m, 2H), 3.19-3.05 (m, 3H), 2.36 (s, 3H), 1.23(d, 6H, J = 6.85 Hz). MS (ESI) m/z 461 [M]+. Anal, calcd for C28H26 ClFN2O: C, 72.95; H, 5.69; N, 6.08. Found: C, 72.70; H, 5.76; N, 6.03.
Example S-8 : 2,4-Difluoro-N-(4-isopropyI-3-methyl-phenyl)-5-(2-isoquinolin-4-yI- ethyl)-benzamide
Figure imgf000144_0002
S-8
Example S-8 was prepared in a similar manner to that described for S-l, except that methyl 2,4-difluoro-5-bromobenzoate was used in place of ethyl 3-iodobenzoate in step (c), and 4-isopropyl-3-methylaniline was used in place of aniline in step (f): H NMR (300 MHz, CDC13) δ 9.15 (s, IH), 8.32 (s, IH), 8.25 (m, IH), 8.10-7.99 (m, 3H), 7.78 (dd, IH, J = 7.3 Hz, J = 8.4 Hz), 7.64 (dd, IH, J = 8.4 Hz, J = 8.0 Hz), 7.47-7.40 (m, 2H), 7.24 (m, IH), 6.92 (dd, IH, J = 11.8 Hz, J = 11.8 Hz), 3.35-3.30 (m, 2H), 3.17-3.07 (m, 3H), 2.36 (s, 3H), 1.24 (d, 6H, J = 6.9 Hz). MS (ESI) m/z 445 [M]+. Anal, calc'd for C28H26 F3N2O: C, 75.66; H, 5.90; N, 6.30. Found: C, 75.42; H, 5.92; N, 6.22.
Example T-l: 2-Fluoro-N-(4-isopropyI-3-methyl-phenyl)-5-(2-isoquinolin-4-yl- ethyl) -benzamide
Figure imgf000145_0001
Figure imgf000145_0002
(a) 5-Bromo-2-fluoro-N-(4-isopropyl-3-methyl-phenyl)-benzamide, T-la, was prepared from 4-isopropyl-3-methyl aniline and 4-bromo-2-fluorobenzoic acid in a manner similar to that described for 3-(2-isoquinolin-4-yl-ethyl)-N-phenyl-benzamide in Example S-l, step (f), except that benzotriazole-1-yl-oxy-tris-pyriOlidino- phosphonium hexafluorophosphate was used in place of l-ethyl-3-(3'- dimethylaminopropyl)carbodiimide'HCl and N-hydroxybenzotriazole: 1H NMR (300 MHz, CDC13) δ 8.29 (dd, J = 10.5, 7.9 Hz, IH), 8.24 (br s, IH), 7.60 (m, IH), 7.42 (m, 2H), 7.24 (d, J = 8.4 Hz, IH), 7.08 (dd, J = 11.4, 8.7 Hz, IH), 3.12 (septet, J = 6.8 Hz, IH), 2.36 (s, 3H), 1.27 (d, J = 6.8 Hz, 6H).
(b) 2-Fluoro-N-(4-isopropyl-3-methyl-phenyl)-5-isoquinolin-4-ylethynyl-benzamide, T-lb, was prepared in the manner similar to that described in Example S-l, step (c) for ethyl 3-isoquinolin-4-ylethynyl-benzoate, S-lc, except that 5-bromo-2-fluoro-N-(4- isopropyl-3-methyl-phenyl)benzamide, T-la, was used in place of ethyl 3- iodobenzoate. 1H NMR (300 MHz, CDC13) δ 9.23 (s, IH), 9.08 (s, IH), 8.47 (dd, J = 7.5, 2.2 Hz, IH), 8.34 (m, 2H), 8.02 (d, J = 8.1 Hz, IH), 7.84 (m, IH), 7.78 (m, IH), 7.69 (m, IH), 7.48 (m, 2H), 7.25 (m, 2H), 3.14 (septet, J = 6.8 Hz, IH), 2.38 (s, 3H), 1.24 (d, J = 6.8 Hz, 6H). (c) 2-Fluoro-N-(4-isopropyl-3-methyl-phenyl)-5-(2-isoquinolin-4-yl-ethyl)-benzamide, T-l, was prepared in a manner similar to that described in Example S-l, step (d) for 3- (2-isoquinolin-4-yl-ethyl)-benzoic acid ethyl ester, S-ld: Η NMR (300 MHz, CDC13) δ 9.14 (s, IH), 8.37 (m, IH), ), 8.29 (s, IH) 8.05-7.99 (m, 3H), 7.77 (dd, IH, J = 8.3 Hz), 7.63 (dd, IH, J = 8.1 Hz), 7.49-7.45 (m, 2H), 7.23 (m, 2H), 7.07 (dd, IH, J = 12 Hz), 3.37-3.32 (m, 2H), 3.18-3.07 (m, 3H), 2.37 (s, 3H), 1.23 (d, 6H, J = 6.9 Hz). MS
(ESI) m/z 427 [M + H]+. Anal, calc'd for C28H27 FN2O: C, 78.85; H, 6.38; N, 6.57.
Found: C, 78.91; H, 6.35; N, 6.39.
Example U-l : N-(2-Methyl-quinolin-6-yl)-3-(2-pyridin-3-yl-ethyl)-benzamide hydrochloride
Figure imgf000146_0001
U-1a: X =CI U-1b: X = l
U-1c: X = P+Ph3 I"
Figure imgf000146_0002
U-1d U-1
(a) A solution of 2-methyl-quinolin-6-ylamine (Maybridge, 836 mg, 5.29 mmol, 1.0 eq) and triethylamine (0.74 mL, 5.29 mmol, 1.0 eq) in dichloromethane (100 mL) was cooled to 0 °C and treated with 3-chloromethyl-benzoyl chloride (Aldrich, 0.75 mL, 5.29 mmol, 1.0 eq). A tan slurry forms within 30 minutes. After 1.0 hour, TLC (4% methanol/chloroform) gave no 2-methyl-quinolin-6-ylamine (R 0.4), and a new spot with R/0.6. A 5% sodium bicarbonate solution (100 mL) was added to the reaction mixture, and the aqueous layer was extracted with 10% isopropanol/chloroform (3 x 100 mL) to give a yellow solid (1.31 g). The product was washed with diethyl ether to give 3-chloromethyl-N-(2-methyl-quinolin-6-yl)-benzamide, U-la, as a yellow solid (1.28 g, 78%): HPLC Rt = 12.8 min.; TLC R = 0.6 (4% methanol/chloroform); 1H ΝMR (300 MHz, DMSO-d6) δ 10.56 (s, IH), 8.46 (d, IH, J = 2.2 Hz), 8.22 (d, IH, J = 8.4 Hz), 8.07-7.90 (m, 4H), 7.70-7.69 (m, IH), 7.58 (t, IH, J = 7.6 Hz), 7.40 (d, IH, J = 8.4 Hz), 4.88 (s, 2H), 2.65 (s, 3H); 13C ΝMR (75 MHz, DMSO- ) □ 165.8, 158.0, 144.2, 138.4, 136.6, 136.5, 135.4, 132.5, 129.3, 128.4, 127.9, 126.7, 124.6, 123.0, 117.0, 116.8, 46.0, 24.7; MS (ESI) m/z 311 [M + H]+.
(b) A solution of 3-chloromethyl-N-(2-methyl-quinolin-6-yl)-benζamide, U-la, (500 mg, 1.6 mmol, 1.0 eq) in acetone (250 mL) was heated to 55 °C and treated with sodium iodide (3.2 g, 150 mmol, 13 eq). After 2.0 h, no starting material was detected by HPLC, and the resulting yellow solution was concentrated under reduced pressure. The resulting residue was treated with water (100 mL) and the aqueous layer was extracted with chloroform (3 x 100 mL). The combined organic extracts were washed with Νa2S O3 (100 mL), brine (100 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give 3-iodomethyl-N-(2-methyl-quinolin-6-yl)- benzamide, U-lb,as a yellow solid (615 mg, 96%): HPLC Rt = 13.6 min.; TLC R = 0.5 (5% methanol/chloroform); !H ΝMR (300 MHz, DMSO- ) δ 10.52 (s, IH), 8.44 (d, IH, J = 2.1 Hz), 8.22 (d, IH, J = 8.5 Hz), 8.12-7.88 (m, 4H), 7.68-7.66 (m, IH), 7.51 (t, IH, J = 7.7 Hz), 7.40 (d, IH, J = 8.5 Hz), 4.72 (s, 2H), 2.65 (s, 3H); MS (ESI) m/z 403 [M + H]+.
(c) A solution of 3-iodomethyl-N-(2-methyl-quinolin-6-yl)-benzamide, U-lb, (565 mg, 1.4 mg, 1.0 eq) in acetone (140 mL) was treated with triphenylphosphine (1.80 g, 7.0 mmol, 5.0 eq) and heated to 55 °C to give a yellow solution. After 18 hours, the resulting slurry gave no starting material (R 0.5) by TLC (5% methanol/chloroform), only product with R 0.0-0.3. The solvent was removed under reduced pressure and the resulting solid was washed with methyl-tert-butyl ether (4 x 25 mL) to give N-(2- methyl-quinolin-6-yl)-3-[(triphenylphosphanyl)-methyl]-benzamide iodide, U-lc, as a yellow solid (809 mg, 87%): HPLC Rf = 14.4 min.; TLC R = 0.0-0.3 (5% methanol/chloroform); 1H ΝMR (500 MHz, DMSO- ) δ 10.24 (s, IH), 8.18 (d, IH, J = 1.1 Hz), 8.02 (d, IH, J = 8.5 Hz), 7.80 (d, IH, J = 7.8 Hz), 7.75-7.71 (m, 5H), 7.60-
7.45 (m, 13H), 7.27-7.21 (m, 2H), 7.00 (d, IH, J = 7.7 Hz), 5.10 (d, 2H, J = 15.7 Hz),
2.46 (s, 3H); MS (ESI) m/z 537 [M + H]+.
(d) A solution of N-(2-methyl-quinolin-6-yl)-3-[(triphenylphosphanyl)-methyl]- benzamide iodide, U-lc, (600 mg, 0.90 mmol, 1.0 eq) in THF (20 mL) was cooled to - 78 °C and treated with a 1.0 M solution of sodium bis(trimethylsilyl)amide in THF (1.9 mL, 1.9 mmol, 2.1 eq) to give a dark orange solution. The solution was aged for 30 min at -78 °C, then treated with pyridine-3-carbaldehyde (93 μL, 0.99 mmol, 1.1 eq). The orange mixture was allowed to gradually warm to -30 °C over 2 h, removed from the cold bath and stirred at room temperature for 1.0 hour. The reaction was quenched with water (100 mL) and the aqueous layer was extracted with chloroform (3 x 100 mL). The combined organic extracts were washed with brine (100 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a black oil (700 mg). The crude product was purified by radial chromatography over silica gel using 3-4% rnethanol/chloiOform to give trαns-N-(2-methyl-quinolin-6-yl)-3-(2- pyridin-3-yl-vinyl)-benzamide, U-ld, as a white solid (59 mg, 18%): HPLC Rt = 12.3 min.; TLC Rf = 0.4 (5% methanol/chloroform); 1H ΝMR (500 MHz, DMSO- ) δ 10.50 (s, IH), 8.45-8.41 (m, 3H), 8.20 (d, IH, J = 8.4 Hz), 7.96 (dd, IH, J = 2.3, 9.1 Hz), 7.91-7.88 (m, 3H), 7.63-7.60 (m, IH), 7.47 (t, IH, J = 7.5 Hz), 7.41-7.39 (m, 2H), 7.31 (dd, IH, J = 4.8, 8.0 Hz), 6.92 (d, IH, J = 12.3 Hz), 6.78 (d, IH, J = 12.3 Hz), 2.64 (s, 3H); MS (ESI) m/z 366 [M + H]+. Anal, calc'd for C24H19Ν3O • 0.2 H2O: C, 78.11; H, 5.30; N, 11.39. Found: C, 78.08; H, 5.38; N, 11.25.
(d) A solution of tr n5,-N-(2-methyl-quinolin-6-yl)-3-(2-pyridin-3-yl-vinyl)- benzamide, U-ld, (44 mg, 0.12 mmol) in methanol (3 mL) was shaken vigorously under hydrogen (40 psi) with 5% palladium on carbon for 24 h. The catalyst was filtered off, and the filtrate was concentrated under reduced pressure to give a clear oil (50 mg). The crade product was purified by radial chromatography over silica gel using 2-4% methanol/dichloiOmethane to give a clear oil. The oil was dissolved in ethanol and treated with 0.1 mL concentrated hydrochloric acid. The solvent was removed under reduced pressure to give N-(2-methyl-quinolin-6-yl)-3-(2-pyridin-3-yl- ethyl)-benzamide hydrochloride, U-l, as a white solid (35 mg, 66%): HPLC Rt 12.4 min.; 1H ΝMR (500 MHz, DMSO- w/ D2O) δ (s, IH), 8.96 (d, IH, J = 8.7 Hz), 8.82- 8.81 (m, 2H), 8.74 (d, IH, J = 5.4 Hz), 8.46 (d, IH, J = 8.0 Hz), 8.38 (dd, IH, J = 1.8, 9.2 Hz), 8.23 (d, IH, J = 9.2 Hz), 7.98-7.89 (m, 4H), 7.53-7.52 (m, 2H), 3.21 (t, 2H, J = 7.8 Hz), 3.11 (t, 2H, J = 7.7 Hz), 2.93 (s, 3H); 13C ΝMR (75 MHz, DMSO- 6 w/ D2O) δ 166.9, 156.6, 146.1, 144.8, 141.8, 141.3, 141.1, 140.2, 139.1, 135.0, 144.4, 132.8, 129.1, 128.5, 128.2, 127.6, 127.0, 126.1, 124.3, 121.4, 117, 35.7, 33.5, 20.9; MS (ESI) m/z 368 [M + H]+. Anal, calc'd for C24H21N3O • 2HC1 • 0.3 H2O: C, 64.66; H, 5.34; N, 9.43; CI, 15.91. Found: C, 64.63; H, 5.40; N, 9.10; CI, 15.62. Example U-2: N-(4-ϊsopropyl-3-methyl-phenyl)-3-(2-pyridin-3-yl-ethyI)- benzamide
Figure imgf000149_0001
U-2
Example U-2 was prepared in a similar manner to that described for U-1, except that 3- methyl-4-isopropylaniline was used in place of 6-amino-2-methylquinoline in step (a): mp 143-144 °C; HPLC Rf = 15.7 min.; TLC R/= 0.4 (2% methanol/dichloiOmethane); 1H NMR (300 MHz, DMSO-d6) δ 10.04 (s, IH), 8.45 (s, IH), 8.40 (d, IH, J = 4.5 Hz), 7.82-7.76 (m, 2H), 7.67 (d, IH, J = 7.5 Hz), 7.55-7.41 (m, 4H), 7.32-7.28 (m, IH), 7.20 (d, IH, J = 8.3 Hz), 3.12-3.03 (m, IH), 2.98 (s, 4H), 2.29 (s, 3H), 1.18 (d, 6H, J = 6.8 Hz); HRMS (FAB) calcd for C24H26N2O [M + H]+ 359.2123, found 359.2117. Example V-l: N-{3-[(lH-pyrazolo[3,4-rf]-pyrimidin-4-ylsulfanylmethyl]phenyl}- (3-bromo-4-methyl)benzamide
Figure imgf000149_0002
V-1a
SOCI2
Figure imgf000149_0003
(a) To a solution of 3-amino benzyl alcohol (123 mg, 1 mmol), 3-bromo-4- methylbenzoic acid (215 mg, 1 mmol) and O-(7-azabenzotriazol-l-yl)-NN,N',N'- tetramethyluronium hexafluorophosphate (HATU, 380 mg, 1 mmol) in 5 mL DMF was added 0.14 mL of triethylamine (1 mmol) and the reaction mixture stirred at 50 °C for 1 h. The solvent was removed in vacuo and the residue was purified by chromatography to obtain 3-bromo-N-[3-hydroxymethyl)phenyl]-4- methylbenzamide,V-la, (310 mg, 96%): 1H ΝMR (300 MHz, DMSO-_i6) δ 10.03 (s, IH), 7.97 (s, IH), 7.67 (d, IH, J = 7.5 Hz), 7.52 (s, IH), 7.43 (d, IH, J = 7.6 Hz), 7.28 (d, IH, J = 6.9 Hz), 7.06 (m, IH), 6.81-6.84 (d, IH, J = 7.1 Hz), 5.01 (br s, IH), 4.27 (d, 2H, J = 4.5 Hz), 2.20 (s, 3H); APCIMS m/z 338 [M + H]+. (b) To 3-bromo-N-[3-hydroxymethyl)phenyl]-4-methylbenzamide, V-la, (310 mg, 0.96 mmol) was added 5 mL of thionyl chloride and the reaction mixture stirred for 15 min. Thionyl chloride was removed in vacuo and the crude dissolved in ethyl acetate and filtered through a plug of silica gel. The filtrate and washings were combined and the solvent removed to obtain 3-bromo-N-[3-chloromethyl)phenyl]-4- methylbenzamide, V-lb (217 mg, 66%): 1H ΝMR (300 MHz, DMSO- 6) δ 10.45 (s, IH), 8.30 (s, IH), 7.97-8.01 (m, 2H), 7.83 (d, IH, J = 8.3 Hz), 7.62 (d, IH, J = 8.3 Hz), 7.42-7.49 (m, IH), 7.27 (d, IH, J = 7.5 Hz), 4.87 (s, 2H), 2.52 (s, 3H). (c) To a solution of 97 mg (0.64 mmol) of 4-mercapto-lH-pyrazolo-[3,4-d]pyrimidine in 2 mL of DMF was added ΝaΗCO3 (80 mg) and 217 mg (0.64 mmol) of 3-bromo-N- [3-chloromethyl)phenyl]-4-methylbenzamide, V-lb. The reaction mixture stirred at 50 °C for 2 h. The solvent was removed and water was added to the residue. The resulting solid was filtered, washed with water and dried. The desired N-{3-[(lH- pyrazolo[3,4-^]-pyrimidin-4-ylsulfanylmethyl]phenyl}-(3-bromo-4-methy)benzamide, V-l, was obtained by silica gel column chromatography purification (85 mg, 30%): 1H ΝMR (300 MHz, DMSO- 6) δ 14.14 (s, IH), 10.31 (s, IH), 8.82 (s, IH), 8.33 (s, IH), 8.20 (s, IH), 7.9-7.93 (m, 2H), 7.71 (d, 1H,J = 6.8 Hz), 7.54 (d, 1H,J = 7.9 Hz), 7.34 (dd, IH, J = 7.50, 7.9 Hz), 7.25 (d, IH, J = 6.8 Hz), 4.73 (s, 2H), 2.54 (s, 3H): APCIMS m/z 454 [M + H]+.
Example V-2: Ν-{3-[(lH-pyrazolo[3,4-d]-pyrimidin-4-ylsulfanylmethyl]phenyl}- 3,5-bis(trifluoromethyl)benzamide
Figure imgf000150_0001
Example V-2 was prepared in a similar manner to that described for V-l, except that
3,5-bis(trifluoromethyl)benzoic acid was used in place of 3-bromo-4-methylbenzoic acid in step (a): Η NMR (300 MHz, DMSO-d6) δ 14.05 (s, IH), 10.60 (s, IH), 8.73
(s, IH), 8.52 (s, 2H), 8.31 (s, IH), 8.23 (s, IH), 7.82 (s, IH), 7.63 (d, IH, J = 7.5 Hz),
7.20-7.32 (m, 2H), 4.66 (s, 2H); APCIMS m/z 498 [M + H]\
Example V-3: N-{3-[(lH-pyraζolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl}-
(4-hydroxy-3-methoxy)benzamide
Figure imgf000151_0001
V-3
Example V-3 was prepared in a similar manner to that described for V-l, except that 4- hydroxy-3-methoxybenzoic acid was used in place of 3-bromo-4-methylbenzoic acid in step (a): 1H NMR (300 MHz, DMSO-_i6) δ 14.05 (s, IH), 9.93 (s, IH), 9.63 (s, IH),
8.72 (s, IH), 8.23 (s, IH), 7.81 (s, IH), 7.58 (m, IH), 7.43 (s, 2H), 7.13-7.25 (m, 2H),
6.78-6.80 (m, IH), 4.66 (s, 2H), 3.27 (s, 3H); APCIMS m/z 408 [M + H]+.
Example V-4: N-{3-[(lH-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl}- (4-hydroxy-3-t-butyl)benzamide
Figure imgf000151_0002
Example V-4 was prepared in a similar manner to that described for V-l, except that 3- t-butyl-4-hydroxybenzoic acid was used in place of 3-bromo-4-methylbenzoic acid in step (a): 1H NMR (300 MHz, DMSO- ) δ 13.96 (s, IH), 9.91 (s, IH), 9.83 (s, IH), 8.63 (s, IH), 8.14 (s, IH), 7.71 (s, IH), 7.57 (s, IH), 7.47-7.53 (m, 2H), 7.11 (dd, IH, J = 7.9, 8.0 Hz), 7.01 (d, IH, J = 7.2 Hz), 6.69 (d, IH, J = 8.3 Hz), 4.52 (s, 2H), 1.22 (s, 9H); APCIMS m/z 434 [M + H]+.
Example V-5: N-{3-[(lH-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl}- 4-t-butylbenzamide
Figure imgf000152_0001
Example V-5 was prepared in a similar manner to that described for V-l, except that 4- t-butylbenzoic acid was used in place of 3-bromo-4-methylbenzoic acid in step (a): 1H NMR (300 MHz, DMSO- ) δ 14.05 (s, IH), 10.02 (s, IH), 8.73 (s, IH), 8.23 (s, IH), 7.85 (s, IH), 7.79 (d, 2H,J = 8.3 Hz), 7.61 (d, IH, J = 7.6 Hz), 7.46(d, 2H,J = 8.3 Hz), 7.23 (dd, 1H,J = 7.50, 7.9 Hz), 7.13 (d, 1H,J = 7.6 Hz), 4.68 (s, 2H), 1.25 (s, 9H); APCIMS m/z 418 [M + H]+. Example V-6: N-{3-[(lH-pyrazolo[3,4-rf]-pyrimidin-4-yl)sulfanylmethyl]phenyl}-
(4-phenoxy)benzamide
SOC |2
Figure imgf000152_0002
Figure imgf000152_0003
Figure imgf000152_0004
V-6
(a) To 3-aminobenzyl alcohol (1.23 g, 10 mmol) was added 20 mL of thionyl chloride and the reaction was stirred at room temperature when a yellow solid separated out within five min. The reaction was monitored by TLC for completion and excess thionyl chloride was removed in vacuo to obtain the hydrochloride salt of 3- aminobenzylchloride (V-6a). To 4-mercapto-lH-pyrazolo-[3,4-<i]pyrimidine (1.5 g, 10 mmol) in 5 mL of DMF was added 4.6 mL of diisopropylethylamine (25 mmol) followed by the addition of the hydrochloride salt of 3 -aminobenzylchloride (V-6a) and the reaction mixture stirred at 50 °C for 1 h. The solvent was removed in vacuo and the product 3-[(lH-pyrazolo[3,4-J]-pyrimidin-4-yl)sulfanylmethyl]aniline, V-6b, crystallized (1.1 g, 42 %): 1H NMR (300 MHz, DMSO- 6) δ 14.13 (s, IH), 8.79 (s, IH), 8.31 (s, IH), 7.18 (dd, IH, J = 8.0, 8.3 Hz), 6.80 (d, IH, J = 8.3 Hz), 4.64 (s, 2H); APCIMS m/z 258 [M + H]+. (b) To a solution of 64.5 mg (0.25 mmol) of 3-[(lH-pyrazolo[3,4- ]-pyrimidin-4- yl)sulfanylmethyl]aniline, V-6b, and 53.5 mg (0.25 mmol) of 4-phenoxybenzoic acid in 2 mL DMF was added 0-(7-azabenzotriazol-l-yl)-NN,N',N'-tetramethyluronium hexafluorophosphate (ΗATU, 95 mg, 0.25 mmol) and triethylamine (0.03 mL, 0.25 mmol). The reaction was stirred at 50 °C for 1 h. After a conventional aqueous work- up, N-{3-[(lH-pyrazolo[3,4- ]-pyrimidin-4-yl)sulfanylmethyl]phenyl}-(4- phenoxy)benzamide, V-6, was obtained by chromatography on silica gel: !Η ΝMR
(300 MHz, DMSO- ) δl4.10 (s, IH), 10.19 (s, IH), 8.79 (s, IH), 8.30 (s, IH), 7.97 (d, 2H,J = 8.7 Hz), 7.90 (s, IH), 7.67 (d, IH, J = 8.3 Hz), 7.46 (dd, 2H,J = 7.60, 8.3 Hz), 7.31 (d, 1H,J = 7.6 Hz), 7.267 (d, 1H,J = 8.3 Hz), 7.19-7.22 (m, 2H), 7.07-7.12 (m, 3H), 4.70 (s, 2H); APCIMS m/z 454 [M + H]+. Example V-6c
0.1 M solutions of different acids, an amine template, HATU, and triethylamine were prepared in anhydrous DMF. To each tube in an array of 8 x 11 culture tubes (10 x 75 mm) was added 105 μL (0.0105) of a different acid. To this was added 100 μL (0.01 mmol) of the amine solution, 105 μL (0.0105 mmol) of the triethylamine solution followed by 105 μL (0.0105 mmol) of the ø-(7-azabenzotriazol-l-yl)-
Ν,Ν,Ν',Ν'-tetra-methyluronium hexafluorophosphate solution. The reactions were stirred in a heating block at 50 °C for 3 h. The reaction mixtures were transferred to a 1 mL 96-well plates using a liquid handler. The solvents were removed using the SpeedVac™ apparatus and the crude reaction mixtures were redissolved in DMSO to give a final theoretical concentration of 10 mM. Example V-6d: Using the general procedure described in Example V-6c above, the following compounds were made:
Figure imgf000155_0001
Figure imgf000156_0001
Figure imgf000157_0001
Figure imgf000158_0001
Figure imgf000159_0001
Figure imgf000160_0001
Example V-7: N-{3 (lH yrazoIo[3,4-^pyrimidin-4-ylsuIfanyl)methyϊ]phenyl}- N 3,5 >is-(trifluoromethyl)phenyl]urea
Figure imgf000161_0001
V-7
To a solution of 64.5 mg (0.25 mmol) of 3-[(lH-pyrazolo[3,4-cf|-pyrimidm-4- yl)sulfanylmethyl] aniline, V-6b, and 3,5-bis(trifluromethyl)phenyl isocyanate (61.2 mg, 0.25 mmol) in 2 mL DMF was added 20 mg of ΝaHCO3 and the reaction stirred at 50 °C for 1 h. After conventional aqueous work-up, purification by silica gel chromatography provided N- { 3 - [( lH-pyrazolo [3 ,4-d]pyrimidin-4-ylsulf anyl)methyl] - phenyl}-N-[3,5-bis-(trifluoromethyl)phenyl]urea, V-7: 1H ΝMR (300 MHz, DMSO-d6) 6 14.09 (s, IH), 9.34 (s, IH), 9.01 (s, IH), 8.78 (s, IH), 8.29 (s, IH), 8.12 (s, 2H), 7.63 (s, 2H), 7.37 (d, IH, J = 7.5 Hz), 7.25 (dd, 1H,J = 7.6, 8.3 Hz), 7.12 (d, IH, J = 7.6 Hz), 4.68 (s, 2H); APCIMS m/z 513 [M + H]+. Example V-7a
0.1 M solutions of the amine template, HATU, and isocyanate were prepared in anhydrous DMF. To each tube in an array of 8 x 11 culture tubes (10 x 75 mm) was added 100 μL (0.01 mmol) of the amine solution. To this was added 100 μL (0.01 mmol) of a different isocyanate solution followed by the addition of 10 mg of sodium bicarbonate. The reactions were stirred at 50 °C for 2 h. The reaction mixtures were transferred to a 1 mL 96-well plate using a liquid handler. The solvents were removed using the SpeedVac™ apparatus and the crude reaction mixtures were redissolved in DMSO to give a final theoretical concentration of 10 mM. Example V-7b:
Using the general procedure described in Example V-7a above, the following compounds were made:
Figure imgf000162_0001
Figure imgf000163_0001
Example V-8 : N-{3-[(lH-pyrazolo[3,4-d]pyrimidin-4-ylsulfanyl)methyl]phenyl}- N'-(pyridin-3-yl)urea
Figure imgf000163_0002
V-8
Example V-8 was prepared in a manner similar to that described in Example V-7, except that 3,5-bis(trifluromethyl)phenyl isocyanate was replaced by 3-pyridyl isocyanate: HPLC Rt = 7.12 min.; 1H NMR (300 MHz, DMSO-d6) δ 14.12 (s, IH), 8.79-8.84 (m, 3H), 8.59 (s, IH), 8.30 (s, IH), 8.17 (s, IH), 7.92 (d, IH, J = 8.3 Hz), 7.59 (s, IH) 7.21-7.38 (m, 3H), 7.09 (d, IH, I = 7.2 Hz), 4.67 (s, 2H); APCIMS m/z 311 [M + H]+.
Example V-9: N-{3-[(lH-pyrazolo[3,4-dT]-pyrimidin-4-yl)sulfanylmethyl]phenyl}- (3,5-di-£-butyl)benzamide
Figure imgf000164_0001
Example V-9 was prepared in a manner similar to that described in Example V-6, except that 3,5-di-(t-butyl)benzoic acid was used in place of 4-phenoxybenzoic acid in step (b): HPLC R, = 5.16 min.; 1H NMR (300 MHz, DMSO- 6) δ 14.12 (s, IH), 10.19 (s, IH), 8.80 (s, IH), 8.30 (s, IH), 7.87 (s, IH), 7.72 (s, 2H), 7.66 (d, 2H,J = 7.8 Hz), 7.60 (s, IH), 7.31 (dd, 1H,J = 7.60, 7.9 Hz), 7.22 (d, 1H,J = 7.5 Hz), 4.70 (s, 2H), 1.33 (s, 18H); APCIMS m/z 474 [M + H]+.
Example V-10: 3-Bromo-4-hydroxy-N-{3-[(lfiT-pyrazolo[3,4-rf]-pyrimidin-4- yl)sulfanylmethyl]phenyl}-benzamide
Figure imgf000164_0002
V-10
Example V-10 was prepared in a manner similar to that described in Example V-6, except that 3-bromo-4-hydroxybenzoic acid was used in place of 4-phenoxybenzoic acid in step (b): 1H ΝMR (300 MHz, DMSO- ) δ 10.07 (s, IH), 8.79 (s, IH), 8.30 (s,
IH), 8.14 (d, IH, J= 2.1 Hz), 7.88 (s, IH), 7.80 (dd, 1 H, J= 2.1, 8.1 Hz), 7.66 (d,
IH, J= 8.6 Hz), 7.29 (dd, IH, J= 7.7, 7.8 Hz), 7.18 (d, IH, J = 7.6 Hz), 7.01 (d, IH,
J = 8.5 Hz), 4.69 (s, 2H); APCIMS m/z 456 [M + H]+.
Example V-ll: N-{3-[(lff-pyrazolo[3,4-rf]-pyrimidin-4-yl)sulfanylmethyl]phenyl}- quinoline-6-carboxamide
Figure imgf000164_0003
V-11
Example V-11 was prepared in a manner similar to that described in Example V-6, except that quinoline-6-carboxylic acid was used in place of 4-phenoxybenzoic acid in step (b): 1H NMR (300 MHz, DMSO- ) δ 14.12 (s, IH), 10.53 (s, IH), 9.00 (dd, IH, J= 1.5, 4.2 Hz), 8.80 (s, IH), 8.61 (d, IH, J= 1.9 Hz), 8.52 (d, IH, J= 8.0 Hz), 8.30 (s, IH), 8.23 (dd, IH, J= 1.9, 8.7 Hz), 8.12 (d, IH, J = 8.7 Hz), 7.96 (s, IH), 7.73 (d, IH, J= 7.9 Hz), 7.64 (dd, 1 H, J = 4.5, 8.4 Hz), 7.34 (dd, IH, J= 7.9, 8.0 Hz), 7.24 (d, IH, J = 7.5 Hz), 7.05-7.12 (m, IH), 4.72 (s, 2H); APCIMS m/z 413 [M + H]+. Example V-12: 5-Fluoro-N-{3-[(lH-pyrazolo[3,4-df]-pyrimidin-4-yl)suIfanyl- methyl]phenyl}-indole-2-carboxamide
Figure imgf000165_0001
Example V-12 was prepared in a manner similar to that described in Example V-6, except that 5-fluoroindole-2-carboxylic acid was used in place of 4-phenoxybenzoic acid in step (b): 1H ΝMR (300 MHz, DMSO-d6) δ 14.12 (s, IH), 11.83 (s, IH), 10.27 (s, IH), 8.80 (s, IH), 8.30 (s, IH), 7.91 (s, IH), 7.73 (d, IH, J = 8.3 Hz), 7.47 (s, IH), 7.44 (dd, IH, J = 4.1, 4.60 Hz), 7.40 (d, 1 H, J= 1.9 Hz), 7.32 (dd, IH, J= 7.5, 8.0 Hz), 7.21 (d, IH, J= 7.1 Hz), 7.05-7.12 (m, IH), 4.71 (s, 2H); APCIMS m/z 419 [M + H]+.
Example V-13: N-{3-[(lH-pyrazolo[3,4-^]-pyrimidin-4-yl)suIfanylmethyl]phenyl}- indole-6-carboxamide
Figure imgf000165_0002
V-13
Example V-13 was prepared in a manner similar to that described in Example V-6, except that indole-6-carboxylic acid was used in place of 4-phenoxybenzoic acid in step (b): 1H ΝMR (300 MHz, DMSO-d6) δ 14.12 (s, IH), 11.45 (s, IH), 10.18 (s, IH), 8.80 (s, IH), 8.31 (s, IH), 8.04 (s, IH), 7.96 (s, IH), 7.70 (d, IH, J= 7.9 Hz), 7.62 (s, 2H), 7.54 (s, IH), 7.31 (dd, IH, J= 7.9, 8.0 Hz), 7.18 (d, 1 H, J = 7.5 Hz), 7.30-6.52 (s, IH), 4.70 (s, 2H); APCIMS m/z 401 [M + H]+. Example V-14: The following compounds were made using the general procedure described above in Example V-6c, except for the use of different acids and amines, which yielded the products indicated below (wherein for convenience, and as understood in the art, not all hydrogen atoms have been expressly indicated for each carbon and/or nitrogen atom).
Figure imgf000167_0001
Figure imgf000168_0001
Figure imgf000169_0001
Example V-15: (R/S)-2-(2-methylphenyl)-N-{3-[(lH-pyrazolo[3,4-d]pyrimidin-4- ylsulfanyl)methyl)methyl}phenyl}butanamide
Figure imgf000170_0001
V-15 Example V-15 was prepared in a manner similar to-that described in Example V-6, except that 3-(o-tolyl)-butyric acid was used in place of 4-phenoxybenzoic acid in step (b): Η NMR (300 MHz, DMSO-d6) δ 14.08 (s, IH), 9.95 (s, IH), 8.76 (s, IH), 8.26 (s, IH), 7.71 (s, IH), 7.50-7.48 (d, IH, J = 8.31 Hz), 7.40-7.37 (dd, IH, J = 2.08, 8.31 Hz), 7.25-7.20 (d, IH, I = 7.74, 7.93 Hz), 7.16-7.09 (m, 4H), 4.64 (s, 2H), 3.76-3.72 (dd, IH, J = 5.48, 5.67 Hz), 2.38 (s, 3H), 1.99-1.92 (m, IH), 1.63-1.60 (m, IH), 0.90- 0.80 (t, 3H, J = 7.18, 7.37 Hz); APCIMS m z 418 [M + H]+.
Example W-l: 3- -Butyl-4-hydroxy-N-{3-[5-(6-methoxy-pyridin-3-yIamino)-2 H- pyrazol-3-ylmethylsulfanyl]-phenyl}-benzamide.
Figure imgf000171_0001
1b
Figure imgf000171_0002
W-1
(a) A solution of 3-t-butyl-4-hydroxy-benzoic acid (1.0 g, 5.2 mmol, 1.0 eq) in acetic anhydride (5.0 mL) was treated with concentrated sulfuric acid (0.03 mL, 0.5 mmol, 0.1 eq). The clear reaction mixture was warmed to 90 °C. After 18 h, the resultant black solution was concentrated under reduced pressure and treated with 1.0 M hydrochloric acid (100 mL). The aqueous layer was extracted with ethyl acetate (3 x 50 mL) and the combined organic extracts were washed with water (50 mL), brine (50 mL), dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give a brown solid (1.2 g). The crude product was purified by radial chromatography over silica gel using 10-20% ethyl acetate/cyclohexane with 0.1% acetic acid to give 4-acetoxy-3-t-butyl-benzoic acid, W-la, as a white solid (309 mg, 26%): mp 123-125 °C; TLC Rf = 0.6 (20% ethyl acetate/cyclohexane with 0.1% acetic acid); IR (KBr) 3418 (br), 1789, 1766 cm-1; IH NMR (300 MHz, DMSO-d6) δ 8.12 (d, IH, I = 2.1 Hz), 8.06 (dd, IH, J = 8.4, 2.1 Hz), 7.36 (d, IH, J = 8.4 Hz), 2.39 (s, 3H), 1.36 (S, 9H).
(b). A slurry of 3-mercaptoaniline (1.00 mL, 9.42 mmol), 2-chloro-N-methoxy-N- methyl-acetamide and cesium carbonate (6.12g, 18.84 mmol) in 5 mL of acetone was stirred for 18h. The reaction mixture was partitioned between ethyl acetate (30 mL) and sat. sodium carbonate (2 x 50 mL) and the organic layer concentrated to dryness to give an amber oil. Purification by chromatography on silica gel using hexane/ethyl acetate (1:1) afforded 1.57g (56%) of 2-(3-aminophenylsulfanyl)-N-methoxy-N- methyl-acetamide, W-lb, as a clear oil . HPLC Rt =5.85 min; 1H NMR (300 MHz, CDC13) δ 7.26 (s, IH), 7.08 (t, IH, J = 8.1 Hz), 6.84-6.82 (m, 2H), 6.54 (d, IH, J = 8.7 Hz), 3.82 (s, 2H), 3.75 (s, 3H), 3.22 (s, 3H).
(c) To a solution of 0.24 g (0.81 mmol) of 2-(3-amino-phenylsulfanyl)-N-methoxy-N- methyl-acetamide, W-lb, in dichloromethane (3 mL) was added 0.18 g (0.89 mmol) of 3-t-butyl-4-acetoxy-benzoic acid , W-lb, and EDC (0.18 g, 0.97 mmol). After 18 h, the reaction was partitioned between ethyl acetate (30 mL) and sat. sodium bicarbonate (2 x 20 mL) and washed with IN HCI (2 x 20 mL). The organic layer was dried over sodium sulfate and concentrated to a give yellow oil, which was purified by chromatography on silica gel using hexane/ethyl acetate (1:1) as eluant to afford 4- ■ acetoxy-3-t -butyl-N- { 3-[(methoxy-methyl-carbamoyl)-methylsulfanyl]- phenyl} benzamide, W-lc, as a colorless oil, 0.31 g (86%). HPLC Rt =13.65 min.; 1H NMR (300 MHz, CDC13) δ 8.41 (br s, IH), 7.94 (d, IH, J = 2.1 Hz), 7.75 (t, IH, J = 1.8 Hz), 7.63 (dd, IH, I = 8.4, 2.1 Hz), 7.57-7.53 (m, IH), 7.28-7.15 (m, 2H), 7.03 (d, IH, J = 8.4 Hz), 5.30 (s, IH), 3.83 (s, 2H), 3.72 (s, 3H), 3.18 (s, 3H), 2.36 (s, 3h), 1.36 (s, 9H). LCESI: Calculated for C23H28N2O5S (M+H+): 445, Found: 445. (d). To a solution of 0.30 g (0.68 mmol) of 4-acetoxy-3-t-Butyl-N- { 3-[(methoxy- methyl-carbamoyl)-methylsulfanyl] -phenyl} benzamide, W-lc, in 7 mL of methanol/acetone/water (1:5:1) was added was potassium carbonate (0.55g, 1.35 mmol). The reaction mixture was stirred for 1 h at room temperature and then partitioned between IN HCI ( 2 x 20 mL) and ethyl acetate (30 mL). The organic dried over sodium sulfate and concentrated to give a yellow oil. Trituration with diethyl ether (2 x 5 mL) gave 0.22 g (81 %) of 3-t -butyl-4-hydroxy-N- { 3-[(methoxy-methyl- carbamoyl)-methylsulfanyl]-phenyl}benzamide, W-ld, as a white solid: HPLC Rt =13.12 min.; 1H NMR (300 MHz, CDC13) δ 8.04 (d, IH, J = 2.1Hz), 8.00 (br s, IH), 7.85 (dd, IH, J = 8.4, 2.4 Hz), 7.74 (d, IH, 7.8 Hz), 7.49 (t, IH, J = 7.8 Hz), 7.39 (d, IH, J = 7.5 Hz), 7.02 (d, IH, J = 8.4 Hz), 4.13 (s, 2H), 3.95 (s, 3H), 3.41 (s, 3H), 1.64 (s, 9H). LCESI: Calculated for C21H26N2O4S (M+H+): 403, Found: 403.
(e). To a solution of 0.24 g (1.31 mmol) of N-(6-memoxy-pyricUn-3-yl)-thioacetamide in anhydrous THF (5 mL) at -78 °C was added dropwise 1.32 mL (2.64 mmol) of LDA (2.0 M in THF). The reaction mixture was stirred for 0.25 h at -78 "C, warmed to 0 °C for lh, and then recooled to -78 °C. To the resulting solution was added dropwise over a 5 min period a solution of 0.17 g (0.41 mmol) of 3-t -butyl-4-hydroxy-N-{3- [(methoxy-methyl-carbamoyl)-methylsulfanyl] -phenyl} benzamide, W-ld, in 5 mL of THF. After 1 h at 0 °C, the reaction was quenched with methanol/acetic acid (0.5 mL:0.5 mL) and then partitioned between 30 mL of ethyl acetate and sat. sodium carbonate (2 x 20 mL). The organic layer was concentrated to give a yellow oil, which was purified by chromatography on silica gel (1: 1 hexane/ethyl acetate) to afford 0.22 g (96 %) of 3-t- Butyl-4-hydroxy-N-{3-[3-(6-methoxy-pyridin-3-ylthiocarbamoyl)-2- oxo-propylsulfanyl] -phenyl} benzamide, W-le, as a pale yellow foam: HPLC Rt =13.12 min.; 1H NMR (300 MHz, CDC13) δ 8.23-8.18 (m, IH), 8.08-7.98 (m, 2H), 7.86-7.70 (m, 2H), 7.58-7.40 (m, 2H), 7.28-7.15 (m, 2H), 6.82-6.68 (m, 2H). 3.94 (s, 3H), 3.89 (s, 2H), 2.74 (s, 2H). 1.36 (s, 9H). LCESI: Calculated for C27H29N3O4S2 (M+H+): 524, Found: 524.
(f) To a solution of 0.18 g (0.33 mmol) of 3-t- butyl-4-hydroxy-N-{3-[3-(6-methoxy- pyridin-3-ylthiocarbamoyl)-2-oxo-proρylsulfanyl]-phenyl } -benzamide, W-le, in ethanol (2 mL) was added hydrazine mono-hydrate (0.25 mL, 0.50 mmol) and acetic acid 0.025 mL, 0.28 mL). After 2 h, the reaction solution was concentrated and the residue was purified by chromatography (4: 1 hexane:ethyl acetate) to afford 0.11 g (62%) of 3-t -Butyl-4-hydroxy-N-{3-[5-(6-methoxy-pyridin-3-ylamino)-2H-pyrazol-3- ylmethylsulfanyl]-phenyl}-benzamide, W-l: HPLC Rt = 13.65 min.; 1H NMR (300 MHz, CDC13) δ 7.88 (br s, IH), 7.73 (d, IH, J = 2.4 Hz), 7.71 (s, IH), 7.53 (dd, IH, J =8.4, 2.4 Hz), 7.44 (br s, IH), 7.17 (t, IH, J = 7.8 Hz), 7.02 (d, IH, J = 7.8Hz), 7.71 (d, IH, J = 8.4 Hz), 7.55 (d, IH J = 8.7 Hz), 5.64 (s, IH), 5.39 (s, IH), 4.03 (s, 2H), 3.71 (s, 3H), 1.33 (s, 9H); LCESI: Calculated for C27H29N5O3S (M+H+): 504, Found: 504. Anal, calc'd for C27H29N5O3S»0.3 CH2C12: C, 61.97; H, 5.64; N, 13.24. Found C, 61.78; H, 5.67; N, 13.16.
Example W-2: 3-^-Butyl-4-hydroxy-N-[3-(pyridin-3-ylmethylsulfanyl)-phenyl]- benzamide
Figure imgf000174_0001
Example W-2 was prepared in a similar manner to that described for the preparation of the intermediate 3-t -butyl-4-hydroxy-Ν-{3-[(methoxy-methyl-carbamoyl)- methylsulfanyl] -phenyl} benzamide, W-ld, in example W-l, except that 3-picolyl chloride hydrochloride was used in place of 2-chloro-N-methoxy-N-methyl-acetamide in step (b): mp 95-100 °C; HPLC Rt = 14.0 min.; TLC R/= 0.5 (5% methanol/dichloromethane); 1H NMR (300 MHz, DMSO- 6) δ 10.15 (s, IH), 10.04 (s, IH), 8.60 (s, IH), 8.48 (d, IH, J = 3.6 Hz), 7.88 (s, IH), 7.84-7.72 (m, 3H), 7.64 (d, IH, J = 8.1 Hz), 7.40-7.29 (m, 2H), 7.10 (d, IH, J = 8.0 Hz), 6.92 (d, IH, J = 8.4 Hz), 4.32 (s, 2H), 1.46 (s, 9H); MS (ESI) m/z 393 [M + H]+. Anal, calc'd for C23H24N2O2S • 0.5 MTBE: C, 72.63; H, 7.16; N, 6.22; S, 7.12. Found: C, 70.40; H, 6.86; N, 6.44; S, 7.17. Example W-3: 3-^-ButyI-4-hydroxy-N-[3-(isoquinolin-4-ylmethyIsulfanyl)- phenyl] -benzamide
Figure imgf000175_0001
W-3 Example W-3, isolated as the hydrochloride salt as described in Example K-2, was prepared in a similar manner to that described for the preparation of the intermediate 3- t -butyl-4-hydroxy-N- { 3-[(methoxy-methyl-carbamoyl)-methylsulfanyl]-phenyl } - benzamide, W-ld, in example W-l, except that 4-chloromethylisoquinoline hydrochloride, K-lc, was used in place of 2-chloro-N-methoxy-N-methyl-acetamide in step (b): mp 205-210 °C; HPLC Rt = 15.2 min.; TLC R = 0.4 (5% methanol/dichloromethane); 1H NMR (300 MHz, DMSO- 6) δ 10.28 (s, IH), 10.15 (s, IH), 9.81 (s, IH), 8.66-8.59 (m, 3H), 8.32 (t, IH, J = 7.8 Hz), 8.11 (t, IH, J = 7.6 Hz), 7.95 (s, IH), 7.88 (d, IH, J = 2.0 Hz), 7.83 (dd, IH, J = 8.0, 2.0 Hz), 7.75 (d, IH, J = 9.0 Hz), 7.41 (t, IH, J = 8.0 Hz), 7.22 (d, IH, J = 7.7 Hz), 7.02 (d, IH, J = 8.4 Hz), 4.95 (s, 2H), 1.52 (s, 9H); MS (ESI) m/z 443 [M + H]+. Anal, calc'd for C27H26N2O2S • HC1 » 0.2 H2O: C, 66.45; H, 5.78; N, 5.743; S, 6.54. Found: C, 66.20; H, 6.23; N, 5.37; S, 6.13.
Example X-l: N-[3-(5-Bromo-pyridin-3-ylmethoxy)-phenyl]-3-t-butyl-4-hydroxy- benzamide
Figure imgf000175_0002
X-1a X-1b
Figure imgf000175_0003
(a) To a solution of 156 mg (1.43 mmol) of 3-aminophenol in DMF at 0 °C was added 115 mg (2.86 mmol) of 60% sodium hydride dispersion in mineral oil. After 45 min, a slurry of 380 mg (1.57 mmol) of 5-bromo-3-chloromethylpyridine hydrochloride, X- la, which was prepared from 5-bromo-3-(hydroxymethyl)pyridine (Hamel, P. et al., J. Med. Chem., 40, 2866-2875 (1997)) according to the procedure described in Example K-l, step (c), in DMF was added. The reaction was allowed to slowly warm to room temperature over 3 h and then partitioned between MTBE and sat. aq. ammonium chloride. The organic layer was washed with brine, dried over MgSO , and concentrated. The residue was purified by radial chromatography with a gradient of 0 to 1% methanol in 40% ethyl acetate/cyclohexane to give 318 mg of 3-(5-bromo- pyridin-3-ylmethoxy)aniline, X-lb, as a clear oil: 1H NMR (300 MHz, DMSO-d6) δ 8.68 (d, IH, J = 2.3 Hz), 8.64 (d, IH, J = 1.7 Hz), 8.10 (t, IH, I = 2.0 Hz), 6.91 (t, IH, J = 8.0 Hz), 6.17-6.22 (m, 3H), 5.10 (br s, 2H), 5.06 (s, 2H); MS (ESI) m/z 279/281 [M + H]+. (b) To a solution of 280 mg (1.0 mmol) 3-(5-bromo-pyridin-3-ylmethoxy)aniline, X- lb, in dichloromethane (10 mL) was sequentially added 326 mg (1.0 mmol) of 3-t- butyl-4-(t-butyl-dimethylsilanyloxy)-benzoyl chloride, X-lc, (Trova, M. P. et al., J. Med. Chem., 36, 580-590 (1993)) and triethylamine (0.15 mL, 1.1 mmol). The resultant clear solution was stirred for 18 h at room temperature and then the solvent was removed under reduced pressure. The reaction mixture was treated with 5% sodium bicarbonate (100 mL) and extracted with 10% isopropanol/chloroform (3 x 50 mL). The combined organic extracts were washed with brine (50 mL), dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give an off- white solid (569 mg). The crude product was purified by radial chromatography over silica gel using 1-2% methanol/dichloromethane to give N-[3-(5-bromo-pyridin-3- ylmethoxy)-phenyl]-3-t-butyl-4-(t-butyl-dimethyl-silanyloxy)-benzamide, X-ld, as a white solid (456 mg, 80%): HPLC Rf = 20.6 min; TLC R = 0.8 (4% methanoVdichloromethane); 1H ΝMR (300 MHz, DMSO- ) δ 9.91 (s, IH), 8.53-8.51 (m, 2H), 8.00 (t, IH, j = 2.0 Hz), 7.64 (d, IH, j = 2.3 Hz), 7.56 (dd, IH, j = 8.5, 2.2 Hz), 7.41 (t, IH, J = 2.0 Hz), 7.19-7.16 (m, IH), 7.09 (t, IH, J = 8.1 Hz), 6.78 (d, IH, J = 8.4 Hz), 6.60 (dd, IH, I = 8.0, 1.6 Hz), 5.00 (s, 2H), 1.23 (s, 9H), 0.86 (s, 9H), 0.20 (s, 6H); MS (ESI) m/z 569/571 [M + H]+.
(c) To a solution of 100 mg (0.18 mmol) N-[3-(5-bromo-pyridin-3-ylmethoxy)- phenyl]-3-t-butyl-4-(t-butyl-dimethyl-silanyloxy)-benzamide, X-ld, in THF (7 mL) at 0 °C was added a 1.0 M solution of tetrabutylammonium fluoride in THF (0.27 mL, 0.27 mmol). The slightly yellow reaction mixture was warmed to room temperature over several hours and stirred an additional 15 h. The cloudy reaction mixture was concentrated under reduced pressure to give a clear oil. The crude product was purified by radial chromatography over silica gel using 2-4% methanol/di- chloromethane to give N-[3-(5-bromo-pyridin-3-ylmethoxy)-phenyl]-3-t-butyl-4- hydroxy-benzamide, X-1, as a white solid (75 mg, 91%): mp 105-111 °C; HPLC Rt = 14.7 min.; TLC R = 0.4 (4% methanol/dichloromethane); 1H ΝMR (300 MHz, DMSO- 6) δ 10.11 (s, IH), 10.01 (s, IH), 8.74-8.72 (m, 2H), 8.21 (t, IH, J = 2.0 Hz), 7.78 (d, IH, J = 2.1 Hz), 7.72 (dd, IH, J = 8.3, 2.2 Hz), 7.61 (t, IH, J = 2.0 Hz), 7.40- 7.37 (m, IH), 7.29 (t, IH, I = 8.1 Hz), 6.91 (d, IH, J = 8.4 Hz), 6.79 (dd, IH, J = 7.8, 2.1 Hz), 5.20 (s, 2H), 1.43 (s, 9H); 13C ΝMR (75 MHz, DMSO- ) δ 166.1, 159.5, 158.4, 150.1, 147.9, 141.2, 138.3, 135.4, 135.3, 129.7, 127.2, 127.1, 125.4, 120.5, 115.9, 113.5, 109.9, 107.2, 66.3, 34.8, 29.5; MS (ESI) m/z 455/457 [M + H]+. Anal, calc'd for C23H23BrΝ2O3: C, 60.67; H, 5.09; Br, 17.55; N, 6.15. Found: C, 60.63; H, 5.24; Br, 17.69; N, 6.01.
Example X-2: 4-Acetoxy-3-^-butyl-N-[3-(pyridin-3-yImethoxy)phenyl]-benζamide
Figure imgf000177_0001
X-2 Example X-2 was prepared from 3-(pyridin-3-ylmethoxy)aniline, X-2a, prepared from 3-picolylchloride hydrochloride and 3-hydroxyaniline as described in Example X-1, step (a), and 4-acetoxy-3-t-butylbenzoic acid, W-la, according to the procedure described in Example W-l, step (c): mp 58-62 °C; HPLC R, = 14.4 min.; TLC Rf = 0.3 (4% methanol/dichloromethane); Η NMR (300 MHz, DMSO-d6) δ 10.25 (s, IH), 8.70
(s, IH), 8.56 (d, IH, J = 4.3 Hz), 7.91-7.80 (m, 3H), 7.58-7.56 (m, IH), 7.46-7.21 (m,
4H), 6.81-6.78 (m, IH), 5.16 (s, 2H), 2.37 (s, 3H), 1.36 (s, 9H); MS (ESI) m/z 419 [M
+ H]+. Anal, calc'd for C25H26N2O4 « 0.4 H2O: C, 70.53; H, 6.35; N, 6.58. Found: C,
70.87; H, 6.28; N, 6.59.
Example X-3: 4-Acetoxy-3-t-butyl-N-[3-(isoquinolin-4-ylmethoxy)phenyl]-benz- amide
Figure imgf000178_0001
X-3 Example X-3 was prepared from 3-(isoquinolin-4-ylmethoxy)aniline, prepared from 4- chloromethylisoquinoline hydrochloride, K-lc, and 3-hydroxyaniline as described in Example X-1, step (a), and 4-acetoxy-3-t-butylbenzoic acid, W-la, according to the procedure described in Example W-l, step (c): mp 83-86 °C; HPLC Rt = 15.6 min.; TLC R = 0.3 (1% methanol/ dichloromethane); 1H ΝMR (300 MHz, DMSO-d6) δ 10.26 (s, IH), 9.37 (s, IH), 8.67 (s, IH), 8.21 (d, IH, J = 7.9 Hz), 8.14 (d, IH, J = 8.8 Hz), 7.91-7.73 (m, 4H), 6.60 (t, IH, J = 2.2 Hz), 7.40-7.37 (m, IH), 7.30 (t, IH, J = 8.1 Hz), 7.22 (d, IH, J = 8.3 Hz), 6.90 (dd, IH, J = 7.6, 2.2 Hz), 5.56 (s, 2H), 2.36 (s, 3H), 1.36 (s, 9H); MS (ESI) m/z 469 [M + H]+. Anal, calc'd for C29H28Ν2O4 • 0.2 H2O: C, 73.77; H, 6.06; N, 5.93. Found: C, 73.46; H, 6.38; N, 5.82. Example X-4: 3-^-Butyl-4-hydroxy-N-[3-(pyridin-3-ylmethoxy)-phenyl]-benz- amide
Figure imgf000178_0002
X-4 Example X-4 was prepared from 4-acetoxy-3-t-butyl-N-[3-(pyridin-3- ylmethoxy)phenyl] -benzamide, X-2, in a manner similar to that described in Example W-l, step (d): mp 104-107 °C; HPLC Rt = 13.6 min; TLC R = 0.5 (5% methanol/dichloromethane); 1H ΝMR (300 MHz, DMSO- ) δ 10.07 (s, IH), 9.96 (s, IH), 8.69 (s, IH), 8.56 (d, IH, J = 4.0 Hz), 7.90 (d, IH, J = 7.9 Hz), 7.74-7.67 (m, 2H), 7.57 (s, IH), 7.47-7.42 (m, IH), 7.35-7.33 (m, IH), 7.24 (t, IH, J = 8.0 Hz), 6.87 (d, IH, J = 8.3 Hz), 6.77-6.74 (m, IH), 5.15 (s, 2H), 1.40 (s, 9H); 13C ΝMR (75 MHz, DMSO- ) δ 166.1, 159.5, 158.6, 149.5, 149.4, 141.2, 136.0, 135.4, 133.0, 130.0, 127.2, 127.1, 125.4, 124.0, 115.9, 113.3, 109.9, 107.2, 67.2, 34.5, 29.5; MS (ESI) m/z 375 [M - H]\
Anal, calc'd for C23H24Ν2O3 • 0.5 MTBE: C, 72.83; H, 7.19; N, 6.66. Found: C,
72.61; H, 7.12; N, 6.66.
Example X-5: 3-t-Butyl-4-hydroxy-N-[3-(isoquinolin-4-yImethoxy)-phenyl]- benzamide
Figure imgf000179_0001
X-5 Example X-5 was prepared from 4-acetoxy-3-t-butyl-N-[3-(isoquinolin-4- ylmethoxy)phenyl] -benzamide, X-3, in a manner similar to that described in Example W-l, step (d): HPLC Rf = 14.8 min; TLC R/= 0.4 (4% methanol/dichloromethane); 1H ΝMR (300 MHz, DMSO-d6) δ 10.09 (s, IH), 9.97 (s, IH), 9.34 (s, IH), 8.65 (s, IH), 8.20 (d, IH, J = 8.2 Hz), 8.13 (d, IH, I = 7.9 Hz), 7.90-8.86 (m, IH), 7.78-7.59 (m, 4H), 7.38-7.35 (m, IH), 7.26 (t, IH, J = 8.0 Hz), 6.85 (d, 2H, J = 8.6 Hz), 5.54 (s, 2H), 1.38 (s, 9H); HRMS (FAB) calcd for C27H26Ν2O3 [M+H]+ 427.2022, found 427.2020. Example Y-l: l-[3-(pyridin-3-ylmethoxy)phenylcarbamoyl]pyrrolidine
Figure imgf000180_0001
A solution of 100 mg (0.50 mmol) of 3-(pyridin-3-ylmethoxy)aniline, X-2a, and 0.076 mL (0.55 mmol) of triethylamine in 2 mL of dichloromethane was added dropwise to a solution of triphosgene (54 mg, 0.18 mmol) in 2 mL of dichloromethane. After 20 min, a solution of pyrrolidine (0.042 mL) and triethylamine (0.076 mL) in 2 mL of dichloromethane was added to the reaction mixture. After 2 h, the reaction was partitioned between dichloromethane and 5% aq. sodium bicarbonate. The organic layer was washed with water and brine, dried over MgSO and concentrated. The residue was purified by radial chromatography with a gradient of 0 to 2% methanol in 1:1 ethyl acetatexyclohexane to give 81 mg (55%) of l-[3-(pyridin-3-ylmethoxy)- phenylcarbamoyl]pyrrolidine, Y-1, as a white solid: mp 138-140 °C; HPLC Rt = 9.7 min.; TLC R = 0.3 (5% methanol/dichloromethane); 1H NMR (300 MHz, DMSO-d6) δ 8.66 (d, IH, J = 1.7 Hz), 8.54 (dd, IH, J = 4.7, 1.5 Hz), 8.08 (s, IH), 7.88-7.85 (m, IH), 7.45-7.41 (m, IH), 7.35-7.34 (m, IH), 7.16-7.09 (m, 2H), 6.61-6.58 (m, IH), 5.09 (s, 2H), 3.40-3.31 (m, 4H), 1.87-1.83 (m, 4H); 13C NMR (75 MHz, DMSO- 6) δ 158.5, 154.1, 149.4, 149.3, 142.3, 135.9, 133.1, 129.4, 123.9, 112.4, 108.0, 106.3, 67.1, 46.0, 25.4; MS (ESI) m/z 298 [M + H]+. Anal, calc'd for C17H19N3O2: C, 68.67; H, 6.44; N, 14.13. Found: C, 68.41; H, 6.50; N, 13.89. Example Y-2: 4-[3-(pyridin-3-ylmethoxy)phenylcarbamoyl]morpholine
Figure imgf000180_0002
Example Y-2 was prepared in a manner similar to that described in Example Y-1, except that morpholine was used in place of pyrrolidine: mp 58-62 °C; HPLC Rt = 8.7 min.; TLC R = 0.3 (5% methanol/methylene chloride); 1H NMR (300 MHz, DMSO- d6) δ 8.96 (s, IH), 8.84 (d, IH, J = 5.3 Hz), 8.63 (s, IH), 8.50 (d, IH, J = 7.8 Hz), 8.00- 7.95 (m, IH), 7.36 (s, IH), 7.16 (t, IH, J= 8.1 Hz), 7.07 (d, IH, J= 7.9 Hz), 6.65-6.63 (m, IH), 5.26 (s, 2H), 3.60 (t, 4H, J = 4.5 Hz), 3.42 (t, 4H, J = 4.5 Hz); 13C NMR (75 MHz, DMSO- s) δ 157.7, 155.0, 143.8, 141.9, 141.1, 136.9, 129.2, 126.8, 112.6, 108.0, 106.2, 66.0, 65.4, 44.2; MS (ESI) m/z 314 [M + H]+. Anal, calc'd for C17H19N3O3 • HCI • 0.3 H2O: C, 57.48; H, 5.85; CI, 9.98; N, 11.83. Found: C, 57.05; H, 5.83; CI, 9.99; N, 11.50.
Example Z-l: 3-[{6-Methoxy-7-(2-methoxyethoxy)cinnoIin-4-yl}suIfanyImethyl]- N-phenyl-benzamide
Figure imgf000181_0001
(a) To a solution of 0.30 g (1.33 mmol) of 3-(chloromethyl)-Ν-phenylbenzamide, Z- la, which prepared in a manner similar to that described in Example A-1, step (a), in 6 mL of ethanol was added 0.20 g (2.65 mmol) of thiourea, and the mixture was heated to 80 °C. After 3 h, 1.0 mL (3 mmol) of 2N aq. sodium hydroxide was added, and heating at 80 °C was continued. After an additional 2.5 h, the reaction was cooled to room temperature and 10 mL of water was added. The mixture was extracted with ethyl acetate, and the aqueous layer was neutralized with IN aq. HCI and extracted again with ethyl acetate. The combined organic layers were washed with water and with brine, dried over sodium sulfate, and concentrated. The residue was purified by chromatography on silica gel, eluting with a gradient of 15% to 30% ethyl acetate in hexane, to provide 174 mg of 3-(mercaptomethyl)-N-phenylbenzamide, Z-lb: 1H NMR (300 MHz, CDC13) δ 7.85 (s, 2H), 7.75 (m, IH), 7.67 (m, 2H), 7.53 (m, IH), 7.40, (m, 3H), 7.17 (m, IH), 3.80 (d, 2H), 1.83 (t, IH). (b) To a solution of 50 mg (0.186 mmol) of 4-chloro-6-methoxy-7-(2- methoxyethoxy)cinnoline, Z-lc, (PCT application WO 97/34876, ρ.51) and 42.5 mg (0.189 mmol) of 3-(mercaptomethyl)-N-phenylbenzamide, Z-lb, in 1.2 mL of isopropanol was added 12.3 mg of potassium hydroxide in 1.2 mL of ethanol. The mixture was heated to 40 °C for 45 min, then cooled to room temperature. The precipitate was collected by filtration and air-dried to give 44.7 mg (47%) of 3-[{6- methoxy-7-(2-methoxyethoxy)cinnolin-4-yl } sulfanylmethyl]-N-phenyl-benzamide, Z- 1: 1H ΝMR (300 MHz, DMSO- ) δlθ.29 (s, IH), 9.19 (s, IH), 8.10 (s, IH), 7.89 (m, IH), 7.76 (m, 4H), 7.54 (m, IH), 7.38 (m, 2H), 7.09 (m, 2H), 4.72 (s, 2H), 4.38 (m, 2H), 3.98 (s, 3H), 3.77 (m, 2H), 3.32 (s, 3H). MSESI (+) : M+H+ 476, M+Νa+ 498, M+K+ 514.
Example AA-1: 3-[2-(6-Acetylamino-pyridin-3-yl)-ethyl]-N-(4-piperazin-l-yl-3- trifluoromethyIphenyI)-benzamide dihydrochloride
Figure imgf000183_0001
AA-1d, R = Nθ2 J H2- Pd/C AA-1e, R = NH2
Figure imgf000183_0002
EDCI, CH2CI2-EtOAC
Figure imgf000183_0003
H2 (45 psi) - Pd/C AcOH - THF - MeOH
Figure imgf000183_0004
(a) To a solution of 5-bromo-ρyridin-2-ylamine (Aldrich, 2.0 g, 11.6 mmol, 1.0 eq) in tetrahydrofuran (100 mL) was added acetic anhydride (3.0 mL, 31.8 mmol, 2.7 eq) and triethylamine (1.8 mL, 12.8 mmol, 1.1 eq). After 3 days, the solvent was removed and the crude reaction mixture was dissolved in ethyl acetate and sequentially washed with aqueous 5% sodium bicarbonate and brine. The crude product was dried over magnesium sulfate to give N-(5-bromo-pyridin-2-yl)-acetamide, AA-la, as a white solid (2.5 g, 100%): HPLC Rt 8.4 min.; TLC Rf 0.7 (2% methanol-dichloromethane); 'H NMR (DMSO- 6, 300 MHz) δ 10.62 (s, IH), 8.42 (dd, IH, J = 2.5, 0.7 Hz), 8.06 (d, IH, J = 9.0 Hz), 7.98 (dd, IH, J = 9.0, 2.4 Hz), 2.09 (s, 3H); 13C NMR (DMSO-d6, 75 MHz) δ 169.8, 151.4, 148.8, 140.8, 115.3, 113.5, 24.2; MS m/z 215/217 (M + H)+.
(b) To a solution of N-(5-bromo-pyridin-2-yl)-acetamide, AA-la, (2.2 g, 10.2 mmol,
1.0 eq) in degassed N,N-dimethylformamide (100 mL) was added diisopropylethylamine (3.6 mL, 20.4 mmol, 2.0 eq), copper(I) iodide (155 mg, 0.82 mmol, 0.08 eq), dichlorobis(triphenylphosphine)palladium(II) (286 mg, 0.41 mmol, 0.04 eq) and triethyl-ethynyl-silane (Aldrich, 3.7 mL, 20.4 mmol, 2.0 eq). The resultant red solution was warmed to 115 °C for 2 days. The crude reaction mixture was poured into water and extracted with methyl-tert-butyl ether/ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and purified over silica, which was eluted with 10% ethyl acetate-cyclohexane, to give N-(5- triethylsilanylethynyl-pyridin-2-yl)-acetamide, AA-lb, as a beige solid (1.2 g, 44%): HPLC Rt 17.8 min.; TLC Rf 0.5 (20% ethyl acetate-cyclohexane); Η NMR (DMSO- 6, 300 MHz) δ 10.69 (s, IH), 8.40 (d, IH, J = 1.7 Hz), 8.08 (d, IH, J = 8.6 Hz), 7.84 (dd, IH, J = 8.7, 2.3 Hz), 2.10 (s, 3H), 1.01 (t, 6H, J = 7.8 Hz), 0.68 (q, 9H, J = 7.8 Hz); MS (ESI) m/z 275 (M + H)+.
(c) To a solution of N-(5-triethylsilanylethynyl-pyridin-2-yl)-acetamide, AA-lb, (1.0 g, 3.6 mmol, 1.0 eq) in tetrahydrofuran (40 mL) was added a solution of tetrabutylammonium fluoride (4.0 mL, 1.0 M, 4.0 mmol, 1.1 eq). The resultant amber solution was stirred at room temperature for 18 h. The solvent was removed under reduced pressure and the crude reaction mixture (1.1 g, tan solid) was dissolved in ethyl acetate and passed through a silica plug, which was eluted with ethyl acetate. The resultant yellow solid (1.0 g) was washed with 10% MTBE-cyclohexane to give N-(5-ethynyl-pyridin-2-yl)-acetamide, AA-lc, as a tan solid (491 mg, 84%): HPLC Rt
7.1 min.; TLC R, 0.5 (30% ethyl acetate-cyclohexane); Η NMR (DMSO-d6, 300 MHz) δ 10.65 (s, IH), 8.41 (d, IH, J = 1.6 Hz), 8.08 (d, IH, I = 8.7 Hz), 7.86 (dd, IH, J = 8.6, 2.2 Hz), 4.29 (s, IH), 2.10 (s, 3H); 13C NMR (DMSO-d6, 75 MHz) δ 169.5, 151.6, 150.8, 141.0, 113.6, 112.7, 82.6, 80.5, 23.9; MS (EST) m/z 161 (M + H)+.
(d) To a solution of 2-chloro-5-nitrobenzotrifluoride (Lancaster, 16.5 mL, 112 mmol, 1.0 eq) and piperazine-1 -carboxylic acid tert-butyl ester (Aldrich, 2.5 g, 134 mmol, 1.2 eq) in N,N-dimethylformamide (225 mL) was added potassium carbonate (46.3 g, 336 mmol, 3.0 eq). The resultant red solution was warmed to 90 °C for 24 h. The crude product was poured into ice water (1.7 L) and extracted with ethyl acetate (3 x 300 mL). The combined organic extracts were diluted with methyl-tert-butyl ether (1.0 L) and sequentially washed with water and brine. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure to give 4-(nitro- trifluoromethyl-phenyl)-piperazine-l -carboxylic acid tert-butyl ester, AA-ld, as an orange solid (43.6 g, 104%): HPLC Rt 17.0 min.; TLC Rf 0.5 (20% ethyl acetate- cyclohexane); 'H NMR (DMSO-d6, 300 MHz) δ 8.46-8.40 (m, 2H), 7.62 (d, IH, J = 8.9 Hz), 3.48 (t, 4H, J = 4.8 Hz), 3.06 (t, 4H, J = 5.0 Hz), 1.43 (s, 9H); MS (ESI) m/z 276 (M + H - BOC)+.
(e) To a solution of 4-(nitro-trifluoromethyl-phenyl)-piperazine-l -carboxylic acid tert- butyl ester, AA-ld, (43.6 g, 116 mmol) and 10% palladium on carbon (4.3 g) in ethyl acetate (1.2 L) was added hydrogen (1 atm). The resultant slurry was stirred for 18 h, filtered through celite and concentrated under reduced pressure to give 4-[4-(t- butoxycarbonyl)piperazin-lyl]-3-trifluoromethylaniline, AA-le, as a yellow solid (40 g, 92%): HPLC Rt 14.8 min.; TLC Rf 0.1 (10% ethyl acetate-cyclohexane); Η NMR (DMSO- 6, 300 MHz) δ 7.22 (d, IH, J = 8.5 Hz), 6.82 (d, IH, J = 2.6 Hz), 6.75 (dd, IH, J = 8.5, 2.5 Hz), 5.37 (s, 2H), 3.37 (br. s, 4H), 2.66 (t, 4H, J = 4.8 Hz), 1.41 (s, 9H); MS (ESI) m/z 346 (M + H)+. (f) To a solution of 4-[4-(t-butoxycarbonyl)piperazin-lyl]-3-trifluoromethylaniline, AA-le, (10.0 g, 29.0 mmol, 1.0 eq) and 3-iodobenzoic acid (Aldrich, 8.6 g, 34.8 mmol, 1.2 eq) in ethyl acetate (300 mL) and dichloromethane (300 mL) was added 1- (3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (6.7 g, 34.8 mmol, 1.2 eq). The resultant brown solution was stirred for 18 h. The solvent was removed under reduced pressure and the crude product was purified over silica, which was eluted with 10-20% ethyl acetate-cyclohexane, to give 4-({[l-(3-iodo-phenyl)- methanoyl] -amino } -trifluoromethyl-phenyl)-piperazine- 1 -carboxylic acid tert-butyl ester, AA-lf, as a beige solid (10.3 g, 62%): HPLC R, 19.7 min.; TLC Rf 0.5 (30% ethyl acetate-cyclohexane); Η NMR (DMSO-d6, 300 MHz) δ 10.53 (s, IH), 8.32 (s, IH), 8.14 (d, IH, J = 2.3 Hz), 8.04 (dd, IH, I = 8.7, 2.3 Hz), 7.99-7.96 (m, 2H), 7.60 (d, IH, J = 8.8 Hz), 7.36 (t, IH, J = 7.8 Hz), 3.44 (br. s, 4H), 2.51 (t, 4H, J = 4.6 Hz), 1.43 (s, 9H); MS (ESI) m/z 576 (M + H)+.
(g) 4- [( { 1 - [3 -(6- Acetylamino-pyridin-3 -ylethynyl)-phenyl] -methanoyl } -amino)- trifluoromethyl-phenyl] -piper azine-1 -carboxylic acid tert-butyl ester, AA-lg, was prepared in the manner similar to that described in example S-l, step (c) for ethyl 3- isoquinolin-4-ylethynyl-benzoate, S-lc, except that 4-({ [l-(3-iodo-phenyl)- methanoyl] -amino } -trifluoromethyl-phenyl)-ρiperazine- 1 -carboxylic acid tert-butyl ester, AA-lf, was used in place of 3-iodobenzoate and N-(5-ethynyl-pyridin-2-yl)- acetamide, AA-lc, was used in place of 4-ethynyl-isoquinoline, S-lb: HPLC Rt 18.1 min.; TLC Rf 0.5 (2% methanol-dichloromethane); Η NMR (DMSO-d6, 300 MHz) δ 10.71 (s, IH), 10.55 (s, IH), 8.17 (s, 2H), 8.14 (s, IH), 8.07 (dd, IH, I = 8.6, 2.4 Hz), 8.01-7.96 (m, 2H), 7.80-7.78 (m, IH), 7.65-7.58 (m, 2H), 3.44 (br. s, 4H), 2.80 (t, 4H, I = 4.8 Hz), 2.13 (s, 3H), 1.44 (s, 9H); MS (ESI) m/z 608 (M + H)+. (h) 4-{ [(l-{ 3-[2-(6-Acetylamino-pyridin-3-yl)-ethyl]-phenyl}-methanoyl)-amino]- trifluoromethyl-phenyl}-piperaζine-l -carboxylic acid tert-butyl ester, AA-lh, was prepared in a manner similar to that described in example S-l, step (d) for 3-(2- isoquinolin-4yl-ethyl)-benzoic acid ethyl ester, S-ld, except 4-[({ l-[3-(6-acetylamino- pyridin-3-ylethynyl)-phenyl]-methanoyl}-amino)-trifluoromethyl-phenyl]-piperazine- 1 -carboxylic acid tert-butyl ester, AA-lg, was used instead of ethyl 3-(isoquinolin-4- ylethynyl)benzoate and the reduction was done at 45 psi of hydrogen in acetic acid- methanol-tetrahydrofuran: HPLC Rt 17.1 min.; TLC Rf 0.6 (4% methanol- dichloromethane); Η NMR (DMSO- 6, 300 MHz) δ 10.40 (s, IH), 10.35 (s, IH), 8.16- 8.14 (m, 2H), 8.05 (dd, IH, J = 8.8, 2.4 Hz), 7.98 (d, IH, J = 8.3 Hz), 7.84 (s, IH), 7.81-7.77 (m, IH), 7.64 (dd, IH, J = 8.6, 2.4 Hz), 7.58 (d, IH, J = 8.8 Hz), 7.44 (d, IH, I = 4.8 Hz), 3.44 (br. s, 4H), 2.98-2.91 (m, 4H), 2.80 (t, 4H, J = 4.6 Hz), 2.06 (s, 3H), 1.43 (s, 9H); MS (ESI) m/z 612 (M + H)+. (i) 3-[2-(6-Acetylamino-pyridin-3-yl)-ethyl]-N-(4-piperazin-l-yl-3-trifluoromethyl- phenyl)-benzamide dihydrochloride, AA-1, was prepared in a manner similar to that described in example R-13, step (b) for 4-fluoro-N-[4-(piperazin-l-yl)-3- trifluoromethylphenyl]-3-(pyridin-3-yl)methoxybenzamide, R-13, except 4-{[(l-{3-[2- (6-acetylamino-pyridin-3-yl)-ethyl]-phenyl}-methanoyl)-amino]-trifluoromethyl- phenyl}-piperazine-l -carboxylic acid tert-butyl ester, AA-lh, was used in place of 4- fluoro-N-[4-{t-butoxycarbonyl)piperazin-l-yl}-3-trifluoromethylphenyl]-3-(pyridin-3- yl)methoxybenzamide, R-13a, and the deprotection was done with HCI in ethanol instead of trifluoroacetic acid in methyiene chloride: HPLC Rt 11.7 min.; TLC Rf 0.4 (15% methanol-chloroform w/ 0.1% ammonium hydroxide); Η NMR (DMSO-d6, 300 MHz) δ 10.97 (s, IH), 10.52 (s, IH), 9.23 (m, 2H), 8.22-8.12 (m, 3H), 7.91-7.82 (m, 4H), 7.56 (d, IH, J = 8.8 Hz), 7.44 (d, 2H, J = 4.7 Hz), 3.17 (br. s, 4H), 3.07 (br. s, 4H), 2.97 (s, 4H), 2.12 (s, 3H); MS (ESI) m/z 512 (M + H)+. Anal, calcd for C27H28F3N5O2 x 2.0 HCI x 1.2 H2O: C, 53.50; H, 5.39; N, 11.56; CI, 11.70. Found: C, 53.44; H, 5.54; N, 11.19; CI, 11.62.
Example AA-2: 3-[2-(6-Amino-pyridin-3-yI)-ethyl]-N-(4-piperazin-l-yI-3- trifluoromethyl-phenyl)-benzamide dihydrochloride
Figure imgf000187_0001
AA-2a, R H == B DOUC 1
HCI - EtOH AA-2. R l =: H -* — ' (a) To a solution of 4-{[(l-{3-[2-(6-acetylamino-pyridin-3-yl)-ethyl]-phenyl}- methanoyl)-amino]-trifluoromethyl-phenyl}-piperazine-l-carboxylic acid tert-butyl ester, AA-lh, (100 mg, 0.16 mmol, 1.0 eq) in ethanol (3 mL) was added aqueous sodium hydroxide (2.8 mL, 1.0 M, 2.8 mmol, 1.8 eq). The clear solution was heated to 55 °C for 18 hours and poured into a mixture of aqueous 50% saturated sodium bicarbonate and ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, filtered and purified by radial chromatography over silica, which was eluted with 3% methanol-chloroform with 0.1% ammonium hydroxide, to give 4- {[(l-{3- [2-(6-amino-pyridin-3 -yl)-ethyl] -phenyl } -methanoyl)-amino] -trifluoromethyl- phenyl}-piperazine-l -carboxylic acid tert-butyl ester, AA-2a, as a white solid (54 mg, 59%): HPLC Rt 17.0 min.; TLC Rf 0.5 (5% methanol-chloroform w/ 0.1% ammonium hydroxide); Η NMR (DMSO-d6, 300 MHz) δ 10.39 (s, IH), 8.16 (d, IH, J = 2.4 Hz), 8.05 (dd, IH, J = 8.6, 2.2 Hz), 7.82-7.76 (m, 2H), 7.74 (dd, IH, J = 2.0 Hz), 7.57 (d, IH, J = 8.8 Hz), 7.44-7.42 (m, 2H), 7.27 (dd, IH, J = 8.4, 2.4 Hz), 6.38 (d, IH, J = 8.4 Hz), 5.63 (s, 2H), 3.44 (br. s, 4H), 2.92-2.72 (s, 8H), 1.43 (s, 9H); MS (ESI) m/z 510 (M + H)+. (b) 3-[2-(6-Amino-pyridin-3-yl)-ethyl]-N-(4-piperazin-l-yl-3-trifluoromethyl-phenyl)- benzamide dihydrochloride, A A-2, was prepared in a manner similar to that described in example AA-1, step (i), except 4-{[(l-{3-[2-(6-amino-pyridin-3-yl)-ethyl]-phenyl}- methanoyl)-amino] -trifluoromethyl-phenyl } -piperazine- 1 -carboxylic acid tert-butyl ester, AA-2a, was used in place of 4-{[(l-{3-[2-(6-acetylamino-pyridin-3-yl)-ethyl]- phenyl } -methanoyl)-amino] -trifluoromethyl-phenyl } -piperazine- 1 -carboxylic acid tert-butyl ester, AA-lh: HPLC Rt 11.2 min.; Η NMR (DMSO-d6, 300 MHz) δ 13.89 (s, IH), 10.59 (s, IH), 9.33 (s, 2H), 8.23 (d, IH, J = 2.2 Hz), 8.15-8.13 (m, IH), 7.95- 7.79 (m, 6H), 7.54 (d, IH, J = 8.7 Hz), 7.45-7.43 (m, 2H), 6.96 (d, IH, J = 9.0 Hz), 3.17 (s, 4H), 3.08 (s, 4H), 2.94-2.93 (m, 2H), 2.88-2.87 (m, 2H); MS (ESI) m/z 470 (M + H)+. Anal, calcd for C25H26F3N5O x 2.0 HCI: C, 55.36; H, 5.20; N, 12.91; CI, 13.07. Found: C, 55.18; H, 5.16; N, 12.65; CI, 13.28.
Example BB-1: 3-[2-(3H-Imidazo[4,5-b]pyridin-6-yl)-ethyl]-N-(4-piperazin-l-yl- 3-trifluoromethyl-phenyl)-benzamide dihydrochloride
Cul
Figure imgf000189_0001
BB-1a, R = N02 BB-1b, R = NH2
Figure imgf000189_0002
Figure imgf000189_0003
BB 1--11 gg,, RR == BBOOCC —- 1
HCI - EtOH BB :--1, R = H -< — '
(a) To a solution of 5-biOmo-3-nitro-pyridin-2-ylamine, BB-la, (Lancaster, 8.9 g, 40.8 mmol, 1.0 eq) in ethanol (450 mL) was added tin(II) chloride dihydrate (32.3 g, 143 mmol, 3.5 eq). The resultant yellow slurry was warmed to 60 °C for 4 h. The solvent was removed under reduce pressure and the crude reaction mixture was treated with 10% ammonium hydroxide and extracted with ethyl acetate. The combined organic extracts were dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give a black solid (7.5 g). The crude product was purified over silica (flash), which was eluted with 2-7% methanol-ethyl acetate, to give 5-bromo-pyridine- 2,3-diamine, BB-lb, as a grey solid (7.0 g, 91%): HPLC R, 5.5 min.; TLC Rf 0.5 (1% methanol-ethyl acetate); Η NMR (DMSO-^6, 300 MHz) δ 7.28 (d, IH, J = 2.0 Hz), 6.80 (d, IH, J = 2.0 Hz), 5.60 (s, 2H), 4.99 (s, 2H); 13C NMR (DMSO-d6, 75 MHz) δ 147.4, 134.0, 131.9, 119.1, 106.4; MS m/z 188/190 (M + H)+.
(b) A round bottom flask was charged with 5-bromo-pyridine-2,3-diamine, BB-lb, (4.6 g, 24.5 mmol) and triethylformate (50 mL). The resultant purple slurry was warmed to 130 °C for 18 h. The solvent was removed under reduced pressure at 85 °C and the resultant brown oil was dissolved in ethanol (70 mL) and treated with concentrated HCI (30 mL). The resultant brown slurry was warmed to 90 °C for 1 hour, concentrated under reduced pressure and treated with water (100 mL). The pH was adjusted to 9 with concentrated ammonium hydroxide and the aqueous layer was extracted with 10% isopropyl alcohol-ethyl acetate (5 x 100 mL). The combined organic layers were washed with aqueous 5% sodium bicarbonate, brine, dried over magnesium sulfate and filtered to give 6-bromo-3H-imidazo[4,5-b]pyridine, BB-lc, as a brown solid (4.5 g, 94%): HPLC Rt 6.1 min.; Η NMR (DMSO-d6, 300 MHz) δ 13.35, 12.93 (2 br. s, IH), 8.56 (s, IH), 8.50 (d, IH, J = 1.6 Hz), 8.37 (br. s, IH); MS (ESI) m/z 196/198 (M - H)\ Anal, calcd for C6H4BrN3: C, 36.39; H, 2.04; N, 21.22; Br, 40.35. Found: C, 36.21; H, 2.09; N, 21.11; Br, 40.28.
(c) 6-Triethylsilanylethynyl-3H-imidazo[4,5-b]pyridine, BB-ld, was prepared in the manner similar to that described in example AA-1, step (b), except 6-bromo-3H- imidazo[4,5-b]pyridine, BB-lc, was used in place of N-(5-bromo-pyridin-2-yl)- acetamide, AA-la: HPLC Rt 14.8 min.; TLC Rf 0.4 (5% methanol-methylene chloride); Η NMR (DMSO- 6, 300 MHz) δ 13.34, 12.88 (2 br. s, IH), 8.53 (s, IH), 8.44 (s, IH), 8.11 (br. s, IH), 1.03 (t, 9H, J = 7.8 Hz), 0.70 (q, 6H, J = 7.8 Hz); MS (ESI) m/z 258 (M + H)+.
(d) To a solution of 6-triethylsilanylethynyl-3H-imidazo[4,5-b]pyridine, BB-ld, (1.4 g, 5.4 mmol, 1.0 eq) in methanol (30 mL) was added aqueous sodium hydroxide (2.2 mL,
10 M, 22 mmol, 4.0 eq). The resultant brown solution was warmed to 40 °C for 24 h. The reaction mixture was poured into aqueous 5% sodium bicarbonate (200 mL) and the aqueous layer was extracted with 10% isopropyl alcohol-chloroform. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a yellow solid (1.3 g). The crade product was washed with methyl-tert-butyl ether/cyclohexane (2:1) to give 6-ethynyl-3H-imidazo[4,5- bjpyridine, BB-le, as a yellow solid (750 mg, 97%): HPLC Rt 5.1 min.; TLC Rf 0.5 (5% methanol-chloroform w/ 0.1% ammonium hydroxide); Η NMR (DMSO- 6, 300 MHz) δ 13.16 (br. s, IH), 8.52 (s, IH), 8.46 (d, IH, J = 1.7 Hz), 8.14 (s, IH), 4.26 (s, IH); MS (ESI) m/z 144 (M + H)+. (e) 4-[({ l-[3-(3H-Imidazo[4,5-b]pyridin-6-ylethynyl)-phenyl]-methanoyl}-amino)- trifluoromethyl-phenyl] -piperazine- 1 -carboxylic acid tert-butyl ester, BB-lf, was prepared in the manner similar to that described in example AA-1, step (g), except 6- ethynyl-3H-imidazo[4,5-b]pyridine, BB-le, was used instead of N-(5-ethynyl-pyridin- 2-yl)-acetamide, AA-lc: HPLC Rt 16.1 min.; TLC Rf 0.5 (5% methanol-chloroform w/ 0.1% ammonium hydroxide); Η NMR (DMSO-rf6, 300 MHz) δ 13.20 (br. s, IH), 10.57 (s, IH), 8.60 (d, IH, J = 1.5 Hz), 8.56 (s, IH), 8.26-8.18 (m, 3H), 8.08 (dd, IH, J = 8.8, 2.2 Hz), 7.83 (d, IH, J = 7.7 Hz), 7.80 (d, IH, J = 8.0 Hz), 7.66-7.59 (m, 2H), 3.44 (br. s, 4H), 2.81 (t, 4H, J = 4.6 Hz), 1.44 (s, 9H); MS (ESI) m/z 591 (M + H)+.
(f) 4- { [(1 - { 3-[2-(3H-Imidazo[4,5-b]pyridin-6-yl)-ethyl]-phenyl }-methanoyl)-amino]- trifluoromethyl-phenyl } -piperazine- 1 -carboxylic acid tert-butyl ester, BB -lg, was prepared in the manner similar to that described in example AA-1, step (h), except 4- [({ l-[3-(3H-imidazo[4,5-b]pyridin-6-ylethynyl)-phenyl]-methanoyl}-amino)- trifluoromethyl-phenyl]-piperazine-l -carboxylic acid tert-butyl ester, BB-lf, was used instead of 4- { [( 1 - { 3- [2-(6-acetylamino-pyridin-3 -yl)-ethyl] -phenyl } -methanoyl)- amino]-trifluoromethyl-phenyl} -piperazine- 1 -carboxylic acid tert-butyl ester, AA-lg: HPLC Rt 15.4 min.; Η NMR (DMSO-d6, 300 MHz) δ 12.93, 12.56 (2br. s, IH), 10.40 (s, IH), 8.35 (s, IH), 8.31 (br. s, IH), 8.16 (d, IH, J = 2.4 Hz), 8.05 (dd, IH, J = 8.8, 2.2 Hz), 7.87 (s, IH), 7.80-7.78 (m, 2H), 7.58 (d, IH, J = 8.8 Hz), 7.46-7.41 (m, 2H), 3.44 (br. s, 4H), 3.11-3.03 (m, 4H), 2.80 (t, 4H, J = 4.6 Hz), 1.43 (s, 9H); MS (ESI) m/z 595 (M + H)+.
(g) 3-[2-(3H-lmidazo[4,5-b]pyridin-6-yl)-ethyl]-N-(4-piperazin-l-yl-3-trifluoromethyl- phenyl)-benzamide, BB-1, was prepared in the manner similar to that described in example AA-1, step (i), except 4-{[(l-{3-[2-(3H-imidazo[4,5-b]pyridin-6-yl)-ethyl]- phenyl } -methanoyl)-amino] -trifluoromethyl-phenyl } -piperazine- 1 -carboxylic acid tert- butyl ester, BB-lg, was used in place of 4-{ [(l-{3-[2-(6-acetylamino-pyridin-3-yl)- ethyl] -phenyl } -methanoyl)-amino] -trifluoromethyl-phenyl } -piperazine- 1 -carboxylic acid tert-butyl ester, AA-lh: HPLC Rt 10.0 min.; Η NMR (DMSO-d6, 300 MHz) δ 10.57 (s, IH), 9.28 (br. s, 3H), 8.54 (s, IH), 8.28-8.22 (m, 2H), 8.14 (d, IH, J = 8.8 Hz), 7.95 (s, IH), 7.83 (d, IH, J = 6.9 Hz), 7.54 (d, IH, J = 8.9 Hz), 7.47-7.44 (m, 2H), 3.18 (br. s, 6H), 3.07 (br. s, 6H); MS (ESI) m/z 495 (M + H)+. Anal, calcd for
C26H25F3N6O x 2.0 HCI x 1.0 H2O x 0.3 CH2C12: C, 51.70; H, 4.88; N, 13.76; CI, 15.09. Found: C, 51.86; H, 4.95; N, 13.32; CI, 14.98.
Example CC-1: 5-{2-[3-(Piperazin-l-yl-trifluoromethyl-phenylcarbamoyl)- phenyl] -ethyl}-nicotinamide dihydrochloride
Figure imgf000193_0001
DIEA, DMF Ma,R = Si(Et)3— j
TBAF, THF Mb, R = H -*— " '
Figure imgf000193_0002
2. (NH2)2CH2-2HCI TEA, dioxane
Figure imgf000193_0003
CC-1 IfT,, R II == B DOC 1
HCI - EtOH
CC 1,R = H -* ' (a) 5-Triethylsilanylethynyl-nicotinic acid methyl ester, CC-la, was prepared in the manner similar to that described in example AA-1, step (b), except 5-bromo-nicotinic acid methyl ester was used in place of N-(5-bromo-pyridin-2-yl)-acetamide, AA-la: HPLC Rt 20.1 min.; TLC Rf 0.4 (20% ethyl acetate-cyclohexane); Η NMR (DMSO-d6, 300 MHz) δ 9.04 (d, IH, I = 2.0 Hz), 8.88 (d, IH, J = 2.0 Hz), 8.25 (t, IH, J = 2.1 Hz), 3.90 (s, 3H), 1.02 (t, 9H, J = 8.1 Hz), 0.70 (q, 6H, J = 7.6 Hz).
(b) 5-Ethynyl-nicotinic acid methyl ester, CC-lb, was prepared in the manner similar to that described in example AA-1, step (c), except 5-triethylsilanylethynyl-nicotinic acid methyl ester, CC-la, was used in place of N-(5-triethylsilanylethynyl-pyridin-2- yl)-acetamide, AA-lb: HPLC Rt 9.3 min.; TLC Rf 0.2 (20% ethyl acetate- cyclohexane); Η NMR (DMSO-d6, 300 MHz) δ 9.06 (s, IH), 8.91 (s, IH), 8.30 (s, IH), 4.58 (s, IH), 3.90 (s, 3H).
(c) 4-({2-[3-(5-Methoxycarbonyl-pyridin-3-ylethynyl)-phenyl]-2-oxo-ethyl}- trifluoromethyl-phenyl)-piperazine-l -carboxylic acid tert-butyl ester, CC-lc, was prepared in the manner similar to that described in example AA-1, step (g), except 5- ethynyl-nicotinic acid methyl ester, CC-lb, was used instead of N-(5-ethynyl-pyridin- 2-yl)-acetamide, AA-lc: HPLC Rt 19.5 min.; TLC Rf 0.3 (30% ethyl acetate- cyclohexane); Η NMR (DMSO-d6, 300 MHz) δ 10.58 (s, IH), 9.10 (d, IH, J = 2.0 Hz), 9.04 (d, IH, J = 2.0 Hz), 8.45 (t, IH, J = 2.1 Hz), 8.24 (s, IH), 8.18 (d, IH, J = 2.3 Hz), 8.09-8.03 (m, 2H), 7.86 (d, IH, J = 7.8 Hz), 7.68-7.59 (m, 2H), 3.93 (s, 3H), 3.44 (br. s, 4H), 2.82-2.79 (m, 4H), 1.41 (s, 9H).
(d) To a solution of 4-({2-[3-(5-methoxycarbonyl-pyridin-3-ylethynyl)-phenyl]-2-oxo- ethyl}-trifluoromethyl-phenyl)-piperazine-l -carboxylic acid tert-butyl ester, CC-lc, (846 mg, 1.4 mmol, 1.0 eq) in isopropyl alcohol (90 mL) was added aqueous sodium hydroxide (4.2 mL, 1.0 M, 4.2 mmol, 3.0 eq). The resultant clear solution was warmed to 50 °C for 5 h. The solvent was removed under reduced pressure and the crude product was dissolved in ethyl acetate, which was sequentially washed with aqueous sodium citrate (0.5 M, pH 4.5) and brine. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure to give 4-({2-[3- (5-carboxy-pyridin-3-ylethynyl)-phenyl]-2-oxo-ethyl}-trifluoromethyl-phenyl)- piperazine-1 -carboxylic acid tert-butyl ester, CC-ld, as a white solid (800 mg, 96%): Η NMR (DMSO- 6, 300 MHz) δ 10.59 (s, IH), 9.08 (d, IH, J = 2.0 Hz), 9.00 (d, IH, J = 2.0 Hz), 8.42 (t, IH, J = 2.1 Hz), 8.24 (s, IH), 8.18 (d, IH, J = 2.4 Hz), 8.09-8.02 (m, 2H), 7.88-7.85 (m, IH), 7.68-7.59 ( , 2H), 3.44 (br. s, 4H), 2.81-2.78 (m, 4H), 1.43 (s, 9H). (e) 4-[(2-{3-[2-(5-Carboxy-pyridin-3-yl)-ethyl]-phenyl}-2-oxo-ethyl)-trifluoromethyl- phenyl]-piperazine-l -carboxylic acid tert-butyl ester, CC-le, was prepared in the manner similar to that described in example AA-1, step (h), except 4-({2-[3-(5- carboxy-pyridin-3-ylethynyl)-phenyl]-2-oxo-ethyl}-trifluoromethyl-phenyl)- piperazine-1 -carboxylic acid tert-butyl ester, CC-ld, was used instead of 4-{[(l-{3-[2- (6-acetylamino-pyridin-3 -yl)-ethyl] -phenyl } -methanoyl)-amino] -trifluoromethyl- phenyl } -piperazine- 1 -carboxylic acid tert-butyl ester, AA-lg: HPLC (TFA buffered method) Rt 16.4 min.; TLC Rf 0.3 (3% methanol-dichloromethane w/ 0.1% acetic acid); Η NMR (DMSO-d6, 300 MHz) δ 10.47 (s, IH), 8.89 (s, IH), 8.57 (s, IH), 8.17- 8.15 (m, 2H), 8.08-8.05 (m, IH), 7.88 (s, IH), 7.81-7.79 (m, IH), 7.58 (d, IH, J = 8.8 Hz), 7.46-7.44 (m, 2H), 3.01 (s, 5H), 2.79 (m, 5H), 1.43 (s, 9H); MS (ESI) m/z 591 (M - H)\
(f) To a solution of 4-[(2-{3-[2-(5-carboxy-pyridin-3-yl)-ethyl]-phenyl}-2-oxo-ethyl)- trifluoromethyl-phenyl] -piperazine- 1 -carboxylic acid tert-butyl ester, CC-le, (250 mg, 0.42 mmol, 1.0 eq) in dioxane (9 mL) was added a solution of 1,3- dicyclohexylcarbodiimide (87 mg, 0.42 mmol, 1.0 eq) and N-hydroxysuccinimide (48 mg, 0.42 mmol, 1.0 eq) in dioxane (1 mL). The cloudy reaction mixture was sequentially stirred for 18 h, passed through a teflon filter (0.45 micron pore size), and the solvent removed under reduced pressure to give a white semi-solid (346 mg). To the crude product in dioxane (8 mL) was added triethylamine (0.23 mL, 1.68 mmol, 4.0 eq) and 1,2-diaminomethane dihydrochloride (50 mg, 0.42 mmol, 1.0 eq) in a minimal amount of water. The white slurry was stirred for 4 h at room temperature. The solvent was removed under reduced pressure and the crude product dissolved in ethyl acetate, which was sequentially washed with water and brine. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a yellow solid (360 mg). The crude product was purified by radial chromatography over silica gel, which was eluted with 3-9% methanol- dichloromethane, to give 4-[(2-{3-[2-(5-carbamoyl-pyridin-3-yl)-ethyl]-phenyl}-2- oxo-ethyl)-trifluoromethyl-phenyl] -piperazine- 1 -carboxylic acid tert-butyl ester, CC- lf, as a white solid (150 mg, 60%): HPLC Rt 15.4 min.; TLC Rf 0.5 (4% methanol- dichloromethane); Η NMR (DMSO-d6, 300 MHz) δ 10.45 (s, IH), 8.68 (d, IH, J = 1.8 Hz), 8.56 (d, IH, J = 1.8 Hz), 8.17-8.04 (m, 3H), 7.87-7.79 (m, IH), 7.61-7.58 (m, 2H), 7.47-7.45 (m, 2H), 5.76 (s, 2H), 3.44 (s, 4H), 3.02 (m, 4H), 2.80 (s, 4H), 1.43 (s, 9H); MS (ESI) m/z 598 (M + H)+.
(g) 5-(2- { 3-[2-(Piperazin-l -yl-trifluoromethyl-phenyl)-ethanoyl]-phenyl } -efhyl)- nicotinamide dihydrochloride, CC-1, was prepared in the manner similar to that described in example AA-1, step (i), except 4-[(2-{3-[2-(5-carbamoyl-pyridin-3-yl)- ethyl] -phenyl } -2-oxo-ethyl)-trifluoromethyl-phenyl] -piperazine- 1 -carboxylic acid tert- butyl ester, CC-lf, was used in place of 4-{[(l-{3-[2-(6-acetylamino-pyridin-3-yl)- ethyl] -phenyl } -methanoyl)-amino] -trifluoromethyl-phenyl } -piperazine- 1 -carboxylic acid tert-butyl ester, AA-lh: HPLC Rt 9.7 min.; Η NMR (DMSO~d6, 300 MHz) δ 10.56 (s, IH), 9.13 (br. s, IH), 9.00 (d, IH, J = 2.0 Hz), 8.75 (d, IH, J = 1.9 Hz), 8.49 (s, IH), 8.33 (s, IH), 8.22 (d, IH, J = 2.5 Hz), 8.13 (dd, IH, J = 8.8, 2.2 Hz), 7.91 (s, IH), 7.83-7.79 (m, 2H), 7.56 (d, IH, I = 8.7 Hz), 7.48-7.45 (m, 2H), 3.13 (s, 4H), 3.07 (m, 8H); MS (ESI) m/z 498 (M + H)+. Anal, calcd for C26H26F3N5O2 x 2.0 HCI x 0.5 H2O: C, 53.89; H, 5.04; N, 12.09; CI, 12.24. Found: C, 53.99; H, 5.19; N, 11.46; CI, 11.79.
Example CC-2: 5-{2-[3-(Piperazin-l-yI-trifluoromethyI-phenylcarbamoyl)- phenyl]-ethyl}-nicotinic acid methyl ester dihydrochloride
Figure imgf000196_0001
CC-2 2aa,, RR == BBOOCC- — |
HCI - EtOH CC-22,, R = H ~* — '
(a) To a solution of 4-[(2-{3-[2-(5-carboxy-pyridin-3-yl)-ethyl]-phenyl}-2-oxo-ethyl)- trifluoromethyl-phenyl]-piperazine-l -carboxylic acid tert-butyl ester, CC-le, (100 mg, 0.17 mmol, 1.0 eq.) in methanol (4 mL) and toluene (4 mL) was added a solution of (trimethylsilyl)diazomethane (0.45 mL, 2.0 M, 0.90 mmol, 5.3 eq). The light yellow solution was stirred for 18 h. The solvent was removed under reduced pressure and the crude product was dissolved in ethyl acetate, which was sequentially washed with aqueous 5% sodium bicarbonate and brine. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a clear residue (105 mg). The crude product was purified by radial chromatography over silica gel, which was eluted with 2% methanol-dichloromethane, to give 4-{[(l-{3-[2- (5-methoxycarbonyl-pyridin-3-yl)-ethyl]-phenyl}-methanoyl)-amino]-trifluoromethyl- phenyl} -piperazine- 1 -carboxylic acid tert-butyl ester, CC-2a, as a white solid (74 mg, 71%)): HPLC Rt 18.1 min.; TLC R, 0.6 (3% methanol-dichloromethane w/ 0.1% acetic acid); Η NMR (DMSO-d6, 300 MHz) δ 10.42 (s, IH), 8.92 (d, IH, J = 1.8 Hz), 8.69 (d, IH, I = 2.0 Hz), 8.21 (s, IH), 8.16 (d, IH, J = 2.2 Hz), 8.07-8.04 (m, IH), 7.86 (s, IH), 7.81-7.79 (m, IH), 7.60 (d, IH, J = 8.2 Hz), 7.48-7.45 (m, 2H), 3.88 (s, 3H), 3.44 (br. s, 4H), 3.04 (s, 4H), 2.80 (t, 4H, J = 4.3 Hz), 1.43 (s, 9H); MS (ESI) m/z 613 (M + H)+.
(b) 5- { 2- [3-(Piperazin- 1 -yl-trifluoromethyl-phenylcarbamoyl)-phenyl]-ethyl } - nicotinic acid methyl ester dihydrochloride, CC-2, was prepared in the manner similar to that described in example AA-1, step (i), except, 4-{[(l-{3-[2-(5-methoxycarbonyl- pyridin-3 -yl)-ethyl] -phenyl } -methanoyl)-amino] -trifluoromethyl-phenyl } -piperazine- 1-carboxylic acid tert-butyl ester, CC-2a, was used in place of 4-{[(l-{3-[2-(6- acetylamino-pyridin-3 -yl)-ethyl] -phenyl } -methanoyl)-amino] -trifluoromethyl-phenyl } - piperazine- 1-carboxylic acid tert-butyl ester, AA-lh: HPLC Rt 12.7 min.; Η NMR (DMSO-d6, 300 MHz) δ 10.58 (s, IH), 9.33 (br. s, 2H), 9.00 (s, IH), 8.80 (s, IH), 8.38 (s, IH), 8.22 (s, IH), 8.14 (d, IH, J = 8.4 Hz), 7.92 (s, IH), 7.84-7.82 (m, IH), 7.56 (d, IH, J = 8.6 Hz), 7.48-7.42 (m, 2H), 3.90 (s, 3H), 3.16 (s, 4H), 3.08 (s, 8H); MS (ESI) m/z 513 (M + H)+. Anal, calcd for C27H27F3N4O3 x 2.0 HCI x 0.5 H2O x 0.5 ethyl acetate: C, 54.55; H, 5.37; N, 8.77. Found: C, 54.47; H, 5.45; N, 8.71. Example DD-1: 4-FIuoro-3-[2-(3H-imidazo[4,5-b]pyridin-6-yl)-ethyl]-N-(4- piperazin-l-yl-3«trifluoromethyl-phenyl)-benzamide dihydrochloride
Figure imgf000198_0001
(a) 4-({[l-(4-Fluoro-3-hydroxy-phenyl)-methanoyl]-amino}-trifluoromethyl-phenyl)- piperazine- 1 -carboxylic acid tert-butyl ester, DD-la, was prepared in a similar manner to that described in example M-1, step (e), except 4-({[l-(3-acetoxy-4-fluoro-phenyl)- methanoyl]-amino}-trifluoromethyl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester was used instead of acetic acid 3-(2-methyl-quinolin-6-ylcarbamoyl)-phenyl ester, M-ld: HPLC Rt 16.2 min.; TLC Rf 0.3 (30% ethyl acetate-cyclohexane); Η NMR (DMSO-d6, 300 MHz) δ 10.37 (s, IH), 10.22 (s, IH), 8.14 (d, 2H, J = 2.4 Hz), 8.00 (dd, IH, J = 8.6, 2.0 Hz), 7.58-7.53 (m, 3H), 7.47-7.42 (m, IH), 7.30 (dd, IH, J = 11.0, 8.6 Hz), 3.43 (br. s, 4H), 2.79 (t, 4H, I = 4.8 Hz), 1.42 (s, 9H); MS (ESI) m/z 484 (M + H)+.
(b) To a solution of 4-({[l-(4-fluoro-3-hydroxy-phenyl)-methanoyl]-amino}- trifluoromethyl-phenyl)-piperazine-l -carboxylic acid tert-butyl ester, DD-la, (900 mg, 1.86 mmol, 1.0 eq), in dioxane (40 mL) was added triethylamine (0.90 mL, 6.5 mmol, 3.0 eq) and l,l,l-trifluoro-N-phenyl-N-[(trifluoromethyl)sulfonyl]methanesulfonamide (1.1 g, 3.0 mmol, 1.4 eq). The clear solution was stirred for 18 h. The solvent was removed under reduced pressure and the resultant oil was passed through a silica plug, which was eluted with ethyl acetate to give an amber oil (2.0 g). The crude product was purified by radial chromatography over silica gel, which was eluted with 15-25% ethyl acetate-cyclohexane, to give 4-({[l-(4-fluoro-3-trifluoiOmethanesulfonyloxy- phenyl)-methanoyl]-amino } -trifluoromethyl-phenyl)-piperazine- 1 -carboxylic acid tert- butyl ester, DD-lb, as a white solid (1.0 g, 91%): HPLC Rt 19.9 min.; TLC Rf 0.5 (30% ethyl acetate-cyclohexane); Η NMR (DMSO- 6, 300 MHz) δ 10.61 (s, IH), 8.25-8.22 (m, IH), 8.12 (d, IH, J = 2.4 Hz), 8.02 (dd, IH, J = 8.8, 2.2 Hz), 7.86-7.80 (m, IH), 7.60 (d, IH, J = 8.7 Hz), 7.30-7.25 (m, IH), 3.44 (br. s, 4H), 2.80 (t, 4H, J = 4.7 Hz), 1.43 (s, 9H); MS (ESI) m/z 638 (M + Na)+.
(c) 4-[({ l-[4-Fluoro-3-(3H-imidazo[4,5-b]pyridin-6-ylethynyl)-phenyl]-methanoyl}- amino)-trifluoromethyl-phenyl]-piperazine-l-carboxylic acid tert-butyl ester, DD-lc, was prepared in the manner similar to that described in example AA-1, step (g), except 6-ethynyl-3H-imidazo[4,5-b]pyridine, BB-le, was used instead of N-(5-ethynyl- pyridin-2-yl)-acetamide, AA-lc, and 4-({[l-(4-fluoro-3-trifluoromethanesulfonyloxy- phenyl)-methanoyl]-amino } -trifluoromethyl-phenyl)-piperazine- 1 -carboxylic acid tert- butyl ester, DD-lb, was used instead of 4-({[l-(3-iodo-phenyl)-methanoyl]-amino}- trifluoromethyl-phenyl)-piperazine-l -carboxylic acid tert-butyl ester, AA-lf: HPLC Rt 16.3 min.; TLC Rf 0.3 (4% methanol-chloroform w/ 0.1% ammonium hydroxide); TI NMR (DMSO-d6, 300 MHz) δ 13.39, 12.93 (2 br. s, IH), 10.56 (s, IH), 8.58-8.55 (m, 3H), 8.33 (s, IH), 8.16 (s, IH), 8.07-8.05 (m, 2H), 7.61-7.52 (m, 2H), 3.44 (br. s, 4H), 2.80 (br. s, 4H), 1.43 (s, 9H); MS (ESI) m/z 609 (M + H)+. (d) 4-{ [(l-{4-Fluoro-3-[2-(3H-imidazo[4,5-b]pyridin-6-yl)-ethyl]-ρhenyl}-methanoyl)- amino]-trifluoromethyl-phenyl} -piperazine- 1 -carboxylic acid tert-butyl ester, DD-ld, was prepared in the manner similar to that described in example AA-1, step (h), except 4-[({ l-[4-fluoro-3-(3H-imidazo[4,5-b]pyridin-6-ylethynyl)-phenyl]-methanoyl}- amino)-trifluoromethyl-phenyl]-piperazine-l-carboxylic acid tert-butyl ester, DD-lc, was used instead of 4- { [(1 - { 3-[2-(6-acetylamino-pyridin-3-yl)-ethyl]-phenyl } - methanoyl)-amino] -trifluoromethyl-phenyl } -piperazine- 1 -carboxylic acid tert-butyl ester, AA-lg: HPLC Rt 15.7 min.; TLC Rf 0.4 (6% methanol-chloroform w/ 0.1% ammonium hydroxide); Η NMR (DMSO-d6, 300 MHz) δ 10.43 (s, IH), 8.37 (s, IH), 8.21 (s, IH), 8.13 (d, IH, I = 8.8 Hz), 8.05-7.97 (m, 2H), 7.91-7.86 (m, 2H), 7.60 (d, IH, I = 8.8 Hz), 7.34-7.28 (m, IH), 3.44 (br. s, 4H), 3.08-3.06 (m, 4H), 2.80 (t, 4H, J = 4.6 Hz), 1.43 (s, 9H); MS (ESI) m/z 613 (M + H)+.
(e) 4-Fluoro-3-[2-(3H-imidaζo[4,5-b]pyridin-6-yl)-ethyl]-N-(4-piperaζin-l-yl-3- trifluoromethyl-phenyl)-benzamide dihydrochloride, DD-1, was prepared in the manner similar to that described in example AA-1, step (i), except 4-{[(l-{4-fluoro-3- [2-(3H-imidazo[4,5-b]pyridin-6-yl)-ethyl]-phenyl}-methanoyl)-amino]- trifluoromethyl-phenyl} -piperazine- 1 -carboxylic acid tert-butyl ester, DD-ld, was used in place of 4-{[(l-{3-[2-(6-acetylamino-pyridin-3-yl)-ethyl]-phenyl}-methanoyl)- amino] -trifluoromethyl-phenyl} -piperazine- 1 -carboxylic acid tert-butyl ester, AA-lh: HPLC Rt 10.5 min.; Η NMR (DMSO- 6, 300 MHz) δ 10.68 (s, IH), 9.36 (br. s, 3H), 8.55 (s, IH), 8.26 (d, 2H, J = 9.8 Hz), 8.12 (t, 2H, J = 8.2 Hz), 7.93 (br. s, IH), 7.56 (d, IH, J = 8.7 Hz), 7.30 (t, IH, J = 9.1 Hz), 3.16 (br. s, 6H), 3.08 (m, 6H); MS (ESI) m/z 513 (M + H)+. Anal, calcd for C26H24F4N6O x 2.0 HCI: C, 52.14; H, 4.63; N, 14.03; CI, 11.84. Found: C, 52.54; H, 4.73; N, 13.41; CI, 11.44.
Example EE-1: 4-Fluoro-3-(5-furan-2-yl-pyridin-3-ylmethoxy)-N-(4-piperazin-l- yl-3-trifluoromethyl-phenyl)-benzamide dihydrochloride
Figure imgf000200_0001
(a) To a solution of 4-[({ l-[3-(5-bromo-pyridin-3-ylmethoxy)-4-fluoro-phenyl]- methanoyl}-amino)-trifluoromethyl-phenyl]-piperazine-l-carboxylic acid tert-butyl ester, R-25c, (80 mg, 0.12 mmol, 1.0 eq) in dioxane (3 mL) was added tributyl-furan- 2-yl-stannane (0.05 mL, 0.14 mmol, 1.2 eq) and tetrakis(triphenylphosphine)palladium(0) (14 mg, 0.01 mmol, 10 mol%). The light yellow solution was warmed to 95 °C for 18 h. The solvent was removed under reduced pressure and the crude product was dissolved in ethyl acetate, which was sequentially washed with aqueous 10% potassium fluoride, water and brine. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a clear oil (127 mg). The crade product was purified by radial chromatography over silica gel, which was eluted with 1-3% methanol- dichloromethane, to give 4-[({ l-[4-fluoro-3-(5-furan-2-yl-pyridin-3-ylmefhoxy)- phenyl]-methanoyl}-amino)-trifluoromethyl-phenyl]-piperazine-l-carboxylic acid tert- butyl ester, EE-la, as a white solid (66 mg, 86%): HPLC Rt 18.9 min.; TLC Rf 0.4 (2% methanol-dichloromethane); Η NMR (DMSO- 6, 300 MHz) δ 10.44 (s, IH), 8.96 (d, IH, J = 2.1 Hz), 8.62 (d, IH, J = 1.9 Hz), 8.19 (t, IH, J = 2.0 Hz), 8.14 (d, IH, J = 2.3 Hz), 8.03 (dd, IH, J = 8.6, 2.2 Hz), 7.89 (dd, IH, J = 8.3, 1.9 Hz), 7.86 (d, IH, J = 1.6 Hz), 7.69-7.65 (m, IH), 7.60 (d, IH, J = 8.8 Hz), 7.44 (dd, IH, J = 11.0, 8.6 Hz),
7.16 (d, IH, J = 3.3 Hz), 6.67 (dd, IH, J = 3.4, 1.8 Hz), 5.38 (s, 2H), 3.44 (br. s, 4H), 2.80 (t, 4H, J = 4.7 Hz), 1.43 (s, 9H); MS (ESI) m/z 641 (M + H)+. (b) 4-Fluoro-3-(5-furan-2-yl-pyridin-3-ylmethoxy)-N-(4-piperaζin-l-yl-3- trifluoromethyl-phenyl)-benzamide dihydrochloride, EE-1, was prepared in the manner similar to that described in example AA-1, step (i), except 4-[({ l-[4-fluoro-3- (5-furan-2-yl-pyridin-3-ylmethoxy)-phenyl]-methanoyl}-amino)-trifluoromethyl- phenyl] -piperazine- 1 -carboxylic acid tert-butyl ester, EE-la, was used in place of 4- . { [(l-{ 3-[2-(6-acetylamino-pyridin-3-yl)-ethyl]-phenyl}-methanoyl)-amino]- trifluoromethyl-phenyl} -piperazine- 1 -carboxylic acid tert-butyl ester, AA-lh: HPLC Rt 14.2 min.; Η NMR (DMSO- 6, 300 MHz) δ 10.66 (s, IH), 9.16 (br. s, 2H), 9.03 (s, IH), 8.70 (s, IH), 8.37 (s, IH), 8.21 (d, IH, J = 2.0 Hz), 8.14 (d, IH, J = 8.9 Hz), 7.99 (d, IH, J = 7.0 Hz), 7.89 (s, IH), 7.72-7.69 (m, IH), 7.56 (d, IH, J = 8.5 Hz), 7.44 (dd, IH, J = 10.8, 8.7 Hz), 7.24 (d, IH, J = 3.3 Hz), 6.69 (d, IH, J = 1.5 Hz), 5.45 (s, 2H),
3.17 (s, 4H), 3.07 (s, 4H); MS (ESI) m/z 541 (M + H)+. Anal, calcd for C28H24F4N4O3 x 2.0 HCI x 1.0 H2O: C, 53.26; H, 4.47; N, 8.87; CI, 11.23. Found: C, 53.27; H, 4.25; N, 8.56; CI, 11.48.
The exemplary compounds described above may be tested for their activity as described below. BIOLOGICAL TESTING: ENZYME ASSAYS
The stimulation of cell proliferation by growth factors such as VEFG, FGF, and others is dependent upon their induction of autophosphorylation of each of their respective receptor's tyrosine kinases. Therefore, the ability of a protein kinase inhibitor to block cellular proliferation induced by these growth factors is directly correlated with its ability to block receptor autophosphorylation. To measure the protein kinase inhibition activity of the compounds, the following constructs were devised.
VEGF-R2 Construct for Assay: A construct (VEGF-R2Δ50) of the cytosolic domain of human vascular endothelial growth factor receptor 2 (VEGF-R2) lacking the 50 central residues of the 68 residues of the kinase insert domain was expressed in a baculo virus/insect cell system. Of the 1356 residues of full-length NEGF-R2, VEGF- R2Δ50 contains residues 806-939 and 990-1171, and also one point mutation (E990V) within the kinase insert domain relative to wild-type VEGF-R2. See commonly assigned, co-pending U.S. Patent Application Serial No. 09/390,326, filed September 7, 1999, incorporated by reference herein, for discussion of VEGF constructs and expression systems. Autophosphorylation of the purified construct was performed by incubation of the enzyme at a concentration of 4 μM in the presence of 3 mM ATP and 40 mM MgCl2 in 100 mM Hepes, pH 7.5, containing 5% glycerol and 5 mM DTT, at 4 °C for 2 h. After autophosphorylation, this construct has been shown to possess catalytic activity essentially equivalent to the wild-type autophosphorylated kinase domain construct. See Parast et al., Biochemistry, 37, 16788-16801 (1998).
FGF-R1 Construct for Assay: The intracellular kinase domain of human FGF- Rl was expressed using the baculovirus vector expression system starting from the endogenous methionine residue 456 to glutamate 766, according to the residue numbering system of Mohammadi et al., Mol Cell Biol, 16, 977-989 (1996). h addition, the construct also has the following 3 amino acid substitutions: L457V, C488A, and C584S.
LCK Construct for Assay: The LCK tyrosine kinase was expressed in insect cells as an N-terminal deletion starting from amino acid residue 223 to the end of the protein at residue 509, with the following two amino acid substitutions at the N- temiinus: P233M and C224D.
CHK-1 Construct for Assay: C-terminally His-tagged full-length human CHK-1 (FL-CHK-1) was expressed using the baculoviras/insect cell system. It contains 6 histidine residues (6 x His-tag) at the C-terminus of the 476 amino acid human CHK-1. The protein was purified by conventional chromatographic techniques.
Catalytically active truncations of CHK-1 may be exchanged for the full length CHK-1 protein. A preferred truncation comprises the kinase domain of CHK-1, which begins between amino acid residues 1 and 16 and terminates between amino acid residues 265 and 291. See commonly assigned, co-pending U.S. Patent
Application Serial No. 09/460,421, filed December 14, 1999, incorporated by reference herein, for discussion of such alternate CHK-1 constructs and expression systems. CDK2/Cyclin A Construct for Assay: CDK2 was purified using published methodology (Rosenblatt et al., J. Mol. Biol, 230, 1317-1319 (1993)) from insect cells that had been infected with a baculovirus expression vector. Cyclin A was purified from E. coli cells expressing full-length recombinant cyclin A, and a truncated cyclin A construct was generated by limited proteolysis and purified as described previously (Jeffrey et al., Nature, 376, 313-320 (1995)).
CDK4/Cyclin D Construct for Assay: A complex of human CDK4 and cyclin D3, or a complex of cyclin DI and a fusion protein of human CDK4 and glutathione-S- transferase (GST-CDK4), was purified using traditional biochemical chromatographic techniques from insect cells that had been co-infected with the corresponding baculovirus expression vectors.
TΕK Construct for Assay: The intracellular kinase domain (residues 775 to 1124, with methionine added at the N-terminus) of human TΕK/Tie-2 was expressed using the baculovirus vector expression system. For assay purposes, the enzyme was autophosphorylated prior to use by incubation overnight at 4°C, at 10 μM enzyme concentration, with 4 mM ATP, 40 mM MgCl2, and 5 mM DTT in 200 mM Hepes buffer at ph 7.5, in 90:10 water: glycerol. VEGF-R2 Assay
Coupled Spectrophotometric (FLNK-P) Assay
The production of ADP from ATP that accompanies phosphoryl transfer was coupled to oxidation of ΝADH using phosphoenolpyruvate (PEP) and a system having pyruvate kinase (PK) and lactic dehydrogenase (LDH). The oxidation of ΝADH was monitored by following the decrease of absorbance at 340 nm (e3 0 = 6.22 cm"1 mM"1) using a Beckman DU 650 spectrophotometer. Assay conditions for phosphorylated VEGF-R2Δ50 (indicated as FLVK-P in the tables below) were the following: 1 mM PEP; 250 μM ΝADH; 50 units of LDH/mL; 20 units of PK/mL; 5 mM DTT; 5.1 mM poly(E4Y ; 1 mM ATP; and 25 mM MgCl2 in 200 mM Hepes, pH 7.5. Assay conditions for unphosphorylated NEGF-R2Δ50 (indicated as FLVK in the tables) were the following: 1 mM PEP; 250 μM ΝADH; 50 units of LDH/mL; 20 units of PK/mL; 5 mM DTT; 20 mM poly(E4Y1); 3 mM ATP; and 60 mM MgCl2 and 2 mM MnCl2 in 200 mM Hepes, pH 7.5. Assays were initiated with 5 to 40 nM of enzyme. Ki values were determined by measuring enzyme activity in the presence of varying concentrations of test compounds. The data were analyzed using Enzyme Kinetic and Kaleidagraph software.
ELISA Assay
Formation of phosphogastrin was monitored using biotinylated gastrin peptide (1-17) as substrate. Biotinylated phosphogastrin was immobilized using streptavidin coated 96-well microtiter plates followed by detection using anti-phosphotyrosine- antibody conjugated to horseradish peroxidase. The activity of horseradish peroxidase was monitored using 2,2'-azino-di-[3-ethylbenzathiazoline sulfonate(6)] diammonium salt (ABTS). Typical assay solutions contained: 2 μM biotinylated gastrin peptide; 5 mM DTT; 20 μM ATP; 26 mM MgCl2; and 2 mM MnCl2 in 200 mM Hepes, pH 7.5.
The assay was initiated with 0.8 nM of phosphorylated VEGF-R2Δ50. Horseradish peroxidase activity was assayed using ABTS, 10 mM. The horseradish peroxidase reaction was quenched by addition of acid (H SO4), followed by absorbance reading at
405 nm. K values were determined by measuring enzyme activity in the presence of varying concentrations of test compounds. The data were analyzed using Enzyme
Kinetic and Kaleidagraph software. FGF-R Assay
The spectrophotometric assay was carried out as described above for VEGF-R2, except for the following changes in concentration: FGF-R = 50 nM, ATP = 2 mM, and poly(E4Yl)=15 mM.
LCK Assay The spectrophotometric assay was carried out as described above for VEGF-R2, except for the following changes in concentration: LCK = 60 nM, MgCl = 40 nM, poly(E4Yl) = 20 mM.
CHK-1 Assay
The production of ADP from ATP that accompanies phosphoryl transfer to the synthetic substrate peptide Syntide-2 (PLARTLSVAGLPGKK) was coupled to oxidation of NADH using phosphoenolpyruvate (PEP) through the actions of pyruvate kinase (PK) and lactic dehydrogenase (LDH). The oxidation of NADH was monitored by following the decrease of absorbance at 340 nm (e 340=6.22 cm"1 mM"1) using a
HP8452 spectrophotometer. Typical reaction solutions contained: 4 mN PEP; 0.15 mM NADH; 28 units of LDH/ml; 16 units of PK/ml; 3 mM DTT; 0.125 mM Syntide-
2; 0.15 mM ATP; 25 mM MgCl2 in 50 mM TRIS, pH 7.5; and 400 mM NaCl. Assays were initiated with 10 nM of FL-CHK-1. Ki values were determined by measuring initial enzyme activity in the presence of varying concentrations of test compounds. The data were analyzed using Enzyme Kinetic and Kaleidagraph software. CDK2/Cvclin A and CDK4/Cvclin D Assays Cyclin-dependent kinase activity was measured by quantifying the enzyme- catalyzed, time-dependent incorporation of radioactive phosphate from [32p] ATP into a recombinant fragment of the retinoblastoma protein. Unless noted otherwise, assays were performed in 96-well plates in a total volume of 50 μL, in the presence of 10 mM HEPES (N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]) (pH 7.4), 10 mM MgCl2, 25 μM adenosine triphosphate (ATP), 1 mg/mL ovalbumin, 5 μg/mL leupeptin, 1 mM dithiothreitol, 10 mM β-glycerophosphate, 0.1 mM sodium vanadate, 1 mM sodium fluoride, 2.5 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N'N'- tetraacetic acid (EGTA), 2% (v/v) dimethylsulfoxide, and 0.03 - 0.2 μCi [32P]ATP. The substrate (0.3-0.5 μg) was purified recombinant retinoblastoma protein fragment (Rb) (residues 386-928 of the native retinoblastoma protein; 62.3 kDa, containing the majority of the phosphorylation sites found in the native 106-kDa protein, as well as a tag of six histidine residues for ease of purification). Reactions were initiated with CDK2 (150 nM CDK2/Cyclin A complex) or CDK4 (50 nM CDK4/Cyclin D3 complex), incubated at 30°C, and terminated after 20 minutes by the addition of ethylenediaminetetraacetic acid (EDTA) to 250 mM. The phosphorylated substrate was then captured on a nitrocellulose membrane using a 96-well filtration manifold, and unincorporated radioactivity was removed by repeated washing with 0.85% phosphoric acid. Radioactivity was quantified by exposing the dried nitrocellulose membranes to a phosphorimager. Apparent K; values were measured by assaying enzyme activity in the presence of different compound concentrations and subtracting the background radioactivity measured in the absence of enzyme. The kinetic parameters (kcat, Km for ATP) were measured for each enzyme under the usual assay conditions by determining the dependence of initial rates on ATP concentration. The data were fit to an equation for competitive inhibition using Kaleidagraph (Synergy Software), or were fit to an equation for competitive tight-binding inhibition using the software KineTic (BioKin, Ltd.). Measured K; values for known inhibitors against CDK4 and CDK2 agreed with published IC50 values. The specific activity of CDK4 was the same whether complexed to full-length cyclin D3 or the truncated Cyclin D3 construct; both complexes also yielded very similar K{ values for selected inhibitors. TEK/Tie-2 Assay The spectrophotometric assay was carried out as described above for VEGF-
R2, except for the following changes in concentration: TEK/Tie-2 = 200 nM, MgCl2 = 40 mM, and ATP = 2 mM. HUVEC Proliferation Assay
This assay determines the ability of a test compound to inhibit the growth factor-stimulated proliferation of human umbilical vein endothelial cells ("HUVEC")- HUVEC cells (passage 3-4, Clonetics, Corp.) were thawed into EGM2 culture medium (Clonetics Corp) in T75 flasks. Fresh EGM2 medium was added to the flasks 24 hours later. Four or five days later, cells were exposed to another culture medium (F12K medium supplemented with 10% fetal bovine serum (FBS), 60 μg/ml endothelial cell growth supplement (ECGS), and 0.1 mg/ml heparin). Exponentially-growing HUVEC cells were used in experiments thereafter. Ten to twelve thousand HUVEC cells were plated in 96-well dishes in 100 μl of rich, culture medium (described above). The cells were allowed to attach for 24 hours in this medium. The medium was then removed by aspiration and 105 μl of starvation media (F12K+1% FBS) was added to each well. After 24 hours, 15 μl of test agent dissolved in 1% DMSO in starvation medium or this vehicle alone was added into each treatment well; the final DMSO concentration was 0.1%. One hour later, 30 μl of VEGF (30 ng/ml) in starvation media was added to all wells except those containing untreated controls; the final VEGF concentration was 6 ng/ml. Cellular proliferation was quantified 72 hours later by MTT dye reduction, at which time cells were exposed for 4 hours MTT (Promega Corp.). Dye reduction was stopped by addition of a stop solution (Promega Corp.) and absorbance at 595 λ was determined on a 96-well spectrophotometer plate reader. Cancer Cell Proliferation (MV522) Assay
The protocol for assessing cellular proliferation in cancer cells is similar to that used for assessments in HUVEC cells. Two thousand lung cancer cells (line MV522, acquired from American Tissue Cultural Collection) were seeded in growth media (RPMI1640 medium supplemented with 2 mM glutamine and 10% FBS). Cells are allowed to attach for 1 day prior to addition of test agents and /or vehicles. Cells are treated simultaneously with the same test agents used in the HUVEC assay. Cellular proliferation is quantified by MTT dye reduction assay 72 hours after exposure to test agents. The total length of the assay is 4 days vs. 5 for HUVEC cells because MV522 cells are not exposed to starvation medium.
The results of the testing of the compounds using various assays are summarized in the table below, where a notation of "% @" indicates the percent inhibition at the stated concentration, "NT' indicates no inhibition, "slow-binding kinetics" indicates that curvature in the progress curves in the enzyme assay precluded the determination of rates, and "NT" indicates compounds "not tested" for a particular activity.
Figure imgf000208_0001
Figure imgf000209_0001
Figure imgf000210_0001
Figure imgf000211_0001
Figure imgf000212_0001
Figure imgf000213_0001
Figure imgf000214_0001
The exemplary compounds described above may be formulated into pharmaceutical compositions according to the following general examples.
Example 1: Parenteral Composition To prepare a parenteral pharmaceutical composition suitable for administration by injection, 100 mg of a water-soluble salt of a compound of Formula I is dissolved in
DMSO and then mixed with 10 mL of 0.9% sterile saline. The mixture is incorporated into a dosage unit form suitable for administration by injection.
Example 2: Oral Composition To prepare a pharmaceutical composition for oral delivery, 100 mg of a compound of Formula I is mixed with 750 mg of lactose. The mixture is incorporated into an oral dosage unit for, such as a hard gelatin capsule, which is suitable for oral administration.
Example 3: Intraocular Composition To prepare a sustained-release pharmaceutical for intraocular delivery, a compound of Formula I is suspended in a neutral, isotonic solution of hyaluronic acid
(1.5% cone.) in phosphate buffer (pH 7.4) to form a 1% suspension.
It is' to be understood that the foregoing description is exemplary and explanatory in nature, and is intended to illustrate the invention and its preferred embodiments. Thus, the scope of the invention should be understood to be defined not by the foregoing description, but by the following claims and their equivalents.

Claims

What is claimed:
1. A compound represented by the Formula I:
Figure imgf000216_0001
wherein:
R1 is a moiety represented by the formula
Figure imgf000216_0002
where
Z is selected from the group consisting of CH and NH, and Q is a moiety such that R1 is a substituted or unsubstituted monocyclic or bicyclic heteroaryl which has at least two carbon atoms in the heteroaryl ring system;
X is selected from the group consisting of CHj, O, S, and NH;
Y is selected from the group consisting of CFL,, O, and S, provided that at least one of X and Y is CH2, or X and Y together with the bond there-between form a cyclopropyl;
R2 and R3 are independently selected from the group consisting of hydrogen, methyl, halogen, trifluoromethyl, and cyano; and
R4 is selected from the group consisting of
Figure imgf000216_0003
where R5 is selected from the group consisting of substituted and unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O-R7, NRSR9, C C8 alkyl, and monocyclic heterocycloalkyl, R6 is selected from the group consisting of substituted and unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkenyl, O-R7, C(O)R7, NR8R9, C2-C8 alkyl, and monocyclic heterocycloalkyl, where R7 is selected from the group consisting of substituted and unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, R8 is selected from the group consisting of hydrogen, and substituted and unsubstituted alkyl, and R9 is selected from the group consisting of substituted and unsubstituted alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, wherein R1 is a substituted or unsubstituted heteroaryl group selected from the group consisting of:
Figure imgf000217_0001
Figure imgf000217_0002
Figure imgf000217_0003
Figure imgf000217_0004
X is selected from the group consisting of CH2, O, and S;
Y is selected from the group consisting of CH2 and S, provided that at least one of X and Y is CH2;
R2 and R3 are independently selected from the group consisting of hydrogen, methyl, fluorine, and chlorine, and R4 is selected from the group consisting of
Figure imgf000218_0001
where R5 is selected from the group consisting of substituted and unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O-R7, NR8R9, -C8 alkyl, and monocyclic heterocycloalkyl, R6 is selected from the group consisting of substituted and unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkenyl, O-R7, C(O)R7, NR8R9, C2-C8 alkyl, and monocyclic heterocycloalkyl, where R7 is selected from the group consisting of substituted and unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, R8 is selected from the group consisting of hydrogen and substituted and unsubstituted alkyl, and R9 is selected from the group consisting of substituted and unsubstituted alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.
3. A compound represented by the Formula II:
Figure imgf000218_0002
wherein:
X is selected from the group consisting of CH2, O, and S;
Y is is selected from the group consisting of CH2 and S, provided that at least one of X and Y is CH2;
R2 and R3 are independently selected from the group consisting of hydrogen, methyl, fluorine, and chlorine;
R4 is selected from the group consisting of
Figure imgf000219_0001
where R5 and R6 are each independently selected from the group consisting of substituted and unsubstituted aryl and heteroaryl; and R10 is selected from the group consisting of substituted and unsubstituted alkenyl, aryl, heteroaryl, and HNR9, where R9 is selected from the group consisting of substituted and unsubstituted alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.
4. A compound according to claim 3, wherein R5 and Rδ are each independently selected from the group consisting of substituted and unsubstituted aryl; or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt of said metabolite.
5. A compound according to claim 3, wherein R5 and R6 are each independently selected from the group consisting of substituted and unsubstituted heteroaryl; or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt of said metabolite.
6. A compound represented by the Formula III:
Figure imgf000219_0002
wherein: X is selected from the group consisting of CH2, O, S, and NH; Y is selected from the group consisting of CH2, O, and S, provided that at least one of X and Y is CH2, or X and Y together with the bond there-between form a cyclopropyl;
R2 and R3 are independently selected from the group consisting of hydrogen, methyl, halogen, trifluoromethyl, and cyano; and R4 is selected from the group consisting of
Figure imgf000220_0001
where R5 is selected from the group consisting of substituted and unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O-R7, NR8R9, Cj-C8 alkyl, and monocyclic heterocycloalkyl, R6 is selected from the group consisting of substituted and unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkenyl, O-R7, C(O)R7, NR8R9, C2-C8 alkyl, and monocyclic heterocycloalkyl, where R7 is selected from the group consisting of substituted and unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, R8 is selected from the group consisting of hydrogen and substituted and unsubstituted alkyl, and R9 is selected from the group consisting of substituted and unsubstituted alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.
7. A compound according to claim 6, wherein:
X is selected from the group consisting of CH2, O, and S;
Y is selected from the group consisting of CH2 and S, provided that at least one of X and Y is CH2;
R2 and R3 are independently selected from the group consisting of hydrogen, methyl, fluorine, and chlorine; and
R4 is selected from the group consisting of
Figure imgf000221_0001
where R5 and R6 are each independently selected from the group consisting of substituted and unsubstituted aryl and heteroaryl; or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt of said metabolite.
8. A compound according to claim 7, wherein R5 and R6 are each independently selected from the group consisting of substituted and unsubstituted aryl; or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrag, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt of said metabolite.
9. A compound according to claim 7, wherein R5 and R6 are each independently selected from the group consisting of substituted and unsubstituted heteroaryl; or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt of said metabolite.
10. A compound according to claim 7, wherein: X is CH2;
Y is S;
R2 and R3 are independently selected from the group consisting of hydrogen, methyl, fluorine, and chlorine; and
R4 is selected from the group consisting of
Figure imgf000221_0002
where R5 and R6 are each independently selected from the group consisting of substituted and unsubstituted aryl and heteroaryl; or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrag, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt of said metabolite.
11. A compound according to claim 10, wherein R5 and Rδ are each independently selected from the group consisting of substituted and unsubstituted aryl; or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrag, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt of said metabolite.
12. A compound selected from the group consisting of N-(3,4,5-Trimethoxyphenyl)-3-[(pyrazin-2-yl)sulfanylmethyl]benzamide; N-(3,4,5-Trimethoxyphenyl)-3-[(5-amino-2H-[l,2,4]triazol-3- yl)sulfanylmethyl] benzamide;
N-(4-Isopropyl-3-methylphenyl)-3-[(pyrazin-2-yl)sulfanylmethyl]- benzamide;
N-(4-Isoρropyl-3-methylphenyl)-3-[(5-amino-2H-[ 1 ,2,4]triazol-3- yl)sulfanylmethyl]benzamide; N-(4-Isopropyl-3-methylphenyl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4- yl)sulfanylmethyl]benzamide;
N-(2-Methylquinolin-6-yl)-3-[(pyrazin-2-yl)sulfanylmethyl]benzamide; N-(3-Isopropylphenyl)-3-[(pyrazin-2-yl)sulfanylmethyl]benzamide; N-(3,5-Dibromo-4-methylphenyl)-3-[(pyrazin-2-yl)sulfanyl- methyljbenzamide;
N-(3,4,5-Trimethoxyphenyl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4- yl)sulfanylmethyl] benzamide;
N-(3,4,5-Trimethoxyphenyl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4- yl)sulfanylmethyl] benzamide; N-(Quinolin-6-yl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4-yl)sulfanyl- methyljbenzamide; N-(5-Methylisoxazol-3 -yl)-3 - [( lH-pyrazolo [3 ,4-d]pyrimidin-4- yl)sulfanylmethyl] benzamide;
N-(Pyridin-4-yl)methyl-3 - [( 1 H-pyrazolo [3 ,4-d]pyrimidin-4-yl)- sulfanylmethyl] benzamide; N-( 1 ,3 -B enzodioxyl-5-ylmethyl)-3 - [( 1 H-pyrazolo [3 ,4-d]pyrimidin-4-yl)- sulfanylmethyl] benzamide;
N-(2-Methoxybenzyl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4-yl)- sulfanylmethyl]benzamide;
N-(2-Phenylethyl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4-yl)sulfanyl- methyl]benzamide;
N-(2-Methoxyphenyl)-3-[(lH-pyrazolo[3,4-d]pyrimidin-4-yl)- sulfanylmethyljbenzamide;
N-[3-(N-Methyl-N-phenylamino)propyl]-3-[(5-methyl-lH-l,2,4-triazol-3- yl) sulfanylmethyl]benzamide; N-(l,3-Benzodioxyl-5-ylmethyl)-3-[(5-methyl-lH-l,2,4-triazol-3- yl)sulfanylmethyl] benzamide;
N- [4-cyano-3 -(trifluoromethyl)phenyl]-3 - [( 1 H-pyrazolo [3 ,4-d]-pyrimidin- 4-yl-sulfanyl) methyl]benzamide;
N-(3,3-Diphenylpropyl)-3-{[(5-methyl-lH-l,2,4-triazol-3-yl)- sulfanyl]methyl}benzamide;
3-{[(5-Methyl-lH-l,2,4-triazol-3-yl)-sulfonyl]methyl}-N-phen- ethylbenzamide;
3 - [( 1 H-Pyrazolo [3 ,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3-iso- propylphenyl)-benzamide; 3-[(lH-Pyrazolo[3,4-d]ρyrimidin-4-yl)sulfanylmethyl]-N(3-tri- fluoromethyl-5-methoxyphenyl)-benzamide;
3-[(lH-Pyrazolo[3,4-djρyrimidin-4-yl)sulfanylmethyl]-N(3,5-bis- trifluoromethylphenyl)-benzamide;
3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3-t-butylphenyl)- benzamide; 3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(4- isoproρylphenyl)-benzamide;
3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(4- trifluoromethoxyphenyl)-benzamide; 3-[(lH-Pyrazolo[3,4-d]ρyrimidin-4-yl)sulfanylmethyl]-N(3,5- dimethylphenyl)-benzamide;
3-[(lH-Pyrazolo[3,4-d]ρyrimidin-4-yl)sulfanylmethyl]-N(3-(2- hydroxyethyl)phenyl)-benzamide;
3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(4- dimethylaminophenyl)-benzamide;
3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3- trifluoromethylsulfonyl phenyl)-benzamide;
3-[(lH-Pyrazolo[3,4-d]pyrimidin-4-yl)sulfanylmethyl]-N(3- dimethylaminophenyl)-benzamide; 3-[(5-Cyanoamino-2H-[l,2,4]triazol-3-yl)sulfanylmethyl]-N-(3,4,5- trimethoxyphenyl) benzamide;
3-[(5-(Methoxycarbonylamino)-2H-[l,2,4]triazol-3-yl)sulfanylmethyl]-N- (3,4,5-trimethoxyphenyl)benzamide;
N-(3,4,5-Trimethoxyphenyl)-3-[(5-acetylamino-2H-[l,2,4]triazol-3- yl)sulfanylmethyl] benzamide;
N-(4-Isopropyl-3-methylphenyl)-3-[(pyrazin-2-yl)methyl- sulfanyl]benzamide;
N-(2-Methylquinolin-6-yl)-3-[(pyrazin-2-yl)methylsulfanyl]benzamide;
N-(2-Methyl-quinolin-6-yl)-3-(pyridin-3-ylmethylsulfanyl)-benzamide dihydrochloride;
N-(2-methyl-quinolin-6-yl)-3-[{5-(phenylamino)-2-H-pyrazol-3- yl} methylsulfanyl] benzamide;
N-(3,4,5-trimethoxyphenyl)-3-[2-(5-phenylamino-2H-pyrazol-3- yl)ethyl]benzamide; 3-[{5-((E)-2-(4-Hydroxy-3-methoxyphenyl)ethenyl)-2H-pyrazol-3-yl}- methylsulfanyl]-N-(2-methylquinolin-6-yl)benzamide; 3-[5-(2-(3,4-Dimethoxyphenyl)ethenyl)-2H-pyrazol-3-yl)methylsulfanyl]- N-(2-methylquinolin-6-yl)benzamide;
3-(2-{5-[(E)-2-(3,4-Dimethoxyρhenyl)ethenyl]-2H-pyrazol-3-yl}-ethyl)-N- (3-methyl-4-isopropylphenyl)-benzamide; 4-Fluoro-3-[{5-((E)-l-proρenyl)-2H-pyrazol-3-yl}methoxy]-N-[4-
(pyrrolidin-l-yl)-3-trifluoromethylphenyl]benzamide;
3-(2-{5-[(E)-2-(3,4-Dimethoxyphenyl)ethenyl]-2H-pyrazol-3-yl}-ethyl)-N- (3-methyl-4-isopropylphenyl)-benzamide;
N-(4-Isopropyl-3-methyl-phenyl)-3- { 2-[5-(4-(methylsulfamoyl)- phenylamino)-2H-pyrazol-3-yl]-ethyl } -benzamide;
N-(2-Methylquinolin-6-yl)-3-[2-(5-phenylamino-2H-pyrazol-3- yl)ethyl]benzamide;
N-(4-isopropyl-3-methylρhenyl)-3-[2-(5-phenylamino-2H-pyrazol-3- yl)ethyl]benzamide; N-(4-Isopropyl-3-methyl-phenyl)-3-{2-[5-(6-methoxypyridin-3-yl)amino-
2H-pyrazol-3-yl]-ethyl}-benzamide;
N-(4-Dimethylamino-3-trifluoromethylphenyl)-3-{2-[5-(6-methoxypyridin- 3-yl)amino-2H-pyrazol-3-yl]ethyl}-benzamide;
N-(6-Dimethylamino-5-trifluoromethylpyridin-3-yl)-3-{2-[5-(6- methoxypyridin-3-yl)amino-2H-pyrazol-3-yl]ethyl } -benzamide;
N-(3,5-Dichloro-4-dimethylaminophenyl)-3-{2-[5-(6-methoxy-pyridin-3- yl)amino-2H-pyrazol-3-yl]ethyl}benzamide;
3-{2-[5-(6-Methoxypyridin-3-yl)amino-2H-pyrazol-3-yl]-ethyl}-N-(4- pyrrolidin- 1 -yl-3-trifluoromethylphenyl)benzamide; 3-{2-[5-(6-Methoxypyridin-3-yl)amino-2H-pyrazol-3-yl]-ethyl)-N-[4-(4-t- butoxycarbonylpiperazin- 1 -y l)-3 -trifluoromethylphenyl]benzamide;
3-{2-[5-(6-Methoxypyridin-3-yl)amino)-2H-pyrazol-3-yl]ethyl}-N-(4- piperazin- 1 -y 1-3 -trifluoromethylphenyl)benzamide ;
4-Fluoro-3-[{5-(pyridin-3-yl)amino-2H-pyrazol-3-yl}methoxy]-N-[((4- pyrrolidin-l-yl)-3-trifluoromethylphenyl)benzamide; N-(4-Isopropyl-3-methyl-phenyl)-3-[2-(5-phenylamino-2-H-pyrazol-3-yl)- cyclopropylj-benzamide;
3-[({3-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-lH-pyrazol-5- yl}methyl)amino]-N-(3-methyl-4-isopropylphenyl)benzamide; 3-[({5-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-lH-pyrazol-3- yl } methyl)amino]-N-phenyl)benzamide;
4-Fluoro-N- [4-(imidazol- 1 -yl)-3 -trifluoromethylphenyl] -3 - [5-(6- methoxypyridin-3 -yl)amino-2H-ρyrazol-3 -ylmethoxy] -benzamide;
4-Fluoro-3-[5-(6-methoxy-pyridin-3-yl)amino-2H-pyrazol-3-yl]methoxy- N-(4-pyrrolidin-l-yl-3-trifluoromethyl-phenyl)-benzamide; .
4-Fluoro-3-[5-(6-methoxypyridin-3-yl)amino-2H-pyrazol-3-yl]methoxy-N- (3-methoxy-5-trifluoromethyl-phenyl)-benzamide;
N-(4-Isopropyl-3-methyl-ρhenyl)-3-(Isoquinolin-4-yl)methoxy-benzamide;
3-(Isoquinolin-4-yl)methoxy-N-(3,4,5-trimethoxyphenyl)benzamide hydrochloride;
3-(Isoquinolin-4-yl)methoxy-N-(2-methyl-quinolin-6-yl)-benzamide hydrochloride;
3-(Isoquinolin-4-yl)methoxy-N-(2-methyl-4-methylsulfanyl-quinolin-6-yl)- benzamide hydrochloride; 3-(Pyridin-3-yl)methoxy-N-(3 ,4,5-trimethoxyphenyl)benzamide;
N-(Naphthalen-2-yl)-3-(pyridin-3-yl)methoxybenzamide;
N-(l-Allyl-lH-indol-5-yl)-3-(pyridin-3-yl)methoxy-benzamide;
3-(Pyridin-3-yl)methoxy-N-quinolin-6-yl-benzamide;
N-(2-Methyl-quinolin-6-yl)-3-(pyridin-3-yl)methoxy-benzamide; N-(4-Isopropyl-3-methyl-phenyl)-4-fluoro-3-(Isoquinolin-4-yl)methoxy- benzamide;
N-(4-Isopropyl-3-methyl-phenyl)-4-methyl-3-(Isoquinolin-4-yl)methoxy- benzamide;
N-(4-Isopropyl-3-methyl-phenyl)-4-chloro-3-(Isoquinolin-4-yl)methoxy- benzamide;
3-(6-Aminopyridin-3-yl)methoxy-N-(4-Isopropyl-3-methyl-phenyl)benzamide; 3-(6-Aminopyridin-3-yl)methoxy-N-(2-methyl-quinolin-6-yl)-benzamide;
3-(6-Acetylaminopyridin-3-yl)methoxy-N-(2-methyl-quinolin-6-yl)-benzamide;
3-(6-Acetylaminopyridin-3-yl)methoxy-N-(4-isopropyl-3-methyl-phenyl)- benzamide; 4-Fluoro-N-(l,2,3,4-tetrahydroquinolin-6-yl)-3-(isoquinolin-4-yl-methoxy)- benzamide bistrifluoroacetic acid salt;
N-(2,2-difluorobenzo[l,3]dioxol-4-yl-ethyl)-benzamide trifluoroacetic acid salt;
4-Fluoro-N-(2-methyl-l,2,3,4-tetrahydroquinolin-6-yl)-3-(isoquinolin-4-yl- methoxy)-benzamide bistrifluoroacetic acid salt;
N'-{4-[3-(4-Isopropyl-3-methyl-phenylcarbamoyl)-phenoxy;
N-(4-Isopropyl-3-methyl-phenyl)-3- { 1 -[N'-(3-methoxy-benzylidene)- hydrazino]-isoquinolin-4-ylmethoxy}-benzamide;
N-(3,5-Diallyl-4-methyl-phenyl)-3-(isoquinolin-4-ylmethoxy)-benzamide; N-(3 ,5-Dibromo-4-methyl-phenyl)-3-(isoquinolin-4-ylmethoxy)-benzamide;
3-(Isoquinolin-4-ylmethoxy)-N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro- naphthalen-2-yl)-benzamide;
3-(Isoquinolin-4-ylmethoxy)-N-(3-trifluoromethoxy-phenyl)-benzamide;
N-(2,4-Dimethylquinolin-6-yl)-3-(isoquinolin-4-ylmethoxy)-benzamide; 3-(Isoquinolin-4-ylmethoxy)-benzoic acid N '-(4-trifluoromethyl-phenyl)- hydrazide;
N-Benzyloxy-3-(isoquinolin-4-ylmethoxy)-benzamide;
3-(Isoquinolin-4-ylmethoxy)-benzoic acid N'-phenyl-hydrazide;
N-(5,7-dimethyl[l,8]naphthydrin-2-yl)-3-(isoquinolin-4-ylmethoxy)- benzamide;
3-(Isoquinolin-4-ylmethoxy)-N-(l',l,3,3-tetramethyl-l,3-dihydroisobenzofuran- 5-yl)-benzamide;
N-(3,5-Dichloro-4-pyrrolidin-l-yl-phenyl)-4-fluoro-3-(pyridin-3-ylmethoxy)- benzamide; 4-FlUoro-N-(4-morpholin-4-yl-3-trifluoromethyl-phenyl)-3-(pyridin-3- ylmethoxy)-benzamide; 4-Fluoro-N-[4-(piperazin-l-yl)-3-trifluoromethylphenyl]-3^(pyridin-3- yl)methoxybenzamide;
4-Fluoro-N-(4-morpholin-4-yl-3-trifluoromethyl-phenyl)-3-(isoquinolin-4- ylmethoxy)-benzamide; 4-Fluoro-N-(4-piperazin-l-yl-3-trifluoromethyl-phenyl)-3-(isoquinolin-4- ylmethoxy)-benzamide;
4-Fluoro-N-(4-morpholin-4-yl-3-trifluoromethyl-phenyl)-3-(quinolin-3- ylmethoxy)-benzamide;
4-Fluoro-Ν-(4-piperazin-l-yl-3-trifluoromethyl-phenyl)-3-(quinolin-3- ylmethoxy)-benzamide;
N-(3,5-Dichloro-4-morpholin-4-yl-phenyl)-4-fluoro-3-(pyridin-3-ylmethoxy)- benzamide;
N-(3,5-Dichloro-4-piperazin-l-yl-phenyl)-4-fluoro-3-(pyridin-3-ylmethoxy)- benzamide; 4-Fluoro-N-[4-(piperazin-l-yl)-3-trifluoromethylphenyl]-3-(pyridin-3- yl)methoxybenzamide;
4-Fluoro-N-(4-(imidazol-l-yl-3-trifluoromethylphenyl]-3-(pyridin-3- yl)methoxybenzamide;
4-Fluoro-N-(4-pyrazol-l-yl-3-trifluoromethyl-phenyl)-3-(pyridin-3- ylmethoxy)-benzamide;
4-Fluoro-3-(pyridin-3-ylmethoxy)-N-(4-[l,2,4]triazol-l-yl-3-trifluoromethyl- phenyl)-benzamide;
N-(3 ,5-Dichloro-4-imidazol- 1 -yl-phenyl)-4-fluoro-3-(pyridin-3-ylmethoxy)- benzamide; 3-(5-Bromo-pyridin-3-ylmethoxy)-4-fluoro-N-(4-piperazin-l-yl-3- trifluoromethyl-phenyl)-benzamide;
3-(2-Isoquinolin-4-yl-ethyl)-N-phenyl-benzamide;
3-(2-Isoquinolin-4-yl-ethyl)-N-(3,3,5-trimethyl-cyclohexyl)-benzamide;
N-(4-Isopropyl-3-methyl-phenyl)-3-(2-isoquinolin-4-yl-ethyl)-benzamide; 3-(2-Isoquinolin-4-yl-ethyl)-N-(2-methyl-quinolin-6-yl)-benzamide;
N-(3,5-Dibromo-4-methyl-phenyl)-3-(2-isoquinolin-4-yl-ethyl)-benzamide; N-(4,6-Dimethyl-pyridin-2-yl)-3-(2-isoquinolin-4-yl-ethyl)-benzamide;
2-Chloro-4-fluoro-N-(4-isopropyl-3-methyl-phenyl)-5-(2-isoquinolin-4-yl- ethyl)-benzamide;
2,4-Difluoro-N-(4-isopropyl-3-methyl-phenyl)-5-(2-isoquinolin-4-yl-ethyl)- benzamide;
2-Fluoro-N-(4-isopropyl-3-methyl-phenyl)-5-(2-isoquinolin-4-yl-ethyl)- benzamide;
N-(2-Methyl-quinolin-6-yl)-3-(2-pyridin-3-yl-ethyl)-benzamide hydrochloride;
N-(4-Isopropyl-3-methyl-phenyl)-3-(2-pyridin-3-yl-ethyl)-benzamide; N-{3-[(lH-pyrazolo[3,4-d]-pyrimidin-4-ylsulfanylmethyl]phenyl}-(3-bromo-4- methyl) benzamide;
N- { 3- [( 1 H-pyrazolo [3 ,4-d] -pyrimidin-4-ylsulf anylmethyl]pheny 1 } -3 ,5- bis(trifluoromethyl) benzamide;
N- { 3 - [( 1 H-pyrazolo [3 ,4-d] -pyrimidin-4-yl)sulf anylmethyl]phenyl } -(4- hydroxy-3-methoxy) benzamide;
N- { 3-[(lH-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl }-(4- hydroxy-3 -t-butyl) benzamide;
N-{3-[(lH-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl}-4-t- butylbenzamide; N- { 3-[(lH-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl } -(4- phenoxy)benzamide;
N-{3-[(lH-pyrazolo[3,4-d]pyrimidin-4-ylsulfanyl)methyl]phenyl}-N'-[3,5-bis- (trifluoromethyl)phenyl]urea;
N- { 3 - [( 1 H-pyrazolo [3 ,4-d]pyrimidin-4-ylsulf anyl)methyl]phenyl } -N'-(pyridin- 3-yl)urea;
N-{3-[(lH-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl}-(3,5-di-t- butyl) benzamide;
3-Bromo-4-hydroxy-N- { 3-[(lH-pyrazolo[3 ,4-d]-pyrimidin-4- yl)sulf anylmethyl]phenyl } -benzamide; N- { 3- [( 1 H-pyrazolo [3 ,4-d] -pyrirnidin-4-yl) sulf anylmethyl]phenyl } -quinoline-
6-carboxamide; 5-Fluoro-N-{3-[(lH-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl}- indole-2-carboxamide;
N-{3-[(lH-pyrazolo[3,4-d]-pyrimidin-4-yl)sulfanylmethyl]phenyl}-indole-6- carboxamide; (R/S)-2-(2-methylphenyl)-N-{3-[(lH-pyrazolo[3,4-d]pyrimidin-4-ylsulfanyl)- methyl)methyl} phenyl }butanamide;
3-t-Butyl-4-hydroxy-N-{3-[5-(6-methoxy-pyridin-3-ylamino)-2 H-pyrazol-3- ylmethyl sulf anyl]-phenyl } -benzamide;
3-t-Butyl-4-hydroxy-N-[3-(pyridin-3-ylmethylsulfanyl)-phenyl}-benzamide; 3-t-Butyl-4-hydroxy-N-[3-(isoquinolin-4-ylmethylsulfanyl)-phenyl}- benzamide;
N-[3-(5-Bromo-pyridin-3-ylmethoxy)-phenyl]-3-t-butyl-4-hydiOxy-benzamide;
4-Acetoxy-3-t-butyl-N-[3-(pyridin-3-ylmethoxy)phenyl]-benzamide;
4-Acetoxy-3-t-butyl-N-[3-(isoquinolin-4-ylmethoxy)phenyl]-benzamide; 3-t-Butyl-4-hydroxy-N-[3-(pyridin-3-ylmethoxy)-phenyl]-benzamide;
3-t-Butyl-4-hydroxy-N-[3-(isoquinolin-4-ylmethoxy)-phenyl]-benzamide; l-[3-(pyridin-3-ylmethoxy)phenylcarbamoyl]pyrrolidine;
4-[3-(pyridin-3-ylmethoxy)phenylcarbamoyl]morpholine;
3-[{6-Methoxy-7-(2-methoxyethoxy)cinnolin-4-yl}sulfanylmethyl]-N-phenyl- benzamide;
3 - [2-(6- Acetylamino-pyridin-3 -yl)-ethyl] -Ν-(4-piperazin- 1 -yl-3-trifluoro- methylphenyl)-benzamide dihydrochloride;
3-[2-(6-Amino-pyridin-3-yl)-ethyl]-N-(4-piperazin-l-yl-3-trifluoromethyl- phenyl)-benzamide dihydrochloride; 3-[2-(3H-Imidazo[4,5-b]pyridin-6-yl)-ethyl]-N-(4-ρiρerazin-l-yl-3- trifluoromethyl-phenyl)-benzamide dihydrochloride;
5-{2-[3-(Piperazin-l-yl-trifluoromethyl-phenylcarbamoyl)-phenyl]-ethyl}- nicotinamide dihydrochloride;
5-{2-[3-(Piperazin-l-yl-trifluoromethyl-phenylcarbamoyl)-phenyl]-ethyl}- nicotinic acid methyl ester dihydrochloride; 4-Fluoro-3-[2-(3H-imidazo[4,5-b]pyridin-6-yl)-ethyl]-N-(4-piperazin-l-yl-3- trifluoromethyl-phenyl)-benzamide dihydrochloride; and
4-Fluoro-3-(5-furan-2-yl-pyridin-3-ylmethoxy)-N-(4-piperazin-l-yl-3- trifluoromethyl-phenyl)-benzamide dihydrochloride; or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite thereof or a pharmaceutically acceptable salt of said metabolite.
13. A compound selected from the group consisting of the compounds corresponding to Example B-27 (Compounds 1-244), Example V-6d (Compounds 1-176), Example V-7b (Compounds 1-43) and Example
V-14 (Compounds 1-88), or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrag, or pharmaceutically active metabolite thereof or a pharmaceutically acceptable salt of said metabolite.
14. A pharmaceutically acceptable salt of a pharmaceutically active metabolite of a compound according to claim 1.
15. A pharmaceutical composition for modulating or inhibiting the activity of a protein kinase receptor comprising:
(a) a therapeutically effective amount of an agent selected from the group consisting of a compound according to claim 1, a pharmaceutically acceptable prodrug thereof, a pharmaceutically active metabolite thereof, and a pharmaceutically acceptable salt thereof; and
(b) a pharmaceutically acceptable carrier, diluent, or vehicle therefor.
16. A pharmaceutical composition for modulating or inhibiting the activity of a protein kinase receptor comprising:
(a) a therapeutically effective amount of a pharmaceutically acceptable salt of a pharmaceutically active metabolite of a compound according to claim 1 ; (b) a pharmaceutically acceptable carrier, diluent, or vehicle therefor.
17. A method of treating a mammalian disease condition mediated by protein kinase activity, comprising administering to a mammal in need thereof a therapeutically effective amount of an agent selected from the group consisting of a compound according to claim 1, a pharmaceutically acceptable prodrag thereof, a pharmaceutically active metabolite thereof, and a pharmaceutically acceptable salt thereof.
18. A method according to claim 17, wherein the mammalian disease condition is associated with tumor growth, cell proliferation, or angiogenesis.
19. A method of modulating or inhibiting the activity of a protein kinase receptor, comprising contacting the kinase receptor with an effective amount of an agent selected from the group consisting of a compound according to claim 1, a pharmaceutically acceptable prodrug thereof, a pharmaceutically active metabolite thereof, and a pharmaceutically acceptable salt thereof.
20. A method according to claim 19, wherein the protein kinase receptor is a VEGF receptor.
PCT/US2001/001723 2000-01-21 2001-01-19 Amide compounds for inhibiting protein kinases WO2001053274A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BR0108025-3A BR0108025A (en) 2000-01-21 2001-01-19 Amide compounds, pharmaceutically acceptable salt of a pharmaceutically active metabolite of the compound, pharmaceutical composition to modulate or inhibit the activity of a protein kinase receptor, method of treating a disease of mammals mediated by protein kinase activity and method to modulate or inhibit the activity of a protein kinase receptor
MXPA02007102A MXPA02007102A (en) 2000-01-21 2001-01-19 Amide compounds for inhibiting protein kinases.
EP01906592A EP1252146A1 (en) 2000-01-21 2001-01-19 Amide compounds for inhibiting protein kinases
JP2001553276A JP2003529558A (en) 2000-01-21 2001-01-19 Amide compounds for inhibiting protein kinases
CA002394703A CA2394703A1 (en) 2000-01-21 2001-01-19 Amide compounds for inhibiting protein kinases
AU2001234484A AU2001234484A1 (en) 2000-01-21 2001-01-19 Amide compounds for inhibiting protein kinases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17705900P 2000-01-21 2000-01-21
US60/177,059 2000-01-21

Publications (1)

Publication Number Publication Date
WO2001053274A1 true WO2001053274A1 (en) 2001-07-26

Family

ID=22647011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/001723 WO2001053274A1 (en) 2000-01-21 2001-01-19 Amide compounds for inhibiting protein kinases

Country Status (14)

Country Link
US (2) US6635641B2 (en)
EP (1) EP1252146A1 (en)
JP (1) JP2003529558A (en)
AR (1) AR029222A1 (en)
AU (1) AU2001234484A1 (en)
BR (1) BR0108025A (en)
CA (1) CA2394703A1 (en)
CO (1) CO5280047A1 (en)
GT (1) GT200100014A (en)
HN (1) HN2001000008A (en)
MX (1) MXPA02007102A (en)
PA (1) PA8510201A1 (en)
PE (1) PE20011047A1 (en)
WO (1) WO2001053274A1 (en)

Cited By (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1223932A1 (en) * 1999-10-01 2002-07-24 SmithKline Beecham Corporation Compounds and methods
WO2003099771A2 (en) 2002-05-29 2003-12-04 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2004011456A1 (en) * 2002-07-31 2004-02-05 Danter Wayne R Protein tyrosine kinase inhibitors
WO2004092217A1 (en) * 2003-04-17 2004-10-28 Pfizer Inc. Crystal structure of vegfrkd: ligand complexes and methods of use thereof
WO2005002552A2 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Benzimidazole derivatives and their use as protein kinases inhibitors
US6849648B2 (en) * 2001-10-12 2005-02-01 Warner-Lambert Company Phenylene alkyne matrix metalloproteinase inhibitors
WO2005012256A1 (en) 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
WO2005039564A1 (en) * 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
JP2005514339A (en) * 2001-10-22 2005-05-19 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク Protein kinases and phosphatase inhibitors, methods of designing them, and methods of using them
JP2005516927A (en) * 2001-12-13 2005-06-09 アボット・ラボラトリーズ 3- (Phenyl-alkoxy) -5- (phenyl) -pyridine derivatives and related compounds as kinase inhibitors for cancer treatment
JP2005538975A (en) * 2002-07-03 2005-12-22 アステックス テクノロジー リミテッド 3- (Hetero) arylmethoxypyridines and their analogs as p38 MAP kinase inhibitors
WO2006044823A3 (en) * 2004-10-18 2006-06-15 Amgen Inc Heteroaryl-substituted alkyne compounds and method of use
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
WO2006077424A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
WO2006077428A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
WO2006117653A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Azole-based phosphodiesterase inhibitors
WO2007008926A1 (en) * 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
WO2006135640A3 (en) * 2005-06-09 2007-08-02 Novartis Ag Process for the synthesis of organic compounds
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008058341A1 (en) * 2006-11-15 2008-05-22 Cytopia Research Pty Ltd Inhibitors of kinase activity
US7396935B2 (en) 2003-05-01 2008-07-08 Bristol-Myers Squibb Company Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
US7399866B2 (en) 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
EP2023933A2 (en) * 2006-05-08 2009-02-18 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
WO2009100536A1 (en) * 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
EP2100891A1 (en) 2002-07-05 2009-09-16 Novartis AG Inhibitors of tyrosine kinases
WO2009153592A1 (en) * 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
JP2010053060A (en) * 2008-08-27 2010-03-11 Kansai Univ Anticancer agent having acylaminophenyl group
US7691882B2 (en) 2005-10-31 2010-04-06 Eisai R&D Management Co., Ltd. Heterocycles substituted pyridine derivatives and antifungal agent containing thereof
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
US7772216B2 (en) 2001-10-22 2010-08-10 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
US7901894B2 (en) 1999-01-13 2011-03-08 The Research Foundation Of State University Of New York Kinase inhibitors
EP2295053A1 (en) * 2002-12-05 2011-03-16 The Institute Of Materia Medica Of Chinese Academy Of Medical Sciences Novel 2H-chromen-2-one-3-carboxamides for medical uses
EP2330105A1 (en) 2005-03-29 2011-06-08 ICOS Corporation Heteroaryl urea derivatives useful for inhibiting CHK1
US7989455B2 (en) 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
US8013163B2 (en) 2005-01-21 2011-09-06 Astex Therapeutics Limited 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors
EP2395000A1 (en) 2004-12-30 2011-12-14 Astex Therapeutics Limited Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases
US8101617B2 (en) 2004-06-17 2012-01-24 Amgen, Inc. Disubstituted ureas and uses thereof in treating heart failure
US8278307B2 (en) 2006-05-08 2012-10-02 Ariad Pharmaceuticals, Inc. Monocyclic Heteroaryl compounds
US8357699B2 (en) 2007-01-10 2013-01-22 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8394826B2 (en) 2009-05-01 2013-03-12 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
US8445495B2 (en) 2005-12-15 2013-05-21 Cytokinetics, Inc. Certain Chemical entities, compositions and methods
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US20130331328A1 (en) * 2011-02-15 2013-12-12 Georgetown University Small molecule inhibitors of agbl2
CN103664924A (en) * 2012-09-18 2014-03-26 江西天新药业有限公司 Preparation method of 3-[(4-amido-2-methyl-5-pyrimidinyl)methyl]-5-(2-chloroethyl)-4-methylthiazol
EP2739143A1 (en) * 2011-08-05 2014-06-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
US8791102B2 (en) 2008-10-17 2014-07-29 Exelixis, Inc. Acetanilide sphingosine-1-phosphate receptor antagonists
US8809326B2 (en) 2006-09-20 2014-08-19 Aerie Pharmaceuticals, Inc. Isoquinolinone Rho kinase inhibitors
US8846664B2 (en) 2008-11-12 2014-09-30 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
US8895556B2 (en) 2007-12-26 2014-11-25 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
AU2013205820B2 (en) * 2005-06-09 2015-11-26 Novartis Ag Process for the synthesis of organic compounds
US9284275B2 (en) 2007-01-11 2016-03-15 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
AU2013273769B2 (en) * 2006-11-15 2016-05-12 Ym Biosciences Australia Pty Ltd Inhibitors of Kinase Activity
US9415043B2 (en) 2013-03-15 2016-08-16 Aerie Pharmaceuticals, Inc. Combination therapy
WO2016165658A1 (en) * 2015-04-15 2016-10-20 中国科学院上海药物研究所 5-aromatic alkynyl substituted benzamide compound and preparation method, pharmaceutical composition, and use thereof
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US9815815B2 (en) 2013-01-10 2017-11-14 Pulmokine, Inc. Non-selective kinase inhibitors
US9856214B2 (en) 2013-11-15 2018-01-02 The Wistar Institute Of Anatomy And Biology EBNA1 inhibitors and their method of use
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
WO2018068739A1 (en) * 2016-10-13 2018-04-19 深圳市塔吉瑞生物医药有限公司 Alkynyl heterocyclic compound for inhibiting protein kinase activity
US9951019B2 (en) * 2015-06-26 2018-04-24 Regents Of The University Of Minnesota Therapeutic compounds
US10231966B2 (en) 2016-10-27 2019-03-19 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
US10442763B2 (en) 2015-05-14 2019-10-15 The Wistar Institute Of Anatomy And Biology EBNA1 inhibitors and methods using same
US10550087B2 (en) 2015-11-17 2020-02-04 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2020179859A1 (en) 2019-03-06 2020-09-10 第一三共株式会社 Pyrrolopyrazole derivative
WO2020206583A1 (en) * 2019-04-08 2020-10-15 Qilu Regor Therapeutics Inc. Kinase inhibitors and uses thereof
US10858339B2 (en) 2017-03-31 2020-12-08 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2021014415A3 (en) * 2019-07-25 2021-03-04 Curadev Pharma Pvt. Ltd. Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
US11242338B2 (en) 2018-05-17 2022-02-08 The Wistar Institute EBNA1 inhibitor crystalline forms, and methods of preparing and using same
CN114340734A (en) * 2019-06-24 2022-04-12 博善人工智能生物科技有限公司 Novel compounds and methods
US11389441B2 (en) 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10021246A1 (en) * 2000-04-25 2001-10-31 Schering Ag New N-substituted benzamide derivatives are tyrosine kinase KDR and FLT inhibitors useful e.g. for treating tumors, psoriasis, rheumatoid arthritis, diabetic retinopathy or liver sclerosis
ES2298563T3 (en) * 2002-10-09 2008-05-16 Critical Outcome Technologies, Inc. INHIBITORS OF PROTEINS TIROSINA KINASAS.
ES2401330T3 (en) * 2003-02-26 2013-04-18 Sugen, Inc. Heteroarylamino protein kinase inhibitor compound
DE102004009238A1 (en) * 2004-02-26 2005-09-08 Merck Patent Gmbh New aryl amide compounds are kinase inhibitors useful for the treatment and/or prophylaxis of e.g. tumors, psoriasis, rheumatoid arthritis, contact dermatitis, inflammations, endometriosis, scar and benign prostatic hyperplasia
US7297817B2 (en) * 2004-04-13 2007-11-20 Cephalon France Thio-substituted arylmethanesulfinyl derivatives
JPWO2005108370A1 (en) * 2004-04-16 2008-03-21 味の素株式会社 Benzene compounds
US7947682B2 (en) * 2004-12-29 2011-05-24 University Of Southern California Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents
WO2006110477A2 (en) * 2005-04-07 2006-10-19 Astrum Therapeutics Pty. Ltd. Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus
GT200600207A (en) * 2005-06-09 2007-01-15 Novartis Ag PROCESS FOR THE SYNTHESIS OF ORGANIC COMPOUNDS
MX2008008152A (en) * 2005-12-23 2008-09-12 Ariad Pharma Inc Bicyclic heteroaryl compounds.
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
NZ569327A (en) * 2005-12-28 2011-09-30 Vertex Pharma 1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis
US7851500B2 (en) * 2007-01-05 2010-12-14 Bristol-Myers Squibb Company Aminopyrazole kinase inhibitors
US8034815B2 (en) 2007-01-11 2011-10-11 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2070929A1 (en) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
CA3167093A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
JP5934658B2 (en) * 2013-01-29 2016-06-15 Ｊｘエネルギー株式会社 IMIDE-UREA COMPOUND AND PROCESS FOR PRODUCING THE SAME, GREASE THINNER, AND GREASE COMPOSITION
WO2014121883A1 (en) * 2013-02-07 2014-08-14 Merck Patent Gmbh Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4
EP3756666A1 (en) * 2013-12-24 2020-12-30 Oncotartis Inc. Nicotinamide compound for use in the treatment of cancer
WO2015143654A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
AU2019326768A1 (en) * 2018-08-24 2021-03-18 Agricultural University Of Athens (Aua) 2,6-bis(((1H-benzo[d]imidazol-2-yl)thio)methyl)pyridine and N2,N6-dibenzylpyridine-2,6-dicarboxamide derivatives and related compounds as phosphoinositide 3-kinase (PI3K) inhibitors for treating cancer
CA3148769A1 (en) * 2019-07-30 2021-02-04 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition
CN113754541A (en) * 2020-06-02 2021-12-07 深圳湾实验室 Micromolecule inhibitor targeting EB virus nuclear antigen protein, preparation method and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500340A (en) * 1981-12-05 1985-02-19 Basf Aktiengesellschaft Urea derivatives and their use for controlling undesirable plant growth
US4826987A (en) * 1985-03-08 1989-05-02 Leo Pharmaceutical Products Ltd. Pyridyl and quinoline derivatives
WO1996023783A1 (en) * 1995-02-02 1996-08-08 Smithkline Beecham Plc Indole derivatives as 5-ht receptor antagonist
EP0731385A1 (en) * 1995-03-09 1996-09-11 Agfa-Gevaert N.V. New photographic useful group releasing system
WO1996030015A1 (en) * 1995-03-29 1996-10-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0767172A1 (en) * 1995-10-06 1997-04-09 Boehringer Ingelheim Pharmaceuticals Inc. 8-Arylalkyl- and 8-arylheteroalkyl-5, 11-dihydro-6H-dipyrido-[3,2-b:2', 3'-e][1,4]diazepines and their use in the prevention or treatment of HIV infection
WO1999059959A1 (en) * 1998-05-15 1999-11-25 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH575397A5 (en) 1971-11-09 1976-05-14 Basf Ag
JPH083564B2 (en) 1986-07-25 1996-01-17 三菱化学株式会社 Polarizing film
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
WO1994014780A1 (en) 1992-12-18 1994-07-07 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
CA2203517A1 (en) 1994-11-10 1996-05-23 Alan M. Laibelman Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
WO1997003967A1 (en) 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US6495526B2 (en) 1996-01-23 2002-12-17 Gpc Biotech, Inc. Inhibitors of cell-cycle progression and uses related thereto
WO1997034876A1 (en) 1996-03-15 1997-09-25 Zeneca Limited Cinnoline derivatives and use as medicine
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US5821243A (en) 1996-07-22 1998-10-13 Viropharma Incorporated Compounds compositions and methods for treating influenza
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
JP2001509805A (en) 1997-02-05 2001-07-24 ワーナー−ランバート・コンパニー Pyrido [2,3-D] pyrimidine and 4-aminopyrimidine as cell growth inhibitors
AU6230098A (en) 1997-02-27 1998-09-18 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
EP1017394B1 (en) 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
FR2767827A1 (en) 1997-09-03 1999-02-26 Adir NOVEL INDOLE AND INDAZOLE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
CN1278725A (en) 1997-10-06 2001-01-03 巴斯福股份公司 Indeno [1,2-c]-naphtho [1,2-C]- and benzo [6,7] cyclohepta [1,2-C] pyrazole derivatives
YU22400A (en) 1997-10-27 2003-08-29 Agouron Pharmaceuticals Inc. Substituted 4-amino-thiazol-2-y compounds as cdks inhibitors
JP2001521926A (en) 1997-11-04 2001-11-13 ファイザー・プロダクツ・インク Indazole bioequivalent replacement of catechol in therapeutically active compounds
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
AP1258A (en) 1998-02-26 2004-03-15 Aventis Pharma Inc 6,9-Disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines.
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
IL136588A0 (en) 1998-02-27 2001-06-14 Pfizer Prod Inc N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500340A (en) * 1981-12-05 1985-02-19 Basf Aktiengesellschaft Urea derivatives and their use for controlling undesirable plant growth
US4826987A (en) * 1985-03-08 1989-05-02 Leo Pharmaceutical Products Ltd. Pyridyl and quinoline derivatives
WO1996023783A1 (en) * 1995-02-02 1996-08-08 Smithkline Beecham Plc Indole derivatives as 5-ht receptor antagonist
EP0731385A1 (en) * 1995-03-09 1996-09-11 Agfa-Gevaert N.V. New photographic useful group releasing system
WO1996030015A1 (en) * 1995-03-29 1996-10-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0767172A1 (en) * 1995-10-06 1997-04-09 Boehringer Ingelheim Pharmaceuticals Inc. 8-Arylalkyl- and 8-arylheteroalkyl-5, 11-dihydro-6H-dipyrido-[3,2-b:2', 3'-e][1,4]diazepines and their use in the prevention or treatment of HIV infection
WO1999059959A1 (en) * 1998-05-15 1999-11-25 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 77, no. 9, 28 August 1972, Columbus, Ohio, US; abstract no. 56406, LIN ET AL.: "Potential antitumor agents..." XP002168327 *
ROSOWSKY ET AL.: "Methotrexate analogues...", J.MED.CHEM., vol. 31, 1988, pages 763 - 768, XP002168326 *

Cited By (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7901894B2 (en) 1999-01-13 2011-03-08 The Research Foundation Of State University Of New York Kinase inhibitors
EP1223932A4 (en) * 1999-10-01 2003-01-15 Smithkline Beecham Corp Compounds and methods
EP1223932A1 (en) * 1999-10-01 2002-07-24 SmithKline Beecham Corporation Compounds and methods
US7304082B2 (en) 1999-10-01 2007-12-04 Smithkline Beecham Corporation 1,2,4-triazole derivatives, compositions, process of making and methods of use
US6849648B2 (en) * 2001-10-12 2005-02-01 Warner-Lambert Company Phenylene alkyne matrix metalloproteinase inhibitors
US7772216B2 (en) 2001-10-22 2010-08-10 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
JP2005514339A (en) * 2001-10-22 2005-05-19 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク Protein kinases and phosphatase inhibitors, methods of designing them, and methods of using them
US8088768B2 (en) 2001-10-22 2012-01-03 The Research Foundation Of The State University Of New York Protein kinase and phosphatase inhibitors
JP2005516927A (en) * 2001-12-13 2005-06-09 アボット・ラボラトリーズ 3- (Phenyl-alkoxy) -5- (phenyl) -pyridine derivatives and related compounds as kinase inhibitors for cancer treatment
WO2003099771A2 (en) 2002-05-29 2003-12-04 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
JP2005527622A (en) * 2002-05-29 2005-09-15 ノバルティス アクチエンゲゼルシャフト Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2003099771A3 (en) * 2002-05-29 2004-04-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
JP2005538975A (en) * 2002-07-03 2005-12-22 アステックス テクノロジー リミテッド 3- (Hetero) arylmethoxypyridines and their analogs as p38 MAP kinase inhibitors
EP2368889A1 (en) 2002-07-05 2011-09-28 Novartis AG Inhibitors of tyrosine kinases
EP2357182A1 (en) 2002-07-05 2011-08-17 Novartis AG Inhibitors of tyrosine kinases
EP2100891A1 (en) 2002-07-05 2009-09-16 Novartis AG Inhibitors of tyrosine kinases
US8252800B2 (en) 2002-07-31 2012-08-28 Critical Outcome Technologies Protein tyrosine kinase inhibitors
US7585866B2 (en) 2002-07-31 2009-09-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
WO2004011456A1 (en) * 2002-07-31 2004-02-05 Danter Wayne R Protein tyrosine kinase inhibitors
EP2295053A1 (en) * 2002-12-05 2011-03-16 The Institute Of Materia Medica Of Chinese Academy Of Medical Sciences Novel 2H-chromen-2-one-3-carboxamides for medical uses
US7491826B2 (en) * 2003-01-14 2009-02-17 Cytokinetics, Inc. Compounds, compositions and methods
US7399866B2 (en) 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
WO2004092217A1 (en) * 2003-04-17 2004-10-28 Pfizer Inc. Crystal structure of vegfrkd: ligand complexes and methods of use thereof
US7605273B2 (en) 2003-05-01 2009-10-20 Bristol-Myers Squibb Company Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
US7396935B2 (en) 2003-05-01 2008-07-08 Bristol-Myers Squibb Company Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
WO2005002552A2 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Benzimidazole derivatives and their use as protein kinases inhibitors
EP2305250A1 (en) 2003-07-03 2011-04-06 Astex Therapeutics Limited Benzimidazole derivatives and their use as protein kinases inhibitors
EP2256106A1 (en) 2003-07-22 2010-12-01 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
US9051278B2 (en) 2003-07-22 2015-06-09 Astex Therapeutics, Ltd. 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
US8779147B2 (en) 2003-07-22 2014-07-15 Astex Therapeutics, Ltd. 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
US7745638B2 (en) 2003-07-22 2010-06-29 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
WO2005012256A1 (en) 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
US8080666B2 (en) 2003-07-22 2011-12-20 Astex Therapeutics, Ltd. 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
WO2005039564A1 (en) * 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
US8871769B2 (en) 2004-06-17 2014-10-28 Cytokinetics, Inc. Ureas and their use in the treatment of heart failure
US8513257B2 (en) 2004-06-17 2013-08-20 Cytokinetics, Incorporated Ureas and their use in the treatment of heart failure
US10975034B2 (en) 2004-06-17 2021-04-13 Cytokinetics, Inc. Compounds, compositions and methods
US10385023B2 (en) 2004-06-17 2019-08-20 Cytokinetics, Inc. Compounds, compositions and methods
US9643925B2 (en) 2004-06-17 2017-05-09 Cytokinetics, Incorporated Compounds, compositions and methods
US9150564B2 (en) 2004-06-17 2015-10-06 Cytokinetics, Inc. Compounds, compositions and methods
US8101617B2 (en) 2004-06-17 2012-01-24 Amgen, Inc. Disubstituted ureas and uses thereof in treating heart failure
US10035770B2 (en) 2004-06-17 2018-07-31 Cytokinetics, Incorporated Compounds, compositions and methods
US8110595B2 (en) 2004-06-17 2012-02-07 Cytokinetics, Inc. Ureas and their use in the treatment of heart failure
US8557996B2 (en) 2004-10-18 2013-10-15 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
WO2006044823A3 (en) * 2004-10-18 2006-06-15 Amgen Inc Heteroaryl-substituted alkyne compounds and method of use
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
EP2395000A1 (en) 2004-12-30 2011-12-14 Astex Therapeutics Limited Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases
WO2006077424A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
US8293767B2 (en) 2005-01-21 2012-10-23 Astex Therapeutics Limited 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
US8013163B2 (en) 2005-01-21 2011-09-06 Astex Therapeutics Limited 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors
WO2006077428A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
EP2330105A1 (en) 2005-03-29 2011-06-08 ICOS Corporation Heteroaryl urea derivatives useful for inhibiting CHK1
WO2006117653A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Azole-based phosphodiesterase inhibitors
EP2292607A3 (en) * 2005-06-09 2011-04-27 Novartis AG Process for the synthesis of organic compounds
AU2006258050B2 (en) * 2005-06-09 2010-12-09 Novartis Ag Process for the synthesis of organic compounds
US7781597B2 (en) 2005-06-09 2010-08-24 Novartis Ag Process for the synthesis of organic compounds
EP2266961A3 (en) * 2005-06-09 2011-07-27 Novartis AG Process for the synthesis of organic compounds
WO2006135640A3 (en) * 2005-06-09 2007-08-02 Novartis Ag Process for the synthesis of organic compounds
TWI380981B (en) * 2005-06-09 2013-01-01 Novartis Ag Process for the synthesis of organic compounds
US8008504B2 (en) 2005-06-09 2011-08-30 Novartis Ag Process for the synthesis of organic compounds
AU2013205820B2 (en) * 2005-06-09 2015-11-26 Novartis Ag Process for the synthesis of organic compounds
KR101283109B1 (en) 2005-06-09 2013-07-05 노파르티스 아게 Process for the Synthesis of Organic Compounds
US7470787B2 (en) 2005-07-11 2008-12-30 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
US8034943B2 (en) 2005-07-11 2011-10-11 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
WO2007008926A1 (en) * 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
US7671205B2 (en) 2005-07-11 2010-03-02 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455647B2 (en) 2005-07-11 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US7691882B2 (en) 2005-10-31 2010-04-06 Eisai R&D Management Co., Ltd. Heterocycles substituted pyridine derivatives and antifungal agent containing thereof
US8841327B2 (en) 2005-10-31 2014-09-23 Eisai R&D Management Co., Ltd. Heterocycles substituted pyridine derivatives and antifungal agent containing thereof
US8445495B2 (en) 2005-12-15 2013-05-21 Cytokinetics, Inc. Certain Chemical entities, compositions and methods
US8871768B2 (en) 2005-12-15 2014-10-28 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US8653081B2 (en) 2005-12-16 2014-02-18 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
US8410108B2 (en) 2005-12-16 2013-04-02 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7989455B2 (en) 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
US9090561B2 (en) 2006-05-08 2015-07-28 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
JP2009536650A (en) * 2006-05-08 2009-10-15 アリアド・ファーマシューティカルズ・インコーポレイテッド Acetylene heteroaryl compounds
EP2023933A4 (en) * 2006-05-08 2011-02-23 Ariad Pharma Inc Acetylenic heteroaryl compounds
US8278307B2 (en) 2006-05-08 2012-10-02 Ariad Pharmaceuticals, Inc. Monocyclic Heteroaryl compounds
US8461167B2 (en) 2006-05-08 2013-06-11 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
AU2007249924B2 (en) * 2006-05-08 2013-07-04 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
EP2023933A2 (en) * 2006-05-08 2009-02-18 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
US8809326B2 (en) 2006-09-20 2014-08-19 Aerie Pharmaceuticals, Inc. Isoquinolinone Rho kinase inhibitors
US10624882B2 (en) 2006-09-20 2020-04-21 Aerie Pharmaceuticals, Inc. Rho kinase inhibitors
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
AU2007321719B2 (en) * 2006-11-15 2013-11-21 Ym Biosciences Australia Pty Ltd Inhibitors of kinase activity
WO2008058341A1 (en) * 2006-11-15 2008-05-22 Cytopia Research Pty Ltd Inhibitors of kinase activity
JP2014065713A (en) * 2006-11-15 2014-04-17 Ym Biosciences Australia Pty Ltd Inhibitors of kinase activity
US9029386B2 (en) 2006-11-15 2015-05-12 Gilead Sciences, Inc. Pyridine derivatives useful as kinase inhibitors
AU2013273769B2 (en) * 2006-11-15 2016-05-12 Ym Biosciences Australia Pty Ltd Inhibitors of Kinase Activity
US8461161B2 (en) 2006-11-15 2013-06-11 Ym Biosciences Australia Pty Ltd Substituted pyrazines as inhibitors of kinase activity
JP2010509375A (en) * 2006-11-15 2010-03-25 サイトピア・リサーチ・ピーティーワイ・リミテッド Inhibitor of kinase activity
US10899714B2 (en) 2007-01-10 2021-01-26 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US10472327B2 (en) 2007-01-10 2019-11-12 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US9890123B2 (en) 2007-01-10 2018-02-13 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US9365518B2 (en) 2007-01-10 2016-06-14 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8357699B2 (en) 2007-01-10 2013-01-22 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8921392B2 (en) 2007-01-10 2014-12-30 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US9284275B2 (en) 2007-01-11 2016-03-15 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US8895556B2 (en) 2007-12-26 2014-11-25 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8871757B2 (en) 2008-01-17 2014-10-28 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
WO2009100536A1 (en) * 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
WO2009153592A1 (en) * 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
CN102123989A (en) * 2008-06-19 2011-07-13 阿斯利康(瑞典)有限公司 Pyrazole compounds 436
US10112920B2 (en) 2008-07-25 2018-10-30 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US9096569B2 (en) 2008-07-25 2015-08-04 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US11021456B2 (en) 2008-07-25 2021-06-01 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US10882840B2 (en) 2008-07-25 2021-01-05 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US10532993B2 (en) 2008-07-25 2020-01-14 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US8759388B2 (en) 2008-07-25 2014-06-24 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US9512101B2 (en) 2008-07-25 2016-12-06 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US9884840B2 (en) 2008-07-25 2018-02-06 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
JP2010053060A (en) * 2008-08-27 2010-03-11 Kansai Univ Anticancer agent having acylaminophenyl group
US8791102B2 (en) 2008-10-17 2014-07-29 Exelixis, Inc. Acetanilide sphingosine-1-phosphate receptor antagonists
US8846664B2 (en) 2008-11-12 2014-09-30 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
US11028081B2 (en) 2009-05-01 2021-06-08 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US9951059B2 (en) 2009-05-01 2018-04-24 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US10174017B2 (en) 2009-05-01 2019-01-08 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US8716310B2 (en) 2009-05-01 2014-05-06 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US11618748B2 (en) 2009-05-01 2023-04-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US10316029B2 (en) 2009-05-01 2019-06-11 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US8394826B2 (en) 2009-05-01 2013-03-12 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US10654844B2 (en) 2009-05-01 2020-05-19 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US9624220B2 (en) 2010-04-01 2017-04-18 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9422282B2 (en) 2010-04-01 2016-08-23 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9199918B2 (en) * 2011-02-15 2015-12-01 Georgetown University Small molecule inhibitors of AGBL2
US20130331328A1 (en) * 2011-02-15 2013-12-12 Georgetown University Small molecule inhibitors of agbl2
US9221805B2 (en) 2011-08-05 2015-12-29 Spacefill Enterprises LLP Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
EP2739143A4 (en) * 2011-08-05 2015-01-07 Gary A Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
EP2739143A1 (en) * 2011-08-05 2014-06-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
US9833455B2 (en) 2011-08-05 2017-12-05 Spacefill Enterprises Llc Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
CN103664924A (en) * 2012-09-18 2014-03-26 江西天新药业有限公司 Preparation method of 3-[(4-amido-2-methyl-5-pyrimidinyl)methyl]-5-(2-chloroethyl)-4-methylthiazol
US10532994B2 (en) 2013-01-10 2020-01-14 Pulmokine, Inc. Non-selective kinase inhibitors
US9815815B2 (en) 2013-01-10 2017-11-14 Pulmokine, Inc. Non-selective kinase inhibitors
US10246438B2 (en) 2013-01-10 2019-04-02 Pulmokine, Inc Non-selective kinase inhibitors
US9415043B2 (en) 2013-03-15 2016-08-16 Aerie Pharmaceuticals, Inc. Combination therapy
US10568878B2 (en) 2013-03-15 2020-02-25 Aerie Pharmaceuticals, Inc. Combination therapy
US11197853B2 (en) 2013-03-15 2021-12-14 Aerie Pharmaceuticals, Inc. Combination therapy
US11185538B2 (en) 2013-03-15 2021-11-30 Aerie Pharmaceuticals, Inc. Compositions for treating glaucoma or reducing intraocular pressure
US9849122B2 (en) 2013-03-15 2017-12-26 Aerie Pharmaceuticals, Inc. Combination therapy
US11020385B2 (en) 2013-03-15 2021-06-01 Aerie Pharmaceuticals, Inc. Combination therapy
US9993470B2 (en) 2013-03-15 2018-06-12 Aerie Pharmaceuticals, Inc. Combination therapy
US9931336B2 (en) 2013-03-15 2018-04-03 Aerie Pharmaceuticals, Inc. Combination therapy
US10588901B2 (en) 2013-03-15 2020-03-17 Aerie Pharmaceuticals, Inc. Combination therapy
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
US11242317B2 (en) 2013-11-15 2022-02-08 The Wistar Institute Of Anatomy And Biology EBNA1 inhibitors and their method of use
US10421718B2 (en) 2013-11-15 2019-09-24 The Wistar Institute Of Anatomy And Biology EBNA1 inhibitors and their method of use
US9856214B2 (en) 2013-11-15 2018-01-02 The Wistar Institute Of Anatomy And Biology EBNA1 inhibitors and their method of use
WO2016165658A1 (en) * 2015-04-15 2016-10-20 中国科学院上海药物研究所 5-aromatic alkynyl substituted benzamide compound and preparation method, pharmaceutical composition, and use thereof
US10618900B2 (en) 2015-04-15 2020-04-14 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences 5-aromatic alkynyl substituted benzamide compound and preparation method, pharmaceutical composition, and use thereof
EA039234B1 (en) * 2015-04-15 2021-12-21 Шанхай Институт Оф Материа Медица, Чиниз Академи Оф Сайенс 5-aromatic alkynyl substituted benzamide compounds and preparation method thereof, pharmaceutical compositions and use thereof
RU2695371C2 (en) * 2015-04-15 2019-07-23 Шанхай Инститьют Оф Матириа Медика, Чайниз Экэдеми Оф Сайэнсиз 5-aromatic alkynyl-substituted benzamide compound and method for production thereof, pharmaceutical composition and use thereof
KR102117453B1 (en) * 2015-04-15 2020-06-01 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 Benzamide-based compound substituted by 5-aryl alkynyl group, manufacturing method thereof, drug composition and use
AU2016248388B2 (en) * 2015-04-15 2019-06-06 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences 5-aromatic alkynyl substituted benzamide compound and preparation method, pharmaceutical composition, and use thereof
KR20170137197A (en) * 2015-04-15 2017-12-12 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 Benzamide-based compounds substituted by 5-arylalkynyl groups, their preparation, pharmaceutical compositions and uses
JP2018514524A (en) * 2015-04-15 2018-06-07 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ 5-Aromatic alkynyl group-substituted benzamide compounds and methods for producing the same, drug compositions and uses
US11912659B2 (en) 2015-05-14 2024-02-27 The Wistar Institute Of Anatomy And Biology EBNA1 inhibitors and methods using same
US10981867B2 (en) 2015-05-14 2021-04-20 The Wistar Institute Of Anatomy And Biology EBNA1 inhibitors and methods using same
US10442763B2 (en) 2015-05-14 2019-10-15 The Wistar Institute Of Anatomy And Biology EBNA1 inhibitors and methods using same
US9951019B2 (en) * 2015-06-26 2018-04-24 Regents Of The University Of Minnesota Therapeutic compounds
US10550087B2 (en) 2015-11-17 2020-02-04 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US11590123B2 (en) 2016-08-31 2023-02-28 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
US11707460B2 (en) 2016-08-31 2023-07-25 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
US11389441B2 (en) 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
WO2018068739A1 (en) * 2016-10-13 2018-04-19 深圳市塔吉瑞生物医药有限公司 Alkynyl heterocyclic compound for inhibiting protein kinase activity
US10231966B2 (en) 2016-10-27 2019-03-19 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
US11364238B2 (en) 2016-10-27 2022-06-21 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
US11312700B2 (en) 2017-03-31 2022-04-26 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US10858339B2 (en) 2017-03-31 2020-12-08 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11242338B2 (en) 2018-05-17 2022-02-08 The Wistar Institute EBNA1 inhibitor crystalline forms, and methods of preparing and using same
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11891376B2 (en) 2018-09-14 2024-02-06 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2020179859A1 (en) 2019-03-06 2020-09-10 第一三共株式会社 Pyrrolopyrazole derivative
WO2020206583A1 (en) * 2019-04-08 2020-10-15 Qilu Regor Therapeutics Inc. Kinase inhibitors and uses thereof
CN114340734A (en) * 2019-06-24 2022-04-12 博善人工智能生物科技有限公司 Novel compounds and methods
CN114269720A (en) * 2019-07-25 2022-04-01 库拉德夫制药私人有限公司 acetyl-CoA synthetase short chains2(ACSS2) Small molecule inhibitors of
WO2021014415A3 (en) * 2019-07-25 2021-03-04 Curadev Pharma Pvt. Ltd. Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof

Also Published As

Publication number Publication date
GT200100014A (en) 2002-03-14
BR0108025A (en) 2002-11-05
CA2394703A1 (en) 2001-07-26
CO5280047A1 (en) 2003-05-30
US6635641B2 (en) 2003-10-21
MXPA02007102A (en) 2003-01-28
JP2003529558A (en) 2003-10-07
PE20011047A1 (en) 2001-11-06
HN2001000008A (en) 2003-12-11
AU2001234484A1 (en) 2001-07-31
AR029222A1 (en) 2003-06-18
EP1252146A1 (en) 2002-10-30
PA8510201A1 (en) 2002-08-26
US20020103203A1 (en) 2002-08-01
US20040092747A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
US6635641B2 (en) Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
KR100861829B1 (en) Aryl and heteroaryl urea chk1 inhibitors for use as radiosensitizers and chemosensitizers
EP1614683B1 (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
EP0596406B1 (en) Imidazo (1,2-a) Pyridines as bradykinin antagonists
DK2599771T3 (en) naphthalene
US6891044B2 (en) Indazole compounds and pharmaceutical compositions for Inhibiting protein kinases, and methods for their use
WO2000075120A1 (en) Diaminothiazoles and their use for inhibiting protein kinases
AU2002258451A1 (en) Aryl and Heteroaryl Urea CHK1 Inhibitors for Use as Radiosensitizers and Chemosensitizers
HU223140B1 (en) Bradikinin antagonists quinolines and theirs heteroanalogues, process for producing thereof and pharmaceutical compositions comprising them
US20040157866A1 (en) Amide compounds
US5574042A (en) Imidazo [1,2-a] pyridines and their pharmaceutical use
JP2008545690A (en) New compounds
JPH10291988A (en) Heterocyclic compound

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2394703

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001906592

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 553276

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/007102

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2001906592

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642